

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Sarilumab (Kevzara®)

Sanofi-Aventis Deutschland GmbH

Modul 4 B – Anhang 4-G

*Polymyalgia rheumatica (PMR) bei erwachsenen
Patienten, die auf Corticosteroide unzureichend
angesprochen haben oder bei denen ein Rezidiv
während des Ausschleichens der Corticosteroide auftritt*

Weitere Analysen

Stand: 03.02.2025

EFC15160_Germany_continuous_05SEP24.....	12
1. Cumulative corticosteroid dose - ITT population	13
Analysis of cumulative corticosteroid dose during treatment period	13
2. PMR activity score - ITT population	15
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	15
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	18
3. CRP component for PMR activity score - ITT population	19
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	19
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	25
4. Morning stiffness duration components for PMR activity score - ITT population	26
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	26
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	32
5. Ability to elevate the upper limbs component for PMR activity score - ITT population.....	33
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	33
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	40
6. MD-VAS - ITT population	41
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	41
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	44
7. FACIT-Fatigue - ITT population	45
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	45
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	48
8. EQ-5D VAS - ITT population	49
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	49
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	52
9. HAQ-DI standardized score - ITT population	53
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	53
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	56
10. HAQ-DI pain score - ITT population	57
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	57
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	60
11. HAQ-DI patient global assessment score - ITT population.....	61
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	61
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	64
12. HAQ-DI Activities Item score - ITT population	65
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	65
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	68
13. HAQ-DI Arising Item score - ITT population	69

Weitere Analysen

Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	69
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	72
14. HAQ-DI Dressing and grooming Item score - ITT population	73
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	73
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	76
15. HAQ-DI Eating Item score - ITT population.....	77
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	77
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	80
16. HAQ-DI Grip Item score - ITT population.....	81
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	81
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	84
17. HAQ-DI Hygiene Item score - ITT population	85
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	85
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	88
18. HAQ-DI Reach Item score - ITT population	89
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	89
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	92
19. HAQ-DI Walking Item score - ITT population	93
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	93
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	96
20. SF-36 mental component summary score - ITT population	97
Analysis of change from baseline over time up to week 52 (MMRM - as-observed).....	97
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	100
21. SF-36 physical component summary score - ITT population.....	101
Analysis of change from baseline over time up to week 52 (MMRM - as-observed)....	101
Plot of LSMean change from baseline over time up to week 52 (MMRM - as-observed)	104
EFC15160_Germany_continuous_subgroup_16SEP24	105
1. Cumulative corticosteroid dose.....	106
Analysis of cumulative corticosteroid dose during treatment period - ITT population .	106
Per gender	106
Per race	108
Per region.....	110
Per age	112
Per baseline CRP	114
Per baseline ESR.....	116
Per baseline CS dose.....	118
Per MTX Add-on Therapy.....	120
Per Number of relapses prior to screening	122
2. PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	124
Summary table of treatment-by-subgroup p-value for all subgroups.....	124

Weitere Analysen

Per gender	125
Per race	128
Per region	131
Per age	134
Per baseline CRP	137
Per baseline ESR.....	140
Per baseline CS dose.....	143
Per MTX Add-on Therapy.....	146
Per Number of relapses prior to screening	149
3. FACIT-Fatigue change from baseline over time up to week 52 (MMRM - as- observed) - ITT population	152
Summary table of treatment-by-subgroup p-value for all subgroups	152
Per gender	153
Per race	156
Per region.....	159
Per age	162
Per baseline CRP	165
Per baseline ESR.....	168
Per baseline CS dose.....	171
Per MTX Add-on Therapy.....	174
Per Number of relapses prior to screening	177
4. EQ-5D VAS change from baseline over time up to week 52 (MMRM - as- observed) - ITT population	180
Summary table of treatment-by-subgroup p-value for all subgroups	180
Per gender	181
Per race	184
Per region.....	187
Per age	190
Per baseline CRP	193
Per baseline ESR.....	196
Per baseline CS dose.....	199
Per MTX Add-on Therapy.....	202
Per Number of relapses prior to screening	205
5. MD-VAS change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	208
Summary table of treatment-by-subgroup p-value for all subgroups	208
Per gender	209
Per race	212
Per region.....	215
Per age	218
Per baseline CRP	221
Per baseline ESR.....	224
Per baseline CS dose.....	227
Per MTX Add-on Therapy.....	230
Per Number of relapses prior to screening	233
6. CRP component for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	236
Summary table of treatment-by-subgroup p-value for all subgroups	236
Per gender	237
Per race	240

Weitere Analysen

Per region.....	243
Per age	246
Per baseline CRP	249
Per baseline ESR.....	252
Per baseline CS dose.....	255
Per MTX Add-on Therapy.....	258
Per Number of relapses prior to screening	261
7. HAQ-DI standardized score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population.....	264
Summary table of treatment-by-subgroup p-value for all subgroups	264
Per gender	265
Per race	268
Per region.....	271
Per age	274
Per baseline CRP	277
Per baseline ESR.....	280
Per baseline CS dose.....	283
Per MTX Add-on Therapy.....	286
Per Number of relapses prior to screening	289
8. HAQ-DI pain score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	292
Summary table of treatment-by-subgroup p-value for all subgroups	292
Per gender	293
Per race	296
Per region.....	299
Per age	302
Per baseline CRP	305
Per baseline ESR.....	308
Per baseline CS dose.....	311
Per MTX Add-on Therapy.....	314
Per Number of relapses prior to screening	317
9. HAQ-DI patient global assessment score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	320
Summary table of treatment-by-subgroup p-value for all subgroups	320
Per gender	321
Per race	324
Per region.....	327
Per age	330
Per baseline CRP	333
Per baseline ESR.....	336
Per baseline CS dose.....	339
Per MTX Add-on Therapy.....	342
Per Number of relapses prior to screening	345
10. SF-36 mental component summary score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	348
Summary table of treatment-by-subgroup p-value for all subgroups	348
Per gender	349
Per race	352
Per region.....	355
Per age	358

Weitere Analysen

Per baseline CRP	361
Per baseline ESR.....	364
Per baseline CS dose.....	367
Per MTX Add-on Therapy.....	370
Per Number of relapses prior to screening	373
11. SF-36 physical component summary score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population	376
Summary table of treatment-by-subgroup p-value for all subgroups	376
Per gender	377
Per race	380
Per region.....	383
Per age	386
Per baseline CRP	389
Per baseline ESR.....	392
Per baseline CS dose.....	395
Per MTX Add-on Therapy.....	398
Per Number of relapses prior to screening	401
12. Morning stiffness duration components for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population.....	404
Summary table of treatment-by-subgroup p-value for all subgroups	404
Per gender	405
Per race	408
Per region.....	411
Per age	414
Per baseline CRP	417
Per baseline ESR.....	420
Per baseline CS dose.....	423
Per MTX Add-on Therapy.....	426
Per Number of relapses prior to screening	429
13. Ability to elevate the upper limbs component for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population.....	432
Summary table of treatment-by-subgroup p-value for all subgroups	432
Per gender	433
Per race	436
Per region.....	439
Per age	442
Per baseline CRP	445
Per baseline ESR.....	448
Per baseline CS dose.....	451
Per MTX Add-on Therapy.....	454
Per Number of relapses prior to screening	457
EFC15160_Germany_binary_subgroup_05SEP24 – (Imputation fehlender Werte)....	460
1. Sustained remission at Week 52 - ITT population.....	461
Summary table of treatment-by-subgroup p-value for all subgroups	461
Per gender	462
Per race	463
Per age	464
Per baseline CS dose.....	465
Per MTX Add-on Therapy.....	467
Per Number of relapses prior to screening	468

2.	Achievement of disease remission no later than Week 12 - ITT population.....	469
	Summary table of treatment-by-subgroup p-value for all subgroups	469
	Per gender	470
	Per race	471
	Per region.....	472
	Per age	473
	Per baseline CRP	474
	Per baseline ESR.....	475
	Per baseline CS dose.....	476
	Per MTX Add-on Therapy.....	477
	Per Number of relapses prior to screening	478
3.	Absence of disease flare from Week 12 through Week 52 - ITT population	479
	Summary table of treatment-by-subgroup p-value for all subgroups	479
	Per gender	480
	Per race	481
	Per region.....	482
	Per age	483
	Per baseline CRP	484
	Per baseline ESR.....	485
	Per baseline CS dose.....	486
	Per MTX Add-on Therapy.....	487
	Per Number of relapses prior to screening	488
4.	Sustained reduction of CRP from Week 12 through Week 52 - ITT population.....	489
	Summary table of treatment-by-subgroup p-value for all subgroups	489
	Per gender	490
	Per race	491
	Per region.....	492
	Per age	493
	Per baseline CRP	494
	Per baseline ESR.....	495
	Per baseline CS dose.....	496
	Per MTX Add-on Therapy.....	497
	Per Number of relapses prior to screening	498
5.	Successful adherence to the prednisone taper from Week 12 through Week 52 - ITT population	499
	Summary table of treatment-by-subgroup p-value for all subgroups	499
	Per gender	500
	Per race	501
	Per region.....	502
	Per age	503
	Per baseline CRP	504
	Per baseline ESR.....	505
	Per baseline CS dose.....	506
	Per MTX Add-on Therapy.....	507
	Per Number of relapses prior to screening	508
6.	VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points at Week 52 - ITT population.....	509
	Summary table of treatment-by-subgroup p-value for all subgroups	509
	Per gender	510
	Per race	511

Weitere Analysen

Per region.....	512
Per age	513
Per baseline CRP	514
Per baseline ESR.....	515
Per baseline CS dose.....	516
Per MTX Add-on Therapy.....	517
Per Number of relapses prior to screening	518
7. VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points at Week 52 - ITT population.....	519
Summary table of treatment-by-subgroup p-value for all subgroups.....	519
Per gender	520
Per race	521
Per region.....	522
Per age	523
Per baseline CRP	524
Per baseline ESR.....	525
Per baseline CS dose.....	526
Per MTX Add-on Therapy.....	527
Per Number of relapses prior to screening	528
8. FACIT-F increase from Baseline $\geq$ 7.8 points at Week 52 - ITT population.....	529
Summary table of treatment-by-subgroup p-value for all subgroups.....	529
Per gender	530
Per race	531
Per region.....	532
Per age	533
Per baseline CRP	534
Per baseline ESR.....	535
Per baseline CS dose.....	536
Per MTX Add-on Therapy.....	537
Per Number of relapses prior to screening	538
9. EQ-5D VAS increase from Baseline $\geq$ 15 points at Week 52 - ITT population	539
Summary table of treatment-by-subgroup p-value for all subgroups.....	539
Per gender	540
Per race	541
Per age	542
Per MTX Add-on Therapy.....	543
10. HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points at Week 52 - ITT population	544
Summary table of treatment-by-subgroup p-value for all subgroups.....	544
Per gender	545
Per race	546
Per region.....	547
Per age	548
Per baseline CRP	549
Per baseline ESR.....	550
Per baseline CS dose.....	551
Per MTX Add-on Therapy.....	552
Per Number of relapses prior to screening	553
11. HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points at week 52 - ITT population.....	554

Weitere Analysen

Summary table of treatment-by-subgroup p-value for all subgroups	554
Per gender	555
Per race	556
Per region.....	557
Per age	558
Per baseline CRP	559
Per baseline ESR.....	560
Per baseline CS dose.....	561
Per MTX Add-on Therapy.....	562
Per Number of relapses prior to screening	563
12. SF-36 Standardized Physical Component Scale increase from Baseline ≥ 10 points at Week 52 - ITT population	564
Summary table of treatment-by-subgroup p-value for all subgroups	564
Per gender	565
Per race	566
Per region.....	567
Per baseline ESR.....	568
Per MTX Add-on Therapy.....	569
EFC15160_Germany_binary_PRO_NI_13SEP24 – (ohne Imputation fehlender Werte)	570
1. VAS Pain (Patient) decrease from Baseline ≥ 1.5 points- Analysis of responders over time up to week 52	571
2. VAS disease activity (Physician) decrease from Baseline ≥ 1.5 points - ITT population- Analysis of responders over time up to week 52	572
3. FACIT-F increase from Baseline ≥ 7.8 points - ITT population- Analysis of responders over time up to week 52.....	573
4. EQ-5D VAS increase from Baseline ≥ 15 points - ITT population- Analysis of responders over time up to week 52.....	574
5. HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points - ITT population- Analysis of responders over time up to week 52	575
6. HAQ-DI patient global assessment score decrease from Baseline ≥ 15 points - ITT population- Analysis of responders over time up to week 52.....	576
7. SF-36 Standardized Physical Component Scale increase from Baseline ≥ 10 points - ITT population- Analysis of responders over time up to week 52	577
8. SF-36 Standardized Mental Component Scale increase from Baseline ≥ 10 points - ITT population- Analysis of responders over time up to week 52	578
9. VAS Pain (Patient) decrease from Baseline ≥ 1.5 points at Week 52 - ITT population.....	579
Summary table of treatment-by-subgroup p-value for all subgroups	579
Per gender	580
Per race	581
Per region.....	582
Per age	583
Per baseline CRP	584
Per baseline ESR.....	585
Per baseline CS dose.....	586
Per MTX Add-on Therapy.....	587
Per Number of relapses prior to screening	588
10. VAS disease activity (Physician) decrease from Baseline ≥ 1.5 points at Week 52 - ITT population.....	589

Weitere Analysen

Summary table of treatment-by-subgroup p-value for all subgroups	589
Per gender	590
Per race	591
Per region.....	592
Per age	593
Per baseline CRP	594
Per baseline ESR.....	595
Per baseline CS dose.....	596
Per MTX Add-on Therapy.....	597
Per Number of relapses prior to screening	598
11. FACIT-F increase from Baseline ≥ 7.8 points at Week 52 - ITT population.....	599
Summary table of treatment-by-subgroup p-value for all subgroups	599
Per gender	600
Per race	601
Per region.....	602
Per age	603
Per baseline CRP	604
Per baseline ESR.....	605
Per baseline CS dose.....	606
Per MTX Add-on Therapy.....	607
Per Number of relapses prior to screening	608
12. EQ-5D VAS increase from Baseline ≥ 15 points at Week 52 - ITT population	609
Summary table of treatment-by-subgroup p-value for all subgroups	609
Per gender	610
Per race	611
Per age	612
Per MTX Add-on Therapy.....	613
13. HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points at Week 52 - ITT population	614
Summary table of treatment-by-subgroup p-value for all subgroups	614
Per gender	615
Per race	616
Per region.....	617
Per age	618
Per baseline CRP	619
Per baseline ESR.....	620
Per baseline CS dose.....	621
Per MTX Add-on Therapy.....	622
Per Number of relapses prior to screening	623
14. SF-36 Standardized Physical Component Scale increase from Baseline ≥ 10 points at Week 52 - ITT population	624
Summary table of treatment-by-subgroup p-value for all subgroups	624
Per gender	625
Per race	626
Per region.....	627
Per baseline ESR.....	628
Per MTX Add-on Therapy.....	629
15. HAQ-DI patient global assessment score decrease from Baseline ≥ 15 points at week 52 - ITT population.....	630
Summary table of treatment-by-subgroup p-value for all subgroups	630

Weitere Analysen

Per gender	631
Per race	633
Per region.....	634
Per age	635
Per baseline CRP	636
Per baseline ESR.....	637
Per baseline CS dose.....	638
Per MTX Add-on Therapy.....	639
Per Number of relapses prior to screening	640
EFC15160_Germany_T2event_subgroup_26JUL24	641
1. Time to First PMR Flare up to 52 weeks - ITT population	642
Overall	642
Per gender	643
Per race	645
Per region.....	647
Per age	649
Per baseline CRP	652
Per baseline ESR.....	654
Per baseline CS dose.....	656
Per MTX Add-on Therapy.....	658
Per Number of relapses prior to screening	660
EFC15160_Germany_safety_subgroup_24JUL24 – Adverse Event Data.....	661
1. Treatment emergent adverse events - Safety population	662
Any TEAE	662
Any mild/moderate TEAE	671
Any Serious TEAE	680
2. Treatment emergent adverse events by SOC/PT - Safety population.....	683
Any TEAE - SOC = Blood and lymphatic system disorders - Safety population.....	683
Any TEAE - SOC = Gastrointestinal disorders - Safety population	691
Any mild/moderate TEAE - SOC = Blood and lymphatic system disorders - Safety population.....	701
Any mild/moderate TEAE - SOC = Gastrointestinal disorders - Safety population.....	708

EFC15160_Germany_continuous_05SEP24

Weitere Analysen

1. Cumulative corticosteroid dose - ITT population*Analysis of cumulative corticosteroid dose during treatment period*

Corticosteroid dose	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Expected cumulative CS dose (mg) ^a		
Number	58	59
Mean (SD)	1780.6 (478.3)	741.9 (99.9)
SE	62.81	13.00
Median (95% CI)	2044.0 (2031.0 , 2044.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1780.0 ; 2044.0	777.0 ; 777.0
Min ; Max	404 ; 2044	224 ; 777
Actual cumulative CS dose (mg) ^b		
Number	58	59
Mean (SD)	2235.8 (839.4)	1039.5 (612.2)
SE	110.21	79.70
Median (95% CI)	2044.0	777.0
Q1 ; Q3	1950.0 ; 2840.0	777.0 ; 1018.5
Min ; Max	404 ; 3676	224 ; 2885
p-value vs. placebo ^c		<.0001

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico52_ger_i_t_x.rtf (05SEP2024 9:32)

Weitere Analysen

Corticosteroid dose	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Difference between actual and expected cumulative CS dose (mg)		
Number	58	59
Mean (SD)	455.1 (548.1)	297.6 (588.7)
SE	71.97	76.64
Median (95% CI)	199.5 (0.0 , 496.0)	0.0 (0.0 , 0.0)
Q1 ; Q3	0.0 ; 846.0	0.0 ; 245.0
Min ; Max	-57 ; 1632	-13 ; 2108
p-value vs. placebo ^c		0.0189

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico52_ger_i_t_x.rtf (05SEP2024 9:32)

Weitere Analysen

2. PMR activity score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

PMR-AS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	52	49
Mean (SD)	22.97 (21.99)	18.07 (9.85)
Baseline for patients with data at Week 52		
Number	28	31
Mean (SD)	20.82 (28.46)	17.55 (8.65)
Week 12		
Value		
Number	31	31
Mean (SD)	9.05 (7.38)	8.83 (12.53)
Change from baseline		
Number	31	31
Mean (SD)	-13.97 (28.29)	-8.09 (18.44)
LS Mean (SE) ^a	-10.46 (1.86)	-10.84 (1.85)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.38 (-5.63 to 4.87)
P-value vs. Placebo+52 week taper ^a		0.8852

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmras_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.04 (-0.54 to 0.47)
Week 24		
Value		
Number	36	28
Mean (SD)	9.56 (9.27)	5.24 (4.47)
Change from baseline		
Number	36	28
Mean (SD)	-12.58 (27.00)	-11.91 (10.80)
LS Mean (SE) ^a	-9.46 (1.29)	-14.22 (1.42)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.76 (-8.59 to -0.93)
P-value vs. Placebo+52 week taper ^a		0.0155
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.62 (-1.11 to -0.12)
Week 52		
Value		
Number	28	31
Mean (SD)	9.11 (6.88)	4.03 (3.29)
Change from baseline		
Number	28	31
Mean (SD)	-11.71 (29.97)	-13.52 (8.68)
LS Mean (SE) ^a	-10.27 (0.97)	-15.57 (0.94)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmras_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.30 (-8.01 to -2.60)
P-value vs. Placebo+52 week taper ^a		0.0002
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.01 (-1.52 to -0.49)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmras_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

3. CRP component for PMR activity score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	60
Mean (SD)	8.92 (11.20)	9.97 (9.79)
Baseline for patients with data at Week 52		
Number	35	43
Mean (SD)	9.81 (12.27)	10.35 (10.02)
Week 2		
Value		
Number	56	57
Mean (SD)	5.94 (6.86)	2.89 (7.11)
Change from baseline		
Number	56	57
Mean (SD)	-3.10 (8.45)	-7.51 (9.05)
LS Mean (SE) ^a	-3.58 (0.76)	-7.23 (0.76)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-3.65 (-5.79 to -1.52)
P-value vs. Placebo+52 week taper ^a		0.0010

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.63 (-1.00 to -0.26)
Week 4		
Value		
Number	57	56
Mean (SD)	7.30 (8.91)	2.76 (7.02)
Change from baseline		
Number	57	56
Mean (SD)	-1.74 (9.72)	-7.82 (8.81)
LS Mean (SE) ^a	-2.32 (0.90)	-7.43 (0.90)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.11 (-7.64 to -2.59)
P-value vs. Placebo+52 week taper ^a		0.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.75 (-1.12 to -0.38)
Week 8		
Value		
Number	53	56
Mean (SD)	8.76 (11.15)	2.99 (7.61)
Change from baseline		
Number	53	56
Mean (SD)	-0.70 (13.50)	-7.58 (8.96)
LS Mean (SE) ^a	-1.13 (1.18)	-7.12 (1.16)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.99 (-9.26 to -2.72)
P-value vs. Placebo+52 week taper ^a		0.0004
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.69 (-1.07 to -0.31)
Week 12		
Value		
Number	46	48
Mean (SD)	7.23 (8.71)	1.49 (5.66)
Change from baseline		
Number	46	48
Mean (SD)	-2.49 (13.05)	-9.06 (9.24)
LS Mean (SE) ^a	-2.53 (1.03)	-8.59 (1.01)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.06 (-8.92 to -3.20)
P-value vs. Placebo+52 week taper ^a		<.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.86 (-1.27 to -0.45)
Week 16		
Value		
Number	46	49
Mean (SD)	10.29 (20.82)	2.15 (7.29)
Change from baseline		
Number	46	49

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Mean (SD)	0.99 (23.54)	-7.84 (11.01)
LS Mean (SE) ^a	1.56 (2.42)	-8.03 (2.36)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-9.59 (-16.27 to -2.90)
P-value vs. Placebo+52 week taper ^a		0.0054
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.58 (-0.98 to -0.17)
Week 20		
Value		
Number	44	48
Mean (SD)	7.12 (7.66)	2.29 (5.85)
Change from baseline		
Number	44	48
Mean (SD)	-2.61 (11.39)	-8.15 (9.06)
LS Mean (SE) ^a	-2.59 (0.87)	-7.94 (0.85)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.35 (-7.76 to -2.95)
P-value vs. Placebo+52 week taper ^a		<.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.91 (-1.32 to -0.50)
Week 24		
Value		
Number	46	46
Mean (SD)	7.02 (7.84)	1.53 (3.44)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Change from baseline		
Number	46	46
Mean (SD)	-2.45 (10.55)	-8.94 (10.31)
LS Mean (SE) ^a	-2.79 (0.79)	-8.62 (0.79)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.83 (-8.06 to -3.61)
P-value vs. Placebo+52 week taper ^a		<.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.08 (-1.49 to -0.66)
Week 32		
Value		
Number	40	41
Mean (SD)	8.41 (10.43)	3.67 (11.40)
Change from baseline		
Number	40	41
Mean (SD)	-1.76 (9.58)	-6.65 (11.88)
LS Mean (SE) ^a	-1.68 (1.39)	-6.70 (1.37)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.02 (-8.89 to -1.15)
P-value vs. Placebo+52 week taper ^a		0.0114
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.57 (-1.01 to -0.13)
Week 40		
Value		

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

CRP (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Number	42	45
Mean (SD)	8.94 (10.22)	3.33 (11.68)
Change from baseline		
Number	42	45
Mean (SD)	-0.75 (9.63)	-6.89 (11.38)
LS Mean (SE) ^a	0.90 (1.51)	-7.12 (1.47)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.01 (-12.19 to -3.83)
P-value vs. Placebo+52 week taper ^a		0.0002
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.81 (-1.23 to -0.39)
Week 52		
Value		
Number	35	43
Mean (SD)	7.93 (6.11)	3.69 (12.87)
Change from baseline		
Number	35	43
Mean (SD)	-1.89 (12.57)	-6.66 (11.92)
LS Mean (SE) ^a	0.79 (1.76)	-6.31 (1.67)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.10 (-11.91 to -2.29)
P-value vs. Placebo+52 week taper ^a		0.0042
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.66 (-1.10 to -0.21)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Placebo+52 week taper	56	57	53	46	46	44	46	40	42	35
Sarilumab 200mg q2w+14 week taper	57	56	56	48	49	48	46	41	45	43

Weitere Analysen

4. Morning stiffness duration components for PMR activity score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	60
Mean (SD)	110.97 (198.22)	66.75 (64.72)
Baseline for patients with data at Week 52		
Number	46	48
Mean (SD)	106.30 (216.84)	66.35 (64.86)
Week 2		
Value		
Number	57	59
Mean (SD)	57.19 (79.10)	54.20 (78.88)
Change from baseline		
Number	57	59
Mean (SD)	-50.46 (198.07)	-12.66 (82.67)
LS Mean (SE) ^a	-31.49 (10.26)	-29.98 (10.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.51 (-27.18 to 30.20)
P-value vs. Placebo+52 week taper ^a		0.9171

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.02 (-0.35 to 0.39)
Week 4		
Value		
Number	58	57
Mean (SD)	52.67 (78.49)	43.04 (75.45)
Change from baseline		
Number	58	57
Mean (SD)	-58.29 (205.54)	-25.12 (88.11)
LS Mean (SE) ^a	-35.36 (10.12)	-42.80 (10.09)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.45 (-35.90 to 21.01)
P-value vs. Placebo+52 week taper ^a		0.6052
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.10 (-0.47 to 0.27)
Week 8		
Value		
Number	57	58
Mean (SD)	38.95 (64.69)	36.72 (73.36)
Change from baseline		
Number	57	58
Mean (SD)	-72.74 (200.78)	-30.26 (92.40)
LS Mean (SE) ^a	-49.16 (9.13)	-48.59 (9.04)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.57 (-25.03 to 26.16)
P-value vs. Placebo+52 week taper ^a		0.9651
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.01 (-0.36 to 0.38)
Week 12		
Value		
Number	52	54
Mean (SD)	28.17 (47.09)	32.31 (82.95)
Change from baseline		
Number	52	54
Mean (SD)	-76.85 (209.37)	-35.19 (106.59)
LS Mean (SE) ^a	-52.34 (10.97)	-40.75 (10.80)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		11.59 (-19.04 to 42.23)
P-value vs. Placebo+52 week taper ^a		0.4550
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.15 (-0.24 to 0.53)
Week 16		
Value		
Number	53	54
Mean (SD)	38.77 (69.76)	39.69 (107.63)
Change from baseline		
Number	53	54

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Mean (SD)	-65.40 (217.47)	-28.93 (109.08)
LS Mean (SE) ^a	-38.74 (13.97)	-36.57 (13.85)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.16 (-36.98 to 41.31)
P-value vs. Placebo+52 week taper ^a		0.9130
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.02 (-0.36 to 0.40)
Week 20		
Value		
Number	52	52
Mean (SD)	51.35 (102.93)	16.58 (56.11)
Change from baseline		
Number	52	52
Mean (SD)	-53.67 (232.41)	-51.21 (74.16)
LS Mean (SE) ^a	-29.53 (12.57)	-58.81 (12.53)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-29.29 (-64.61 to 6.03)
P-value vs. Placebo+52 week taper ^a		0.1032
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.32 (-0.71 to 0.07)
Week 24		
Value		
Number	50	52
Mean (SD)	44.14 (78.84)	16.83 (48.27)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Change from baseline		
Number	50	52
Mean (SD)	-59.08 (226.06)	-50.96 (85.61)
LS Mean (SE) ^a	-32.41 (11.56)	-53.45 (11.41)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-21.03 (-53.35 to 11.29)
P-value vs. Placebo+52 week taper ^a		0.2000
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.25 (-0.65 to 0.14)
Week 32		
Value		
Number	46	48
Mean (SD)	36.96 (78.80)	12.40 (25.07)
Change from baseline		
Number	46	48
Mean (SD)	-66.74 (232.75)	-53.96 (68.56)
LS Mean (SE) ^a	-44.31 (8.58)	-73.03 (8.42)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-28.72 (-52.62 to -4.82)
P-value vs. Placebo+52 week taper ^a		0.0189
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.49 (-0.90 to -0.08)
Week 40		
Value		

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Morning stiffness duration (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Number	44	48
Mean (SD)	29.20 (47.48)	8.81 (19.42)
Change from baseline		
Number	44	48
Mean (SD)	-73.07 (229.34)	-57.54 (65.30)
LS Mean (SE) ^a	-54.91 (5.66)	-73.68 (5.51)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-18.77 (-34.48 to -3.07)
P-value vs. Placebo+52 week taper ^a		0.0196
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.49 (-0.90 to -0.08)
Week 52		
Value		
Number	46	48
Mean (SD)	30.98 (52.19)	7.98 (20.42)
Change from baseline		
Number	46	48
Mean (SD)	-75.33 (226.09)	-58.38 (68.71)
LS Mean (SE) ^a	-53.18 (5.98)	-75.61 (5.87)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-22.43 (-39.09 to -5.77)
P-value vs. Placebo+52 week taper ^a		0.0088
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.55 (-0.96 to -0.14)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

5. Ability to elevate the upper limbs component for PMR activity score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	60
Mean (SD)	0.53 (0.68)	0.52 (0.79)
Baseline for patients with data at Week 52		
Number	46	48
Mean (SD)	0.46 (0.62)	0.52 (0.80)
Week 2		
Value		
Number	57	59
Mean (SD)	0.28 (0.62)	0.20 (0.48)
Change from baseline		
Number	57	59
Mean (SD)	-0.25 (0.81)	-0.32 (0.84)
LS Mean (SE) ^a	-0.23 (0.07)	-0.32 (0.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.09 (-0.29 to 0.11)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
P-value vs. Placebo+52 week taper ^a		0.3905
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.16 (-0.52 to 0.21)
Week 4		
Value		
Number	58	57
Mean (SD)	0.33 (0.69)	0.25 (0.61)
Change from baseline		
Number	58	57
Mean (SD)	-0.21 (0.83)	-0.30 (0.76)
LS Mean (SE) ^a	-0.20 (0.08)	-0.28 (0.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.09 (-0.31 to 0.14)
P-value vs. Placebo+52 week taper ^a		0.4405
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.14 (-0.51 to 0.22)
Week 8		
Value		
Number	57	58
Mean (SD)	0.23 (0.57)	0.10 (0.41)
Change from baseline		
Number	57	58

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Mean (SD)	-0.32 (0.85)	-0.43 (0.86)
LS Mean (SE) ^a	-0.29 (0.07)	-0.42 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.12 (-0.31 to 0.06)
P-value vs. Placebo+52 week taper ^a		0.1818
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.25 (-0.62 to 0.12)
Week 12		
Value		
Number	52	54
Mean (SD)	0.12 (0.38)	0.19 (0.52)
Change from baseline		
Number	52	54
Mean (SD)	-0.44 (0.67)	-0.33 (0.91)
LS Mean (SE) ^a	-0.38 (0.06)	-0.31 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.07 (-0.11 to 0.25)
P-value vs. Placebo+52 week taper ^a		0.4356
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.15 (-0.23 to 0.53)
Week 16		
Value		
Number	53	54

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Mean (SD)	0.21 (0.53)	0.22 (0.54)
Change from baseline		
Number	53	54
Mean (SD)	-0.34 (0.83)	-0.30 (0.88)
LS Mean (SE) ^a	-0.25 (0.08)	-0.29 (0.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.04 (-0.25 to 0.18)
P-value vs. Placebo+52 week taper ^a		0.7441
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.06 (-0.44 to 0.32)
Week 20		
Value		
Number	52	52
Mean (SD)	0.21 (0.54)	0.08 (0.27)
Change from baseline		
Number	52	52
Mean (SD)	-0.35 (0.79)	-0.42 (0.80)
LS Mean (SE) ^a	-0.25 (0.06)	-0.41 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.16 (-0.34 to 0.02)
P-value vs. Placebo+52 week taper ^a		0.0822
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.34 (-0.73 to 0.04)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Week 24		
Value		
Number	50	52
Mean (SD)	0.16 (0.47)	0.06 (0.24)
Change from baseline		
Number	50	52
Mean (SD)	-0.36 (0.66)	-0.44 (0.75)
LS Mean (SE) ^a	-0.33 (0.05)	-0.45 (0.05)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.12 (-0.26 to 0.02)
P-value vs. Placebo+52 week taper ^a		0.0833
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.34 (-0.73 to 0.05)
Week 32		
Value		
Number	46	48
Mean (SD)	0.07 (0.25)	0.06 (0.24)
Change from baseline		
Number	46	48
Mean (SD)	-0.39 (0.61)	-0.46 (0.71)
LS Mean (SE) ^a	-0.42 (0.04)	-0.44 (0.04)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.02 (-0.12 to 0.08)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
P-value vs. Placebo+52 week taper ^a		0.6938
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.08 (-0.49 to 0.33)
Week 40		
Value		
Number	45	48
Mean (SD)	0.22 (0.56)	0.10 (0.37)
Change from baseline		
Number	45	48
Mean (SD)	-0.22 (0.70)	-0.42 (0.82)
LS Mean (SE) ^a	-0.29 (0.07)	-0.43 (0.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.14 (-0.33 to 0.05)
P-value vs. Placebo+52 week taper ^a		0.1559
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.29 (-0.70 to 0.11)
Week 52		
Value		
Number	46	48
Mean (SD)	0.26 (0.53)	0.04 (0.20)
Change from baseline		
Number	46	48

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Mean (SD)	-0.20 (0.69)	-0.48 (0.82)
LS Mean (SE) ^a	-0.23 (0.06)	-0.47 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.24 (-0.40 to -0.08)
P-value vs. Placebo+52 week taper ^a		0.0044
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.60 (-1.00 to -0.19)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


Note: No imputation was used for missing values.

EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



EUL: ability to elevate the upper limbs (3=none, 2=below shoulder girdle, 1=up to shoulder girdle, 0=above shoulder girdle)

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_lsmeanchg_overt_ger_i_f.sas OUT=REPORT/OUTPUT/eff_lsmechg_lromshol_ger_o_52_i_f_x.rtf (04SEP2024 18:06)

Sarilumab (Kevzara®)

Weitere Analysen

6. MD-VAS - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

MD-VAS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	52	49
Mean (SD)	53.58 (25.13)	52.92 (23.51)
Baseline for patients with data at Week 52		
Number	31	33
Mean (SD)	48.32 (24.78)	55.03 (16.96)
Week 12		
Value		
Number	35	34
Mean (SD)	26.49 (27.03)	24.03 (23.44)
Change from baseline		
Number	35	34
Mean (SD)	-26.49 (32.37)	-27.09 (31.95)
LS Mean (SE) ^a	-25.46 (4.18)	-27.54 (4.28)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-2.08 (-13.97 to 9.81)
P-value vs. Placebo+52 week taper ^a		0.7284

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_vas0901_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

MD-VAS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.08 (-0.56 to 0.39)
Week 24		
Value		
Number	38	30
Mean (SD)	19.71 (22.20)	18.93 (20.35)
Change from baseline		
Number	38	30
Mean (SD)	-31.58 (27.40)	-33.17 (24.64)
LS Mean (SE) ^a	-28.93 (3.38)	-32.60 (3.72)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-3.67 (-13.67 to 6.32)
P-value vs. Placebo+52 week taper ^a		0.4670
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.18 (-0.66 to 0.30)
Week 52		
Value		
Number	31	33
Mean (SD)	18.97 (22.86)	10.21 (15.44)
Change from baseline		
Number	31	33
Mean (SD)	-29.35 (28.91)	-44.82 (20.62)
LS Mean (SE) ^a	-30.49 (3.46)	-40.58 (3.40)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_vas0901_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

MD-VAS (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-10.10 (-19.78 to -0.42)
P-value vs. Placebo+52 week taper ^a		0.0411
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.52 (-1.01 to -0.02)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

7. FACIT-Fatigue - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

FACIT-Fatigue (0-52) (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	59
Mean (SD)	29.17 (11.92)	31.39 (10.90)
Baseline for patients with data at Week 52		
Number	36	42
Mean (SD)	31.97 (11.92)	32.81 (10.66)
Week 12		
Value		
Number	47	47
Mean (SD)	33.89 (11.76)	35.96 (10.64)
Change from baseline		
Number	47	47
Mean (SD)	5.38 (11.28)	3.51 (8.94)
LS Mean (SE) ^a	4.11 (1.33)	4.04 (1.31)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.07 (-3.78 to 3.65)
P-value vs. Placebo+52 week taper ^a		0.9721

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_fatigue_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.01 (-0.41 to 0.40)
Week 24		
Value		
Number	43	41
Mean (SD)	35.81 (11.30)	37.56 (9.60)
Change from baseline		
Number	43	41
Mean (SD)	4.44 (8.54)	3.80 (10.09)
LS Mean (SE) ^a	3.94 (1.25)	4.40 (1.28)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.46 (-3.09 to 4.01)
P-value vs. Placebo+52 week taper ^a		0.7969
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.06 (-0.37 to 0.49)
Week 52		
Value		
Number	36	42
Mean (SD)	36.78 (10.87)	40.74 (9.29)
Change from baseline		
Number	36	42
Mean (SD)	4.81 (10.95)	7.93 (9.55)
LS Mean (SE) ^a	4.17 (1.42)	7.91 (1.33)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		3.74 (-0.11 to 7.59)
P-value vs. Placebo+52 week taper ^a		0.0567
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.43 (-0.01 to 0.88)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

8. EQ-5D VAS - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

VAS for EQ-5D (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	54.24 (22.15)	58.48 (21.63)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	58.60 (19.83)	61.19 (20.43)
Week 12		
Value		
Number	47	46
Mean (SD)	58.60 (22.48)	65.85 (18.47)
Change from baseline		
Number	47	46
Mean (SD)	4.04 (28.75)	6.33 (26.43)
LS Mean (SE) ^a	0.12 (2.94)	6.47 (2.96)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.35 (-1.93 to 14.63)
P-value vs. Placebo+52 week taper ^a		0.1311

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

VAS for EQ-5D (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.31 (-0.10 to 0.72)
Week 24		
Value		
Number	43	41
Mean (SD)	63.98 (23.35)	68.39 (22.25)
Change from baseline		
Number	43	41
Mean (SD)	3.79 (29.86)	5.59 (25.97)
LS Mean (SE) ^a	2.55 (3.37)	7.31 (3.45)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		4.75 (-4.80 to 14.31)
P-value vs. Placebo+52 week taper ^a		0.3258
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.21 (-0.22 to 0.64)
Week 52		
Value		
Number	35	42
Mean (SD)	61.94 (22.13)	68.95 (23.19)
Change from baseline		
Number	35	42
Mean (SD)	3.34 (26.85)	7.76 (29.37)
LS Mean (SE) ^a	-0.46 (3.68)	8.37 (3.46)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

VAS for EQ-5D (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		8.83 (-1.19 to 18.85)
P-value vs. Placebo+52 week taper ^a		0.0835
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.40 (-0.05 to 0.85)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

9. HAQ-DI standardized score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI standardized score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.15 (0.75)	1.14 (0.74)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.95 (0.77)	1.14 (0.69)
Week 12		
Value		
Number	47	46
Mean (SD)	0.86 (0.79)	0.76 (0.58)
Change from baseline		
Number	47	46
Mean (SD)	-0.33 (0.67)	-0.36 (0.62)
LS Mean (SE) ^a	-0.30 (0.08)	-0.36 (0.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.06 (-0.29 to 0.16)
P-value vs. Placebo+52 week taper ^a		0.5824

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.11 (-0.52 to 0.29)
Week 24		
Value		
Number	43	41
Mean (SD)	0.81 (0.74)	0.64 (0.56)
Change from baseline		
Number	43	41
Mean (SD)	-0.20 (0.51)	-0.38 (0.63)
LS Mean (SE) ^a	-0.18 (0.08)	-0.36 (0.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.18 (-0.40 to 0.04)
P-value vs. Placebo+52 week taper ^a		0.1131
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.35 (-0.77 to 0.08)
Week 52		
Value		
Number	35	42
Mean (SD)	0.76 (0.65)	0.69 (0.64)
Change from baseline		
Number	35	42
Mean (SD)	-0.20 (0.65)	-0.45 (0.68)
LS Mean (SE) ^a	-0.15 (0.09)	-0.39 (0.09)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.25 (-0.50 to 0.00)
P-value vs. Placebo+52 week taper ^a		0.0543
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.44 (-0.89 to 0.01)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

10. HAQ-DI pain score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI pain score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	54.79 (23.20)	45.07 (28.31)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	54.34 (23.55)	44.05 (25.42)
Week 12		
Value		
Number	47	46
Mean (SD)	39.09 (26.86)	34.83 (26.75)
Change from baseline		
Number	47	46
Mean (SD)	-15.96 (33.58)	-9.02 (38.87)
LS Mean (SE) ^a	-10.20 (3.97)	-13.96 (3.99)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-3.76 (-15.04 to 7.52)
P-value vs. Placebo+52 week taper ^a		0.5098

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

HAQ-DI pain score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.14 (-0.55 to 0.28)
Week 24		
Value		
Number	43	41
Mean (SD)	35.00 (25.99)	29.66 (23.92)
Change from baseline		
Number	43	41
Mean (SD)	-18.63 (30.99)	-12.05 (31.42)
LS Mean (SE) ^a	-13.22 (3.82)	-17.73 (3.94)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.52 (-15.56 to 6.53)
P-value vs. Placebo+52 week taper ^a		0.4194
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.18 (-0.61 to 0.26)
Week 52		
Value		
Number	35	42
Mean (SD)	35.00 (26.53)	27.02 (26.29)
Change from baseline		
Number	35	42
Mean (SD)	-19.34 (36.31)	-17.02 (33.75)
LS Mean (SE) ^a	-12.04 (4.49)	-20.57 (4.13)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

HAQ-DI pain score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.53 (-20.78 to 3.71)
P-value vs. Placebo+52 week taper ^a		0.1698
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.32 (-0.77 to 0.14)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_o_52_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

11. HAQ-DI patient global assessment score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI patient global assessment score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	50.57 (25.22)	44.55 (25.74)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	46.60 (24.79)	42.88 (24.06)
Week 12		
Value		
Number	47	46
Mean (SD)	38.62 (24.30)	39.65 (24.06)
Change from baseline		
Number	47	46
Mean (SD)	-11.23 (30.99)	-2.67 (30.42)
LS Mean (SE) ^a	-7.91 (3.41)	-5.00 (3.43)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.91 (-6.72 to 12.55)
P-value vs. Placebo+52 week taper ^a		0.5499

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.12 (-0.29 to 0.53)
Week 24		
Value		
Number	43	41
Mean (SD)	38.28 (26.47)	30.66 (25.29)
Change from baseline		
Number	43	41
Mean (SD)	-8.67 (24.51)	-9.95 (29.31)
LS Mean (SE) ^a	-5.43 (3.64)	-10.34 (3.74)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.91 (-15.30 to 5.48)
P-value vs. Placebo+52 week taper ^a		0.3507
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.20 (-0.64 to 0.23)
Week 52		
Value		
Number	35	42
Mean (SD)	37.63 (26.48)	28.60 (25.46)
Change from baseline		
Number	35	42
Mean (SD)	-8.97 (35.58)	-14.29 (32.13)
LS Mean (SE) ^a	-6.08 (4.33)	-15.01 (4.00)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.93 (-20.65 to 2.79)
P-value vs. Placebo+52 week taper ^a		0.1337
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.34 (-0.79 to 0.11)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

12. HAQ-DI Activities Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Activities Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.48 (0.98)	1.43 (0.94)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	1.37 (1.06)	1.38 (0.91)
Week 12		
Value		
Number	47	46
Mean (SD)	1.26 (1.09)	1.17 (0.82)
Change from baseline		
Number	47	46
Mean (SD)	-0.32 (0.98)	-0.22 (0.94)
LS Mean (SE) ^a	-0.22 (0.12)	-0.23 (0.12)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.01 (-0.36 to 0.33)
P-value vs. Placebo+52 week taper ^a		0.9457

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haact_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

HAQ-DI Activities Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.01 (-0.42 to 0.39)
Week 24		
Value		
Number	43	41
Mean (SD)	0.95 (1.07)	0.98 (0.88)
Change from baseline		
Number	43	41
Mean (SD)	-0.42 (0.79)	-0.29 (0.96)
LS Mean (SE) ^a	-0.39 (0.12)	-0.29 (0.12)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.10 (-0.24 to 0.45)
P-value vs. Placebo+52 week taper ^a		0.5473
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.13 (-0.30 to 0.56)
Week 52		
Value		
Number	35	42
Mean (SD)	1.09 (1.01)	1.02 (0.92)
Change from baseline		
Number	35	42
Mean (SD)	-0.29 (0.83)	-0.36 (1.06)
LS Mean (SE) ^a	-0.16 (0.13)	-0.33 (0.13)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haact_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

HAQ-DI Activities Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.17 (-0.54 to 0.19)
P-value vs. Placebo+52 week taper ^a		0.3477
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.21 (-0.66 to 0.24)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqact_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

13. HAQ-DI Arising Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Arising Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.09 (0.86)	1.12 (0.82)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.94 (0.87)	1.10 (0.79)
Week 12		
Value		
Number	47	46
Mean (SD)	0.64 (0.76)	0.65 (0.74)
Change from baseline		
Number	47	46
Mean (SD)	-0.47 (0.80)	-0.46 (0.91)
LS Mean (SE) ^a	-0.46 (0.10)	-0.43 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.03 (-0.25 to 0.31)
P-value vs. Placebo+52 week taper ^a		0.8373

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqari_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Arising Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.04 (-0.37 to 0.45)
Week 24		
Value		
Number	43	41
Mean (SD)	0.74 (0.85)	0.76 (0.70)
Change from baseline		
Number	43	41
Mean (SD)	-0.23 (0.92)	-0.27 (0.90)
LS Mean (SE) ^a	-0.23 (0.11)	-0.24 (0.12)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.00 (-0.32 to 0.32)
P-value vs. Placebo+52 week taper ^a		0.9788
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.01 (-0.44 to 0.42)
Week 52		
Value		
Number	35	42
Mean (SD)	0.74 (0.78)	0.64 (0.73)
Change from baseline		
Number	35	42
Mean (SD)	-0.20 (1.08)	-0.45 (0.89)
LS Mean (SE) ^a	-0.22 (0.12)	-0.41 (0.11)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqari_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Arising Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.18 (-0.52 to 0.15)
P-value vs. Placebo+52 week taper ^a		0.2809
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.25 (-0.70 to 0.20)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqari_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

14. HAQ-DI Dressing and grooming Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Dressing and grooming Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.16 (0.91)	1.05 (0.98)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.86 (0.88)	1.02 (0.90)
Week 12		
Value		
Number	47	46
Mean (SD)	0.81 (0.95)	0.59 (0.72)
Change from baseline		
Number	47	46
Mean (SD)	-0.36 (0.90)	-0.50 (0.96)
LS Mean (SE) ^a	-0.29 (0.11)	-0.46 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.17 (-0.47 to 0.14)
P-value vs. Placebo+52 week taper ^a		0.2744

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdre_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Dressing and grooming Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.23 (-0.63 to 0.18)
Week 24		
Value		
Number	43	41
Mean (SD)	0.67 (0.84)	0.49 (0.71)
Change from baseline		
Number	43	41
Mean (SD)	-0.30 (0.83)	-0.44 (0.95)
LS Mean (SE) ^a	-0.24 (0.11)	-0.47 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.23 (-0.54 to 0.08)
P-value vs. Placebo+52 week taper ^a		0.1483
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.32 (-0.74 to 0.11)
Week 52		
Value		
Number	35	42
Mean (SD)	0.57 (0.74)	0.60 (0.83)
Change from baseline		
Number	35	42
Mean (SD)	-0.29 (0.96)	-0.43 (1.11)
LS Mean (SE) ^a	-0.19 (0.13)	-0.43 (0.12)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdre_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Dressing and grooming Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.24 (-0.59 to 0.11)
P-value vs. Placebo+52 week taper ^a		0.1787
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.31 (-0.76 to 0.14)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdre_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

15. HAQ-DI Eating Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Eating Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	0.95 (0.93)	0.84 (0.93)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.83 (1.01)	0.86 (0.90)
Week 12		
Value		
Number	47	46
Mean (SD)	0.64 (0.82)	0.57 (0.75)
Change from baseline		
Number	47	46
Mean (SD)	-0.38 (0.92)	-0.26 (1.00)
LS Mean (SE) ^a	-0.30 (0.11)	-0.31 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.01 (-0.31 to 0.29)
P-value vs. Placebo+52 week taper ^a		0.9529

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqeat_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Eating Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.01 (-0.42 to 0.40)
Week 24		
Value		
Number	43	41
Mean (SD)	0.60 (0.95)	0.41 (0.59)
Change from baseline		
Number	43	41
Mean (SD)	-0.26 (0.69)	-0.34 (0.73)
LS Mean (SE) ^a	-0.26 (0.09)	-0.37 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.11 (-0.38 to 0.15)
P-value vs. Placebo+52 week taper ^a		0.4008
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.18 (-0.61 to 0.25)
Week 52		
Value		
Number	35	42
Mean (SD)	0.71 (1.02)	0.48 (0.63)
Change from baseline		
Number	35	42
Mean (SD)	-0.11 (0.87)	-0.38 (0.88)
LS Mean (SE) ^a	-0.08 (0.12)	-0.37 (0.11)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqeat_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Eating Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.28 (-0.60 to 0.03)
P-value vs. Placebo+52 week taper ^a		0.0799
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.40 (-0.85 to 0.05)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqeat_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

16. HAQ-DI Grip Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Grip Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.00 (0.94)	1.05 (0.96)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.86 (0.94)	1.12 (0.94)
Week 12		
Value		
Number	47	46
Mean (SD)	0.68 (0.96)	0.74 (0.88)
Change from baseline		
Number	47	46
Mean (SD)	-0.34 (1.09)	-0.30 (1.15)
LS Mean (SE) ^a	-0.35 (0.13)	-0.29 (0.13)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.06 (-0.30 to 0.42)
P-value vs. Placebo+52 week taper ^a		0.7250

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqgri_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Grip Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.07 (-0.34 to 0.48)
Week 24		
Value		
Number	43	41
Mean (SD)	0.74 (0.88)	0.29 (0.56)
Change from baseline		
Number	43	41
Mean (SD)	-0.16 (0.97)	-0.71 (1.08)
LS Mean (SE) ^a	-0.18 (0.11)	-0.66 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.48 (-0.79 to -0.18)
P-value vs. Placebo+52 week taper ^a		0.0023
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.68 (-1.11 to -0.25)
Week 52		
Value		
Number	35	42
Mean (SD)	0.51 (0.74)	0.55 (0.86)
Change from baseline		
Number	35	42
Mean (SD)	-0.34 (0.91)	-0.57 (1.02)
LS Mean (SE) ^a	-0.28 (0.13)	-0.46 (0.12)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqgri_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Grip Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.18 (-0.52 to 0.17)
P-value vs. Placebo+52 week taper ^a		0.3076
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.23 (-0.68 to 0.22)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqgri_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

17. HAQ-DI Hygiene Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Hygiene Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.17 (1.16)	1.26 (1.04)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.77 (1.03)	1.24 (0.98)
Week 12		
Value		
Number	47	46
Mean (SD)	0.94 (1.19)	0.87 (1.00)
Change from baseline		
Number	47	46
Mean (SD)	-0.32 (0.75)	-0.37 (0.77)
LS Mean (SE) ^a	-0.30 (0.10)	-0.36 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.06 (-0.35 to 0.22)
P-value vs. Placebo+52 week taper ^a		0.6595

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqhyg_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Hygiene Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.09 (-0.50 to 0.32)
Week 24		
Value		
Number	43	41
Mean (SD)	0.84 (1.11)	0.83 (1.02)
Change from baseline		
Number	43	41
Mean (SD)	-0.12 (0.93)	-0.27 (1.03)
LS Mean (SE) ^a	-0.15 (0.13)	-0.23 (0.14)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.08 (-0.46 to 0.30)
P-value vs. Placebo+52 week taper ^a		0.6717
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.09 (-0.52 to 0.34)
Week 52		
Value		
Number	35	42
Mean (SD)	0.94 (1.11)	0.74 (0.99)
Change from baseline		
Number	35	42
Mean (SD)	0.17 (0.98)	-0.50 (0.77)
LS Mean (SE) ^a	0.11 (0.14)	-0.44 (0.12)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqhyg_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Hygiene Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.56 (-0.92 to -0.19)
P-value vs. Placebo+52 week taper ^a		0.0034
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.69 (-1.14 to -0.23)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqhyg_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

18. HAQ-DI Reach Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Reaching Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	1.40 (0.97)	1.48 (1.00)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	1.26 (0.98)	1.55 (0.94)
Week 12		
Value		
Number	47	46
Mean (SD)	1.19 (1.04)	1.02 (0.83)
Change from baseline		
Number	47	46
Mean (SD)	-0.23 (0.94)	-0.46 (0.84)
LS Mean (SE) ^a	-0.23 (0.11)	-0.44 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.21 (-0.52 to 0.11)
P-value vs. Placebo+52 week taper ^a		0.1927

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqrea_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Reaching Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.27 (-0.68 to 0.14)
Week 24		
Value		
Number	43	41
Mean (SD)	1.19 (1.03)	0.95 (0.89)
Change from baseline		
Number	43	41
Mean (SD)	-0.05 (1.00)	-0.44 (1.03)
LS Mean (SE) ^a	-0.09 (0.13)	-0.41 (0.14)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.32 (-0.70 to 0.06)
P-value vs. Placebo+52 week taper ^a		0.0938
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.37 (-0.80 to 0.06)
Week 52		
Value		
Number	35	42
Mean (SD)	0.89 (0.99)	0.81 (0.77)
Change from baseline		
Number	35	42
Mean (SD)	-0.37 (0.88)	-0.74 (1.01)
LS Mean (SE) ^a	-0.35 (0.13)	-0.63 (0.12)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqrea_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Reaching Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.28 (-0.64 to 0.08)
P-value vs. Placebo+52 week taper ^a		0.1266
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.35 (-0.80 to 0.10)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqrea_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

19. HAQ-DI Walking Item score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

HAQ-DI Walking Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	0.95 (0.80)	0.84 (0.79)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	0.74 (0.74)	0.83 (0.76)
Week 12		
Value		
Number	47	46
Mean (SD)	0.72 (0.97)	0.50 (0.72)
Change from baseline		
Number	47	46
Mean (SD)	-0.19 (1.01)	-0.35 (0.71)
LS Mean (SE) ^a	-0.15 (0.11)	-0.34 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.19 (-0.50 to 0.13)
P-value vs. Placebo+52 week taper ^a		0.2357

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqwal_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Walking Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.25 (-0.65 to 0.16)
Week 24		
Value		
Number	43	41
Mean (SD)	0.70 (0.83)	0.44 (0.59)
Change from baseline		
Number	43	41
Mean (SD)	-0.09 (0.84)	-0.32 (0.69)
LS Mean (SE) ^a	-0.08 (0.10)	-0.32 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.24 (-0.52 to 0.04)
P-value vs. Placebo+52 week taper ^a		0.0895
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.37 (-0.80 to 0.06)
Week 52		
Value		
Number	35	42
Mean (SD)	0.60 (0.65)	0.67 (0.82)
Change from baseline		
Number	35	42
Mean (SD)	-0.14 (0.81)	-0.17 (0.73)
LS Mean (SE) ^a	-0.17 (0.11)	-0.14 (0.10)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqwal_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

HAQ-DI Walking Item score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.03 (-0.27 to 0.33)
P-value vs. Placebo+52 week taper ^a		0.8460
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.04 (-0.41 to 0.49)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqwal_ger_o_52_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

20. SF-36 mental component summary score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

SF-36-mental component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	44.99 (13.01)	46.83 (11.60)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	46.25 (13.26)	47.51 (11.69)
Week 12		
Value		
Number	47	47
Mean (SD)	46.27 (12.38)	47.67 (11.33)
Change from baseline		
Number	47	47
Mean (SD)	0.83 (12.18)	1.29 (9.34)
LS Mean (SE) ^a	0.33 (1.33)	1.18 (1.33)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.84 (-2.89 to 4.57)
P-value vs. Placebo+52 week taper ^a		0.6561

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.09 (-0.31 to 0.50)
Week 24		
Value		
Number	43	41
Mean (SD)	47.54 (12.98)	51.28 (11.34)
Change from baseline		
Number	43	41
Mean (SD)	1.49 (8.65)	2.74 (10.35)
LS Mean (SE) ^a	0.54 (1.44)	3.39 (1.47)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.84 (-1.24 to 6.93)
P-value vs. Placebo+52 week taper ^a		0.1706
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.30 (-0.13 to 0.73)
Week 52		
Value		
Number	35	42
Mean (SD)	46.81 (12.39)	50.83 (9.75)
Change from baseline		
Number	35	42
Mean (SD)	0.56 (12.80)	3.32 (9.84)
LS Mean (SE) ^a	-1.71 (1.57)	3.04 (1.47)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		4.75 (0.48 to 9.01)
P-value vs. Placebo+52 week taper ^a		0.0295
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.50 (0.05 to 0.95)


^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)



Weitere Analysen

21. SF-36 physical component summary score - ITT population***Analysis of change from baseline over time up to week 52 (MMRM - as-observed)***

SF-36-physical component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Baseline		
Number	58	58
Mean (SD)	33.56 (9.62)	35.15 (9.74)
Baseline for patients with data at Week 52		
Number	35	42
Mean (SD)	36.36 (8.38)	35.76 (8.58)
Week 12		
Value		
Number	47	47
Mean (SD)	38.01 (10.48)	40.55 (8.72)
Change from baseline		
Number	47	47
Mean (SD)	4.84 (9.02)	4.68 (9.89)
LS Mean (SE) ^a	3.84 (1.23)	5.24 (1.22)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.40 (-2.05 to 4.85)
P-value vs. Placebo+52 week taper ^a		0.4232

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.17 (-0.24 to 0.57)
Week 24		
Value		
Number	43	41
Mean (SD)	39.82 (9.22)	42.35 (9.13)
Change from baseline		
Number	43	41
Mean (SD)	4.40 (9.09)	5.41 (9.11)
LS Mean (SE) ^a	3.88 (1.22)	5.74 (1.26)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.85 (-1.63 to 5.33)
P-value vs. Placebo+52 week taper ^a		0.2938
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.23 (-0.20 to 0.66)
Week 52		
Value		
Number	35	42
Mean (SD)	39.44 (8.11)	43.67 (9.99)
Change from baseline		
Number	35	42
Mean (SD)	3.08 (10.77)	7.91 (10.04)
LS Mean (SE) ^a	2.87 (1.45)	7.65 (1.34)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen


SF-36-physical component summary score (MMRM)	Placebo+52 week taper (N=58)	Sarilumab 200mg q2w+14 week taper (N=60)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		4.78 (0.87 to 8.70)
P-value vs. Placebo+52 week taper ^a		0.0172
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.55 (0.10 to 1.00)

^a Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_allwk_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_o_52_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LS Mean change from baseline over time up to week 52 (MMRM - as-observed)

Placebo+52 week taper	47	43	35
Sarilumab 200mg q2w+14 week taper	47	41	42

EFC15160_Germany_continuous_subgroup_16SEP24

Weitere Analysen

1. Cumulative corticosteroid dose***Analysis of cumulative corticosteroid dose during treatment period - ITT population******Per gender***

Corticosteroid dose	Gender			
	Male (N=36)		Female (N=82)	
	Placebo+52 week taper (N=21)	Sarilumab 200mg q2w+14 week taper (N=15)	Placebo+52 week taper (N=37)	Sarilumab 200mg q2w+14 week taper (N=45)
Expected cumulative CS dose (mg) ^a				
Number	21	14	37	45
Mean (SD)	1757.8 (566.4)	737.5 (147.8)	1793.6 (428.5)	743.3 (81.8)
SE	123.59	39.50	70.44	12.19
Median (95% CI)	2044.0 (1950.0 , 2044.0)	777.0 (1920.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1950.0 ; 2044.0	777.0 ; 777.0	1650.0 ; 2044.0	777.0 ; 777.0
Min ; Max	404 ; 2044	224 ; 777	640 ; 2044	452 ; 777
Actual cumulative CS dose (mg) ^b				
Number	21	14	37	45

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_gender_i_t_x.rtf (05SEP2024 9:32)

Weitere Analysen

Corticosteroid dose	Gender			
	Male (N=36)		Female (N=82)	
	Placebo+52 week taper (N=21)	Sarilumab 200mg q2w+14 week taper (N=15)	Placebo+52 week taper (N=37)	Sarilumab 200mg q2w+14 week taper (N=45)
Mean (SD)	2192.1 (927.5)	1068.8 (725.5)	2260.5 (797.4)	1030.4 (581.5)
SE	202.40	193.89	131.09	86.68
Median (95% CI)	2044.0	777.0	2044.0	777.0
Q1 ; Q3	1950.0 ; 2840.0	777.0 ; 916.0	2034.0 ; 2813.8	777.0 ; 1018.5
Min ; Max	404 ; 3676	224 ; 2885	640 ; 3664	440 ; 2796
P-value vs. Placebo+52 week taper ^c		0.0015		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	21	14	37	45
Mean (SD)	434.3 (557.3)	331.3 (690.1)	467.0 (550.2)	287.1 (561.8)
SE	121.62	184.45	90.46	83.74
Median (95% CI)	203.0 (0.0 , 799.0)	0.0 (0.0 , 759.0)	197.0 (0.0 , 745.0)	0.0 (0.0 , 15.0)
Q1 ; Q3	0.0 ; 799.0	0.0 ; 139.0	0.0 ; 846.0	0.0 ; 245.0
Min ; Max	-57 ; 1632	0 ; 2108	0 ; 1622	-13 ; 2019
P-value vs. Placebo+52 week taper ^c		0.2964		0.0353

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_gender_i_t_x.rtf (05SEP2024 9:32)

Weitere Analysen

Per race

Corticosteroid dose	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo+52 week taper (N=48)	Sarilumab 200mg q2w+14 week taper (N=50)	Placebo+52 week taper (N=10)	Sarilumab 200mg q2w+14 week taper (N=10)
Expected cumulative CS dose (mg) ^a				
Number	48	50	10	9
Mean (SD)	1773.1 (475.5)	744.4 (101.0)	1816.4 (516.2)	728.1 (97.8)
SE	68.64	14.29	163.25	32.58
Median (95% CI)	2043.5 (2006.0 , 2044.0)	777.0 (1615.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (581.0 , 777.0)
Q1 ; Q3	1715.0 ; 2044.0	777.0 ; 777.0	1837.0 ; 2044.0	777.0 ; 777.0
Min ; Max	590 ; 2044	224 ; 777	404 ; 2044	533 ; 777
Actual cumulative CS dose (mg) ^b				
Number	48	50	10	9
Mean (SD)	2239.4 (850.0)	1007.5 (600.1)	2218.4 (829.7)	1217.3 (684.9)
SE	122.69	84.87	262.36	228.29
Median (95% CI)	2044.0	777.0	2044.0	777.0
Q1 ; Q3	1815.5 ; 2895.3	777.0 ; 906.0	2044.0 ; 2540.0	777.0 ; 1824.0
Min ; Max	620 ; 3664	224 ; 2885	404 ; 3676	548 ; 2424

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_race_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo+52 week taper (N=48)	Sarilumab 200mg q2w+14 week taper (N=50)	Placebo+52 week taper (N=10)	Sarilumab 200mg q2w+14 week taper (N=10)
P-value vs. Placebo+52 week taper ^c		<.0001		0.0120
Difference between actual and expected cumulative CS dose (mg)				
Number	48	50	10	9
Mean (SD)	466.2 (552.0)	263.1 (576.5)	402.0 (554.7)	489.2 (654.3)
SE	79.68	81.52	175.40	218.09
Median (95% CI)	202.5 (0.0 , 742.5)	0.0 (0.0 , 855.0)	98.5 (0.0 , 0.0)	15.0 (0.0 , 1256.0)
Q1 ; Q3	0.0 ; 876.8	0.0 ; 134.0	0.0 ; 840.0	0.0 ; 1047.0
Min ; Max	-57 ; 1622	-13 ; 2108	0 ; 1632	0 ; 1647
P-value vs. Placebo+52 week taper ^c		0.0050		0.6408

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_race_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo+52 week taper (N=44)	Sarilumab 200mg q2w+14 week taper (N=47)	Placebo+52 week taper (N=14)	Sarilumab 200mg q2w+14 week taper (N=13)
Corticosteroid dose				
Expected cumulative CS dose (mg) ^a				
Number	44	46	14	13
Mean (SD)	1742.6 (502.2)	748.3 (77.3)	1899.9 (385.8)	719.4 (158.4)
SE	75.71	11.40	103.11	43.93
Median (95% CI)	2042.0 (1942.0 , 2044.0)	777.0 (2044.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1632.5 ; 2044.0	777.0 ; 777.0	2044.0 ; 2044.0	777.0 ; 777.0
Min ; Max	404 ; 2044	452 ; 777	640 ; 2044	224 ; 777
Actual cumulative CS dose (mg) ^b				
Number	44	46	14	13
Mean (SD)	2245.5 (896.3)	1050.5 (595.1)	2205.1 (656.2)	1000.8 (693.7)
SE	135.12	87.74	175.38	192.40
Median (95% CI)	2044.0	777.0	2044.0	777.0
Q1 ; Q3	1815.5 ; 3010.0	777.0 ; 1018.5	2044.0 ; 2553.0	777.0 ; 827.0
Min ; Max	404 ; 3676	440 ; 2796	640 ; 3455	224 ; 2885

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_region_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo+52 week taper (N=44)	Sarilumab 200mg q2w+14 week taper (N=47)	Placebo+52 week taper (N=14)	Sarilumab 200mg q2w+14 week taper (N=13)
P-value vs. Placebo+52 week taper ^c		<.0001		0.0009
Difference between actual and expected cumulative CS dose (mg)				
Number	44	46	14	13
Mean (SD)	502.9 (573.9)	302.1 (578.1)	305.2 (442.9)	281.4 (648.8)
SE	86.51	85.24	118.38	179.96
Median (95% CI)	202.5 (13.0 , 769.8)	0.0 (0.0 , 759.0)	0.0 (0.0 , 15.0)	0.0 (0.0 , 245.0)
Q1 ; Q3	0.0 ; 967.5	0.0 ; 322.0	0.0 ; 509.0	0.0 ; 50.0
Min ; Max	-57 ; 1632	-13 ; 2019	0 ; 1411	0 ; 2108
P-value vs. Placebo+52 week taper ^c		0.0194		0.5196

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_region_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
Corticosteroid dose	Placebo+52 week taper (N=25)	Sarilumab 200mg q2w+14 week taper (N=34)	Placebo+52 week taper (N=33)	Sarilumab 200mg q2w+14 week taper (N=26)
Expected cumulative CS dose (mg) ^a				
Number	25	34	33	25
Mean (SD)	1765.1 (518.0)	739.0 (116.2)	1792.4 (453.8)	745.9 (74.2)
SE	103.61	19.93	79.00	14.84
Median (95% CI)	2044.0 (1920.0 , 2044.0)	777.0 (1942.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1792.0 ; 2044.0	777.0 ; 777.0	1780.0 ; 2044.0	777.0 ; 777.0
Min ; Max	404 ; 2044	224 ; 777	590 ; 2044	533 ; 777
Actual cumulative CS dose (mg) ^b				
Number	25	34	33	25
Mean (SD)	2366.2 (940.9)	892.6 (448.5)	2136.9 (753.4)	1239.4 (746.3)
SE	188.18	76.91	131.15	149.25
Median (95% CI)	2444.5	777.0	2044.0	777.0
Q1 ; Q3	2044.0 ; 3069.5	777.0 ; 827.0	1950.0 ; 2540.0	777.0 ; 1824.0
Min ; Max	404 ; 3676	224 ; 2885	620 ; 3664	548 ; 2796

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_age_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo+52 week taper (N=25)	Sarilumab 200mg q2w+14 week taper (N=34)	Placebo+52 week taper (N=33)	Sarilumab 200mg q2w+14 week taper (N=26)
P-value vs. Placebo+52 week taper ^c		<.0001		0.0002
Difference between actual and expected cumulative CS dose (mg)				
Number	25	34	33	25
Mean (SD)	601.2 (584.6)	153.6 (418.8)	344.5 (499.6)	493.4 (725.9)
SE	116.91	71.82	86.97	145.17
Median (95% CI)	480.0 (0.0 , 907.5)	0.0 (0.0 , 306.0)	30.0 (0.0 , 0.0)	0.0 (0.0 , 763.8)
Q1 ; Q3	0.0 ; 1027.5	0.0 ; 50.0	0.0 ; 509.0	0.0 ; 1047.0
Min ; Max	-57 ; 1632	-13 ; 2108	0 ; 1622	0 ; 2019
P-value vs. Placebo+52 week taper ^c		0.0021		0.9866

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_age_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per baseline CRP

Corticosteroid dose	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo+52 week taper (N=31)	Sarilumab 200mg q2w+14 week taper (N=28)	Placebo+52 week taper (N=27)	Sarilumab 200mg q2w+14 week taper (N=32)
Expected cumulative CS dose (mg) ^a				
Number	31	27	27	32
Mean (SD)	1781.4 (463.8)	739.3 (122.9)	1779.7 (503.4)	744.2 (77.3)
SE	83.30	23.66	96.87	13.67
Median (95% CI)	2042.0 (1837.0 , 2044.0)	777.0 (2042.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1780.0 ; 2044.0	777.0 ; 777.0	1615.0 ; 2044.0	777.0 ; 777.0
Min ; Max	590 ; 2044	224 ; 777	404 ; 2044	533 ; 777
Actual cumulative CS dose (mg) ^b				
Number	31	27	27	32
Mean (SD)	2312.7 (893.8)	1149.0 (724.3)	2147.5 (779.5)	947.1 (491.8)
SE	160.54	139.39	150.01	86.94
Median (95% CI)	2044.0	777.0	2044.0	777.0
Q1 ; Q3	1851.0 ; 3152.0	777.0 ; 1522.0	2044.0 ; 2813.8	777.0 ; 854.5
Min ; Max	620 ; 3676	224 ; 2885	404 ; 3455	548 ; 2424

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_crp_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo+52 week taper (N=31)	Sarilumab 200mg q2w+14 week taper (N=28)	Placebo+52 week taper (N=27)	Sarilumab 200mg q2w+14 week taper (N=32)
P-value vs. Placebo+52 week taper ^c		<.0001		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	31	27	27	32
Mean (SD)	531.2 (612.2)	409.8 (690.7)	367.8 (459.8)	202.9 (477.5)
SE	109.96	132.92	88.49	84.41
Median (95% CI)	259.0 (0.0 , 846.0)	0.0 (0.0 , 769.8)	15.0 (0.0 , 420.0)	0.0 (0.0 , 15.0)
Q1 ; Q3	0.0 ; 1108.0	0.0 ; 745.0	0.0 ; 799.0	0.0 ; 77.5
Min ; Max	-57 ; 1632	-13 ; 2108	0 ; 1411	0 ; 1647
P-value vs. Placebo+52 week taper ^c		0.1504		0.0939

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_crp_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
Corticosteroid dose	Placebo+52 week taper (N=31)	Sarilumab 200mg q2w+14 week taper (N=28)	Placebo+52 week taper (N=27)	Sarilumab 200mg q2w+14 week taper (N=32)
Expected cumulative CS dose (mg) ^a				
Number	31	27	27	32
Mean (SD)	1804.5 (429.4)	764.8 (62.5)	1753.1 (536.1)	722.7 (120.6)
SE	77.12	12.03	103.17	21.32
Median (95% CI)	2042.0 (1837.0 , 2044.0)	777.0 (2041.0 , 2044.0)	2044.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1780.0 ; 2044.0	777.0 ; 777.0	1555.0 ; 2044.0	777.0 ; 777.0
Min ; Max	718 ; 2044	452 ; 777	404 ; 2044	224 ; 777
Actual cumulative CS dose (mg) ^b				
Number	31	27	27	32
Mean (SD)	2348.2 (813.7)	1067.2 (590.5)	2106.6 (865.0)	1016.2 (638.3)
SE	146.14	113.64	166.47	112.84
Median (95% CI)	2303.0	777.0	2044.0	777.0
Q1 ; Q3	2034.0 ; 3069.5	777.0 ; 916.0	1705.5 ; 2840.0	777.0 ; 1020.3
Min ; Max	718 ; 3676	440 ; 2796	404 ; 3664	224 ; 2885

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_esr_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo+52 week taper (N=31)	Sarilumab 200mg q2w+14 week taper (N=28)	Placebo+52 week taper (N=27)	Sarilumab 200mg q2w+14 week taper (N=32)
P-value vs. Placebo+52 week taper ^c		<.0001		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	31	27	27	32
Mean (SD)	543.7 (565.1)	302.5 (580.4)	353.5 (519.8)	293.5 (604.8)
SE	101.49	111.69	100.03	106.91
Median (95% CI)	306.0 (107.0 , 840.0)	0.0 (0.0 , 759.0)	0.0 (0.0 , 134.0)	0.0 (0.0 , 50.0)
Q1 ; Q3	0.0 ; 1027.5	0.0 ; 139.0	0.0 ; 799.0	0.0 ; 283.5
Min ; Max	-57 ; 1632	-13 ; 2019	0 ; 1622	0 ; 2108
P-value vs. Placebo+52 week taper ^c		0.0169		0.4515

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_esr_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
Corticosteroid dose	Placebo+52 week taper (N=34)	Sarilumab 200mg q2w+14 week taper (N=30)	Placebo+52 week taper (N=24)	Sarilumab 200mg q2w+14 week taper (N=30)
Expected cumulative CS dose (mg) ^a				
Number	34	30	24	29
Mean (SD)	1844.3 (402.6)	755.3 (66.6)	1690.4 (565.7)	728.2 (125.2)
SE	69.04	12.16	115.47	23.25
Median (95% CI)	2044.0 (2006.0 , 2044.0)	777.0 (1650.0 , 2044.0)	2042.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	1837.0 ; 2044.0	777.0 ; 777.0	1496.5 ; 2044.0	777.0 ; 777.0
Min ; Max	640 ; 2044	533 ; 777	404 ; 2044	224 ; 777
Actual cumulative CS dose (mg) ^b				
Number	34	30	24	29
Mean (SD)	2142.8 (701.9)	961.0 (434.0)	2367.4 (1004.1)	1120.7 (753.5)
SE	120.37	79.23	204.97	139.92
Median (95% CI)	2044.0	777.0	2475.5	777.0
Q1 ; Q3	1950.0 ; 2540.0	777.0 ; 882.0	1874.8 ; 3254.3	777.0 ; 1018.5
Min ; Max	640 ; 3676	548 ; 2245	404 ; 3664	224 ; 2885

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_cs_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Baseline CS dose			
	<= median		> median	
	(N=64)		(N=54)	
	Placebo+52 week taper (N=34)	Sarilumab 200mg q2w+14 week taper (N=30)	Placebo+52 week taper (N=24)	Sarilumab 200mg q2w+14 week taper (N=30)
P-value vs. Placebo+52 week taper ^c		<.0001		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	34	30	24	29
Mean (SD)	298.5 (475.1)	205.8 (418.2)	677.1 (577.2)	392.6 (719.9)
SE	81.47	76.35	117.82	133.68
Median (95% CI)	0.0 (0.0 , 306.0)	0.0 (202.0 , 1058.5)	784.4 (0.0 , 15.0)	0.0 (0.0 , 139.0)
Q1 ; Q3	0.0 ; 496.0	0.0 ; 105.0	68.5 ; 1211.3	0.0 ; 322.0
Min ; Max	-57 ; 1632	0 ; 1468	0 ; 1622	-13 ; 2108
P-value vs. Placebo+52 week taper ^c		0.3531		0.0220

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_cs_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
Corticosteroid dose	Placebo+52 week taper (N=17)	Sarilumab 200mg q2w+14 week taper (N=12)	Placebo+52 week taper (N=41)	Sarilumab 200mg q2w+14 week taper (N=48)
Expected cumulative CS dose (mg) ^a				
Number	17	12	41	47
Mean (SD)	1601.2 (600.1)	722.3 (98.6)	1855.0 (403.3)	747.0 (100.6)
SE	145.55	28.46	62.98	14.68
Median (95% CI)	2042.0 (790.0 , 2044.0)	777.0 (2041.0 , 2044.0)	2044.0 (581.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	790.0 ; 2044.0	676.5 ; 777.0	1920.0 ; 2044.0	777.0 ; 777.0
Min ; Max	640 ; 2044	533 ; 777	404 ; 2044	224 ; 777
Actual cumulative CS dose (mg) ^b				
Number	17	12	41	47
Mean (SD)	2086.2 (1028.9)	761.5 (151.7)	2297.7 (753.0)	1110.5 (664.6)
SE	249.55	43.80	117.60	96.94
Median (95% CI)	2044.0	777.0	2044.0	777.0
Q1 ; Q3	948.0 ; 2553.0	679.0 ; 777.0	2044.0 ; 2840.0	777.0 ; 1197.0
Min ; Max	640 ; 3676	548 ; 1099	404 ; 3569	224 ; 2885

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_mtx_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
Corticosteroid dose	Placebo+52 week taper (N=17)	Sarilumab 200mg q2w+14 week taper (N=12)	Placebo+52 week taper (N=41)	Sarilumab 200mg q2w+14 week taper (N=48)
P-value vs. Placebo+52 week taper ^c		0.0005		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	17	12	41	47
Mean (SD)	485.1 (618.3)	39.3 (96.9)	442.7 (524.1)	363.5 (642.5)
SE	149.95	27.99	81.86	93.72
Median (95% CI)	107.0 (0.0 , 846.0)	0.0 (0.0 , 742.5)	202.0 (0.0 , 15.0)	0.0 (0.0 , 50.0)
Q1 ; Q3	0.0 ; 846.0	0.0 ; 7.5	0.0 ; 799.0	0.0 ; 437.5
Min ; Max	0 ; 1632	0 ; 322	-57 ; 1525	-13 ; 2108
P-value vs. Placebo+52 week taper ^c		0.0347		0.1326

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_mtx_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
Corticosteroid dose	Placebo+52 week taper (N=23)	Sarilumab 200mg q2w+14 week taper (N=24)	Placebo+52 week taper (N=35)	Sarilumab 200mg q2w+14 week taper (N=36)
Expected cumulative CS dose (mg) ^a				
Number	23	23	35	36
Mean (SD)	1890.0 (398.6)	724.0 (135.7)	1708.7 (517.1)	753.4 (67.9)
SE	83.11	28.29	87.40	11.32
Median (95% CI)	2044.0 (2041.0 , 2044.0)	777.0 (1792.0 , 2044.0)	2043.0 (777.0 , 777.0)	777.0 (777.0 , 777.0)
Q1 ; Q3	2031.0 ; 2044.0	777.0 ; 777.0	1545.0 ; 2044.0	777.0 ; 777.0
Min ; Max	640 ; 2044	224 ; 777	404 ; 2044	533 ; 777
Actual cumulative CS dose (mg) ^b				
Number	23	23	35	36
Mean (SD)	2428.1 (835.7)	954.5 (587.7)	2109.4 (829.3)	1093.9 (629.4)
SE	174.25	122.54	140.18	104.90
Median (95% CI)	2303.0	777.0	2044.0	777.0
Q1 ; Q3	2044.0 ; 3232.5	777.0 ; 777.0	1735.0 ; 2684.5	777.0 ; 1148.0
Min ; Max	640 ; 3664	224 ; 2796	404 ; 3676	548 ; 2885

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_nrp_i_t_x.rtf (05SEP2024 9:33)

Weitere Analysen

Corticosteroid dose	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo+52 week taper (N=23)	Sarilumab 200mg q2w+14 week taper (N=24)	Placebo+52 week taper (N=35)	Sarilumab 200mg q2w+14 week taper (N=36)
P-value vs. Placebo+52 week taper ^c		<.0001		<.0001
Difference between actual and expected cumulative CS dose (mg)				
Number	23	23	35	36
Mean (SD)	538.0 (606.6)	230.5 (555.8)	400.7 (507.9)	340.4 (612.5)
SE	126.48	115.89	85.85	102.09
Median (95% CI)	259.0 (0.0 , 1027.5)	0.0 (0.0 , 509.0)	197.0 (0.0 , 0.0)	0.0 (0.0 , 139.0)
Q1 ; Q3	0.0 ; 1188.5	0.0 ; 0.0	0.0 ; 769.8	0.0 ; 371.0
Min ; Max	0 ; 1622	-13 ; 2019	-57 ; 1632	0 ; 2108
P-value vs. Placebo+52 week taper ^c		0.0222		0.2542

CS: Corticosteroids, CI: Confidence interval, SE: Standard error or the mean

^a Expected cumulative dose based on CS tapering regimen up to end of treatment, assuming that the taper was continued without error.

^b Cumulative dose of CS up to the end of treatment, including expected prednisone in tapering regimen per protocol, add-on prednisone, CS used in rescue therapy and the use of commercial prednisone.

^c P value from Wilcoxon rank-sum test.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/dem_cortico_ger_i_t.sas OUT=REPORT/OUTPUT/dem_cortico_ger_nrp_i_t_x.rtf(05SEP2024 9:33)

2. PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
PMR-AS (MMRM)	Gender (Male , Female)	0.1557
	Race (Caucasian/White , All other races)	0.1070
	Region (Western Countries , Rest of World (including South America))	0.0505
	Age (Age < 70 , Age >= 70)	0.0553
	Baseline CRP (<= median , > median)	0.3261
	Baseline CS dose (<= median , > median)	0.6422
	Baseline ESR (<= median , > median)	0.6890
	MTX Add-on Therapy (Yes , No)	0.7515
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.6471

Weitere Analysen

Per gender

PMR-AS (MMRM)	Gender			
	Placebo (N=21)	Male (N=36) Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Female (N=82) Sarilumab 200mg q2w (N=45)
Baseline				
Number	20	13	32	36
Mean (SD)	26.57 (33.50)	17.16 (12.61)	20.72 (9.71)	18.40 (8.84)
Baseline for patients with data at Week 52				
Number	12	7	16	24
Mean (SD)	26.87 (42.52)	12.43 (7.31)	16.29 (9.01)	19.04 (8.56)
Week 52				
Value				
Number	12	7	16	24
Mean (SD)	6.19 (5.37)	2.93 (3.59)	11.30 (7.21)	4.35 (3.20)
Change from baseline				
Number	12	7	16	24
Mean (SD)	-20.69 (43.55)	-9.50 (5.40)	-4.98 (10.64)	-14.69 (9.18)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmr_gender_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-16.33 (1.39)	-19.00 (1.72)	-6.60 (1.28)	-13.94 (1.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-2.67 (-7.28 to 1.94)		-7.34 (-10.70 to -3.98)
P-value vs. Placebo+52 week taper ^a		0.2436		<.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.55 (-1.49 to 0.40)	-	-1.39 (-2.03 to -0.76)
Treatment-by-subgroup p-value ^b				0.1557

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_gender_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

PMR-AS (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	44	41	8	8
Mean (SD)	23.67 (23.12)	18.55 (9.91)	19.11 (14.89)	15.64 (9.84)
Baseline for patients with data at Week 52				
Number	22	24	6	7
Mean (SD)	22.27 (31.25)	18.37 (8.19)	15.51 (15.18)	14.71 (10.24)
Week 52				
Value				
Number	22	24	6	7
Mean (SD)	8.06 (6.39)	3.79 (2.97)	12.96 (7.83)	4.85 (4.39)
Change from baseline				
Number	22	24	6	7
Mean (SD)	-14.21 (32.78)	-14.59 (8.47)	-2.55 (14.47)	-9.87 (9.03)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_race_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-12.66 (0.99)	-16.95 (0.97)	-0.31 (2.79)	-10.47 (2.76)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.29 (-7.07 to -1.51)		-10.16 (-18.80 to -1.51)
P-value vs. Placebo+52 week taper ^a		0.0030		0.0253
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.90 (-1.48 to -0.32)	-	-1.33 (-2.47 to -0.20)
Treatment-by-subgroup p-value ^b				0.1070

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_race_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

PMR-AS (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	40	38	12	11
Mean (SD)	24.47 (24.69)	17.46 (10.53)	17.96 (6.79)	20.21 (7.03)
Baseline for patients with data at Week 52				
Number	20	24	8	7
Mean (SD)	23.25 (33.42)	17.09 (9.30)	14.76 (5.82)	19.12 (6.22)
Week 52				
Value				
Number	20	24	8	7
Mean (SD)	10.39 (7.36)	3.60 (3.35)	5.89 (4.35)	5.49 (2.78)
Change from baseline				
Number	20	24	8	7
Mean (SD)	-12.85 (35.38)	-13.49 (8.85)	-8.87 (7.36)	-13.63 (8.73)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmr_ger_region_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

PMR-AS (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-9.61 (1.21)	-16.52 (1.13)	-12.46 (1.21)	-12.68 (1.31)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.91 (-10.23 to -3.58)		-0.22 (-4.08 to 3.65)
P-value vs. Placebo+52 week taper ^a		0.0001		0.9057
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.25 (-1.85 to -0.65)	-	-0.06 (-1.13 to 1.01)
Treatment-by-subgroup p-value ^b				0.0505

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmras_ger_region_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

PMR-AS (MMRM)	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	23	32	29	17
Mean (SD)	20.55 (11.16)	16.86 (9.05)	24.89 (27.83)	20.35 (11.14)
Baseline for patients with data at Week 52				
Number	14	21	14	10
Mean (SD)	14.98 (8.71)	16.99 (6.77)	26.67 (39.15)	18.71 (12.05)
Week 52				
Value				
Number	14	21	14	10
Mean (SD)	12.36 (7.11)	4.27 (3.21)	5.86 (4.99)	3.52 (3.56)
Change from baseline				
Number	14	21	14	10
Mean (SD)	-2.62 (8.42)	-12.73 (6.39)	-20.81 (40.21)	-15.19 (12.48)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrns_ger_age_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-4.64 (1.22)	-12.68 (1.00)	-16.92 (1.22)	-19.57 (1.45)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.04 (-11.23 to -4.84)		-2.65 (-6.51 to 1.21)
P-value vs. Placebo+52 week taper ^a		<.0001		0.1722
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.72 (-2.40 to -1.04)	-	-0.57 (-1.40 to 0.26)
Treatment-by-subgroup p-value ^b				0.0553

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmras_ger_age_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
PMR-AS (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	27	24	25	25
Mean (SD)	19.21 (9.70)	14.83 (10.35)	27.03 (29.88)	21.18 (8.43)
Baseline for patients with data at Week 52				
Number	14	15	14	16
Mean (SD)	15.46 (8.68)	14.91 (9.29)	26.18 (39.31)	20.02 (7.45)
Week 52				
Value				
Number	14	15	14	16
Mean (SD)	8.56 (7.13)	3.88 (3.15)	9.66 (6.84)	4.17 (3.51)
Change from baseline				
Number	14	15	14	16
Mean (SD)	-6.90 (8.01)	-11.03 (8.78)	-16.53 (41.85)	-15.86 (8.17)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_crp_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

PMR-AS (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-7.30 (1.32)	-11.27 (1.30)	-11.78 (1.50)	-19.44 (1.47)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-3.96 (-7.72 to -0.20)		-7.66 (-11.92 to -3.39)
P-value vs. Placebo+52 week taper ^a		0.0394		0.0008
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.78 (-1.52 to -0.04)	-	-1.30 (-2.03 to -0.58)
Treatment-by-subgroup p-value ^b				0.3261

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_crp_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline ESR

PMR-AS (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	28	26	24	23
Mean (SD)	20.95 (11.73)	16.64 (11.77)	25.32 (30.01)	19.69 (7.03)
Baseline for patients with data at Week 52				
Number	15	17	13	14
Mean (SD)	16.34 (11.94)	17.25 (10.16)	26.00 (40.02)	17.91 (6.73)
Week 52				
Value				
Number	15	17	13	14
Mean (SD)	9.87 (7.26)	4.00 (3.17)	8.23 (6.59)	4.06 (3.54)
Change from baseline				
Number	15	17	13	14
Mean (SD)	-6.47 (10.75)	-13.25 (9.54)	-17.77 (42.57)	-13.85 (7.85)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_esr_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

PMR-AS (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-7.17 (1.24)	-12.94 (1.20)	-13.90 (1.41)	-19.09 (1.39)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.77 (-9.24 to -2.30)		-5.19 (-9.24 to -1.13)
P-value vs. Placebo+52 week taper ^a		0.0017		0.0140
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.17 (-1.87 to -0.46)	-	-0.98 (-1.75 to -0.21)
Treatment-by-subgroup p-value ^b				0.6890

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmras_ger_esr_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
PMR-AS (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	29	25	23	24
Mean (SD)	24.08 (27.31)	18.92 (8.26)	21.57 (12.97)	17.19 (11.40)
Baseline for patients with data at Week 52				
Number	17	16	11	15
Mean (SD)	25.22 (35.50)	17.90 (7.24)	14.03 (9.31)	17.17 (10.19)
Week 52				
Value				
Number	17	16	11	15
Mean (SD)	9.45 (7.43)	4.53 (3.31)	8.59 (6.23)	3.50 (3.29)
Change from baseline				
Number	17	16	11	15
Mean (SD)	-15.77 (37.72)	-13.38 (8.02)	-5.45 (8.80)	-13.68 (9.61)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmr_ger_cs_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-12.38 (1.39)	-17.80 (1.44)	-6.93 (1.35)	-13.28 (1.19)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.42 (-9.48 to -1.36)		-6.35 (-10.02 to -2.69)
P-value vs. Placebo+52 week taper ^a		0.0101		0.0013
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.93 (-1.62 to -0.23)	-	-1.36 (-2.15 to -0.58)
Treatment-by-subgroup p-value ^b				0.6422

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pmr_ger_cs_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

PMR-AS (MMRM)	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	14	9	38	40
Mean (SD)	24.27 (12.06)	16.49 (7.41)	22.49 (24.79)	18.43 (10.37)
Baseline for patients with data at Week 52				
Number	8	4	20	27
Mean (SD)	18.85 (9.79)	19.46 (4.47)	21.61 (33.37)	17.26 (9.13)
Week 52				
Value				
Number	8	4	20	27
Mean (SD)	9.64 (8.07)	4.06 (2.37)	8.90 (6.56)	4.02 (3.44)
Change from baseline				
Number	8	4	20	27
Mean (SD)	-9.21 (10.03)	-15.40 (4.73)	-12.72 (35.15)	-13.24 (9.15)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_mtx_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

PMR-AS (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	-8.28 (2.55)	-13.20 (3.58)	-10.88 (1.04)	-15.87 (0.93)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.91 (-14.60 to 4.78)		-4.99 (-7.79 to -2.20)
P-value vs. Placebo+52 week taper ^a		0.2881		0.0007
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.64 (-1.89 to 0.62)	-	-1.04 (-1.62 to -0.46)
Treatment-by-subgroup p-value ^b				0.7515

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_mtx_i_t_x.rtf (04SEP2024 17:53)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

PMR-AS (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	20	18	32	31
Mean (SD)	27.10 (33.22)	13.85 (10.44)	20.39 (10.08)	20.53 (8.76)
Baseline for patients with data at Week 52				
Number	13	11	15	20
Mean (SD)	26.77 (41.10)	13.78 (9.28)	15.67 (7.28)	19.62 (7.75)
Week 52				
Value				
Number	13	11	15	20
Mean (SD)	9.33 (7.94)	3.73 (3.38)	8.92 (6.08)	4.19 (3.31)
Change from baseline				
Number	13	11	15	20
Mean (SD)	-17.44 (43.15)	-10.05 (9.65)	-6.75 (8.93)	-15.43 (7.68)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_nrp_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

PMR-AS (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-10.90 (1.62)	-17.64 (1.85)	-8.72 (1.24)	-14.46 (1.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.74 (-11.83 to -1.66)		-5.74 (-9.08 to -2.40)
P-value vs. Placebo+52 week taper ^a		0.0111		0.0012
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.10 (-1.93 to -0.27)	-	-1.17 (-1.86 to -0.49)
Treatment-by-subgroup p-value ^b				0.6471

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pmrn_ger_nrp_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LSMean change from baseline



3. FACIT-Fatigue change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
FACIT-Fatigue (0-52) (MMRM)	Gender (Male , Female)	0.9238
	Race (Caucasian/White , All other races)	0.3033
	Region (Western Countries , Rest of World (including South America))	0.3333
	Age (Age < 70 , Age >= 70)	0.0708
	Baseline CRP (<= median , > median)	0.3544
	Baseline CS dose (<= median , > median)	0.0282
	Baseline ESR (<= median , > median)	0.0335
	MTX Add-on Therapy (Yes , No)	0.3559
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7542

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	15	37	44
Mean (SD)	32.76 (12.57)	35.33 (10.93)	27.14 (11.20)	30.05 (10.68)
Baseline for patients with data at Week 52				
Number	15	11	21	31
Mean (SD)	34.93 (12.31)	35.36 (11.21)	29.86 (11.45)	31.90 (10.49)
Week 52				
Value				
Number	15	11	21	31
Mean (SD)	38.40 (10.67)	44.09 (6.67)	35.62 (11.12)	39.55 (9.88)
Change from baseline				
Number	15	11	21	31
Mean (SD)	3.47 (11.35)	8.73 (6.90)	5.76 (10.83)	7.65 (10.41)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_gender_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	3.67 (1.98)	7.92 (2.32)	4.70 (1.95)	8.30 (1.63)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		4.25 (-1.99 to 10.50)		3.60 (-1.49 to 8.68)
P-value vs. Placebo+52 week taper ^a		0.1743		0.1632
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.54 (-0.25 to 1.33)	-	0.39 (-0.16 to 0.95)
Treatment-by-subgroup p-value ^b				0.9238

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_gender_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	10
Mean (SD)	28.83 (10.75)	32.10 (10.95)	30.80 (17.13)	27.90 (10.44)
Baseline for patients with data at Week 52				
Number	29	35	7	7
Mean (SD)	31.59 (11.26)	33.37 (11.05)	33.57 (15.27)	30.00 (8.56)
Week 52				
Value				
Number	29	35	7	7
Mean (SD)	38.07 (8.81)	41.51 (9.19)	31.43 (16.89)	36.86 (9.51)
Change from baseline				
Number	29	35	7	7
Mean (SD)	6.48 (11.16)	8.14 (10.21)	-2.14 (6.94)	6.86 (5.49)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_race_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	5.70 (1.51)	8.52 (1.40)	-3.09 (2.52)	6.16 (2.53)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.81 (-1.29 to 6.91)		9.26 (1.56 to 16.95)
P-value vs. Placebo+52 week taper ^a		0.1763		0.0218
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.34 (-0.16 to 0.83)	-	1.31 (0.22 to 2.40)
Treatment-by-subgroup p-value ^b				0.3033

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_race_i_t_x.rtf (04SEP2024 17:54)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	46	14	13
Mean (SD)	28.77 (12.51)	32.96 (11.00)	30.43 (10.15)	25.85 (8.78)
Baseline for patients with data at Week 52				
Number	26	33	10	9
Mean (SD)	31.54 (12.54)	34.30 (10.79)	33.10 (10.64)	27.33 (8.56)
Week 52				
Value				
Number	26	33	10	9
Mean (SD)	34.65 (11.80)	41.00 (9.86)	42.30 (5.03)	39.78 (7.28)
Change from baseline				
Number	26	33	10	9
Mean (SD)	3.12 (11.73)	6.70 (9.57)	9.20 (7.38)	12.44 (8.44)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_region_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	2.00 (1.78)	6.96 (1.61)	10.79 (1.67)	10.95 (1.76)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		4.96 (0.16 to 9.76)		0.16 (-5.01 to 5.33)
P-value vs. Placebo+52 week taper ^a		0.0430		0.9485
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.53 (0.02 to 1.05)	-	0.03 (-0.91 to 0.97)
Treatment-by-subgroup p-value ^b				0.3333

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_region_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

FACIT-Fatigue (0-52) (MMRM)	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	25
Mean (SD)	28.56 (10.46)	32.71 (9.80)	29.64 (13.06)	29.60 (12.21)
Baseline for patients with data at Week 52				
Number	15	27	21	15
Mean (SD)	31.87 (10.85)	33.48 (9.67)	32.05 (12.89)	31.60 (12.51)
Week 52				
Value				
Number	15	27	21	15
Mean (SD)	36.13 (9.30)	42.85 (7.56)	37.24 (12.07)	36.93 (11.08)
Change from baseline				
Number	15	27	21	15
Mean (SD)	4.27 (11.44)	9.37 (7.65)	5.19 (10.86)	5.33 (12.13)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_age_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	3.44 (1.83)	9.90 (1.39)	3.86 (2.29)	2.79 (2.70)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.46 (1.84 to 11.08)		-1.07 (-8.17 to 6.03)
P-value vs. Placebo+52 week taper ^a		0.0071		0.7635
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.89 (0.25 to 1.52)	-	-0.10 (-0.77 to 0.57)
Treatment-by-subgroup p-value ^b				0.0708

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_age_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	31
Mean (SD)	30.52 (10.40)	35.46 (11.20)	27.63 (13.50)	27.71 (9.33)
Baseline for patients with data at Week 52				
Number	19	19	17	23
Mean (SD)	32.16 (9.87)	36.47 (11.56)	31.76 (14.17)	29.78 (9.00)
Week 52				
Value				
Number	19	19	17	23
Mean (SD)	37.95 (10.18)	42.16 (10.84)	35.47 (11.76)	39.57 (7.85)
Change from baseline				
Number	19	19	17	23
Mean (SD)	5.79 (11.20)	5.68 (7.44)	3.71 (10.90)	9.78 (10.80)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_crp_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	3.29 (2.05)	5.09 (2.12)	4.35 (2.06)	9.64 (1.78)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.80 (-4.20 to 7.79)		5.29 (-0.17 to 10.76)
P-value vs. Placebo+52 week taper ^a		0.5497		0.0575
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.19 (-0.45 to 0.84)	-	0.61 (-0.02 to 1.24)
Treatment-by-subgroup p-value ^b				0.3544

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger__crp_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	31
Mean (SD)	27.48 (11.89)	33.75 (10.96)	31.11 (11.89)	29.26 (10.56)
Baseline for patients with data at Week 52				
Number	19	21	17	21
Mean (SD)	29.32 (11.61)	33.76 (10.85)	34.94 (11.88)	31.86 (10.64)
Week 52				
Value				
Number	19	21	17	21
Mean (SD)	34.00 (13.10)	43.67 (6.64)	39.88 (6.77)	37.81 (10.72)
Change from baseline				
Number	19	21	17	21
Mean (SD)	4.68 (9.64)	9.90 (10.10)	4.94 (12.56)	5.95 (8.75)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_esr_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	2.58 (1.99)	9.57 (1.98)	6.16 (2.00)	5.21 (1.79)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.99 (1.29 to 12.69)		-0.95 (-6.36 to 4.47)
P-value vs. Placebo+52 week taper ^a		0.0173		0.7270
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.78 (0.14 to 1.41)	-	-0.11 (-0.76 to 0.53)
Treatment-by-subgroup p-value ^b				0.0335

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_esr_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	29
Mean (SD)	30.91 (13.14)	30.20 (10.05)	26.71 (9.68)	32.62 (11.76)
Baseline for patients with data at Week 52				
Number	22	23	14	19
Mean (SD)	33.86 (13.65)	33.09 (9.18)	29.00 (8.11)	32.47 (12.47)
Week 52				
Value				
Number	22	23	14	19
Mean (SD)	34.91 (13.18)	41.39 (7.77)	39.71 (4.70)	39.95 (11.03)
Change from baseline				
Number	22	23	14	19
Mean (SD)	1.05 (11.39)	8.30 (10.08)	10.71 (7.19)	7.47 (9.11)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_cs_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	1.20 (1.93)	8.42 (1.91)	9.26 (1.84)	7.88 (1.59)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		7.22 (1.79 to 12.64)		-1.38 (-6.33 to 3.57)
P-value vs. Placebo+52 week taper ^a		0.0100		0.5768
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.78 (0.19 to 1.37)	-	-0.20 (-0.90 to 0.51)
Treatment-by-subgroup p-value ^b				0.0282

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_cs_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
FACIT-Fatigue (0-52) (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	48
Mean (SD)	29.00 (12.85)	25.18 (9.61)	29.24 (11.68)	32.81 (10.76)
Baseline for patients with data at Week 52				
Number	10	5	26	37
Mean (SD)	34.00 (12.20)	27.60 (11.30)	31.19 (11.95)	33.51 (10.53)
Week 52				
Value				
Number	10	5	26	37
Mean (SD)	36.90 (7.62)	41.20 (9.91)	36.73 (12.02)	40.68 (9.35)
Change from baseline				
Number	10	5	26	37
Mean (SD)	2.90 (12.50)	13.60 (16.38)	5.54 (10.47)	7.16 (8.30)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_mtx_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	4.94 (3.11)	11.08 (4.23)	4.30 (1.60)	7.10 (1.36)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.14 (-4.81 to 17.09)		2.80 (-1.39 to 7.00)
P-value vs. Placebo+52 week taper ^a		0.2581		0.1875
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.61 (-0.48 to 1.70)	-	0.34 (-0.17 to 0.84)
Treatment-by-subgroup p-value ^b				0.3559

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger_mtx_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

FACIT-Fatigue (0-52) (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	23	35	36
Mean (SD)	29.52 (11.35)	30.96 (12.70)	28.94 (12.44)	31.67 (9.75)
Baseline for patients with data at Week 52				
Number	18	15	18	27
Mean (SD)	30.17 (12.51)	33.40 (12.72)	33.78 (11.36)	32.48 (9.57)
Week 52				
Value				
Number	18	15	18	27
Mean (SD)	36.78 (11.24)	43.47 (7.38)	36.78 (10.80)	39.22 (10.01)
Change from baseline				
Number	18	15	18	27
Mean (SD)	6.61 (9.88)	10.07 (8.65)	3.00 (11.94)	6.74 (9.97)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger__nrp_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

FACIT-Fatigue (0-52) (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	5.41 (1.76)	10.51 (1.96)	2.78 (2.20)	6.50 (1.81)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.09 (-0.27 to 10.45)		3.71 (-1.96 to 9.39)
P-value vs. Placebo+52 week taper ^a		0.0619		0.1955
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.66 (-0.03 to 1.36)	-	0.39 (-0.21 to 0.99)
Treatment-by-subgroup p-value ^b				0.7542

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_fatigue_ger__nrp_i_t_x.rtf (04SEP2024 17:55)

Weitere Analysen

Plot of LSMean change from baseline



4. EQ-5D VAS change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
VAS for EQ-5D (MMRM)	Gender (Male , Female)	0.3897
	Race (Caucasian/White , All other races)	0.7416
	Region (Western Countries , Rest of World (including South America))	0.9814
	Age (Age < 70 , Age >= 70)	0.5804
	Baseline CRP (<= median , > median)	0.2111
	Baseline CS dose (<= median , > median)	0.5922
	Baseline ESR (<= median , > median)	0.2970
	MTX Add-on Therapy (Yes , No)	0.5865
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.6836

Weitere Analysen

Per gender

VAS for EQ-5D (MMRM)	Gender			
	Placebo (N=21)	Male (N=36) Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Female (N=82) Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	61.19 (21.34)	64.79 (21.28)	50.30 (21.89)	56.48 (21.60)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	63.93 (17.27)	66.27 (19.41)	55.05 (21.01)	59.39 (20.78)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	60.43 (26.02)	77.73 (21.74)	62.95 (19.74)	65.84 (23.22)
Change from baseline				
Number	14	11	21	31
Mean (SD)	-3.50 (30.31)	11.45 (17.49)	7.90 (23.96)	6.45 (32.72)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_gender_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

VAS for EQ-5D (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-5.69 (6.19)	10.00 (7.13)	3.08 (4.66)	8.64 (3.96)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		15.69 (-3.66 to 35.03)		5.55 (-6.67 to 17.78)
P-value vs. Placebo+52 week taper ^a		0.1080		0.3680
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.65 (-0.15 to 1.46)	-	0.25 (-0.30 to 0.81)
Treatment-by-subgroup p-value ^b				0.3897

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_gender_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
VAS for EQ-5D (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	55.15 (22.38)	58.06 (21.78)	49.90 (21.58)	60.78 (21.94)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	60.14 (20.47)	59.51 (21.58)	52.43 (16.94)	69.57 (10.74)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	64.14 (21.53)	69.74 (24.24)	53.14 (23.98)	65.00 (18.00)
Change from baseline				
Number	28	35	7	7
Mean (SD)	4.00 (26.89)	10.23 (30.57)	0.71 (28.68)	-4.57 (19.72)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_race_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

VAS for EQ-5D (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	1.80 (4.17)	9.57 (3.84)	-4.74 (8.25)	2.85 (8.52)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		7.77 (-3.49 to 19.04)		7.59 (-19.56 to 34.73)
P-value vs. Placebo+52 week taper ^a		0.1738		0.5584
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.34 (-0.15 to 0.84)	-	0.32 (-0.83 to 1.48)
Treatment-by-subgroup p-value ^b				0.7416

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_race_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
VAS for EQ-5D (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	55.18 (21.92)	61.09 (21.04)	51.29 (23.42)	49.46 (22.04)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	59.20 (20.41)	63.82 (19.17)	57.10 (19.26)	51.56 (23.15)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	62.28 (22.44)	69.64 (24.31)	61.10 (22.48)	66.44 (19.59)
Change from baseline				
Number	25	33	10	9
Mean (SD)	3.08 (26.03)	5.82 (28.16)	4.00 (30.28)	14.89 (34.32)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger__region_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

VAS for EQ-5D (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-1.67 (4.52)	7.28 (4.09)	3.73 (6.74)	11.30 (7.29)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		8.95 (-3.23 to 21.12)		7.57 (-13.20 to 28.34)
P-value vs. Placebo+52 week taper ^a		0.1474		0.4560
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.38 (-0.14 to 0.91)	-	0.34 (-0.59 to 1.26)
Treatment-by-subgroup p-value ^b				0.9814

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger__region_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per age

VAS for EQ-5D (MMRM)	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	57.36 (21.06)	58.65 (21.13)	51.88 (22.97)	58.25 (22.78)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	61.00 (17.27)	59.74 (20.49)	56.80 (21.82)	63.80 (20.76)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	65.07 (19.89)	68.89 (23.97)	59.60 (23.90)	69.07 (22.54)
Change from baseline				
Number	15	27	20	15
Mean (SD)	4.07 (24.25)	9.15 (27.78)	2.80 (29.26)	5.27 (32.92)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_age_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

VAS for EQ-5D (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	3.11 (5.65)	8.59 (4.39)	-3.85 (4.95)	7.61 (5.74)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.48 (-8.88 to 19.85)		11.46 (-3.87 to 26.79)
P-value vs. Placebo+52 week taper ^a		0.4469		0.1395
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.24 (-0.39 to 0.87)	-	0.51 (-0.17 to 1.19)
Treatment-by-subgroup p-value ^b				0.5804

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_age_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

VAS for EQ-5D (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	56.77 (21.43)	67.41 (18.27)	51.33 (23.00)	50.71 (21.57)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	56.21 (18.21)	69.84 (17.81)	61.44 (21.85)	54.04 (20.01)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	61.63 (22.35)	77.47 (17.63)	62.31 (22.59)	61.91 (25.17)
Change from baseline				
Number	19	19	16	23
Mean (SD)	5.42 (27.23)	7.63 (24.51)	0.88 (27.06)	7.87 (33.41)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_crp_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

VAS for EQ-5D (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-5.06 (4.65)	12.94 (4.82)	2.56 (5.96)	6.15 (5.00)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		17.99 (4.13 to 31.85)		3.58 (-12.08 to 19.24)
P-value vs. Placebo+52 week taper ^a		0.0120		0.6480
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.86 (0.20 to 1.52)	-	0.15 (-0.50 to 0.79)
Treatment-by-subgroup p-value ^b				0.2111

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_crp_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

VAS for EQ-5D (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	54.97 (20.03)	59.48 (23.81)	53.41 (24.72)	57.61 (19.90)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	56.21 (16.74)	60.19 (22.91)	61.44 (23.22)	62.19 (18.13)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	58.32 (22.41)	70.67 (25.42)	66.25 (21.69)	67.24 (21.23)
Change from baseline				
Number	19	21	16	21
Mean (SD)	2.11 (19.63)	10.48 (30.46)	4.81 (34.17)	5.05 (28.73)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_esr_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

VAS for EQ-5D (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-3.26 (5.28)	10.50 (5.20)	2.34 (5.08)	6.51 (4.52)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		13.76 (-1.14 to 28.66)		4.16 (-9.51 to 17.84)
P-value vs. Placebo+52 week taper ^a		0.0696		0.5430
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.58 (-0.05 to 1.20)	-	0.20 (-0.46 to 0.85)
Treatment-by-subgroup p-value ^b				0.2970

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_esr_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

VAS for EQ-5D (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	56.71 (23.10)	56.83 (19.39)	50.75 (20.69)	60.25 (24.04)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	62.05 (18.70)	58.96 (20.14)	52.77 (21.07)	63.89 (20.99)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	61.23 (22.37)	64.48 (25.37)	63.15 (22.56)	74.37 (19.54)
Change from baseline				
Number	22	23	13	19
Mean (SD)	-0.82 (22.48)	5.52 (32.91)	10.38 (32.75)	10.47 (25.04)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_cs_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

VAS for EQ-5D (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-2.29 (4.99)	4.13 (5.04)	2.08 (5.55)	13.45 (4.73)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.42 (-7.80 to 20.64)		11.36 (-3.60 to 26.33)
P-value vs. Placebo+52 week taper ^a		0.3698		0.1328
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.27 (-0.32 to 0.86)	-	0.55 (-0.17 to 1.27)
Treatment-by-subgroup p-value ^b				0.5922

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_cs_i_t_x.rtf (04SEP2024 17:56)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

VAS for EQ-5D (MMRM)	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	51.76 (19.70)	46.18 (21.20)	55.27 (23.24)	61.36 (20.91)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	61.60 (17.08)	49.20 (19.56)	57.40 (21.04)	62.81 (20.25)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	61.80 (21.27)	59.00 (23.31)	62.00 (22.89)	70.30 (23.16)
Change from baseline				
Number	10	5	25	37
Mean (SD)	0.20 (28.28)	9.80 (38.37)	4.60 (26.76)	7.49 (28.61)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_mtx_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

VAS for EQ-5D (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	4.67 (6.59)	6.37 (9.38)	-1.20 (4.45)	8.34 (3.75)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.70 (-22.33 to 25.74)		9.54 (-2.10 to 21.18)
P-value vs. Placebo+52 week taper ^a		0.8848		0.1067
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.08 (-1.03 to 1.19)	-	0.42 (-0.09 to 0.93)
Treatment-by-subgroup p-value ^b				0.5865

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_mtx_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

VAS for EQ-5D (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	47.78 (20.69)	53.95 (26.42)	58.49 (22.32)	61.25 (17.96)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	48.82 (21.09)	60.33 (23.62)	67.83 (13.49)	61.67 (18.89)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	63.18 (19.16)	75.87 (19.79)	60.78 (25.11)	65.11 (24.38)
Change from baseline				
Number	17	15	18	27
Mean (SD)	14.35 (26.93)	15.53 (24.67)	-7.06 (22.89)	3.44 (31.28)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_eq5dvas_ger_nrp_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

VAS for EQ-5D (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	7.49 (4.63)	18.65 (4.98)	-5.44 (5.62)	2.07 (4.69)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		11.16 (-2.81 to 25.12)		7.52 (-7.15 to 22.18)
P-value vs. Placebo+52 week taper ^a		0.1140		0.3095
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.57 (-0.14 to 1.28)	-	0.31 (-0.29 to 0.91)
Treatment-by-subgroup p-value ^b				0.6836

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_eq5dvas_ger_nrp_i_t_x.rtf (04SEP2024 17:57)

Weitere Analysen

Plot of LSMean change from baseline



5. MD-VAS change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
MD-VAS (MMRM)	Gender (Male , Female)	0.0328
	Race (Caucasian/White , All other races)	0.4270
	Region (Western Countries , Rest of World (including South America))	0.2536
	Age (Age < 70 , Age >= 70)	0.3111
	Baseline CRP (<= median , > median)	0.7369
	Baseline CS dose (<= median , > median)	0.5441
	Baseline ESR (<= median , > median)	0.6459
	MTX Add-on Therapy (Yes , No)	0.7856
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4416

Weitere Analysen

Per gender

MD-VAS (MMRM)	Gender			
	Placebo (N=21)	Male (N=36) Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Female (N=82) Sarilumab 200mg q2w (N=45)
Baseline				
Number	20	13	32	36
Mean (SD)	53.35 (23.33)	52.46 (25.57)	53.72 (26.56)	53.08 (23.10)
Baseline for patients with data at Week 52				
Number	12	9	19	24
Mean (SD)	46.75 (21.70)	54.33 (21.09)	49.32 (27.07)	55.29 (15.66)
Week 52				
Value				
Number	12	9	19	24
Mean (SD)	7.75 (8.90)	9.89 (21.66)	26.05 (26.19)	10.33 (12.98)
Change from baseline				
Number	12	9	19	24
Mean (SD)	-39.00 (19.63)	-44.44 (25.60)	-23.26 (32.51)	-44.96 (19.07)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_gender_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

MD-VAS (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-41.12 (4.44)	-40.03 (5.16)	-23.43 (4.52)	-41.69 (4.15)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		1.09 (-13.03 to 15.21)		-18.26 (-30.59 to -5.93)
P-value vs. Placebo+52 week taper ^a		0.8748		0.0044
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.07 (-0.82 to 0.96)	-	-0.90 (-1.50 to -0.29)
Treatment-by-subgroup p-value ^b				0.0328

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_vas0901_ger_gender_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
MD-VAS (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	44	41	8	8
Mean (SD)	55.09 (24.60)	53.66 (24.31)	45.25 (28.12)	49.13 (19.83)
Baseline for patients with data at Week 52				
Number	25	26	6	7
Mean (SD)	50.92 (23.68)	58.00 (16.54)	37.50 (28.60)	44.00 (14.62)
Week 52				
Value				
Number	25	26	6	7
Mean (SD)	19.44 (23.46)	11.92 (16.65)	17.00 (22.13)	3.86 (7.58)
Change from baseline				
Number	25	26	6	7
Mean (SD)	-31.48 (30.02)	-46.08 (22.28)	-20.50 (23.94)	-40.14 (12.98)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_race_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

MD-VAS (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-32.71 (4.09)	-40.78 (4.07)	-20.72 (5.82)	-40.57 (5.48)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.08 (-19.66 to 3.50)		-19.85 (-37.32 to -2.37)
P-value vs. Placebo+52 week taper ^a		0.1686		0.0292
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.39 (-0.94 to 0.17)	-	-1.29 (-2.43 to -0.15)
Treatment-by-subgroup p-value ^b				0.4270

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_race_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
MD-VAS (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	40	38	12	11
Mean (SD)	49.75 (26.06)	49.53 (23.48)	66.33 (17.03)	64.64 (20.44)
Baseline for patients with data at Week 52				
Number	21	25	10	8
Mean (SD)	40.48 (23.83)	52.52 (16.90)	64.80 (18.40)	62.88 (15.59)
Week 52				
Value				
Number	21	25	10	8
Mean (SD)	21.71 (25.50)	10.12 (15.54)	13.20 (15.60)	10.50 (16.19)
Change from baseline				
Number	21	25	10	8
Mean (SD)	-18.76 (26.97)	-42.40 (20.93)	-51.60 (18.95)	-52.38 (18.86)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger__region_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

MD-VAS (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-22.69 (4.44)	-37.28 (4.09)	-50.40 (4.82)	-53.16 (5.44)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-14.59 (-26.84 to -2.33)		-2.76 (-18.18 to 12.66)
P-value vs. Placebo+52 week taper ^a		0.0204		0.7091
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.71 (-1.30 to -0.11)	-	-0.17 (-1.13 to 0.79)
Treatment-by-subgroup p-value ^b				0.2536

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger__region_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per age

MD-VAS (MMRM)	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	23	32	29	17
Mean (SD)	52.87 (25.84)	52.72 (23.71)	54.14 (25.00)	53.29 (23.85)
Baseline for patients with data at Week 52				
Number	14	23	17	10
Mean (SD)	43.14 (28.14)	58.91 (14.36)	52.59 (21.56)	46.10 (19.78)
Week 52				
Value				
Number	14	23	17	10
Mean (SD)	26.93 (22.92)	13.57 (17.46)	12.41 (21.27)	2.50 (2.84)
Change from baseline				
Number	14	23	17	10
Mean (SD)	-16.21 (26.85)	-45.35 (21.07)	-40.18 (26.57)	-43.60 (20.60)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_age_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

MD-VAS (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-24.07 (5.04)	-40.82 (3.95)	-34.98 (4.09)	-43.57 (5.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-16.75 (-30.02 to -3.48)		-8.59 (-21.78 to 4.60)
P-value vs. Placebo+52 week taper ^a		0.0145		0.1954
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.87 (-1.56 to -0.18)	-	-0.51 (-1.29 to 0.27)
Treatment-by-subgroup p-value ^b				0.3111

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_age_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
MD-VAS (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	27	24	25	25
Mean (SD)	54.67 (21.33)	46.46 (26.84)	52.40 (29.10)	59.12 (18.25)
Baseline for patients with data at Week 52				
Number	16	15	15	18
Mean (SD)	48.75 (20.71)	48.93 (19.56)	47.87 (29.24)	60.11 (12.88)
Week 52				
Value				
Number	16	15	15	18
Mean (SD)	20.00 (26.41)	5.33 (5.14)	17.87 (19.24)	14.28 (19.72)
Change from baseline				
Number	16	15	15	18
Mean (SD)	-28.75 (27.07)	-43.60 (20.76)	-30.00 (31.71)	-45.83 (21.06)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_vas0901_ger__crp_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

MD-VAS (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-28.80 (4.82)	-41.03 (5.01)	-31.88 (5.13)	-39.46 (4.76)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-12.23 (-26.29 to 1.84)		-7.59 (-21.95 to 6.77)
P-value vs. Placebo+52 week taper ^a		0.0866		0.2925
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.62 (-1.33 to 0.09)	-	-0.37 (-1.07 to 0.33)
Treatment-by-subgroup p-value ^b				0.7369

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_crp_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

MD-VAS (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	28	26	24	23
Mean (SD)	53.21 (24.14)	44.46 (22.28)	54.00 (26.76)	62.48 (21.49)
Baseline for patients with data at Week 52				
Number	17	18	14	15
Mean (SD)	45.12 (26.39)	51.28 (18.25)	52.21 (23.01)	59.53 (14.59)
Week 52				
Value				
Number	17	18	14	15
Mean (SD)	20.12 (25.91)	13.72 (17.02)	17.57 (19.40)	6.00 (12.59)
Change from baseline				
Number	17	18	14	15
Mean (SD)	-25.00 (26.71)	-37.56 (22.32)	-34.64 (31.56)	-53.53 (14.77)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_vas0901_ger_esr_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

MD-VAS (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-26.80 (4.90)	-33.63 (4.84)	-37.61 (4.54)	-49.06 (4.41)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.83 (-20.74 to 7.08)		-11.45 (-24.40 to 1.50)
P-value vs. Placebo+52 week taper ^a		0.3285		0.0814
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.33 (-1.00 to 0.34)	-	-0.66 (-1.40 to 0.09)
Treatment-by-subgroup p-value ^b				0.6459

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_esr_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CS dose

MD-VAS (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	29	25	23	24
Mean (SD)	51.28 (24.70)	57.80 (15.95)	56.48 (25.92)	47.83 (28.90)
Baseline for patients with data at Week 52				
Number	18	17	13	16
Mean (SD)	46.78 (23.15)	58.76 (14.24)	50.46 (27.69)	51.06 (19.09)
Week 52				
Value				
Number	18	17	13	16
Mean (SD)	20.72 (27.04)	13.71 (18.59)	16.54 (16.12)	6.50 (10.58)
Change from baseline				
Number	18	17	13	16
Mean (SD)	-26.06 (29.15)	-45.06 (20.35)	-33.92 (29.10)	-44.56 (21.57)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_cs_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

MD-VAS (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-30.93 (5.33)	-40.07 (5.57)	-29.55 (4.04)	-41.99 (3.73)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-9.13 (-24.97 to 6.71)		-12.43 (-23.60 to -1.27)
P-value vs. Placebo+52 week taper ^a		0.2518		0.0300
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.39 (-1.08 to 0.29)	-	-0.83 (-1.57 to -0.08)
Treatment-by-subgroup p-value ^b				0.5441

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_cs_i_t_x.rtf (04SEP2024 17:58)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
MD-VAS (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	14	9	38	40
Mean (SD)	58.00 (15.90)	49.44 (30.53)	51.95 (27.78)	53.70 (22.03)
Baseline for patients with data at Week 52				
Number	8	4	23	29
Mean (SD)	50.38 (15.66)	59.50 (13.33)	47.61 (27.51)	54.41 (17.50)
Week 52				
Value				
Number	8	4	23	29
Mean (SD)	19.25 (25.59)	13.00 (16.83)	18.87 (22.46)	9.83 (15.52)
Change from baseline				
Number	8	4	23	29
Mean (SD)	-31.13 (26.74)	-46.50 (29.68)	-28.74 (30.18)	-44.59 (19.78)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_mtx_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

MD-VAS (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	-12.51 (12.56)	-38.29 (16.78)	-31.41 (3.82)	-40.45 (3.45)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-25.78 (-70.33 to 18.77)		-9.04 (-19.37 to 1.29)
P-value vs. Placebo+52 week taper ^a		0.2377		0.0852
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.70 (-1.92 to 0.51)	-	-0.48 (-1.04 to 0.07)
Treatment-by-subgroup p-value ^b				0.7856

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_mtx_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

MD-VAS (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	20	18	32	31
Mean (SD)	55.95 (22.45)	45.22 (29.53)	52.09 (26.91)	57.39 (18.27)
Baseline for patients with data at Week 52				
Number	15	12	16	21
Mean (SD)	51.60 (22.80)	46.67 (22.50)	45.25 (26.87)	59.81 (10.76)
Week 52				
Value				
Number	15	12	16	21
Mean (SD)	15.80 (19.34)	6.08 (10.48)	21.94 (26.02)	12.57 (17.47)
Change from baseline				
Number	15	12	16	21
Mean (SD)	-35.80 (26.59)	-40.58 (27.16)	-23.31 (30.52)	-47.24 (16.06)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_nrp_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

MD-VAS (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-32.47 (4.45)	-39.52 (5.00)	-26.21 (5.32)	-42.86 (4.65)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.05 (-20.77 to 6.67)		-16.65 (-31.27 to -2.03)
P-value vs. Placebo+52 week taper ^a		0.3029		0.0265
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.40 (-1.17 to 0.38)	-	-0.77 (-1.45 to -0.09)
Treatment-by-subgroup p-value ^b				0.4416

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_vas0901_ger_nrp_i_t_x.rtf (04SEP2024 17:59)

Weitere Analysen

Plot of LS Mean change from baseline



6. CRP component for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
CRP (MMRM)	Gender (Male , Female)	0.0556
	Race (Caucasian/White , All other races)	0.8209
	Region (Western Countries , Rest of World (including South America))	0.8852
	Age (Age < 70 , Age >= 70)	0.6392
	Baseline CRP (<= median , > median)	0.8838
	Baseline CS dose (<= median , > median)	0.3180
	Baseline ESR (<= median , > median)	0.6160
	MTX Add-on Therapy (Yes , No)	0.7264
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4441

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
CRP (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	15	37	45
Mean (SD)	8.17 (9.74)	8.39 (11.94)	9.34 (12.06)	10.50 (9.06)
Baseline for patients with data at Week 52				
Number	14	9	21	34
Mean (SD)	9.29 (10.30)	7.10 (11.82)	10.16 (13.67)	11.21 (9.51)
Week 52				
Value				
Number	14	9	21	34
Mean (SD)	5.92 (5.29)	9.03 (26.43)	9.27 (6.37)	2.27 (5.62)
Change from baseline				
Number	14	9	21	34
Mean (SD)	-3.38 (8.80)	1.93 (14.88)	-0.89 (14.68)	-8.93 (10.09)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_gender_i_t_x.rtf (04SEP2024 18:13)

Weitere Analysen

CRP (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-0.28 (2.53)	0.02 (3.14)	-0.57 (1.33)	-8.26 (1.09)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.31 (-7.92 to 8.53)		-7.69 (-11.11 to -4.27)
P-value vs. Placebo+52 week taper ^a		0.9400		<.0001
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.03 (-0.82 to 0.88)	-	-1.22 (-1.76 to -0.68)
Treatment-by-subgroup p-value ^b				0.0556

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t_x.rtf OUT=REPORT/OUTPUT/eff_mmrn_crp_gender_i_t_x.rtf (04SEP2024 18:13)

Weitere Analysen

Plot of LSMean change from baseline



Placebo+52 week taper / Gender : Male	21	20	21	19	16	17	16	17	16	16	14
Sarilumab 200mg q2w+14 week taper / Gender : Male	15	13	13	13	13	12	12	11	10	10	9
Placebo+52 week taper / Gender : Female	37	36	36	34	30	29	28	29	24	26	21
Sarilumab 200mg q2w+14 week taper / Gender : Female	45	44	43	43	35	37	36	35	31	35	34

Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
CRP (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	50	10	10
Mean (SD)	8.22 (11.50)	10.29 (9.89)	12.25 (9.42)	8.34 (9.60)
Baseline for patients with data at Week 52				
Number	27	36	8	7
Mean (SD)	9.11 (12.92)	10.56 (9.94)	12.17 (10.17)	9.26 (11.21)
Week 52				
Value				
Number	27	36	8	7
Mean (SD)	7.43 (5.85)	4.34 (14.00)	9.59 (7.07)	0.32 (0.20)
Change from baseline				
Number	27	36	8	7
Mean (SD)	-1.68 (13.69)	-6.22 (12.15)	-2.58 (8.36)	-8.94 (11.23)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_race_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

CRP (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	1.64 (2.16)	-5.75 (2.03)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.39 (-13.28 to -1.50)		NE
P-value vs. Placebo+52 week taper ^a		0.0145		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.62 (-1.12 to -0.13)		NE
Treatment-by-subgroup p-value ^b				0.8209

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_race_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
CRP (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	47	14	13
Mean (SD)	9.31 (11.95)	9.30 (9.66)	7.70 (8.68)	12.40 (10.27)
Baseline for patients with data at Week 52				
Number	27	35	8	8
Mean (SD)	10.06 (12.97)	10.05 (10.40)	8.99 (10.31)	11.65 (8.64)
Week 52				
Value				
Number	27	35	8	8
Mean (SD)	7.96 (6.46)	3.14 (13.37)	7.82 (5.12)	6.09 (10.81)
Change from baseline				
Number	27	35	8	8
Mean (SD)	-2.10 (13.53)	-6.91 (12.31)	-1.17 (9.28)	-5.56 (10.75)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_region_i_t_x.rtf (04SEP2024 18:17)

Weitere Analysen

CRP (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	0.09 (1.74)	-6.66 (1.64)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.75 (-11.51 to -1.99)		NE
P-value vs. Placebo+52 week taper ^a		0.0060		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.71 (-1.21 to -0.21)		NE
Treatment-by-subgroup p-value ^b				0.8852

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_region_i_t_x.rtf (04SEP2024 18:17)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
CRP (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	26
Mean (SD)	7.06 (6.06)	11.17 (10.75)	10.32 (13.82)	8.40 (8.31)
Baseline for patients with data at Week 52				
Number	16	27	19	16
Mean (SD)	7.45 (5.43)	10.81 (10.49)	11.80 (15.84)	9.56 (9.46)
Week 52				
Value				
Number	16	27	19	16
Mean (SD)	9.84 (6.94)	5.41 (16.08)	6.32 (4.93)	0.77 (0.98)
Change from baseline				
Number	16	27	19	16
Mean (SD)	2.39 (6.78)	-5.40 (13.21)	-5.48 (15.17)	-8.79 (9.38)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_age_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

CRP (MMRM)	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	5.53 (2.76)	-5.80 (2.32)	-4.94 (0.92)	-9.56 (1.02)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-11.33 (-18.66 to -4.00)		-4.63 (-7.38 to -1.87)
P-value vs. Placebo+52 week taper ^a		0.0031		0.0014
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.95 (-1.57 to -0.34)	-	-1.13 (-1.80 to -0.46)
Treatment-by-subgroup p-value ^b				0.6392

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_age_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

Plot of LSMean change from baseline



Placebo+52 week taper / Age : Age < 70	25	25	25	24	19	19	16	18	18	19	16
Sarilumab 200mg q2w+14 week taper / Age : Age < 70	34	33	33	31	28	26	26	25	25	28	27
Placebo+52 week taper / Age : Age >= 70	33	31	32	29	27	27	28	28	22	23	19
Sarilumab 200mg q2w+14 week taper / Age : Age >= 70	26	24	23	25	20	23	22	21	16	17	16

Weitere Analysen

Per baseline CRP

CRP (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	2.75 (1.84)	2.35 (1.55)	15.99 (13.18)	16.63 (9.06)
Baseline for patients with data at Week 52				
Number	17	20	18	23
Mean (SD)	2.81 (1.81)	2.49 (1.48)	16.42 (14.24)	17.18 (9.22)
Week 52				
Value				
Number	17	20	18	23
Mean (SD)	6.17 (5.52)	0.66 (1.26)	9.59 (6.32)	6.32 (17.30)
Change from baseline				
Number	17	20	18	23
Mean (SD)	3.36 (5.55)	-1.83 (1.62)	-6.84 (15.28)	-10.86 (15.15)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_crp_i_t_x.rtf (04SEP2024 18:16)

Weitere Analysen

CRP (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	3.84 (1.25)	-2.20 (1.28)	-1.70 (3.98)	-10.42 (3.61)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.04 (-9.64 to -2.45)		-8.72 (-19.48 to 2.04)
P-value vs. Placebo+52 week taper ^a		0.0014		0.1101
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.09 (-1.74 to -0.44)	-	-0.50 (-1.12 to 0.12)
Treatment-by-subgroup p-value ^b				0.8838

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_crp_i_t_x.rtf (04SEP2024 18:16)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

CRP (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	5.59 (6.16)	5.79 (6.01)	12.73 (14.24)	13.63 (11.02)
Baseline for patients with data at Week 52				
Number	19	22	16	21
Mean (SD)	6.33 (6.84)	6.02 (5.64)	13.95 (15.86)	14.88 (11.64)
Week 52				
Value				
Number	19	22	16	21
Mean (SD)	8.68 (7.05)	0.80 (1.60)	7.03 (4.83)	6.71 (18.07)
Change from baseline				
Number	19	22	16	21
Mean (SD)	2.35 (8.66)	-5.22 (5.04)	-6.92 (14.77)	-8.17 (16.35)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_esr_i_t_x.rtf (04SEP2024 18:16)

Weitere Analysen

CRP (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	2.45 (1.04)	-4.77 (1.04)	-0.96 (3.87)	-8.50 (3.53)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.22 (-10.17 to -4.27)		-7.54 (-18.03 to 2.96)
P-value vs. Placebo+52 week taper ^a		<.0001		0.1557
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.51 (-2.12 to -0.89)	-	-0.47 (-1.12 to 0.18)
Treatment-by-subgroup p-value ^b				0.6160

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_esr_i_t_x.rtf (04SEP2024 18:16)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

CRP (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	30
Mean (SD)	10.62 (13.47)	12.02 (10.19)	6.51 (6.35)	7.92 (9.08)
Baseline for patients with data at Week 52				
Number	22	23	13	20
Mean (SD)	11.91 (14.32)	12.37 (11.07)	6.27 (6.81)	8.02 (8.34)
Week 52				
Value				
Number	22	23	13	20
Mean (SD)	8.37 (5.83)	6.11 (17.32)	7.18 (6.72)	0.90 (1.82)
Change from baseline				
Number	22	23	13	20
Mean (SD)	-3.54 (13.95)	-6.26 (14.60)	0.91 (9.67)	-7.12 (8.18)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_cs_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

CRP (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-0.68 (2.42)	-5.75 (2.50)	-2.34 (2.28)	-7.12 (2.02)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-5.07 (-12.03 to 1.89)		-4.78 (-10.90 to 1.35)
P-value vs. Placebo+52 week taper ^a		0.1501		0.1236
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.43 (-1.02 to 0.16)	-	-0.54 (-1.23 to 0.15)
Treatment-by-subgroup p-value ^b				0.3180

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_cs_i_t_x.rtf (04SEP2024 18:14)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

CRP (MMRM)	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	12	41	48
Mean (SD)	8.16 (8.96)	11.04 (9.16)	9.23 (12.10)	9.70 (10.01)
Baseline for patients with data at Week 52				
Number	9	7	26	36
Mean (SD)	8.09 (9.53)	11.10 (11.62)	10.41 (13.20)	10.20 (9.86)
Week 52				
Value				
Number	9	7	26	36
Mean (SD)	5.63 (4.02)	2.00 (2.87)	8.72 (6.56)	4.01 (14.02)
Change from baseline				
Number	9	7	26	36
Mean (SD)	-2.46 (6.79)	-9.10 (11.75)	-1.69 (14.14)	-6.18 (12.06)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_mtx_i_t_x.rtf (04SEP2024 18:15)

Weitere Analysen

CRP (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	NE	NE	0.95 (2.20)	-5.94 (2.00)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		NE		-6.89 (-12.80 to -0.98)
P-value vs. Placebo+52 week taper ^a		NE		0.0229
Hedges'g vs. Placebo+52 week taper (95% CI)		NE	-	-0.58 (-1.09 to -0.08)
Treatment-by-subgroup p-value ^b				0.7264

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_mtx_i_t_x.rtf (04SEP2024 18:15)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

CRP (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	24	35	36
Mean (SD)	9.59 (14.65)	9.87 (11.98)	8.47 (8.42)	10.04 (8.20)
Baseline for patients with data at Week 52				
Number	16	16	19	27
Mean (SD)	12.38 (16.86)	11.22 (12.77)	7.65 (6.06)	9.83 (8.21)
Week 52				
Value				
Number	16	16	19	27
Mean (SD)	8.21 (6.19)	5.80 (19.73)	7.69 (6.20)	2.43 (6.21)
Change from baseline				
Number	16	16	19	27
Mean (SD)	-4.17 (16.77)	-5.42 (15.99)	0.04 (7.45)	-7.40 (8.98)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_crp_ger_nrp_i_t_x.rtf (04SEP2024 18:15)

Weitere Analysen

CRP (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	NE	NE	1.00 (1.44)	-6.82 (1.32)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		NE		-7.83 (-11.73 to -3.92)
P-value vs. Placebo+52 week taper ^a		NE		0.0002
Hedges'g vs. Placebo+52 week taper (95% CI)		NE	-	-1.17 (-1.75 to -0.59)
Treatment-by-subgroup p-value ^b				0.4441

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_crp_ger_nrp_i_t_x.rtf (04SEP2024 18:15)

Weitere Analysen

Plot of LS Mean change from baseline



7. HAQ-DI standardized score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI standardized score (MMRM)	Gender (Male , Female)	0.7013
	Race (Caucasian/White , All other races)	0.8175
	Region (Western Countries , Rest of World (including South America))	0.9047
	Age (Age < 70 , Age >= 70)	0.6377
	Baseline CRP (<= median , > median)	0.8460
	Baseline CS dose (<= median , > median)	0.7646
	Baseline ESR (<= median , > median)	0.3603
	MTX Add-on Therapy (Yes , No)	0.1127
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4075

Weitere Analysen

Per gender

HAQ-DI standardized score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	0.84 (0.66)	0.79 (0.66)	1.32 (0.75)	1.24 (0.74)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	0.71 (0.68)	0.75 (0.60)	1.12 (0.80)	1.27 (0.67)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	0.41 (0.45)	0.23 (0.34)	0.99 (0.68)	0.85 (0.65)
Change from baseline				
Number	14	11	21	31
Mean (SD)	-0.29 (0.47)	-0.52 (0.60)	-0.13 (0.75)	-0.42 (0.71)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_gender_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-0.30 (0.09)	-0.52 (0.10)	-0.03 (0.13)	-0.36 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.22 (-0.51 to 0.06)		-0.33 (-0.66 to 0.00)
P-value vs. Placebo+52 week taper ^a		0.1190		0.0532
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.63 (-1.44 to 0.17)	-	-0.55 (-1.10 to 0.01)
Treatment-by-subgroup p-value ^b				0.7013

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_gender_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per race

HAQ-DI standardized score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	1.17 (0.76)	1.11 (0.71)	1.03 (0.72)	1.26 (0.94)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	1.00 (0.82)	1.19 (0.70)	0.75 (0.54)	0.88 (0.60)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	0.72 (0.65)	0.65 (0.62)	0.89 (0.69)	0.88 (0.76)
Change from baseline				
Number	28	35	7	7
Mean (SD)	-0.28 (0.63)	-0.54 (0.68)	0.14 (0.64)	0.00 (0.43)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_race_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-0.22 (0.10)	-0.47 (0.09)	0.26 (0.21)	0.00 (0.22)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.25 (-0.52 to 0.02)		-0.26 (-0.91 to 0.39)
P-value vs. Placebo+52 week taper ^a		0.0647		0.4058
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.47 (-0.97 to 0.03)	-	-0.43 (-1.51 to 0.65)
Treatment-by-subgroup p-value ^b				0.8175

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_race_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

HAQ-DI standardized score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	1.10 (0.69)	1.04 (0.73)	1.29 (0.93)	1.48 (0.70)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	0.92 (0.70)	1.03 (0.66)	1.05 (0.96)	1.54 (0.66)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	0.74 (0.63)	0.62 (0.65)	0.80 (0.74)	0.94 (0.60)
Change from baseline				
Number	25	33	10	9
Mean (SD)	-0.18 (0.74)	-0.41 (0.66)	-0.25 (0.36)	-0.60 (0.74)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger__region_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-0.11 (0.11)	-0.36 (0.10)	-0.25 (0.15)	-0.53 (0.16)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.25 (-0.55 to 0.05)		-0.28 (-0.75 to 0.19)
P-value vs. Placebo+52 week taper ^a		0.1064		0.2287
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.43 (-0.95 to 0.09)	-	-0.56 (-1.50 to 0.38)
Treatment-by-subgroup p-value ^b				0.9047

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger__region_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

HAQ-DI standardized score (MMRM)	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	1.03 (0.51)	1.06 (0.70)	1.24 (0.89)	1.24 (0.80)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	0.84 (0.55)	1.16 (0.68)	1.04 (0.91)	1.10 (0.72)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	0.73 (0.59)	0.64 (0.61)	0.78 (0.71)	0.78 (0.72)
Change from baseline				
Number	15	27	20	15
Mean (SD)	-0.12 (0.75)	-0.52 (0.68)	-0.26 (0.58)	-0.33 (0.67)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_ger_age_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-0.16 (0.14)	-0.41 (0.12)	-0.18 (0.12)	-0.30 (0.13)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.25 (-0.63 to 0.13)		-0.12 (-0.47 to 0.24)
P-value vs. Placebo+52 week taper ^a		0.1911		0.5071
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.41 (-1.04 to 0.21)	-	-0.22 (-0.90 to 0.45)
Treatment-by-subgroup p-value ^b				0.6377

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_ger_age_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

HAQ-DI standardized score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	1.07 (0.64)	0.88 (0.68)	1.24 (0.86)	1.35 (0.74)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	0.93 (0.67)	0.92 (0.69)	0.98 (0.90)	1.32 (0.64)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	0.64 (0.60)	0.51 (0.57)	0.89 (0.71)	0.84 (0.67)
Change from baseline				
Number	19	19	16	23
Mean (SD)	-0.29 (0.58)	-0.41 (0.71)	-0.09 (0.72)	-0.48 (0.66)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger__crp_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-0.23 (0.12)	-0.43 (0.12)	-0.07 (0.14)	-0.37 (0.12)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.20 (-0.53 to 0.14)		-0.30 (-0.69 to 0.08)
P-value vs. Placebo+52 week taper ^a		0.2453		0.1158
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.38 (-1.02 to 0.27)	-	-0.51 (-1.15 to 0.13)
Treatment-by-subgroup p-value ^b				0.8460

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_ger_crp_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

HAQ-DI standardized score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	1.23 (0.67)	0.94 (0.76)	1.05 (0.84)	1.30 (0.70)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	1.06 (0.70)	1.07 (0.76)	0.83 (0.85)	1.20 (0.62)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	0.83 (0.74)	0.58 (0.72)	0.67 (0.55)	0.79 (0.56)
Change from baseline				
Number	19	21	16	21
Mean (SD)	-0.23 (0.65)	-0.49 (0.68)	-0.16 (0.67)	-0.41 (0.68)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_esr_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-0.12 (0.13)	-0.45 (0.13)	-0.21 (0.13)	-0.31 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.33 (-0.71 to 0.04)		-0.10 (-0.45 to 0.24)
P-value vs. Placebo+52 week taper ^a		0.0788		0.5463
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.56 (-1.18 to 0.07)	-	-0.20 (-0.86 to 0.46)
Treatment-by-subgroup p-value ^b				0.3603

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_esr_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CS dose

HAQ-DI standardized score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	1.00 (0.70)	1.26 (0.67)	1.35 (0.78)	1.00 (0.80)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	0.81 (0.73)	1.22 (0.64)	1.20 (0.80)	1.04 (0.75)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	0.80 (0.67)	0.73 (0.60)	0.69 (0.64)	0.64 (0.70)
Change from baseline				
Number	22	23	13	19
Mean (SD)	-0.01 (0.67)	-0.49 (0.61)	-0.51 (0.48)	-0.40 (0.76)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_cs_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-0.12 (0.12)	-0.39 (0.12)	-0.17 (0.16)	-0.39 (0.14)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.27 (-0.60 to 0.06)		-0.22 (-0.65 to 0.20)
P-value vs. Placebo+52 week taper ^a		0.1097		0.2974
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.49 (-1.09 to 0.11)	-	-0.37 (-1.09 to 0.34)
Treatment-by-subgroup p-value ^b				0.7646

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_ger_cs_i_t_x.rtf (04SEP2024 18:00)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

HAQ-DI standardized score (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	1.13 (0.82)	1.39 (0.81)	1.16 (0.73)	1.08 (0.72)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	0.81 (0.83)	1.53 (0.64)	1.01 (0.75)	1.08 (0.68)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	0.63 (0.57)	1.28 (0.55)	0.81 (0.69)	0.61 (0.62)
Change from baseline				
Number	10	5	25	37
Mean (SD)	-0.19 (0.53)	-0.25 (0.29)	-0.20 (0.70)	-0.48 (0.71)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_mtx_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

HAQ-DI standardized score (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	-0.07 (0.15)	0.03 (0.20)	-0.14 (0.11)	-0.46 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		0.10 (-0.43 to 0.63)		-0.31 (-0.60 to -0.02)
P-value vs. Placebo+52 week taper ^a		0.7099		0.0372
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.20 (-0.89 to 1.28)	-	-0.54 (-1.05 to -0.03)
Treatment-by-subgroup p-value ^b				0.1127

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_mtx_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

HAQ-DI standardized score (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	1.20 (0.79)	1.06 (0.88)	1.12 (0.74)	1.18 (0.65)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	1.05 (0.85)	1.01 (0.77)	0.86 (0.70)	1.21 (0.64)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	0.69 (0.68)	0.48 (0.68)	0.82 (0.65)	0.80 (0.61)
Change from baseline				
Number	17	15	18	27
Mean (SD)	-0.36 (0.63)	-0.53 (0.66)	-0.04 (0.64)	-0.41 (0.69)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haqdi_ger_nrp_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

HAQ-DI standardized score (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-0.34 (0.13)	-0.49 (0.14)	0.02 (0.13)	-0.35 (0.11)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.15 (-0.54 to 0.23)		-0.37 (-0.71 to -0.02)
P-value vs. Placebo+52 week taper ^a		0.4203		0.0374
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.28 (-0.99 to 0.42)	-	-0.64 (-1.24 to -0.04)
Treatment-by-subgroup p-value ^b				0.4075

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haqdi_ger_nrp_i_t_x.rtf (04SEP2024 18:01)

Weitere Analysen

Plot of LSMean change from baseline



8. HAQ-DI pain score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI pain score (MMRM)	Gender (Male , Female)	0.5523
	Race (Caucasian/White , All other races)	0.9795
	Region (Western Countries , Rest of World (including South America))	0.0422
	Age (Age < 70 , Age >= 70)	0.0739
	Baseline CRP (<= median , > median)	0.4217
	Baseline CS dose (<= median , > median)	0.5484
	Baseline ESR (<= median , > median)	0.1037
	MTX Add-on Therapy (Yes , No)	0.5201
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4177

Weitere Analysen

Per gender

HAQ-DI pain score (MMRM)	Gender			
	Placebo (N=21)	Male (N=36) Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Female (N=82) Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	50.14 (23.04)	40.50 (27.90)	57.43 (23.18)	46.52 (28.60)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	49.79 (23.83)	38.55 (28.09)	57.38 (23.44)	46.00 (24.59)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	25.79 (22.69)	18.18 (19.71)	41.14 (27.62)	30.16 (27.86)
Change from baseline				
Number	14	11	21	31
Mean (SD)	-24.00 (28.41)	-20.36 (27.48)	-16.24 (41.12)	-15.84 (36.05)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_gender_gender_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

HAQ-DI pain score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-19.53 (5.48)	-21.92 (6.25)	-7.48 (6.17)	-20.84 (5.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-2.40 (-19.62 to 14.82)		-13.35 (-29.50 to 2.79)
P-value vs. Placebo+52 week taper ^a		0.7779		0.1035
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.11 (-0.93 to 0.70)	-	-0.47 (-1.03 to 0.10)
Treatment-by-subgroup p-value ^b				0.5523

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_gender_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

HAQ-DI pain score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	55.29 (22.04)	44.24 (28.41)	52.40 (29.38)	49.56 (28.97)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	55.61 (23.66)	45.23 (26.36)	49.29 (24.21)	38.14 (20.71)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	31.14 (25.89)	23.57 (21.49)	50.43 (25.02)	44.29 (41.08)
Change from baseline				
Number	28	35	7	7
Mean (SD)	-24.46 (34.97)	-21.66 (32.27)	1.14 (36.78)	6.14 (33.64)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_race_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

HAQ-DI pain score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-17.29 (4.44)	-24.70 (4.03)	2.20 (13.06)	2.82 (13.14)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-7.41 (-19.45 to 4.63)		0.62 (-39.79 to 41.03)
P-value vs. Placebo+52 week taper ^a		0.2247		0.9742
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.31 (-0.81 to 0.19)	-	0.02 (-1.09 to 1.12)
Treatment-by-subgroup p-value ^b				0.9795

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger_race_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

HAQ-DI pain score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	53.89 (23.65)	41.11 (27.35)	57.64 (22.30)	58.77 (28.31)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	52.84 (24.62)	39.39 (22.86)	58.10 (21.37)	61.11 (28.34)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	39.00 (28.75)	23.64 (25.92)	25.00 (17.33)	39.44 (25.17)
Change from baseline				
Number	25	33	10	9
Mean (SD)	-13.84 (38.96)	-15.76 (30.78)	-33.10 (25.24)	-21.67 (44.92)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger__region_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

HAQ-DI pain score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-6.33 (5.55)	-20.57 (4.88)	-27.22 (6.68)	-19.82 (7.36)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-14.23 (-29.22 to 0.76)		7.40 (-13.33 to 28.13)
P-value vs. Placebo+52 week taper ^a		0.0624		0.4650
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.51 (-1.04 to 0.03)	-	0.33 (-0.59 to 1.25)
Treatment-by-subgroup p-value ^b				0.0422

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_region_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

HAQ-DI pain score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	56.60 (23.01)	42.09 (27.01)	53.42 (23.60)	49.29 (30.13)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	51.20 (24.97)	44.59 (24.83)	56.70 (22.79)	43.07 (27.30)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	43.60 (21.01)	24.37 (22.04)	28.55 (28.85)	31.80 (32.91)
Change from baseline				
Number	15	27	20	15
Mean (SD)	-7.60 (37.74)	-20.22 (28.87)	-28.15 (33.45)	-11.27 (41.62)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_age_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

HAQ-DI pain score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-2.70 (5.56)	-22.47 (4.24)	-18.83 (7.03)	-14.61 (8.13)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-19.78 (-33.90 to -5.65)		4.22 (-17.77 to 26.21)
P-value vs. Placebo+52 week taper ^a		0.0070		0.7014
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.89 (-1.53 to -0.25)	-	0.13 (-0.56 to 0.82)
Treatment-by-subgroup p-value ^b				0.0739

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_age_i_t_x.rtf (04SEP2024 18:02)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

HAQ-DI pain score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	53.58 (23.34)	38.81 (25.93)	56.19 (23.40)	50.52 (29.56)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	55.05 (23.66)	36.47 (24.40)	53.50 (24.17)	50.30 (25.02)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	33.32 (27.37)	28.79 (29.13)	37.00 (26.24)	25.57 (24.27)
Change from baseline				
Number	19	19	16	23
Mean (SD)	-21.74 (28.19)	-7.68 (32.86)	-16.50 (44.93)	-24.74 (33.19)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger__crp_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

HAQ-DI pain score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-15.52 (6.47)	-13.16 (6.58)	-9.97 (6.16)	-25.74 (5.21)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.36 (-16.84 to 21.56)		-15.77 (-31.99 to 0.45)
P-value vs. Placebo+52 week taper ^a		0.8059		0.0564
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.08 (-0.58 to 0.75)	-	-0.63 (-1.27 to 0.02)
Treatment-by-subgroup p-value ^b				0.4217

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

HAQ-DI pain score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	53.42 (22.03)	42.67 (28.96)	56.37 (24.79)	47.16 (28.04)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	51.68 (21.77)	44.43 (27.89)	57.50 (25.86)	43.67 (23.37)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	42.11 (28.19)	25.29 (26.51)	26.56 (22.41)	28.76 (26.59)
Change from baseline				
Number	19	21	16	21
Mean (SD)	-9.58 (32.07)	-19.14 (33.24)	-30.94 (38.59)	-14.90 (34.94)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_esr_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

HAQ-DI pain score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-5.19 (6.28)	-20.35 (6.04)	-21.00 (6.32)	-21.61 (5.55)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-15.16 (-32.74 to 2.42)		-0.60 (-17.84 to 16.63)
P-value vs. Placebo+52 week taper ^a		0.0894		0.9441
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.54 (-1.17 to 0.09)	-	-0.02 (-0.69 to 0.65)
Treatment-by-subgroup p-value ^b				0.1037

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_esr_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CS dose

HAQ-DI pain score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	54.38 (23.91)	46.37 (26.07)	55.38 (22.64)	43.68 (30.95)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	56.59 (24.11)	43.91 (22.19)	50.54 (23.01)	44.21 (29.49)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	39.77 (28.56)	29.26 (24.77)	26.92 (21.32)	24.32 (28.46)
Change from baseline				
Number	22	23	13	19
Mean (SD)	-16.82 (40.09)	-14.65 (32.53)	-23.62 (29.83)	-19.89 (35.85)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_cs_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

HAQ-DI pain score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-6.79 (5.77)	-21.11 (5.67)	-19.82 (7.12)	-21.64 (5.94)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-14.31 (-30.79 to 2.16)		-1.81 (-20.60 to 16.98)
P-value vs. Placebo+52 week taper ^a		0.0873		0.8465
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.52 (-1.12 to 0.08)	-	-0.07 (-0.78 to 0.65)
Treatment-by-subgroup p-value ^b				0.5484

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_cs_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

HAQ-DI pain score (MMRM)	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	59.71 (20.11)	43.55 (37.65)	52.76 (24.30)	45.43 (26.15)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	57.10 (22.57)	55.00 (27.06)	53.24 (24.30)	42.57 (25.21)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	35.10 (21.83)	38.00 (31.31)	34.96 (28.61)	25.54 (25.67)
Change from baseline				
Number	10	5	25	37
Mean (SD)	-22.00 (26.52)	-17.00 (41.68)	-18.28 (39.99)	-17.03 (33.23)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger_mtx_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

HAQ-DI pain score (MMRM)	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	-16.06 (8.19)	-16.92 (11.52)	-10.45 (5.43)	-20.40 (4.49)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.86 (-30.13 to 28.40)		-9.96 (-24.14 to 4.22)
P-value vs. Placebo+52 week taper ^a		0.9520		0.1660
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.03 (-1.13 to 1.06)	-	-0.36 (-0.88 to 0.15)
Treatment-by-subgroup p-value ^b				0.5201

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger_mtx_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

HAQ-DI pain score (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	51.04 (23.38)	43.18 (32.24)	57.26 (23.08)	46.22 (26.04)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	52.29 (24.88)	43.47 (30.63)	56.28 (22.77)	44.37 (22.65)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	25.41 (23.10)	20.47 (23.95)	44.06 (26.97)	30.67 (27.24)
Change from baseline				
Number	17	15	18	27
Mean (SD)	-26.88 (35.16)	-23.00 (33.87)	-12.22 (36.91)	-13.70 (33.86)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0846_ger__nrp_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

HAQ-DI pain score (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-21.25 (5.82)	-26.23 (6.18)	-1.58 (6.38)	-19.34 (5.33)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.97 (-22.29 to 12.34)		-17.76 (-34.65 to -0.87)
P-value vs. Placebo+52 week taper ^a		0.5640		0.0396
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.20 (-0.91 to 0.50)	-	-0.64 (-1.25 to -0.03)
Treatment-by-subgroup p-value ^b				0.4177

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0846_ger_nrp_i_t_x.rtf (04SEP2024 18:03)

Weitere Analysen

Plot of LS Mean change from baseline



9. HAQ-DI patient global assessment score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI patient global assessment score (MMRM)	Gender (Male , Female)	0.0469
	Race (Caucasian/White , All other races)	0.9992
	Region (Western Countries , Rest of World (including South America))	0.0245
	Age (Age < 70 , Age >= 70)	0.0082
	Baseline CRP (<= median , > median)	0.8385
	Baseline CS dose (<= median , > median)	0.6531
	Baseline ESR (<= median , > median)	0.0643
	MTX Add-on Therapy (Yes , No)	0.4553
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.9047

Weitere Analysen

Per gender

HAQ-DI patient global assessment score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	44.76 (25.75)	35.14 (23.40)	53.86 (24.66)	47.55 (25.98)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	33.29 (18.12)	33.64 (20.72)	55.48 (25.00)	46.16 (24.60)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	42.14 (30.04)	14.55 (14.26)	34.62 (24.13)	33.58 (26.83)
Change from baseline				
Number	14	11	21	31
Mean (SD)	8.86 (34.78)	-19.09 (21.69)	-20.86 (31.54)	-12.58 (35.25)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_gender_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	7.97 (6.67)	-17.38 (7.52)	-13.91 (5.60)	-15.16 (4.65)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-25.35 (-45.89 to -4.81)		-1.25 (-15.87 to 13.37)
P-value vs. Placebo+52 week taper ^a		0.0173		0.8651
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.99 (-1.79 to -0.19)	-	-0.05 (-0.61 to 0.51)
Treatment-by-subgroup p-value ^b				0.0469

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_gender_i_t_x.rtf (04SEP2024 18:04)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

HAQ-DI patient global assessment score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	51.06 (25.14)	43.69 (25.27)	48.20 (26.85)	49.22 (29.32)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	47.46 (26.55)	43.77 (24.56)	43.14 (17.15)	38.43 (22.53)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	34.93 (27.05)	26.14 (24.22)	48.43 (22.61)	40.86 (29.93)
Change from baseline				
Number	28	35	7	7
Mean (SD)	-12.54 (37.32)	-17.63 (33.27)	5.29 (24.66)	2.43 (19.77)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_race_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-9.16 (4.78)	-18.08 (4.33)	8.14 (8.29)	0.62 (8.58)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-8.93 (-21.77 to 3.92)		-7.52 (-33.18 to 18.13)
P-value vs. Placebo+52 week taper ^a		0.1707		0.5396
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.35 (-0.85 to 0.15)	-	-0.32 (-1.41 to 0.77)
Treatment-by-subgroup p-value ^b				0.9992

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_race_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

HAQ-DI patient global assessment score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	49.86 (25.81)	43.20 (25.82)	52.79 (24.07)	49.23 (25.94)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	43.60 (25.01)	40.82 (23.54)	54.10 (23.82)	50.44 (25.83)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	41.84 (26.50)	25.36 (25.58)	27.10 (24.60)	40.44 (22.47)
Change from baseline				
Number	25	33	10	9
Mean (SD)	-1.76 (32.48)	-15.45 (31.48)	-27.00 (38.24)	-10.00 (36.05)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_region_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-0.05 (5.02)	-15.75 (4.48)	-18.54 (7.64)	-9.93 (8.14)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-15.70 (-29.11 to -2.29)		8.61 (-14.69 to 31.92)
P-value vs. Placebo+52 week taper ^a		0.0223		0.4498
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.61 (-1.13 to -0.09)	-	0.34 (-0.58 to 1.27)
Treatment-by-subgroup p-value ^b				0.0245

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_region_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per age

HAQ-DI patient global assessment score (MMRM)	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	55.44 (22.88)	43.12 (23.31)	46.88 (26.61)	46.58 (29.24)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	49.47 (22.31)	43.33 (23.27)	44.45 (26.87)	42.07 (26.23)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	49.53 (24.42)	25.56 (23.17)	28.70 (24.90)	34.07 (29.19)
Change from baseline				
Number	15	27	20	15
Mean (SD)	0.07 (36.51)	-17.78 (29.97)	-15.75 (34.21)	-8.00 (35.89)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_age_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	5.15 (6.07)	-20.32 (4.64)	-12.69 (5.98)	-5.68 (6.92)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-25.47 (-40.88 to -10.06)		7.01 (-11.37 to 25.40)
P-value vs. Placebo+52 week taper ^a		0.0017		0.4470
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.05 (-1.69 to -0.41)	-	0.26 (-0.42 to 0.93)
Treatment-by-subgroup p-value ^b				0.0082

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_age_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

HAQ-DI patient global assessment score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	52.00 (23.26)	37.67 (23.09)	48.93 (27.67)	50.55 (26.78)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	50.11 (22.33)	35.79 (22.27)	42.44 (27.59)	48.74 (24.36)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	36.74 (27.93)	26.26 (28.82)	38.69 (25.52)	30.52 (22.80)
Change from baseline				
Number	19	19	16	23
Mean (SD)	-13.37 (30.08)	-9.53 (32.45)	-3.75 (41.59)	-18.22 (32.04)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_crp_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-9.64 (6.45)	-13.93 (6.57)	-3.01 (5.90)	-14.10 (5.02)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-4.29 (-23.28 to 14.71)		-11.09 (-26.69 to 4.51)
P-value vs. Placebo+52 week taper ^a		0.6523		0.1595
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.15 (-0.81 to 0.51)	-	-0.46 (-1.10 to 0.19)
Treatment-by-subgroup p-value ^b				0.8385

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

HAQ-DI patient global assessment score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	49.74 (23.97)	44.00 (28.02)	51.52 (27.02)	45.03 (24.04)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	48.26 (21.24)	47.24 (27.90)	44.63 (29.06)	38.52 (19.18)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	43.95 (26.16)	24.05 (23.98)	30.13 (25.65)	33.14 (26.66)
Change from baseline				
Number	19	21	16	21
Mean (SD)	-4.32 (27.19)	-23.19 (30.13)	-14.50 (43.83)	-5.38 (32.28)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_esr_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-3.00 (5.37)	-21.02 (5.28)	-11.45 (6.58)	-9.99 (5.81)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-18.03 (-33.15 to -2.91)		1.46 (-16.26 to 19.17)
P-value vs. Placebo+52 week taper ^a		0.0204		0.8691
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.75 (-1.37 to -0.12)	-	0.05 (-0.60 to 0.71)
Treatment-by-subgroup p-value ^b				0.0643

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_esr_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

HAQ-DI patient global assessment score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	48.79 (27.39)	45.90 (24.05)	53.08 (22.12)	43.11 (27.81)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	45.77 (26.79)	41.26 (21.81)	48.00 (21.97)	44.84 (27.00)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	35.82 (24.34)	29.70 (22.21)	40.69 (30.56)	27.26 (29.50)
Change from baseline				
Number	22	23	13	19
Mean (SD)	-9.95 (33.29)	-11.57 (30.91)	-7.31 (40.52)	-17.58 (34.10)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_cs_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-6.61 (4.85)	-13.54 (4.85)	-7.06 (8.24)	-16.90 (6.90)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-6.94 (-20.69 to 6.82)		-9.83 (-31.56 to 11.90)
P-value vs. Placebo+52 week taper ^a		0.3168		0.3664
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.30 (-0.89 to 0.29)	-	-0.32 (-1.04 to 0.39)
Treatment-by-subgroup p-value ^b				0.6531

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_cs_i_t_x.rtf (04SEP2024 18:05)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

HAQ-DI patient global assessment score (MMRM)	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	46.53 (17.92)	52.45 (32.41)	52.24 (27.72)	42.70 (23.96)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	40.40 (16.57)	61.40 (29.81)	49.08 (27.30)	40.38 (22.50)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	39.70 (22.32)	43.40 (16.01)	36.80 (28.36)	26.59 (25.99)
Change from baseline				
Number	10	5	25	37
Mean (SD)	-0.70 (18.75)	-18.00 (34.57)	-12.28 (40.27)	-13.78 (32.26)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_mtx_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	-6.72 (5.83)	-9.63 (9.08)	-5.81 (5.43)	-16.24 (4.49)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-2.91 (-25.96 to 20.13)		-10.43 (-24.57 to 3.71)
P-value vs. Placebo+52 week taper ^a		0.7961		0.1460
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.15 (-1.32 to 1.02)	-	-0.38 (-0.89 to 0.13)
Treatment-by-subgroup p-value ^b				0.4553

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_mtx_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

HAQ-DI patient global assessment score (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	45.13 (23.75)	43.95 (31.41)	54.14 (25.85)	44.92 (22.06)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	46.53 (26.32)	44.80 (30.62)	46.67 (24.04)	41.81 (20.11)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	31.82 (22.53)	20.87 (21.96)	43.11 (29.31)	32.89 (26.63)
Change from baseline				
Number	17	15	18	27
Mean (SD)	-14.71 (35.30)	-23.93 (27.94)	-3.56 (35.98)	-8.93 (33.52)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_haq0847_ger_nrp_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

HAQ-DI patient global assessment score (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-10.46 (5.28)	-22.06 (5.73)	-2.04 (6.53)	-11.94 (5.43)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-11.61 (-27.37 to 4.16)		-9.90 (-26.91 to 7.11)
P-value vs. Placebo+52 week taper ^a		0.1443		0.2492
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.52 (-1.22 to 0.19)	-	-0.35 (-0.95 to 0.25)
Treatment-by-subgroup p-value ^b				0.9047

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_haq0847_ger_nrp_i_t_x.rtf (04SEP2024 18:06)

Weitere Analysen

Plot of LSMean change from baseline



10. SF-36 mental component summary score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
SF-36-mental component summary score (MMRM)	Gender (Male , Female)	0.4056
	Race (Caucasian/White , All other races)	0.4165
	Region (Western Countries , Rest of World (including South America))	0.6795
	Age (Age < 70 , Age >= 70)	0.6697
	Baseline CRP (<= median , > median)	0.5374
	Baseline CS dose (<= median , > median)	0.3258
	Baseline ESR (<= median , > median)	0.0299
	MTX Add-on Therapy (Yes , No)	0.2402
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7287

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
SF-36-mental component summary score (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	49.77 (10.04)	50.34 (9.91)	42.27 (13.82)	45.72 (11.97)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	52.02 (8.29)	49.93 (10.15)	42.40 (14.68)	46.66 (12.22)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	52.42 (11.47)	54.40 (7.62)	43.07 (11.79)	49.57 (10.21)
Change from baseline				
Number	14	11	21	31
Mean (SD)	0.40 (11.56)	4.47 (5.82)	0.67 (13.84)	2.91 (10.97)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_gender_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	1.03 (2.37)	4.19 (2.65)	-3.58 (2.00)	3.29 (1.73)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		3.16 (-4.12 to 10.44)		6.88 (1.57 to 12.19)
P-value vs. Placebo+52 week taper ^a		0.3819		0.0119
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.35 (-0.45 to 1.15)	-	0.72 (0.16 to 1.27)
Treatment-by-subgroup p-value ^b				0.4056

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_gender_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
SF-36-mental component summary score (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	44.90 (12.24)	48.36 (11.21)	45.43 (16.99)	38.51 (10.56)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	46.12 (12.14)	48.81 (11.60)	46.78 (18.25)	41.04 (10.57)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	48.62 (10.95)	52.27 (7.53)	39.57 (15.95)	43.64 (15.99)
Change from baseline				
Number	28	35	7	7
Mean (SD)	2.50 (11.33)	3.46 (9.76)	-7.21 (16.18)	2.60 (11.02)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_race_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-0.01 (1.49)	3.63 (1.38)	-7.96 (4.99)	1.58 (5.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		3.65 (-0.40 to 7.70)		9.53 (-5.86 to 24.93)
P-value vs. Placebo+52 week taper ^a		0.0771		0.2054
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.45 (-0.05 to 0.95)	-	0.68 (-0.42 to 1.77)
Treatment-by-subgroup p-value ^b				0.4165

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_race_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
SF-36-mental component summary score (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	44.99 (13.78)	47.89 (11.63)	44.98 (10.66)	43.16 (11.13)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	45.66 (14.75)	49.21 (11.52)	47.72 (9.01)	41.30 (10.68)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	44.93 (13.62)	50.89 (9.87)	51.51 (7.18)	50.61 (9.88)
Change from baseline				
Number	25	33	10	9
Mean (SD)	-0.73 (14.66)	1.68 (9.41)	3.79 (5.39)	9.31 (9.51)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__region_i_t_x.rtf (04SEP2024 18:13)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-4.06 (1.97)	1.81 (1.78)	3.03 (2.29)	7.48 (2.50)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.86 (0.54 to 11.19)		4.45 (-2.78 to 11.67)
P-value vs. Placebo+52 week taper ^a		0.0312		0.2139
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.58 (0.05 to 1.10)	-	0.58 (-0.36 to 1.52)
Treatment-by-subgroup p-value ^b				0.6795

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__region_i_t_x.rtf (04SEP2024 18:13)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
SF-36-mental component summary score (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	44.14 (10.96)	48.08 (10.62)	45.63 (14.50)	45.06 (12.88)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	46.10 (12.47)	47.88 (11.28)	46.36 (14.14)	46.86 (12.77)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	46.20 (11.10)	51.51 (7.53)	47.26 (13.55)	49.61 (13.06)
Change from baseline				
Number	15	27	20	15
Mean (SD)	0.10 (8.19)	3.64 (9.88)	0.90 (15.60)	2.74 (10.09)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_age_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-1.15 (1.81)	3.97 (1.41)	-3.56 (2.69)	0.85 (3.09)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.12 (0.49 to 9.74)		4.41 (-3.82 to 12.64)
P-value vs. Placebo+52 week taper ^a		0.0309		0.2872
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.70 (0.07 to 1.33)	-	0.36 (-0.31 to 1.04)
Treatment-by-subgroup p-value ^b				0.6697

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_age_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
SF-36-mental component summary score (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	44.75 (11.30)	48.93 (11.03)	45.26 (14.95)	45.01 (11.94)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	46.87 (10.70)	50.23 (11.17)	45.52 (16.13)	45.27 (11.87)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	45.90 (12.24)	52.34 (11.71)	47.89 (12.89)	49.59 (7.83)
Change from baseline				
Number	19	19	16	23
Mean (SD)	-0.97 (12.43)	2.11 (8.32)	2.38 (13.39)	4.31 (11.03)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__crp_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-3.91 (2.32)	1.97 (2.41)	0.50 (2.15)	3.45 (1.85)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.87 (-0.90 to 12.65)		2.95 (-2.74 to 8.64)
P-value vs. Placebo+52 week taper ^a		0.0877		0.3035
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.56 (-0.09 to 1.21)	-	0.33 (-0.31 to 0.97)
Treatment-by-subgroup p-value ^b				0.5374

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__crp_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
SF-36-mental component summary score (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	44.12 (13.68)	47.99 (10.74)	45.98 (12.37)	45.83 (12.38)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	45.19 (13.82)	48.44 (11.41)	47.51 (12.89)	46.59 (12.16)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	42.55 (14.26)	52.13 (7.69)	51.87 (7.34)	49.53 (11.49)
Change from baseline				
Number	19	21	16	21
Mean (SD)	-2.64 (13.01)	3.70 (10.20)	4.36 (11.83)	2.94 (9.70)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_mcs_ger_esr_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-4.85 (2.23)	3.77 (2.17)	2.34 (2.06)	2.45 (1.85)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		8.62 (2.36 to 14.88)		0.10 (-5.46 to 5.67)
P-value vs. Placebo+52 week taper ^a		0.0079		0.9699
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.87 (0.24 to 1.49)	-	0.01 (-0.64 to 0.67)
Treatment-by-subgroup p-value ^b				0.0299

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__esr_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
SF-36-mental component summary score (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	42.78 (13.83)	48.19 (11.43)	48.12 (11.29)	45.38 (11.81)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	45.21 (14.78)	49.94 (11.01)	48.00 (10.53)	44.58 (12.10)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	44.46 (13.51)	52.77 (7.49)	50.79 (9.41)	48.48 (11.71)
Change from baseline				
Number	22	23	13	19
Mean (SD)	-0.76 (14.99)	2.84 (11.00)	2.79 (7.88)	3.90 (8.48)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_cs_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-3.36 (2.13)	4.06 (2.13)	0.30 (2.12)	2.91 (1.84)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		7.42 (1.33 to 13.51)		2.61 (-3.10 to 8.31)
P-value vs. Placebo+52 week taper ^a		0.0179		0.3613
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.72 (0.13 to 1.32)	-	0.32 (-0.39 to 1.04)
Treatment-by-subgroup p-value ^b				0.3258

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_cs_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
SF-36-mental component summary score (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	43.41 (11.78)	43.33 (13.96)	45.64 (13.57)	47.65 (10.98)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	45.13 (11.14)	45.03 (18.26)	46.70 (14.21)	47.85 (10.84)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	48.74 (8.98)	46.77 (6.93)	46.04 (13.61)	51.38 (10.01)
Change from baseline				
Number	10	5	25	37
Mean (SD)	3.61 (11.11)	1.75 (15.29)	-0.66 (13.43)	3.53 (9.16)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_mtx_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

SF-36-mental component summary score (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	3.59 (2.36)	1.97 (3.28)	-3.43 (1.89)	3.12 (1.63)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-1.62 (-9.96 to 6.72)		6.55 (1.56 to 11.53)
P-value vs. Placebo+52 week taper ^a		0.6908		0.0107
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.21 (-1.30 to 0.88)	-	0.67 (0.16 to 1.17)
Treatment-by-subgroup p-value ^b				0.2402

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_mtx_i_t_x.rtf (04SEP2024 18:11)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

SF-36-mental component summary score (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	42.36 (16.42)	44.75 (12.94)	46.72 (10.08)	48.11 (10.69)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	44.22 (16.55)	46.32 (13.86)	48.17 (9.26)	48.18 (10.52)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	46.03 (14.37)	51.98 (12.78)	47.54 (10.57)	50.19 (7.79)
Change from baseline				
Number	17	15	18	27
Mean (SD)	1.82 (15.44)	5.66 (9.96)	-0.63 (10.00)	2.02 (9.71)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger__nrp_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

SF-36-mental component summary score (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	0.95 (2.64)	4.62 (2.83)	-3.12 (1.91)	1.99 (1.62)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		3.66 (-4.19 to 11.51)		5.12 (0.11 to 10.12)
P-value vs. Placebo+52 week taper ^a		0.3509		0.0453
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.33 (-0.38 to 1.03)	-	0.61 (0.01 to 1.20)
Treatment-by-subgroup p-value ^b				0.7287

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mcs_ger_nrp_i_t_x.rtf (04SEP2024 18:12)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

11. SF-36 physical component summary score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
SF-36-physical component summary score (MMRM)	Gender (Male , Female)	0.9317
	Race (Caucasian/White , All other races)	0.4124
	Region (Western Countries , Rest of World (including South America))	0.2670
	Age (Age < 70 , Age >= 70)	0.5460
	Baseline CRP (<= median , > median)	0.8811
	Baseline CS dose (<= median , > median)	0.8947
	Baseline ESR (<= median , > median)	0.1512
	MTX Add-on Therapy (Yes , No)	0.6674
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2068

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
SF-36-physical component summary score (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	14	37	44
Mean (SD)	35.27 (11.69)	39.35 (11.14)	32.60 (8.24)	33.82 (8.98)
Baseline for patients with data at Week 52				
Number	14	11	21	31
Mean (SD)	38.33 (9.90)	40.41 (8.66)	35.05 (7.15)	34.10 (8.05)
Week 52				
Value				
Number	14	11	21	31
Mean (SD)	42.97 (9.13)	48.81 (9.20)	37.09 (6.57)	41.84 (9.75)
Change from baseline				
Number	14	11	21	31
Mean (SD)	4.65 (14.30)	8.40 (10.86)	2.04 (7.83)	7.74 (9.91)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_gender_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	3.33 (2.52)	8.52 (2.89)	2.11 (1.74)	7.62 (1.44)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.19 (-2.69 to 13.06)		5.51 (1.01 to 10.01)
P-value vs. Placebo+52 week taper ^a		0.1885		0.0171
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.53 (-0.28 to 1.34)	-	0.68 (0.13 to 1.24)
Treatment-by-subgroup p-value ^b				0.9317

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_gender_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
SF-36-physical component summary score (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	49	10	9
Mean (SD)	33.89 (9.01)	35.41 (9.94)	32.00 (12.61)	33.78 (8.94)
Baseline for patients with data at Week 52				
Number	28	35	7	7
Mean (SD)	36.76 (7.96)	35.61 (8.80)	34.76 (10.45)	36.47 (7.93)
Week 52				
Value				
Number	28	35	7	7
Mean (SD)	39.47 (8.65)	44.26 (9.87)	39.34 (6.03)	40.73 (10.85)
Change from baseline				
Number	28	35	7	7
Mean (SD)	2.70 (10.33)	8.64 (10.12)	4.58 (13.17)	4.25 (9.48)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_race_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	2.69 (1.63)	8.21 (1.47)	4.54 (3.17)	4.89 (3.29)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.52 (1.16 to 9.89)		0.34 (-9.47 to 10.16)
P-value vs. Placebo+52 week taper ^a		0.0138		0.9416
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.63 (0.13 to 1.13)	-	0.04 (-1.05 to 1.12)
Treatment-by-subgroup p-value ^b				0.4124

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_race_i_t_x.rtf (04SEP2024 18:07)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
SF-36-physical component summary score (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	45	14	13
Mean (SD)	32.96 (10.01)	36.53 (9.81)	35.47 (8.32)	30.40 (8.11)
Baseline for patients with data at Week 52				
Number	25	33	10	9
Mean (SD)	36.12 (8.81)	36.80 (8.81)	36.96 (7.60)	31.94 (6.78)
Week 52				
Value				
Number	25	33	10	9
Mean (SD)	37.89 (7.82)	44.11 (10.90)	43.32 (7.88)	42.05 (5.71)
Change from baseline				
Number	25	33	10	9
Mean (SD)	1.77 (11.81)	7.31 (10.40)	6.36 (7.06)	10.11 (8.75)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_region_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	1.27 (1.84)	7.44 (1.62)	7.05 (2.06)	8.89 (2.22)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		6.17 (1.30 to 11.05)		1.84 (-4.63 to 8.31)
P-value vs. Placebo+52 week taper ^a		0.0137		0.5596
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.66 (0.14 to 1.18)	-	0.27 (-0.68 to 1.21)
Treatment-by-subgroup p-value ^b				0.2670

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pcs_ger_region_i_t_x.rtf (04SEP2024 18:10)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
SF-36-physical component summary score (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	24
Mean (SD)	33.16 (9.88)	36.31 (9.33)	33.87 (9.56)	33.52 (10.25)
Baseline for patients with data at Week 52				
Number	15	27	20	15
Mean (SD)	37.02 (7.35)	36.22 (8.01)	35.87 (9.23)	34.92 (9.75)
Week 52				
Value				
Number	15	27	20	15
Mean (SD)	39.80 (6.82)	44.80 (9.76)	39.17 (9.13)	41.63 (10.42)
Change from baseline				
Number	15	27	20	15
Mean (SD)	2.77 (9.14)	8.58 (8.44)	3.31 (12.08)	6.72 (12.66)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_age_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	2.94 (2.01)	8.38 (1.53)	3.04 (2.08)	6.02 (2.40)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.45 (0.38 to 10.51)		2.98 (-3.39 to 9.36)
P-value vs. Placebo+52 week taper ^a		0.0355		0.3515
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.68 (0.05 to 1.31)	-	0.32 (-0.36 to 0.99)
Treatment-by-subgroup p-value ^b				0.5460

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_age_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
SF-36-physical component summary score (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	34.31 (8.69)	38.51 (10.38)	32.70 (10.68)	32.23 (8.22)
Baseline for patients with data at Week 52				
Number	19	19	16	23
Mean (SD)	35.35 (7.90)	39.53 (8.82)	37.56 (9.02)	32.64 (7.14)
Week 52				
Value				
Number	19	19	16	23
Mean (SD)	39.19 (8.84)	45.59 (9.83)	39.74 (7.42)	42.08 (10.06)
Change from baseline				
Number	19	19	16	23
Mean (SD)	3.84 (11.66)	6.06 (11.31)	2.18 (9.91)	9.44 (8.81)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger__crp_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	1.93 (2.13)	7.59 (2.18)	3.38 (2.12)	8.28 (1.75)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		5.66 (-0.57 to 11.90)		4.90 (-0.72 to 10.51)
P-value vs. Placebo+52 week taper ^a		0.0740		0.0861
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.59 (-0.06 to 1.24)	-	0.57 (-0.08 to 1.23)
Treatment-by-subgroup p-value ^b				0.8811

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger__crp_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
SF-36-physical component summary score (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	27	27	31
Mean (SD)	32.50 (9.50)	37.73 (10.63)	34.78 (9.79)	32.91 (8.42)
Baseline for patients with data at Week 52				
Number	19	21	16	21
Mean (SD)	34.29 (8.90)	36.58 (10.03)	38.82 (7.22)	34.93 (6.99)
Week 52				
Value				
Number	19	21	16	21
Mean (SD)	37.86 (6.83)	45.86 (10.64)	41.31 (9.28)	41.48 (9.02)
Change from baseline				
Number	19	21	16	21
Mean (SD)	3.57 (9.38)	9.27 (10.02)	2.49 (12.51)	6.55 (10.11)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_esr_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	2.54 (1.86)	9.58 (1.79)	4.64 (2.31)	5.58 (1.97)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		7.04 (1.84 to 12.23)		0.94 (-5.23 to 7.11)
P-value vs. Placebo+52 week taper ^a		0.0089		0.7607
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.85 (0.22 to 1.48)	-	0.10 (-0.56 to 0.77)
Treatment-by-subgroup p-value ^b				0.1512

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_esr_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
SF-36-physical component summary score (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	28
Mean (SD)	35.50 (9.48)	32.55 (8.52)	30.82 (9.33)	37.94 (10.32)
Baseline for patients with data at Week 52				
Number	22	23	13	19
Mean (SD)	37.56 (8.87)	34.20 (8.49)	34.33 (7.36)	37.64 (8.52)
Week 52				
Value				
Number	22	23	13	19
Mean (SD)	39.41 (8.82)	42.41 (8.88)	39.50 (7.09)	45.19 (11.25)
Change from baseline				
Number	22	23	13	19
Mean (SD)	1.85 (12.23)	8.21 (9.77)	5.17 (7.71)	7.55 (10.61)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_cs_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	3.55 (1.86)	7.53 (1.81)	2.11 (2.37)	7.31 (2.03)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		3.98 (-1.25 to 9.21)		5.20 (-1.23 to 11.62)
P-value vs. Placebo+52 week taper ^a		0.1335		0.1100
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.45 (-0.14 to 1.04)	-	0.58 (-0.14 to 1.31)
Treatment-by-subgroup p-value ^b				0.8947

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_cs_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
SF-36-physical component summary score (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	11	41	47
Mean (SD)	34.10 (10.92)	32.13 (10.18)	33.34 (9.16)	35.86 (9.60)
Baseline for patients with data at Week 52				
Number	10	5	25	37
Mean (SD)	38.44 (8.57)	30.14 (9.06)	35.53 (8.33)	36.52 (8.35)
Week 52				
Value				
Number	10	5	25	37
Mean (SD)	38.75 (11.10)	38.94 (13.87)	39.72 (6.84)	44.31 (9.42)
Change from baseline				
Number	10	5	25	37
Mean (SD)	0.31 (13.41)	8.80 (10.08)	4.19 (9.62)	7.79 (10.17)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pcs_ger_mtx_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

SF-36-physical component summary score (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	1.17 (3.77)	3.90 (5.02)	3.39 (1.60)	8.00 (1.34)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		2.73 (-10.81 to 16.26)		4.61 (0.45 to 8.78)
P-value vs. Placebo+52 week taper ^a		0.6806		0.0302
Hedges'g vs. Placebo+52 week taper (95% CI)	-	0.23 (-0.89 to 1.34)	-	0.57 (0.06 to 1.08)
Treatment-by-subgroup p-value ^b				0.6674

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger__mtx_i_t_x.rtf (04SEP2024 18:08)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

SF-36-physical component summary score (MMRM)	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	22	35	36
Mean (SD)	34.26 (8.38)	37.32 (11.75)	33.11 (10.44)	33.83 (8.17)
Baseline for patients with data at Week 52				
Number	17	15	18	27
Mean (SD)	34.63 (8.42)	39.04 (9.67)	37.99 (8.24)	33.93 (7.48)
Week 52				
Value				
Number	17	15	18	27
Mean (SD)	38.27 (5.94)	48.13 (8.66)	40.55 (9.78)	41.19 (9.96)
Change from baseline				
Number	17	15	18	27
Mean (SD)	3.64 (9.52)	9.09 (9.65)	2.55 (12.09)	7.26 (10.37)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_pcs_ger_nrp_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

SF-36-physical component summary score (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	1.95 (1.72)	10.40 (1.85)	3.33 (2.30)	6.39 (1.86)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		8.45 (3.25 to 13.64)		3.05 (-2.92 to 9.03)
P-value vs. Placebo+52 week taper ^a		0.0022		0.3111
Hedges'g vs. Placebo+52 week taper (95% CI)	-	1.16 (0.45 to 1.88)	-	0.31 (-0.30 to 0.92)
Treatment-by-subgroup p-value ^b				0.2068

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_pcs_ger_nrp_i_t_x.rtf (04SEP2024 18:09)

Weitere Analysen

Plot of LS Mean change from baseline



12. Morning stiffness duration components for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Morning stiffness duration (MMRM)	Gender (Male , Female)	0.8893
	Race (Caucasian/White , All other races)	0.0125
	Region (Western Countries , Rest of World (including South America))	0.1710
	Age (Age < 70 , Age >= 70)	0.7308
	Baseline CRP (<= median , > median)	0.1350
	Baseline CS dose (<= median , > median)	0.6826
	Baseline ESR (<= median , > median)	0.0638
	MTX Add-on Therapy (Yes , No)	0.8476
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4641

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
Morning stiffness duration (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	15	37	45
Mean (SD)	155.95 (313.38)	66.67 (76.71)	85.43 (76.16)	66.78 (61.19)
Baseline for patients with data at Week 52				
Number	17	11	29	37
Mean (SD)	160.59 (345.28)	57.27 (69.33)	74.48 (67.85)	69.05 (64.22)
Week 52				
Value				
Number	17	11	29	37
Mean (SD)	19.41 (40.65)	0.27 (0.90)	37.76 (57.49)	10.27 (22.82)
Change from baseline				
Number	17	11	29	37
Mean (SD)	-141.18 (347.84)	-57.00 (69.20)	-36.72 (93.98)	-58.78 (69.52)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_gender_i_t_x.rtf (04SEP2024 18:17)

Weitere Analysen

	Gender			
	Male (N=36)		Female (N=82)	
Morning stiffness duration (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	-97.25 (8.30)	-112.87 (10.29)	-32.22 (7.87)	-57.59 (7.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-15.62 (-42.76 to 11.52)		-25.38 (-46.46 to -4.29)
P-value vs. Placebo+52 week taper ^a		0.2498		0.0190
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.45 (-1.22 to 0.33)	-	-0.59 (-1.08 to -0.10)
Treatment-by-subgroup p-value ^b				0.8893

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_gender_i_t_x.rtf (04SEP2024 18:17)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
Morning stiffness duration (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	50	10	10
Mean (SD)	116.90 (211.99)	69.30 (61.86)	82.50 (114.29)	54.00 (80.06)
Baseline for patients with data at Week 52				
Number	38	41	8	7
Mean (SD)	112.89 (232.50)	68.17 (59.12)	75.00 (123.17)	55.71 (97.49)
Week 52				
Value				
Number	38	41	8	7
Mean (SD)	23.29 (38.94)	9.34 (21.84)	67.50 (87.46)	0.00 (0.00)
Change from baseline				
Number	38	41	8	7
Mean (SD)	-89.61 (238.31)	-58.83 (64.19)	-7.50 (148.49)	-55.71 (97.49)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_race_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

Morning stiffness duration (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-64.34 (5.46)	-77.09 (5.28)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-12.75 (-27.91 to 2.41)		NE
P-value vs. Placebo+52 week taper ^a		0.0982		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.37 (-0.82 to 0.07)		NE
Treatment-by-subgroup p-value ^b				0.0125

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_race_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
Morning stiffness duration (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	47	14	13
Mean (SD)	131.73 (223.17)	70.21 (71.04)	45.71 (38.52)	54.23 (32.14)
Baseline for patients with data at Week 52				
Number	35	38	11	10
Mean (SD)	128.57 (244.43)	70.00 (70.34)	35.45 (34.38)	52.50 (36.91)
Week 52				
Value				
Number	35	38	11	10
Mean (SD)	37.71 (57.45)	9.16 (22.72)	9.55 (19.29)	3.50 (5.30)
Change from baseline				
Number	35	38	11	10
Mean (SD)	-90.86 (257.01)	-60.84 (74.93)	-25.91 (43.52)	-49.00 (38.06)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger__region_i_t_x.rtf (04SEP2024 18:22)

Weitere Analysen

Morning stiffness duration (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-57.43 (7.41)	-87.78 (7.10)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-30.35 (-50.88 to -9.82)		NE
P-value vs. Placebo+52 week taper ^a		0.0042		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.69 (-1.15 to -0.22)		NE
Treatment-by-subgroup p-value ^b				0.1710

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger__region_i_t_x.rtf (04SEP2024 18:22)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	26
Mean (SD)	96.80 (91.21)	57.79 (54.29)	121.70 (251.94)	78.46 (75.79)
Baseline for patients with data at Week 52				
Number	19	30	27	18
Mean (SD)	76.58 (80.92)	57.50 (55.72)	127.22 (275.22)	81.11 (77.24)
Week 52				
Value				
Number	19	30	27	18
Mean (SD)	33.16 (45.44)	6.77 (22.39)	29.44 (57.27)	10.00 (17.06)
Change from baseline				
Number	19	30	27	18
Mean (SD)	-43.42 (85.72)	-50.73 (63.03)	-97.78 (286.56)	-71.11 (77.45)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_age_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	-35.02 (8.37)	-54.86 (6.89)	-75.87 (8.83)	-94.51 (10.65)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-19.84 (-41.73 to 2.05)		-18.64 (-46.43 to 9.15)
P-value vs. Placebo+52 week taper ^a		0.0748		0.1844
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.53 (-1.11 to 0.05)	-	-0.40 (-1.00 to 0.20)
Treatment-by-subgroup p-value ^b				0.7308

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_age_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

Plot of LSMean change from baseline



Placebo+52 week taper / Age: Age < 70	25	25	25	22	23	22	20	19	19	19
Sarilumab 200mg q2w+14 week taper / Age: Age < 70	34	34	33	33	31	30	30	30	30	30
Placebo+52 week taper / Age: Age >= 70	33	32	33	32	30	30	30	27	25	27
Sarilumab 200mg q2w+14 week taper / Age: Age >= 70	26	25	24	25	23	24	22	22	18	18

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	80.84 (81.11)	53.57 (67.11)	145.56 (276.08)	78.28 (61.28)
Baseline for patients with data at Week 52				
Number	24	22	22	26
Mean (SD)	69.38 (68.78)	45.91 (60.27)	146.59 (303.83)	83.65 (64.65)
Week 52				
Value				
Number	24	22	22	26
Mean (SD)	41.25 (61.97)	3.55 (9.15)	19.77 (37.14)	11.73 (26.11)
Change from baseline				
Number	24	22	22	26
Mean (SD)	-28.13 (94.49)	-42.36 (60.97)	-126.82 (307.29)	-71.92 (73.05)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger__crp_i_t_x.rtf (04SEP2024 18:20)

Weitere Analysen

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-22.12 (9.18)	-57.84 (9.71)	-83.87 (7.64)	-93.62 (7.02)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-35.72 (-62.64 to -8.80)		-9.75 (-30.66 to 11.16)
P-value vs. Placebo+52 week taper ^a		0.0102		0.3543
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.78 (-1.37 to -0.19)	-	-0.27 (-0.84 to 0.31)
Treatment-by-subgroup p-value ^b				0.1350

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger__crp_i_t_x.rtf (04SEP2024 18:20)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	96.48 (98.14)	67.86 (85.22)	127.59 (272.92)	65.78 (40.56)
Baseline for patients with data at Week 52				
Number	25	24	21	24
Mean (SD)	79.80 (84.16)	66.25 (82.98)	137.86 (308.82)	66.46 (41.38)
Week 52				
Value				
Number	25	24	21	24
Mean (SD)	42.00 (60.78)	8.25 (25.37)	17.86 (36.93)	7.71 (14.44)
Change from baseline				
Number	25	24	21	24
Mean (SD)	-37.80 (96.06)	-58.00 (89.99)	-120.00 (316.35)	-58.75 (39.35)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_esr_i_t_x.rtf (04SEP2024 18:21)

Weitere Analysen

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
Morning stiffness duration (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-32.81 (9.27)	-68.36 (9.58)	-79.29 (6.08)	-87.64 (5.66)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-35.55 (-62.29 to -8.82)		-8.35 (-25.11 to 8.42)
P-value vs. Placebo+52 week taper ^a		0.0101		0.3229
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.75 (-1.32 to -0.19)	-	-0.30 (-0.89 to 0.30)
Treatment-by-subgroup p-value ^b				0.0638

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_esr_i_t_x.rtf (04SEP2024 18:21)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
Morning stiffness duration (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	30
Mean (SD)	122.09 (245.67)	67.50 (58.13)	95.21 (101.67)	66.00 (71.71)
Baseline for patients with data at Week 52				
Number	29	26	17	22
Mean (SD)	124.66 (264.93)	69.81 (59.69)	75.00 (88.11)	62.27 (71.71)
Week 52				
Value				
Number	29	26	17	22
Mean (SD)	31.03 (58.09)	6.73 (12.72)	30.88 (41.92)	9.45 (27.14)
Change from baseline				
Number	29	26	17	22
Mean (SD)	-93.62 (276.34)	-63.08 (58.92)	-44.12 (92.08)	-52.82 (79.83)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_cs_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
Morning stiffness duration (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-66.49 (7.95)	-89.69 (8.36)	-33.02 (9.83)	-52.06 (8.82)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-23.20 (-46.37 to -0.02)		-19.04 (-45.65 to 7.56)
P-value vs. Placebo+52 week taper ^a		0.0498		0.1567
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.54 (-1.07 to -0.00)	-	-0.46 (-1.10 to 0.18)
Treatment-by-subgroup p-value ^b				0.6826

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_cs_i_t_x.rtf (04SEP2024 18:18)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
Morning stiffness duration (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	12	41	48
Mean (SD)	121.76 (107.51)	60.00 (42.43)	106.49 (226.48)	68.44 (69.44)
Baseline for patients with data at Week 52				
Number	11	8	35	40
Mean (SD)	95.45 (92.53)	63.75 (40.69)	109.71 (244.26)	66.88 (69.08)
Week 52				
Value				
Number	11	8	35	40
Mean (SD)	34.09 (48.42)	20.63 (43.13)	30.00 (53.96)	5.45 (11.37)
Change from baseline				
Number	11	8	35	40
Mean (SD)	-61.36 (103.59)	-43.13 (70.56)	-79.71 (253.80)	-61.43 (68.84)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_mtx_i_t_x.rtf (04SEP2024 18:19)

Weitere Analysen

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
Morning stiffness duration (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	NE	NE	-57.07 (6.58)	-78.35 (6.20)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		NE		-21.28 (-39.33 to -3.23)
P-value vs. Placebo+52 week taper ^a		NE		0.0214
Hedges'g vs. Placebo+52 week taper (95% CI)		NE	-	-0.54 (-1.00 to -0.08)
Treatment-by-subgroup p-value ^b				0.8476

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_mtx_i_t_x.rtf (04SEP2024 18:19)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
Morning stiffness duration (MMRM)	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	24	35	36
Mean (SD)	149.83 (298.88)	46.25 (44.87)	85.43 (79.84)	80.42 (72.51)
Baseline for patients with data at Week 52				
Number	19	18	27	30
Mean (SD)	156.32 (328.15)	41.67 (47.03)	71.11 (60.94)	81.17 (70.12)
Week 52				
Value				
Number	19	18	27	30
Mean (SD)	29.21 (44.85)	9.33 (29.57)	32.22 (57.60)	7.17 (12.71)
Change from baseline				
Number	19	18	27	30
Mean (SD)	-127.11 (334.57)	-32.33 (56.94)	-38.89 (87.39)	-74.00 (71.25)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_nrp_i_t_x.rtf (04SEP2024 18:19)

Weitere Analysen

Morning stiffness duration (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-62.36 (14.65)	-66.11 (14.78)	-46.10 (7.69)	-72.25 (7.27)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-3.75 (-46.36 to 38.85)		-26.15 (-47.28 to -5.02)
P-value vs. Placebo+52 week taper ^a		0.8599		0.0161
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.06 (-0.72 to 0.60)	-	-0.65 (-1.17 to -0.12)
Treatment-by-subgroup p-value ^b				0.4641

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_mornstif_ger_nrp_i_t_x.rtf (04SEP2024 18:19)

Weitere Analysen

Plot of LS Mean change from baseline



13. Ability to elevate the upper limbs component for PMR activity score change from baseline over time up to week 52 (MMRM - as-observed) - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Ability to elevate the upper limbs (MMRM)	Gender (Male , Female)	0.9939
	Race (Caucasian/White , All other races)	0.3425
	Region (Western Countries , Rest of World (including South America))	0.5402
	Age (Age < 70 , Age >= 70)	0.1192
	Baseline CRP (<= median , > median)	0.0131
	Baseline CS dose (<= median , > median)	0.7821
	Baseline ESR (<= median , > median)	0.8363
	MTX Add-on Therapy (Yes , No)	0.7308
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.0851

Weitere Analysen

Per gender

	Gender			
	Male (N=36)		Female (N=82)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Baseline				
Number	21	15	37	45
Mean (SD)	0.43 (0.68)	0.20 (0.56)	0.59 (0.69)	0.62 (0.83)
Baseline for patients with data at Week 52				
Number	17	11	29	37
Mean (SD)	0.35 (0.61)	0.27 (0.65)	0.52 (0.63)	0.59 (0.83)
Week 52				
Value				
Number	17	11	29	37
Mean (SD)	0.18 (0.39)	0.00 (0.00)	0.31 (0.60)	0.05 (0.23)
Change from baseline				
Number	17	11	29	37
Mean (SD)	-0.18 (0.64)	-0.27 (0.65)	-0.21 (0.73)	-0.54 (0.87)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_fromshol_gender_i_t_x.rtf (04SEP2024 18:23)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
LS Mean (SE) ^a	NE	NE	-0.31 (0.08)	-0.53 (0.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		NE		-0.23 (-0.43 to -0.02)
P-value vs. Placebo+52 week taper ^a		NE		0.0299
Hedges'g vs. Placebo+52 week taper (95% CI)		NE	-	-0.54 (-1.03 to -0.05)
Treatment-by-subgroup p-value ^b				0.9939

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_lromshol_gender_i_t_x.rtf (04SEP2024 18:23)

Weitere Analysen

Plot of LS Mean change from baseline



Placebo+52 week taper / Gender : Male	21	20	21	21	18	19	18	17	17	16	17
Sarilumab 200mg q2w+14 week taper / Gender : Male	15	14	13	13	13	13	13	13	11	11	11
Placebo+52 week taper / Gender : Female	37	37	37	36	34	34	34	33	29	29	29
Sarilumab 200mg q2w+14 week taper / Gender : Female	45	45	44	45	41	41	39	39	37	37	37

Weitere Analysen

Per race

	Race			
	Caucasian/White (N=98)		All other races (N=20)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Baseline				
Number	48	50	10	10
Mean (SD)	0.54 (0.65)	0.56 (0.81)	0.50 (0.85)	0.30 (0.67)
Baseline for patients with data at Week 52				
Number	38	41	8	7
Mean (SD)	0.53 (0.65)	0.61 (0.83)	0.13 (0.35)	0.00 (0.00)
Week 52				
Value				
Number	38	41	8	7
Mean (SD)	0.29 (0.57)	0.05 (0.22)	0.13 (0.35)	0.00 (0.00)
Change from baseline				
Number	38	41	8	7
Mean (SD)	-0.24 (0.71)	-0.56 (0.87)	0.00 (0.53)	0.00 (0.00)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_race_i_t_x.rtf (04SEP2024 18:24)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
LS Mean (SE) ^a	-0.25 (0.07)	-0.52 (0.06)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.27 (-0.45 to -0.08)		NE
P-value vs. Placebo+52 week taper ^a		0.0052		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.64 (-1.08 to -0.20)		NE
Treatment-by-subgroup p-value ^b				0.3425

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_race_i_t_x.rtf (04SEP2024 18:24)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per region

	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Baseline				
Number	44	47	14	13
Mean (SD)	0.55 (0.70)	0.51 (0.80)	0.50 (0.65)	0.54 (0.78)
Baseline for patients with data at Week 52				
Number	35	38	11	10
Mean (SD)	0.43 (0.61)	0.50 (0.80)	0.55 (0.69)	0.60 (0.84)
Week 52				
Value				
Number	35	38	11	10
Mean (SD)	0.23 (0.49)	0.05 (0.23)	0.36 (0.67)	0.00 (0.00)
Change from baseline				
Number	35	38	11	10
Mean (SD)	-0.20 (0.68)	-0.45 (0.83)	-0.18 (0.75)	-0.60 (0.84)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_lromshol_ger__region_i_t_x.rtf (04SEP2024 18:27)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
LS Mean (SE) ^a	-0.21 (0.07)	-0.43 (0.07)	NE	NE
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.22 (-0.41 to -0.03)		NE
P-value vs. Placebo+52 week taper ^a		0.0213		NE
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.54 (-1.01 to -0.08)		NE
Treatment-by-subgroup p-value ^b				0.5402

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_lromshol_ger_region_i_t_x.rtf (04SEP2024 18:27)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per age

	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Baseline				
Number	25	34	33	26
Mean (SD)	0.40 (0.65)	0.47 (0.71)	0.64 (0.70)	0.58 (0.90)
Baseline for patients with data at Week 52				
Number	19	30	27	18
Mean (SD)	0.32 (0.58)	0.50 (0.73)	0.56 (0.64)	0.56 (0.92)
Week 52				
Value				
Number	19	30	27	18
Mean (SD)	0.37 (0.60)	0.03 (0.18)	0.19 (0.48)	0.06 (0.24)
Change from baseline				
Number	19	30	27	18
Mean (SD)	0.05 (0.62)	-0.47 (0.78)	-0.37 (0.69)	-0.50 (0.92)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger__age_i_t_x.rtf (04SEP2024 18:24)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Age			
	Age < 70 (N=59)		Age >= 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
LS Mean (SE) ^a	0.04 (0.10)	-0.40 (0.08)	-0.40 (0.08)	-0.51 (0.10)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.43 (-0.68 to -0.18)		-0.11 (-0.37 to 0.14)
P-value vs. Placebo+52 week taper ^a		0.0009		0.3783
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.01 (-1.58 to -0.43)	-	-0.27 (-0.86 to 0.33)
Treatment-by-subgroup p-value ^b				0.1192

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_age_i_t_x.rtf (04SEP2024 18:24)

Weitere Analysen

Plot of LSMean change from baseline



Placebo+52 week taper / Age : Age < 70	25	25	25	22	23	22	20	19	19	19
Sarilumab 200mg q2w+14 week taper / Age : Age < 70	34	34	33	31	30	30	30	30	30	30
Placebo+52 week taper / Age : Age >= 70	33	32	33	32	30	30	30	27	26	27
Sarilumab 200mg q2w+14 week taper / Age : Age >= 70	26	25	24	25	23	24	22	22	18	18

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=59)		> median (N=59)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	0.61 (0.72)	0.36 (0.62)	0.44 (0.64)	0.66 (0.90)
Baseline for patients with data at Week 52				
Number	24	22	22	26
Mean (SD)	0.58 (0.72)	0.45 (0.67)	0.32 (0.48)	0.58 (0.90)
Week 52				
Value				
Number	24	22	22	26
Mean (SD)	0.42 (0.65)	0.00 (0.00)	0.09 (0.29)	0.08 (0.27)
Change from baseline				
Number	24	22	22	26
Mean (SD)	-0.17 (0.76)	-0.45 (0.67)	-0.23 (0.61)	-0.50 (0.95)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger__crp_i_t_x.rtf (04SEP2024 18:26)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	0.06 (0.11)	-0.49 (0.12)	-0.42 (0.06)	-0.43 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.55 (-0.87 to -0.23)		-0.01 (-0.18 to 0.15)
P-value vs. Placebo+52 week taper ^a		0.0011		0.8810
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-1.01 (-1.60 to -0.42)	-	-0.04 (-0.62 to 0.53)
Treatment-by-subgroup p-value ^b				0.0131

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmr_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmr_lromshol_ger__crp_i_t_x.rtf (04SEP2024 18:26)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Baseline				
Number	31	28	27	32
Mean (SD)	0.55 (0.72)	0.46 (0.74)	0.52 (0.64)	0.56 (0.84)
Baseline for patients with data at Week 52				
Number	25	24	21	24
Mean (SD)	0.44 (0.65)	0.54 (0.78)	0.48 (0.60)	0.50 (0.83)
Week 52				
Value				
Number	25	24	21	24
Mean (SD)	0.24 (0.52)	0.04 (0.20)	0.29 (0.56)	0.04 (0.20)
Change from baseline				
Number	25	24	21	24
Mean (SD)	-0.20 (0.71)	-0.50 (0.83)	-0.19 (0.68)	-0.46 (0.83)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_esr_i_t_x.rtf (04SEP2024 18:27)

Weitere Analysen

	Baseline ESR			
	<= median (N=59)		> median (N=59)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
LS Mean (SE) ^a	-0.22 (0.08)	-0.46 (0.09)	-0.24 (0.09)	-0.49 (0.08)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.25 (-0.49 to -0.01)		-0.25 (-0.49 to -0.02)
P-value vs. Placebo+52 week taper ^a		0.0435		0.0371
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.58 (-1.15 to -0.02)	-	-0.63 (-1.22 to -0.04)
Treatment-by-subgroup p-value ^b				0.8363

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_esr_i_t_x.rtf (04SEP2024 18:27)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Baseline				
Number	34	30	24	30
Mean (SD)	0.47 (0.71)	0.53 (0.82)	0.63 (0.65)	0.50 (0.78)
Baseline for patients with data at Week 52				
Number	29	26	17	22
Mean (SD)	0.48 (0.69)	0.50 (0.81)	0.41 (0.51)	0.55 (0.80)
Week 52				
Value				
Number	29	26	17	22
Mean (SD)	0.28 (0.53)	0.00 (0.00)	0.24 (0.56)	0.09 (0.29)
Change from baseline				
Number	29	26	17	22
Mean (SD)	-0.21 (0.68)	-0.50 (0.81)	-0.18 (0.73)	-0.45 (0.86)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_cs_i_t_x.rtf (04SEP2024 18:25)

Weitere Analysen

	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
LS Mean (SE) ^a	-0.23 (0.07)	-0.50 (0.07)	-0.05 (0.14)	-0.32 (0.13)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.27 (-0.47 to -0.08)		-0.27 (-0.66 to 0.11)
P-value vs. Placebo+52 week taper ^a		0.0073		0.1603
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.74 (-1.27 to -0.21)	-	-0.45 (-1.09 to 0.18)
Treatment-by-subgroup p-value ^b				0.7821

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_cs_i_t_x.rtf (04SEP2024 18:25)

Weitere Analysen

Plot of LS Mean change from baseline



Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Baseline				
Number	17	12	41	48
Mean (SD)	0.47 (0.62)	0.92 (0.90)	0.56 (0.71)	0.42 (0.74)
Baseline for patients with data at Week 52				
Number	11	8	35	40
Mean (SD)	0.45 (0.52)	1.00 (0.93)	0.46 (0.66)	0.43 (0.75)
Week 52				
Value				
Number	11	8	35	40
Mean (SD)	0.45 (0.69)	0.25 (0.46)	0.20 (0.47)	0.00 (0.00)
Change from baseline				
Number	11	8	35	40
Mean (SD)	0.00 (0.77)	-0.75 (1.16)	-0.26 (0.66)	-0.43 (0.75)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger_mtx_i_t_x.rtf (04SEP2024 18:25)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
LS Mean (SE) ^a	NE	NE	-0.31 (0.06)	-0.51 (0.06)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		NE		-0.20 (-0.36 to -0.04)
P-value vs. Placebo+52 week taper ^a		NE		0.0157
Hedges'g vs. Placebo+52 week taper (95% CI)		NE	-	-0.57 (-1.02 to -0.11)
Treatment-by-subgroup p-value ^b				0.7308

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.


^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger__mtx_i_t_x.rtf (04SEP2024 18:25)

Weitere Analysen

Plot of LSMean change from baseline



Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
Ability to elevate the upper limbs (MMRM)	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Baseline				
Number	23	24	35	36
Mean (SD)	0.57 (0.66)	0.46 (0.78)	0.51 (0.70)	0.56 (0.81)
Baseline for patients with data at Week 52				
Number	19	18	27	30
Mean (SD)	0.58 (0.61)	0.50 (0.79)	0.37 (0.63)	0.53 (0.82)
Week 52				
Value				
Number	19	18	27	30
Mean (SD)	0.21 (0.42)	0.11 (0.32)	0.30 (0.61)	0.00 (0.00)
Change from baseline				
Number	19	18	27	30
Mean (SD)	-0.37 (0.68)	-0.39 (0.85)	-0.07 (0.68)	-0.53 (0.82)

^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger__nrp_i_t_x.rtf (04SEP2024 18:26)

Weitere Analysen

Ability to elevate the upper limbs (MMRM)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
LS Mean (SE) ^a	-0.36 (0.09)	-0.41 (0.09)	-0.18 (0.08)	-0.50 (0.07)
LS Mean Diff vs. Placebo+52 week taper (95% CI) ^a		-0.05 (-0.30 to 0.20)		-0.32 (-0.53 to -0.11)
P-value vs. Placebo+52 week taper ^a		0.6804		0.0038
Hedges'g vs. Placebo+52 week taper (95% CI)	-	-0.13 (-0.79 to 0.52)	-	-0.79 (-1.31 to -0.26)
Treatment-by-subgroup p-value ^b				0.0851


^a Derived from two separate MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, visit, baseline-by-visit interaction and treatment-by-visit interaction as covariates.

^b Derived from MMRM model with change from baseline up to week 52 as the response variable and corresponding baseline value, treatment group, subgroup, visit, baseline-by-visit interaction, treatment-by-visit interaction, treatment-by-subgroup interaction and treatment-by-subgroup-by-visit interaction as covariates.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_mmrn_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_mmrn_lromshol_ger__nrp_i_t_x.rtf (04SEP2024 18:26)

Weitere Analysen

Plot of LS Mean change from baseline

EFC15160_Germany_binary_subgroup_05SEP24 – (Imputation fehlender Werte)

Weitere Analysen

1. Sustained remission at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Sustained remission at Week 52	Gender (Male , Female)	0.5017
	Race (Caucasian/White , All other races)	0.9253
	Age (Age < 70 , Age >= 70)	0.0973
	Baseline CS dose (<= median , > median)	0.9748
	MTX Add-on Therapy (Yes , No)	0.7292
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2641

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.
PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_susrms3_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		2 (9.5) / 0	6 (40.0) / 0	4 (10.8) / 0	11 (24.4) / 0
Non-responder / Imputed non-responder		19 (90.5) / 3 (14.3)	9 (60.0) / 4 (26.7)	33 (89.2) / 6 (16.2)	34 (75.6) / 9 (20.0)
Odds Ratio (95% CI) vs Placebo ^a		-	6.33 (0.99 to 40.36)	-	2.67 (0.76 to 9.41)
p-value for Odds Ratio ^a			0.0507		0.1248
Risk Ratio (95% CI) vs Placebo ^a		-	4.20 (0.93 to 19.02)	-	2.26 (0.77 to 6.62)
Reversed Risk ratio (95% CI)		-	0.24 (0.05 to 1.08)	-	0.44 (0.15 to 1.30)
p-value for Risk Ratio ^a			0.0626		0.1368
Risk Difference (95% CI) vs Placebo ^a		-	30.48 (1.66 to 59.29)	-	13.63 (-2.67 to 29.94)
p-value for Risk Difference ^a			0.0388		0.1000
Treatment-by-subgroup p-value of RR ^b					0.5017

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_gender_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		5 (10.4) / 0	14 (28.0) / 0	1 (10.0) / 0	3 (30.0) / 0
Non-responder / Imputed non-responder		43 (89.6) / 8 (16.7)	36 (72.0) / 11 (22.0)	9 (90.0) / 1 (10.0)	7 (70.0) / 2 (20.0)
Odds Ratio (95% CI) vs Placebo ^a		-	3.34 (1.08 to 10.32)	-	3.86 (0.27 to 54.43)
p-value for Odds Ratio ^a			0.0361		0.2981
Risk Ratio (95% CI) vs Placebo ^a		-	2.69 (1.04 to 6.97)	-	3.00 (0.32 to 28.08)
Reversed Risk ratio (95% CI)		-	0.37 (0.14 to 0.97)	-	0.33 (0.04 to 3.12)
p-value for Risk Ratio ^a			0.0420		0.3357
Risk Difference (95% CI) vs Placebo ^a		-	17.58 (2.24 to 32.93)	-	20.00 (-16.39 to 56.39)
p-value for Risk Difference ^a			0.0252		0.2633
Treatment-by-subgroup p-value of RR ^b					0.9253

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3 ger_race_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		1 (4.0) / 0	12 (35.3) / 0	5 (15.2) / 0	5 (19.2) / 0
Non-responder / Imputed non-responder		24 (96.0) / 4 (16.0)	22 (64.7) / 5 (14.7)	28 (84.8) / 5 (15.2)	21 (80.8) / 8 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	13.09 (1.50 to 114.24)	-	1.33 (0.33 to 5.36)
p-value for Odds Ratio ^a			0.0208		0.6806
Risk Ratio (95% CI) vs Placebo ^a		-	8.82 (1.17 to 66.27)	-	1.27 (0.40 to 4.02)
Reversed Risk ratio (95% CI)		-	0.11 (0.02 to 0.85)	-	0.79 (0.25 to 2.49)
p-value for Risk Ratio ^a			0.0343		0.6851
Risk Difference (95% CI) vs Placebo ^a		-	31.29 (13.10 to 49.49)	-	4.08 (-15.81 to 23.97)
p-value for Risk Difference ^a			0.0011		0.6829
Treatment-by-subgroup p-value of RR ^b					0.0973

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_ger_age_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		6 (17.6) / 0	10 (33.3) / 0	0 / 0	7 (23.3) / 0
Non-responder / Imputed non-responder		28 (82.4) / 7 (20.6)	20 (66.7) / 6 (20.0)	24 (100) / 2 (8.3)	23 (76.7) / 7 (23.3)
Odds Ratio (95% CI) vs Placebo ^a		-	2.33 (0.71 to 7.64)	-	1752378 (0.00 to NE)
p-value for Odds Ratio ^a			0.1585		0.9767
Peto Odds Ratio (95% CI) vs Placebo ^a				-	7.61 (1.56 to 37.07)
Reversed Peto Odds Ratio (95% CI)				-	0.13 (0.03 to 0.64)
p-value for Peto Odds Ratio					0.0120
Risk Ratio (95% CI) vs Placebo ^a		-	1.89 (0.77 to 4.66)	-	12.10 (0.73 to 201.69)
Reversed Risk ratio (95% CI)		-	0.53 (0.21 to 1.31)	-	0.08 (0.00 to 1.38)
p-value for Risk Ratio ^a			0.1673		0.0825

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_ger_cs_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Risk Difference (95% CI) vs Placebo ^a		-	15.69 (-5.92 to 37.29)	-	23.33 (NE to NE)
p-value for Risk Difference ^a			0.1517		<0.0001
Treatment-by-subgroup p-value of RR ^b					0.9748

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table). Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_ger_cs_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		2 (11.8) / 0	3 (25.0) / 0	4 (9.8) / 0	14 (29.2) / 0
Non-responder / Imputed non-responder		15 (88.2) / 4 (23.5)	9 (75.0) / 3 (25.0)	37 (90.2) / 5 (12.2)	34 (70.8) / 10 (20.8)
Odds Ratio (95% CI) vs Placebo ^a		-	2.50 (0.32 to 19.68)	-	3.81 (1.12 to 12.92)
p-value for Odds Ratio ^a			0.3702		0.0323
Risk Ratio (95% CI) vs Placebo ^a		-	2.13 (0.39 to 11.70)	-	2.99 (1.05 to 8.50)
Reversed Risk ratio (95% CI)		-	0.47 (0.09 to 2.59)	-	0.33 (0.12 to 0.95)
p-value for Risk Ratio ^a			0.3864		0.0399
Risk Difference (95% CI) vs Placebo ^a		-	13.24 (-17.01 to 43.48)	-	19.41 (3.45 to 35.38)
p-value for Risk Difference ^a			0.3772		0.0178
Treatment-by-subgroup p-value of RR ^b					0.7292

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_ger_mtx_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Sustained remission at Week 52 [n (%)]					
Responder / Imputed responder		2 (8.7) / 0	10 (41.7) / 0	4 (11.4) / 0	7 (19.4) / 0
Non-responder / Imputed non-responder		21 (91.3) / 5 (21.7)	14 (58.3) / 5 (20.8)	31 (88.6) / 4 (11.4)	29 (80.6) / 8 (22.2)
Odds Ratio (95% CI) vs Placebo ^a		-	7.50 (1.36 to 41.38)	-	1.87 (0.48 to 7.23)
p-value for Odds Ratio ^a			0.0218		0.3588
Risk Ratio (95% CI) vs Placebo ^a		-	4.79 (1.13 to 20.33)	-	1.70 (0.53 to 5.41)
Reversed Risk ratio (95% CI)		-	0.21 (0.05 to 0.89)	-	0.59 (0.18 to 1.87)
p-value for Risk Ratio ^a			0.0336		0.3681
Risk Difference (95% CI) vs Placebo ^a		-	32.97 (9.50 to 56.44)	-	8.02 (-8.96 to 24.99)
p-value for Risk Difference ^a			0.0069		0.3495
Treatment-by-subgroup p-value of RR ^b					0.2641

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients who withdrew from the study before Week 52 and did not experience a disease flare prior to withdrawal are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_susrms3_ger_nrp_i_t_x.rtf (04SEP2024 11:00)

2. Achievement of disease remission no later than Week 12 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Achievement of disease remission no later than Week 12	Gender (Male , Female)	0.4635
	Race (Caucasian/White , All other races)	0.9730
	Region (Western Countries , Rest of World (including South America))	0.4881
	Age (Age < 70 , Age >= 70)	0.5060
	Baseline CRP (<= median , > median)	0.1742
	Baseline ESR (<= median , > median)	0.5895
	Baseline CS dose (<= median , > median)	0.0100
	MTX Add-on Therapy (Yes , No)	0.9182
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7358

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_dsrms1_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		9 (42.9)	10 (66.7)	13 (35.1)	18 (40.0)
Non-responder		12 (57.1)	5 (33.3)	24 (64.9)	27 (60.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.67 (0.64 to 11.13)	-	1.23 (0.49 to 3.07)
p-value for Odds Ratio ^a			0.1721		0.6526
Risk Ratio (95% CI) vs Placebo ^a		-	1.56 (0.83 to 2.93)	-	1.14 (0.64 to 2.02)
Reversed Risk ratio (95% CI)		-	0.64 (0.34 to 1.21)	-	0.88 (0.49 to 1.56)
p-value for Risk Ratio ^a			0.1709		0.6580
Risk Difference (95% CI) vs Placebo ^a		-	23.81 (-9.26 to 56.88)	-	4.86 (-16.47 to 26.20)
p-value for Risk Difference ^a			0.1526		0.6512
Treatment-by-subgroup p-value of RR ^b					0.4635

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_gender_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		18 (37.5)	23 (46.0)	4 (40.0)	5 (50.0)
Non-responder		30 (62.5)	27 (54.0)	6 (60.0)	5 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.42 (0.63 to 3.21)	-	1.50 (0.22 to 10.01)
p-value for Odds Ratio ^a			0.3966		0.6590
Risk Ratio (95% CI) vs Placebo ^a		-	1.23 (0.76 to 1.98)	-	1.25 (0.44 to 3.57)
Reversed Risk ratio (95% CI)		-	0.82 (0.51 to 1.32)	-	0.80 (0.28 to 2.29)
p-value for Risk Ratio ^a			0.4030		0.6772
Risk Difference (95% CI) vs Placebo ^a		-	8.50 (-11.20 to 28.20)	-	10.00 (-36.51 to 56.51)
p-value for Risk Difference ^a			0.3939		0.6568
Treatment-by-subgroup p-value of RR ^b					0.9730

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_race_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		19 (43.2)	23 (48.9)	3 (21.4)	5 (38.5)
Non-responder		25 (56.8)	24 (51.1)	11 (78.6)	8 (61.5)
Odds Ratio (95% CI) vs Placebo ^a		-	1.26 (0.55 to 2.91)	-	2.29 (0.39 to 13.63)
p-value for Odds Ratio ^a			0.5837		0.3472
Risk Ratio (95% CI) vs Placebo ^a		-	1.13 (0.72 to 1.78)	-	1.79 (0.50 to 6.44)
Reversed Risk ratio (95% CI)		-	0.88 (0.56 to 1.39)	-	0.56 (0.16 to 2.00)
p-value for Risk Ratio ^a			0.5888		0.3696
Risk Difference (95% CI) vs Placebo ^a		-	5.75 (-14.98 to 26.49)	-	17.03 (-18.78 to 52.84)
p-value for Risk Difference ^a			0.5828		0.3367
Treatment-by-subgroup p-value of RR ^b					0.4881

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_region_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		8 (32.0)	16 (47.1)	14 (42.4)	12 (46.2)
Non-responder		17 (68.0)	18 (52.9)	19 (57.6)	14 (53.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.89 (0.63 to 5.68)	-	1.16 (0.40 to 3.35)
p-value for Odds Ratio ^a			0.2519		0.7756
Risk Ratio (95% CI) vs Placebo ^a		-	1.47 (0.74 to 2.93)	-	1.09 (0.60 to 1.96)
Reversed Risk ratio (95% CI)		-	0.68 (0.34 to 1.35)	-	0.92 (0.51 to 1.65)
p-value for Risk Ratio ^a			0.2720		0.7785
Risk Difference (95% CI) vs Placebo ^a		-	15.06 (-10.30 to 40.41)	-	3.73 (-22.35 to 29.81)
p-value for Risk Difference ^a			0.2392		0.7756
Treatment-by-subgroup p-value of RR ^b					0.5060

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_age_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		10 (32.3)	15 (53.6)	12 (44.4)	13 (40.6)
Non-responder		21 (67.7)	13 (46.4)	15 (55.6)	19 (59.4)
Odds Ratio (95% CI) vs Placebo ^a		-	2.42 (0.82 to 7.14)	-	0.86 (0.30 to 2.47)
p-value for Odds Ratio ^a			0.1065		0.7685
Risk Ratio (95% CI) vs Placebo ^a		-	1.66 (0.89 to 3.12)	-	0.91 (0.50 to 1.68)
Reversed Risk ratio (95% CI)		-	0.60 (0.32 to 1.13)		
p-value for Risk Ratio ^a			0.1140		0.7718
Risk Difference (95% CI) vs Placebo ^a		-	21.31 (-3.96 to 46.59)	-	-3.82 (-29.68 to 22.04)
p-value for Risk Difference ^a			0.0968		0.7685
Treatment-by-subgroup p-value of RR ^b					0.1742

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_crp_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		13 (41.9)	13 (46.4)	9 (33.3)	15 (46.9)
Non-responder		18 (58.1)	15 (53.6)	18 (66.7)	17 (53.1)
Odds Ratio (95% CI) vs Placebo ^a		-	1.20 (0.42 to 3.44)	-	1.76 (0.60 to 5.21)
p-value for Odds Ratio ^a			0.7299		0.2978
Risk Ratio (95% CI) vs Placebo ^a		-	1.11 (0.62 to 1.99)	-	1.41 (0.72 to 2.73)
Reversed Risk ratio (95% CI)		-	0.90 (0.50 to 1.62)	-	0.71 (0.37 to 1.38)
p-value for Risk Ratio ^a			0.7339		0.3132
Risk Difference (95% CI) vs Placebo ^a		-	4.49 (-21.41 to 30.40)	-	13.54 (-11.80 to 38.88)
p-value for Risk Difference ^a			0.7297		0.2891
Treatment-by-subgroup p-value of RR ^b					0.5895

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_esr_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		19 (55.9)	13 (43.3)	3 (12.5)	15 (50.0)
Non-responder		15 (44.1)	17 (56.7)	21 (87.5)	15 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.60 (0.22 to 1.66)	-	7.00 (1.66 to 29.52)
p-value for Odds Ratio ^a			0.3215		0.0090
Risk Ratio (95% CI) vs Placebo ^a		-	0.78 (0.46 to 1.30)	-	4.00 (1.27 to 12.56)
Reversed Risk ratio (95% CI)				-	0.25 (0.08 to 0.78)
p-value for Risk Ratio ^a			0.3347		0.0175
Risk Difference (95% CI) vs Placebo ^a		-	-12.55 (-37.38 to 12.29)	-	37.50 (14.72 to 60.28)
p-value for Risk Difference ^a			0.3164		0.0017
Treatment-by-subgroup p-value of RR ^b					0.0100

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrmst_ger_cs_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		5 (29.4)	4 (33.3)	17 (41.5)	24 (50.0)
Non-responder		12 (70.6)	8 (66.7)	24 (58.5)	24 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.20 (0.23 to 6.34)	-	1.41 (0.60 to 3.31)
p-value for Odds Ratio ^a			0.8239		0.4234
Risk Ratio (95% CI) vs Placebo ^a		-	1.13 (0.36 to 3.54)	-	1.21 (0.76 to 1.92)
Reversed Risk ratio (95% CI)		-	0.88 (0.28 to 2.75)	-	0.83 (0.52 to 1.32)
p-value for Risk Ratio ^a			0.8294		0.4323
Risk Difference (95% CI) vs Placebo ^a		-	3.92 (-32.05 to 39.89)	-	8.54 (-12.43 to 29.50)
p-value for Risk Difference ^a			0.8247		0.4206
Treatment-by-subgroup p-value of RR ^b					0.9182

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_mtx_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Achievement of disease remission no later than Week 12 [n (%)]					
Responder		7 (30.4)	10 (41.7)	15 (42.9)	18 (50.0)
Non-responder		16 (69.6)	14 (58.3)	20 (57.1)	18 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.63 (0.47 to 5.62)	-	1.33 (0.51 to 3.45)
p-value for Odds Ratio ^a			0.4287		0.5486
Risk Ratio (95% CI) vs Placebo ^a		-	1.37 (0.62 to 3.05)	-	1.17 (0.70 to 1.95)
Reversed Risk ratio (95% CI)		-	0.73 (0.33 to 1.63)	-	0.86 (0.51 to 1.43)
p-value for Risk Ratio ^a			0.4415		0.5551
Risk Difference (95% CI) vs Placebo ^a		-	11.23 (-16.77 to 39.24)	-	7.14 (-16.41 to 30.70)
p-value for Risk Difference ^a			0.4235		0.5472
Treatment-by-subgroup p-value of RR ^b					0.7358

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_dsrm1_ger_nrp_i_t_x.rtf (04SEP2024 11:00)

3. Absence of disease flare from Week 12 through Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Absence of disease flare from Week 12 through Week 52	Gender (Male , Female)	0.8460
	Race (Caucasian/White , All other races)	0.5200
	Region (Western Countries , Rest of World (including South America))	0.1750
	Age (Age < 70 , Age >= 70)	0.0887
	Baseline CRP (<= median , > median)	0.9050
	Baseline ESR (<= median , > median)	0.0332
	Baseline CS dose (<= median , > median)	0.2197
	MTX Add-on Therapy (Yes , No)	0.9533
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7293

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_nodsfla3_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		7 (33.3)	9 (60.0)	12 (32.4)	24 (53.3)
Non-responder		14 (66.7)	6 (40.0)	25 (67.6)	21 (46.7)
Odds Ratio (95% CI) vs Placebo ^a		-	3.00 (0.72 to 12.48)	-	2.38 (0.95 to 5.96)
p-value for Odds Ratio ^a			0.1266		0.0636
Risk Ratio (95% CI) vs Placebo ^a		-	1.80 (0.84 to 3.85)	-	1.64 (0.95 to 2.84)
Reversed Risk ratio (95% CI)		-	0.56 (0.26 to 1.19)	-	0.61 (0.35 to 1.05)
p-value for Risk Ratio ^a			0.1293		0.0751
Risk Difference (95% CI) vs Placebo ^a		-	26.67 (-6.47 to 59.80)	-	20.90 (-0.40 to 42.20)
p-value for Risk Difference ^a			0.1112		0.0543
Treatment-by-subgroup p-value of RR ^b					0.8460

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_gender_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		15 (31.3)	28 (56.0)	4 (40.0)	5 (50.0)
Non-responder		33 (68.8)	22 (44.0)	6 (60.0)	5 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.80 (1.21 to 6.47)	-	1.50 (0.22 to 10.01)
p-value for Odds Ratio ^a			0.0165		0.6590
Risk Ratio (95% CI) vs Placebo ^a		-	1.79 (1.10 to 2.93)	-	1.25 (0.44 to 3.57)
Reversed Risk ratio (95% CI)		-	0.56 (0.34 to 0.91)	-	0.80 (0.28 to 2.29)
p-value for Risk Ratio ^a			0.0202		0.6772
Risk Difference (95% CI) vs Placebo ^a		-	24.75 (5.50 to 44.00)	-	10.00 (-36.51 to 56.51)
p-value for Risk Difference ^a			0.0123		0.6568
Treatment-by-subgroup p-value of RR ^b					0.5200

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_race_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		12 (27.3)	26 (55.3)	7 (50.0)	7 (53.8)
Non-responder		32 (72.7)	21 (44.7)	7 (50.0)	6 (46.2)
Odds Ratio (95% CI) vs Placebo ^a		-	3.30 (1.36 to 8.04)	-	1.17 (0.24 to 5.72)
p-value for Odds Ratio ^a			0.0091		0.8433
Risk Ratio (95% CI) vs Placebo ^a		-	2.03 (1.17 to 3.53)	-	1.08 (0.50 to 2.31)
Reversed Risk ratio (95% CI)		-	0.49 (0.28 to 0.86)	-	0.93 (0.43 to 1.99)
p-value for Risk Ratio ^a			0.0124		0.8491
Risk Difference (95% CI) vs Placebo ^a		-	28.05 (8.41 to 47.68)	-	3.85 (-35.76 to 43.45)
p-value for Risk Difference ^a			0.0056		0.8431
Treatment-by-subgroup p-value of RR ^b					0.1750

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_region_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		7 (28.0)	23 (67.6)	12 (36.4)	10 (38.5)
Non-responder		18 (72.0)	11 (32.4)	21 (63.6)	16 (61.5)
Odds Ratio (95% CI) vs Placebo ^a		-	5.38 (1.69 to 17.07)	-	1.09 (0.37 to 3.24)
p-value for Odds Ratio ^a			0.0051		0.8692
Risk Ratio (95% CI) vs Placebo ^a		-	2.42 (1.22 to 4.79)	-	1.06 (0.54 to 2.08)
Reversed Risk ratio (95% CI)		-	0.41 (0.21 to 0.82)	-	0.95 (0.48 to 1.86)
p-value for Risk Ratio ^a			0.0116		0.8712
Risk Difference (95% CI) vs Placebo ^a		-	39.65 (15.53 to 63.76)	-	2.10 (-23.32 to 27.52)
p-value for Risk Difference ^a			0.0017		0.8693
Treatment-by-subgroup p-value of RR ^b					0.0887

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_age_i_t_x.rtf (04SEP2024 11:00)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		9 (29.0)	13 (46.4)	10 (37.0)	20 (62.5)
Non-responder		22 (71.0)	15 (53.6)	17 (63.0)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a		-	2.12 (0.71 to 6.35)	-	2.83 (0.96 to 8.36)
p-value for Odds Ratio ^a			0.1760		0.0590
Risk Ratio (95% CI) vs Placebo ^a		-	1.60 (0.80 to 3.20)	-	1.69 (0.95 to 2.99)
Reversed Risk ratio (95% CI)		-	0.63 (0.31 to 1.25)	-	0.59 (0.33 to 1.05)
p-value for Risk Ratio ^a			0.1848		0.0732
Risk Difference (95% CI) vs Placebo ^a		-	17.40 (-7.56 to 42.35)	-	25.46 (0.16 to 50.76)
p-value for Risk Difference ^a			0.1681		0.0486
Treatment-by-subgroup p-value of RR ^b					0.9050

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_crp_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		7 (22.6)	18 (64.3)	12 (44.4)	15 (46.9)
Non-responder		24 (77.4)	10 (35.7)	15 (55.6)	17 (53.1)
Odds Ratio (95% CI) vs Placebo ^a		-	6.17 (1.92 to 19.84)	-	1.10 (0.39 to 3.16)
p-value for Odds Ratio ^a			0.0028		0.8526
Risk Ratio (95% CI) vs Placebo ^a		-	2.85 (1.38 to 5.87)	-	1.05 (0.60 to 1.87)
Reversed Risk ratio (95% CI)		-	0.35 (0.17 to 0.72)	-	0.95 (0.53 to 1.68)
p-value for Risk Ratio ^a			0.0046		0.8553
Risk Difference (95% CI) vs Placebo ^a		-	41.71 (18.15 to 65.26)	-	2.43 (-23.62 to 28.48)
p-value for Risk Difference ^a			0.0008		0.8525
Treatment-by-subgroup p-value of RR ^b					0.0332

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_esr_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		10 (29.4)	19 (63.3)	9 (37.5)	14 (46.7)
Non-responder		24 (70.6)	11 (36.7)	15 (62.5)	16 (53.3)
Odds Ratio (95% CI) vs Placebo ^a		-	4.15 (1.43 to 12.06)	-	1.46 (0.48 to 4.47)
p-value for Odds Ratio ^a			0.0099		0.5022
Risk Ratio (95% CI) vs Placebo ^a		-	2.15 (1.18 to 3.92)	-	1.24 (0.64 to 2.40)
Reversed Risk ratio (95% CI)		-	0.46 (0.26 to 0.85)	-	0.80 (0.42 to 1.55)
p-value for Risk Ratio ^a			0.0121		0.5148
Risk Difference (95% CI) vs Placebo ^a		-	33.92 (10.40 to 57.44)	-	9.17 (-17.80 to 36.13)
p-value for Risk Difference ^a			0.0054		0.4982
Treatment-by-subgroup p-value of RR ^b					0.2197

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_cs_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		5 (29.4)	6 (50.0)	14 (34.1)	27 (56.3)
Non-responder		12 (70.6)	6 (50.0)	27 (65.9)	21 (43.8)
Odds Ratio (95% CI) vs Placebo ^a		-	2.40 (0.48 to 12.02)	-	2.48 (1.04 to 5.94)
p-value for Odds Ratio ^a			0.2747		0.0418
Risk Ratio (95% CI) vs Placebo ^a		-	1.70 (0.64 to 4.49)	-	1.65 (1.00 to 2.72)
Reversed Risk ratio (95% CI)		-	0.59 (0.22 to 1.56)	-	0.61 (0.37 to 1.00)
p-value for Risk Ratio ^a			0.2847		0.0503
Risk Difference (95% CI) vs Placebo ^a		-	20.59 (-16.71 to 57.89)	-	22.10 (1.63 to 42.58)
p-value for Risk Difference ^a			0.2674		0.0347
Treatment-by-subgroup p-value of RR ^b					0.9533

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_mtx_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
Absence of disease flare from Week 12 through Week 52 [n (%)]					
Responder		9 (39.1)	17 (70.8)	10 (28.6)	16 (44.4)
Non-responder		14 (60.9)	7 (29.2)	25 (71.4)	20 (55.6)
Odds Ratio (95% CI) vs Placebo ^a		-	3.78 (1.08 to 13.17)	-	2.00 (0.73 to 5.45)
p-value for Odds Ratio ^a			0.0374		0.1722
Risk Ratio (95% CI) vs Placebo ^a		-	1.81 (1.01 to 3.25)	-	1.56 (0.81 to 2.98)
Reversed Risk ratio (95% CI)		-	0.55 (0.31 to 0.99)	-	0.64 (0.34 to 1.23)
p-value for Risk Ratio ^a			0.0473		0.1827
Risk Difference (95% CI) vs Placebo ^a		-	31.70 (3.97 to 59.44)	-	15.87 (-6.60 to 38.35)
p-value for Risk Difference ^a			0.0260		0.1633
Treatment-by-subgroup p-value of RR ^b					0.7293

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_nodsfla3_ger_nrp_i_t_x.rtf (04SEP2024 11:01)

4. Sustained reduction of CRP from Week 12 through Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Sustained reduction of CRP from Week 12 through Week 52	Gender (Male , Female)	0.0210
	Race (Caucasian/White , All other races)	0.8605
	Region (Western Countries , Rest of World (including South America))	0.0412
	Age (Age < 70 , Age >= 70)	0.1816
	Baseline CRP (<= median , > median)	0.5162
	Baseline ESR (<= median , > median)	0.0391
	Baseline CS dose (<= median , > median)	0.9514
	MTX Add-on Therapy (Yes , No)	0.3390
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.4397

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_crpnmw52_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		14 (66.7)	9 (60.0)	12 (32.4)	31 (68.9)
Non-responder		7 (33.3)	6 (40.0)	25 (67.6)	14 (31.1)
Odds Ratio (95% CI) vs Placebo ^a		-	0.75 (0.18 to 3.12)	-	4.61 (1.79 to 11.91)
p-value for Odds Ratio ^a			0.6843		0.0019
Risk Ratio (95% CI) vs Placebo ^a		-	0.90 (0.53 to 1.53)	-	2.12 (1.27 to 3.55)
Reversed Risk ratio (95% CI)				-	0.47 (0.28 to 0.79)
p-value for Risk Ratio ^a			0.6973		0.0040
Risk Difference (95% CI) vs Placebo ^a		-	-6.67 (-39.80 to 26.47)	-	36.46 (15.89 to 57.03)
p-value for Risk Difference ^a			0.6852		0.0007
Treatment-by-subgroup p-value of RR ^b					0.0210

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_gender_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		21 (43.8)	33 (66.0)	5 (50.0)	7 (70.0)
Non-responder		27 (56.3)	17 (34.0)	5 (50.0)	3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.50 (1.09 to 5.71)	-	2.33 (0.33 to 16.67)
p-value for Odds Ratio ^a			0.0307		0.3773
Risk Ratio (95% CI) vs Placebo ^a		-	1.51 (1.03 to 2.21)	-	1.40 (0.63 to 3.10)
Reversed Risk ratio (95% CI)		-	0.66 (0.45 to 0.97)	-	0.71 (0.32 to 1.58)
p-value for Risk Ratio ^a			0.0350		0.4063
Risk Difference (95% CI) vs Placebo ^a		-	22.25 (2.79 to 41.71)	-	20.00 (-25.06 to 65.06)
p-value for Risk Difference ^a			0.0255		0.3634
Treatment-by-subgroup p-value of RR ^b					0.8605

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_race_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		15 (34.1)	30 (63.8)	11 (78.6)	10 (76.9)
Non-responder		29 (65.9)	17 (36.2)	3 (21.4)	3 (23.1)
Odds Ratio (95% CI) vs Placebo ^a		-	3.41 (1.42 to 8.17)	-	0.91 (0.13 to 6.12)
p-value for Odds Ratio ^a			0.0064		0.9188
Risk Ratio (95% CI) vs Placebo ^a		-	1.87 (1.17 to 3.00)	-	0.98 (0.64 to 1.50)
Reversed Risk ratio (95% CI)		-	0.53 (0.33 to 0.85)		
p-value for Risk Ratio ^a			0.0089		0.9221
Risk Difference (95% CI) vs Placebo ^a		-	29.74 (9.85 to 49.63)	-	-1.65 (-34.65 to 31.36)
p-value for Risk Difference ^a			0.0038		0.9189
Treatment-by-subgroup p-value of RR ^b					0.0412

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_region_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		9 (36.0)	24 (70.6)	17 (51.5)	16 (61.5)
Non-responder		16 (64.0)	10 (29.4)	16 (48.5)	10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	4.27 (1.39 to 13.13)	-	1.51 (0.52 to 4.38)
p-value for Odds Ratio ^a			0.0124		0.4454
Risk Ratio (95% CI) vs Placebo ^a		-	1.96 (1.10 to 3.50)	-	1.19 (0.75 to 1.89)
Reversed Risk ratio (95% CI)		-	0.51 (0.29 to 0.91)	-	0.84 (0.53 to 1.32)
p-value for Risk Ratio ^a			0.0225		0.4478
Risk Difference (95% CI) vs Placebo ^a		-	34.59 (9.80 to 59.38)	-	10.02 (-15.83 to 35.88)
p-value for Risk Difference ^a			0.0071		0.4408
Treatment-by-subgroup p-value of RR ^b					0.1816

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_age_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		12 (38.7)	18 (64.3)	14 (51.9)	22 (68.8)
Non-responder		19 (61.3)	10 (35.7)	13 (48.1)	10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	2.85 (0.97 to 8.40)	-	2.04 (0.69 to 6.05)
p-value for Odds Ratio ^a			0.0574		0.1928
Risk Ratio (95% CI) vs Placebo ^a		-	1.66 (0.97 to 2.83)	-	1.33 (0.85 to 2.06)
Reversed Risk ratio (95% CI)		-	0.60 (0.35 to 1.03)	-	0.75 (0.49 to 1.17)
p-value for Risk Ratio ^a			0.0623		0.2104
Risk Difference (95% CI) vs Placebo ^a		-	25.58 (0.36 to 50.79)	-	16.90 (-8.40 to 42.20)
p-value for Risk Difference ^a			0.0469		0.1863
Treatment-by-subgroup p-value of RR ^b					0.5162

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger__crp_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		10 (32.3)	20 (71.4)	16 (59.3)	20 (62.5)
Non-responder		21 (67.7)	8 (28.6)	11 (40.7)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a		-	5.25 (1.68 to 16.37)	-	1.15 (0.39 to 3.35)
p-value for Odds Ratio ^a			0.0050		0.8002
Risk Ratio (95% CI) vs Placebo ^a		-	2.21 (1.25 to 3.93)	-	1.05 (0.69 to 1.61)
Reversed Risk ratio (95% CI)		-	0.45 (0.25 to 0.80)	-	0.95 (0.62 to 1.44)
p-value for Risk Ratio ^a			0.0066		0.8042
Risk Difference (95% CI) vs Placebo ^a		-	39.17 (15.19 to 63.15)	-	3.24 (-22.30 to 28.78)
p-value for Risk Difference ^a			0.0018		0.8003
Treatment-by-subgroup p-value of RR ^b					0.0391

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_esr_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		16 (47.1)	21 (70.0)	10 (41.7)	19 (63.3)
Non-responder		18 (52.9)	9 (30.0)	14 (58.3)	11 (36.7)
Odds Ratio (95% CI) vs Placebo ^a		-	2.62 (0.92 to 7.51)	-	2.42 (0.78 to 7.46)
p-value for Odds Ratio ^a			0.0714		0.1217
Risk Ratio (95% CI) vs Placebo ^a		-	1.49 (0.96 to 2.30)	-	1.52 (0.87 to 2.66)
Reversed Risk ratio (95% CI)		-	0.67 (0.44 to 1.04)	-	0.66 (0.38 to 1.15)
p-value for Risk Ratio ^a			0.0736		0.1421
Risk Difference (95% CI) vs Placebo ^a		-	22.94 (-0.99 to 46.87)	-	21.67 (-5.16 to 48.49)
p-value for Risk Difference ^a			0.0599		0.1111
Treatment-by-subgroup p-value of RR ^b					0.9514

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_cs_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		8 (47.1)	6 (50.0)	18 (43.9)	34 (70.8)
Non-responder		9 (52.9)	6 (50.0)	23 (56.1)	14 (29.2)
Odds Ratio (95% CI) vs Placebo ^a		-	1.12 (0.24 to 5.29)	-	3.10 (1.28 to 7.55)
p-value for Odds Ratio ^a			0.8771		0.0131
Risk Ratio (95% CI) vs Placebo ^a		-	1.06 (0.48 to 2.35)	-	1.61 (1.09 to 2.40)
Reversed Risk ratio (95% CI)		-	0.94 (0.43 to 2.08)	-	0.62 (0.42 to 0.92)
p-value for Risk Ratio ^a			0.8809		0.0180
Risk Difference (95% CI) vs Placebo ^a		-	2.94 (-35.71 to 41.59)	-	26.93 (6.75 to 47.11)
p-value for Risk Difference ^a			0.8771		0.0095
Treatment-by-subgroup p-value of RR ^b					0.3390

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_mtx_i_t_x.rtf (04SEP2024 11:01)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Sustained reduction of CRP from Week 12 through Week 52 [n (%)]					
Responder		12 (52.2)	16 (66.7)	14 (40.0)	24 (66.7)
Non-responder		11 (47.8)	8 (33.3)	21 (60.0)	12 (33.3)
Odds Ratio (95% CI) vs Placebo ^a		-	1.83 (0.55 to 6.16)	-	3.00 (1.12 to 8.04)
p-value for Odds Ratio ^a			0.3189		0.0294
Risk Ratio (95% CI) vs Placebo ^a		-	1.28 (0.78 to 2.10)	-	1.67 (1.04 to 2.68)
Reversed Risk ratio (95% CI)		-	0.78 (0.48 to 1.29)	-	0.60 (0.37 to 0.97)
p-value for Risk Ratio ^a			0.3329		0.0351
Risk Difference (95% CI) vs Placebo ^a		-	14.49 (-14.07 to 43.05)	-	26.67 (3.89 to 49.44)
p-value for Risk Difference ^a			0.3122		0.0224
Treatment-by-subgroup p-value of RR ^b					0.4397

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_crpnmw52_ger_nrp_i_t_x.rtf (04SEP2024 11:01)

5. Successful adherence to the prednisone taper from Week 12 through Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Successful adherence to the prednisone taper from Week 12 through Week 52	Gender (Male , Female)	0.8479
	Race (Caucasian/White , All other races)	0.6797
	Region (Western Countries , Rest of World (including South America))	0.1568
	Age (Age < 70 , Age >= 70)	0.0274
	Baseline CRP (<= median , > median)	0.9813
	Baseline ESR (<= median , > median)	0.0766
	Baseline CS dose (<= median , > median)	0.6124
	MTX Add-on Therapy (Yes , No)	0.9531
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.1257

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_adhpn3_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Successful adherence to the prednisone taper from Week 12 through Week 52					
[n (%)]					
Responder		5 (23.8)	8 (53.3)	9 (24.3)	22 (48.9)
Non-responder		16 (76.2)	7 (46.7)	28 (75.7)	23 (51.1)
Odds Ratio (95% CI) vs Placebo ^a		-	3.66 (0.83 to 16.07)	-	2.98 (1.13 to 7.82)
p-value for Odds Ratio ^a			0.0839		0.0275
Risk Ratio (95% CI) vs Placebo ^a		-	2.24 (0.88 to 5.69)	-	2.01 (1.05 to 3.86)
Reversed Risk ratio (95% CI)		-	0.45 (0.18 to 1.13)	-	0.50 (0.26 to 0.95)
p-value for Risk Ratio ^a			0.0902		0.0358
Risk Difference (95% CI) vs Placebo ^a		-	29.52 (-2.76 to 61.80)	-	24.56 (4.15 to 44.98)
p-value for Risk Difference ^a			0.0717		0.0190
Treatment-by-subgroup p-value of RR ^b					0.8479

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpn3_gender_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		11 (22.9)	25 (50.0)	3 (30.0)	5 (50.0)
Non-responder		37 (77.1)	25 (50.0)	7 (70.0)	5 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	3.36 (1.39 to 8.13)	-	2.33 (0.33 to 16.67)
p-value for Odds Ratio ^a			0.0076		0.3773
Risk Ratio (95% CI) vs Placebo ^a		-	2.18 (1.20 to 3.96)	-	1.67 (0.50 to 5.61)
Reversed Risk ratio (95% CI)		-	0.46 (0.25 to 0.83)	-	0.60 (0.18 to 2.02)
p-value for Risk Ratio ^a			0.0103		0.4091
Risk Difference (95% CI) vs Placebo ^a		-	27.08 (8.59 to 45.58)	-	20.00 (-25.06 to 65.06)
p-value for Risk Difference ^a			0.0045		0.3634
Treatment-by-subgroup p-value of RR ^b					0.6797

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpn3_ger_race_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		8 (18.2)	23 (48.9)	6 (42.9)	7 (53.8)
Non-responder		36 (81.8)	24 (51.1)	8 (57.1)	6 (46.2)
Odds Ratio (95% CI) vs Placebo ^a		-	4.31 (1.64 to 11.37)	-	1.56 (0.32 to 7.68)
p-value for Odds Ratio ^a			0.0035		0.5739
Risk Ratio (95% CI) vs Placebo ^a		-	2.69 (1.34 to 5.43)	-	1.26 (0.55 to 2.87)
Reversed Risk ratio (95% CI)		-	0.37 (0.18 to 0.75)	-	0.80 (0.35 to 1.82)
p-value for Risk Ratio ^a			0.0056		0.5884
Risk Difference (95% CI) vs Placebo ^a		-	30.75 (12.22 to 49.29)	-	10.99 (-28.42 to 50.40)
p-value for Risk Difference ^a			0.0014		0.5709
Treatment-by-subgroup p-value of RR ^b					0.1568

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpn3_ger_region_i_t.x.rtf (04SEP2024 11:02)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		4 (16.0)	22 (64.7)	10 (30.3)	8 (30.8)
Non-responder		21 (84.0)	12 (35.3)	23 (69.7)	18 (69.2)
Odds Ratio (95% CI) vs Placebo ^a		-	9.62 (2.60 to 35.59)	-	1.02 (0.33 to 3.20)
p-value for Odds Ratio ^a			0.0010		0.9693
Risk Ratio (95% CI) vs Placebo ^a		-	4.04 (1.56 to 10.48)	-	1.02 (0.46 to 2.24)
Reversed Risk ratio (95% CI)		-	0.25 (0.10 to 0.64)	-	0.98 (0.45 to 2.17)
p-value for Risk Ratio ^a			0.0040		0.9698
Risk Difference (95% CI) vs Placebo ^a		-	48.71 (26.69 to 70.73)	-	0.47 (-23.72 to 24.66)
p-value for Risk Difference ^a			<0.0001		0.9694
Treatment-by-subgroup p-value of RR ^b					0.0274

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpn3_ger_age_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		6 (19.4)	11 (39.3)	8 (29.6)	19 (59.4)
Non-responder		25 (80.6)	17 (60.7)	19 (70.4)	13 (40.6)
Odds Ratio (95% CI) vs Placebo ^a		-	2.70 (0.82 to 8.91)	-	3.47 (1.14 to 10.53)
p-value for Odds Ratio ^a			0.1021		0.0286
Risk Ratio (95% CI) vs Placebo ^a		-	2.03 (0.85 to 4.85)	-	2.00 (1.03 to 3.89)
Reversed Risk ratio (95% CI)		-	0.49 (0.21 to 1.18)	-	0.50 (0.26 to 0.97)
p-value for Risk Ratio ^a			0.1115		0.0396
Risk Difference (95% CI) vs Placebo ^a		-	19.93 (-3.38 to 43.24)	-	29.75 (5.01 to 54.48)
p-value for Risk Difference ^a			0.0923		0.0193
Treatment-by-subgroup p-value of RR ^b					0.9813

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpns3_ger_crp_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		5 (16.1)	16 (57.1)	9 (33.3)	14 (43.8)
Non-responder		26 (83.9)	12 (42.9)	18 (66.7)	18 (56.3)
Odds Ratio (95% CI) vs Placebo ^a		-	6.93 (2.00 to 23.99)	-	1.56 (0.53 to 4.60)
p-value for Odds Ratio ^a			0.0028		0.4183
Risk Ratio (95% CI) vs Placebo ^a		-	3.54 (1.46 to 8.57)	-	1.31 (0.67 to 2.58)
Reversed Risk ratio (95% CI)		-	0.28 (0.12 to 0.68)	-	0.76 (0.39 to 1.50)
p-value for Risk Ratio ^a			0.0050		0.4310
Risk Difference (95% CI) vs Placebo ^a		-	41.01 (18.09 to 63.94)	-	10.42 (-14.85 to 35.68)
p-value for Risk Difference ^a			0.0007		0.4125
Treatment-by-subgroup p-value of RR ^b					0.0766

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpns3_ger_esr_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		10 (29.4)	17 (56.7)	4 (16.7)	13 (43.3)
Non-responder		24 (70.6)	13 (43.3)	20 (83.3)	17 (56.7)
Odds Ratio (95% CI) vs Placebo ^a		-	3.14 (1.10 to 8.99)	-	3.82 (1.02 to 14.38)
p-value for Odds Ratio ^a			0.0337		0.0473
Risk Ratio (95% CI) vs Placebo ^a		-	1.93 (1.04 to 3.58)	-	2.60 (0.95 to 7.12)
Reversed Risk ratio (95% CI)		-	0.52 (0.28 to 0.96)	-	0.38 (0.14 to 1.05)
p-value for Risk Ratio ^a			0.0380		0.0630
Risk Difference (95% CI) vs Placebo ^a		-	27.25 (3.36 to 51.15)	-	26.67 (2.95 to 50.39)
p-value for Risk Difference ^a			0.0261		0.0283
Treatment-by-subgroup p-value of RR ^b					0.6124

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpns3_ger_cs_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		4 (23.5)	6 (50.0)	10 (24.4)	24 (50.0)
Non-responder		13 (76.5)	6 (50.0)	31 (75.6)	24 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	3.25 (0.61 to 17.22)	-	3.10 (1.23 to 7.80)
p-value for Odds Ratio ^a			0.1584		0.0169
Risk Ratio (95% CI) vs Placebo ^a		-	2.13 (0.73 to 6.23)	-	2.05 (1.11 to 3.80)
Reversed Risk ratio (95% CI)		-	0.47 (0.16 to 1.38)	-	0.49 (0.26 to 0.90)
p-value for Risk Ratio ^a			0.1694		0.0226
Risk Difference (95% CI) vs Placebo ^a		-	26.47 (-9.90 to 62.84)	-	25.61 (6.03 to 45.19)
p-value for Risk Difference ^a			0.1469		0.0110
Treatment-by-subgroup p-value of RR ^b					0.9531

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpns3_ger_mtx_i_t_x.rtf (04SEP2024 11:02)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
Successful adherence to the prednisone taper from Week 12 through Week 52 [n (%)]					
Responder		4 (17.4)	15 (62.5)	10 (28.6)	15 (41.7)
Non-responder		19 (82.6)	9 (37.5)	25 (71.4)	21 (58.3)
Odds Ratio (95% CI) vs Placebo ^a		-	7.92 (1.96 to 31.98)	-	1.79 (0.65 to 4.88)
p-value for Odds Ratio ^a			0.0046		0.2542
Risk Ratio (95% CI) vs Placebo ^a		-	3.59 (1.36 to 9.47)	-	1.46 (0.75 to 2.83)
Reversed Risk ratio (95% CI)		-	0.28 (0.11 to 0.73)	-	0.69 (0.35 to 1.33)
p-value for Risk Ratio ^a			0.0097		0.2644
Risk Difference (95% CI) vs Placebo ^a		-	45.11 (19.62 to 70.59)	-	13.10 (-9.28 to 35.47)
p-value for Risk Difference ^a			0.0009		0.2471
Treatment-by-subgroup p-value of RR ^b					0.1257

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

No imputation.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_adhpn3_ger_nrp_i_t_x.rtf (04SEP2024 11:02)

6. VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points	Gender (Male , Female)	0.7736
	Race (Caucasian/White , All other races)	0.9652
	Region (Western Countries , Rest of World (including South America))	0.2843
	Age (Age < 70 , Age $\geq$ 70)	0.1063
	Baseline CRP ($\leq$ median , > median)	0.0808
	Baseline ESR ($\leq$ median , > median)	0.1960
	Baseline CS dose ($\leq$ median , > median)	0.9127
	MTX Add-on Therapy (Yes , No)	0.5677
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2339

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_vaspat_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)			Female (N=82)
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		8 (38.1) / 0	5 (33.3) / 0	12 (32.4) / 0	15 (33.3) / 0
Non-responder / Imputed non-responder		13 (61.9) / 7 (33.3)	10 (66.7) / 4 (26.7)	25 (67.6) / 16 (43.2)	30 (66.7) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	0.81 (0.19 to 3.43)	-	1.04 (0.41 to 2.67)
p-value for Odds Ratio ^a			0.7712		0.9314
Risk Ratio (95% CI) vs Placebo ^a		-	0.87 (0.34 to 2.22)	-	1.03 (0.55 to 1.93)
Reversed Risk ratio (95% CI)				-	0.97 (0.52 to 1.83)
p-value for Risk Ratio ^a			0.7791		0.9322
Risk Difference (95% CI) vs Placebo ^a		-	-4.76 (-37.56 to 28.04)	-	0.90 (-19.84 to 21.64)
p-value for Risk Difference ^a			0.7697		0.9313
Treatment-by-subgroup p-value of RR ^b					0.7736

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_gender_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		18 (37.5) / 0	18 (36.0) / 0	2 (20.0) / 0	2 (20.0) / 0
Non-responder / Imputed non-responder		30 (62.5) / 20 (41.7)	32 (64.0) / 14 (28.0)	8 (80.0) / 3 (30.0)	8 (80.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.94 (0.41 to 2.15)	-	1.00 (0.10 to 10.47)
p-value for Odds Ratio ^a			0.8780		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	0.96 (0.57 to 1.62)	-	1.00 (0.15 to 6.55)
p-value for Risk Ratio ^a			0.8791		1.0000
Risk Difference (95% CI) vs Placebo ^a		-	-1.50 (-20.84 to 17.84)	-	0.00 (-37.58 to 37.58)
p-value for Risk Difference ^a			0.8780		1.0000
Treatment-by-subgroup p-value of RR ^b					0.9652

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_race_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		13 (29.5) / 0	16 (34.0) / 0	7 (50.0) / 0	4 (30.8) / 0
Non-responder / Imputed non-responder		31 (70.5) / 19 (43.2)	31 (66.0) / 13 (27.7)	7 (50.0) / 4 (28.6)	9 (69.2) / 4 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.23 (0.50 to 3.02)	-	0.44 (0.08 to 2.33)
p-value for Odds Ratio ^a			0.6468		0.3230
Risk Ratio (95% CI) vs Placebo ^a		-	1.15 (0.62 to 2.13)	-	0.62 (0.22 to 1.70)
Reversed Risk ratio (95% CI)		-	0.87 (0.47 to 1.60)		
p-value for Risk Ratio ^a			0.6510		0.3501
Risk Difference (95% CI) vs Placebo ^a		-	4.50 (-14.88 to 23.87)	-	-19.23 (-57.34 to 18.88)
p-value for Risk Difference ^a			0.6458		0.3086
Treatment-by-subgroup p-value of RR ^b					0.2843

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_region_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		6 (24.0) / 0	13 (38.2) / 0	14 (42.4) / 0	7 (26.9) / 0
Non-responder / Imputed non-responder		19 (76.0) / 10 (40.0)	21 (61.8) / 7 (20.6)	19 (57.6) / 13 (39.4)	19 (73.1) / 10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	1.96 (0.61 to 6.34)	-	0.50 (0.16 to 1.55)
p-value for Odds Ratio ^a			0.2558		0.2252
Risk Ratio (95% CI) vs Placebo ^a		-	1.59 (0.69 to 3.67)	-	0.63 (0.30 to 1.36)
Reversed Risk ratio (95% CI)		-	0.63 (0.27 to 1.45)		
p-value for Risk Ratio ^a			0.2747		0.2433
Risk Difference (95% CI) vs Placebo ^a		-	14.24 (-9.66 to 38.13)	-	-15.50 (-40.00 to 9.00)
p-value for Risk Difference ^a			0.2379		0.2103
Treatment-by-subgroup p-value of RR ^b					0.1063

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_age_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		12 (38.7) / 0	6 (21.4) / 0	8 (29.6) / 0	14 (43.8) / 0
Non-responder / Imputed non-responder		19 (61.3) / 12 (38.7)	22 (78.6) / 9 (32.1)	19 (70.4) / 11 (40.7)	18 (56.3) / 8 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.43 (0.13 to 1.41)	-	1.85 (0.61 to 5.58)
p-value for Odds Ratio ^a			0.1601		0.2708
Risk Ratio (95% CI) vs Placebo ^a		-	0.55 (0.24 to 1.30)	-	1.48 (0.72 to 3.02)
Reversed Risk ratio (95% CI)				-	0.68 (0.33 to 1.39)
p-value for Risk Ratio ^a			0.1749		0.2866
Risk Difference (95% CI) vs Placebo ^a		-	-17.28 (-40.69 to 6.13)	-	14.12 (-10.74 to 38.98)
p-value for Risk Difference ^a			0.1448		0.2601
Treatment-by-subgroup p-value of RR ^b					0.0808

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_crp_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		9 (29.0) / 0	11 (39.3) / 0	11 (40.7) / 0	9 (28.1) / 0
Non-responder / Imputed non-responder		22 (71.0) / 12 (38.7)	17 (60.7) / 7 (25.0)	16 (59.3) / 11 (40.7)	23 (71.9) / 10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	1.58 (0.52 to 4.79)	-	0.57 (0.19 to 1.73)
p-value for Odds Ratio ^a			0.4109		0.3142
Risk Ratio (95% CI) vs Placebo ^a		-	1.35 (0.65 to 2.82)	-	0.69 (0.33 to 1.44)
Reversed Risk ratio (95% CI)		-	0.74 (0.36 to 1.54)		
p-value for Risk Ratio ^a			0.4188		0.3213
Risk Difference (95% CI) vs Placebo ^a		-	10.25 (-14.41 to 34.91)	-	-12.62 (-37.35 to 12.12)
p-value for Risk Difference ^a			0.4085		0.3114
Treatment-by-subgroup p-value of RR ^b					0.1960

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_esr_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		12 (35.3) / 0	10 (33.3) / 0	8 (33.3) / 0	10 (33.3) / 0
Non-responder / Imputed non-responder		22 (64.7) / 12 (35.3)	20 (66.7) / 7 (23.3)	16 (66.7) / 11 (45.8)	20 (66.7) / 10 (33.3)
Odds Ratio (95% CI) vs Placebo ^a		-	0.92 (0.32 to 2.63)	-	1.00 (0.31 to 3.21)
p-value for Odds Ratio ^a			0.8696		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	0.94 (0.47 to 1.89)	-	1.00 (0.46 to 2.18)
Reversed Risk ratio (95% CI)				-	1.00 (0.46 to 2.18)
p-value for Risk Ratio ^a			0.8718		1.0000
Risk Difference (95% CI) vs Placebo ^a		-	-1.96 (-25.72 to 21.80)	-	-0.00 (-25.91 to 25.91)
p-value for Risk Difference ^a			0.8695		1.0000
Treatment-by-subgroup p-value of RR ^b					0.9127

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_cs_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)	
		Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		6 (35.3) / 0	3 (25.0) / 0	14 (34.1) / 0	17 (35.4) / 0
Non-responder / Imputed non-responder		11 (64.7) / 7 (41.2)	9 (75.0) / 6 (50.0)	27 (65.9) / 16 (39.0)	31 (64.6) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	0.61 (0.11 to 3.41)	-	1.06 (0.44 to 2.57)
p-value for Odds Ratio ^a			0.5616		0.9005
Risk Ratio (95% CI) vs Placebo ^a		-	0.71 (0.21 to 2.42)	-	1.04 (0.58 to 1.85)
Reversed Risk ratio (95% CI)				-	0.96 (0.54 to 1.72)
p-value for Risk Ratio ^a			0.5819		0.9017
Risk Difference (95% CI) vs Placebo ^a		-	-10.29 (-45.27 to 24.68)	-	1.27 (-18.85 to 21.39)
p-value for Risk Difference ^a			0.5510		0.9004
Treatment-by-subgroup p-value of RR ^b					0.5677

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_mtx_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		11 (47.8) / 0	8 (33.3) / 0	9 (25.7) / 0	12 (33.3) / 0
Non-responder / Imputed non-responder		12 (52.2) / 6 (26.1)	16 (66.7) / 8 (33.3)	26 (74.3) / 17 (48.6)	24 (66.7) / 9 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.55 (0.16 to 1.83)	-	1.44 (0.51 to 4.11)
p-value for Odds Ratio ^a			0.3189		0.4852
Risk Ratio (95% CI) vs Placebo ^a		-	0.70 (0.34 to 1.44)	-	1.30 (0.62 to 2.72)
Reversed Risk ratio (95% CI)				-	0.77 (0.37 to 1.62)
p-value for Risk Ratio ^a			0.3313		0.4926
Risk Difference (95% CI) vs Placebo ^a		-	-14.49 (-43.05 to 14.07)	-	7.62 (-13.90 to 29.13)
p-value for Risk Difference ^a			0.3122		0.4823
Treatment-by-subgroup p-value of RR ^b					0.2339

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ger_nrp_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

7. VAS disease activity (Physician) decrease from Baseline >= 1.5 points at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
VAS disease activity (Physician) decrease from Baseline >= 1.5 points	Gender (Male , Female)	0.1989
	Race (Caucasian/White , All other races)	0.2685
	Region (Western Countries , Rest of World (including South America))	0.0615
	Age (Age < 70 , Age >= 70)	0.0424
	Baseline CRP (<= median , > median)	0.9216
	Baseline ESR (<= median , > median)	0.3991
	Baseline CS dose (<= median , > median)	0.6574
	MTX Add-on Therapy (Yes , No)	0.4304
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.0748

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_vasphy_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		11 (52.4) / 0	8 (53.3) / 0	10 (27.0) / 0	22 (48.9) / 0
Non-responder / Imputed non-responder		10 (47.6) / 8 (38.1)	7 (46.7) / 5 (33.3)	27 (73.0) / 18 (48.6)	23 (51.1) / 16 (35.6)
Odds Ratio (95% CI) vs Placebo ^a		-	1.04 (0.26 to 4.12)	-	2.58 (1.00 to 6.65)
p-value for Odds Ratio ^a			0.9553		0.0493
Risk Ratio (95% CI) vs Placebo ^a		-	1.02 (0.53 to 1.95)	-	1.81 (0.98 to 3.35)
Reversed Risk ratio (95% CI)		-	0.98 (0.51 to 1.88)	-	0.55 (0.30 to 1.02)
p-value for Risk Ratio ^a			0.9565		0.0598
Risk Difference (95% CI) vs Placebo ^a		-	0.95 (-33.34 to 35.24)	-	21.86 (1.10 to 42.62)
p-value for Risk Difference ^a			0.9553		0.0393
Treatment-by-subgroup p-value of RR ^b					0.1989

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_gender_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		18 (37.5) / 0	23 (46.0) / 0	3 (30.0) / 0	7 (70.0) / 0
Non-responder / Imputed non-responder		30 (62.5) / 23 (47.9)	27 (54.0) / 18 (36.0)	7 (70.0) / 3 (30.0)	3 (30.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.42 (0.63 to 3.21)	-	5.44 (0.70 to 42.30)
p-value for Odds Ratio ^a			0.3966		0.0996
Risk Ratio (95% CI) vs Placebo ^a		-	1.23 (0.76 to 1.98)	-	2.33 (0.77 to 7.04)
Reversed Risk ratio (95% CI)		-	0.82 (0.51 to 1.32)	-	0.43 (0.14 to 1.29)
p-value for Risk Ratio ^a			0.4030		0.1326
Risk Difference (95% CI) vs Placebo ^a		-	8.50 (-11.20 to 28.20)	-	40.00 (-3.06 to 83.06)
p-value for Risk Difference ^a			0.3939		0.0667
Treatment-by-subgroup p-value of RR ^b					0.2685

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_race_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		11 (25.0) / 0	22 (46.8) / 0	10 (71.4) / 0	8 (61.5) / 0
Non-responder / Imputed non-responder		33 (75.0) / 22 (50.0)	25 (53.2) / 16 (34.0)	4 (28.6) / 4 (28.6)	5 (38.5) / 5 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	2.64 (1.07 to 6.51)	-	0.64 (0.12 to 3.48)
p-value for Odds Ratio ^a			0.0355		0.5918
Risk Ratio (95% CI) vs Placebo ^a		-	1.87 (1.02 to 3.42)	-	0.86 (0.49 to 1.52)
Reversed Risk ratio (95% CI)		-	0.53 (0.29 to 0.98)		
p-value for Risk Ratio ^a			0.0418		0.6084
Risk Difference (95% CI) vs Placebo ^a		-	21.81 (2.38 to 41.24)	-	-9.89 (-47.18 to 27.40)
p-value for Risk Difference ^a			0.0282		0.5898
Treatment-by-subgroup p-value of RR ^b					0.0615

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_region_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		7 (28.0) / 0	21 (61.8) / 0	14 (42.4) / 0	9 (34.6) / 0
Non-responder / Imputed non-responder		18 (72.0) / 10 (40.0)	13 (38.2) / 10 (29.4)	19 (57.6) / 16 (48.5)	17 (65.4) / 11 (42.3)
Odds Ratio (95% CI) vs Placebo ^a		-	4.15 (1.33 to 12.96)	-	0.72 (0.24 to 2.13)
p-value for Odds Ratio ^a			0.0151		0.5445
Risk Ratio (95% CI) vs Placebo ^a		-	2.21 (1.10 to 4.43)	-	0.82 (0.42 to 1.60)
Reversed Risk ratio (95% CI)		-	0.45 (0.23 to 0.91)		
p-value for Risk Ratio ^a			0.0260		0.5550
Risk Difference (95% CI) vs Placebo ^a		-	33.76 (9.23 to 58.30)	-	-7.81 (-33.22 to 17.61)
p-value for Risk Difference ^a			0.0078		0.5408
Treatment-by-subgroup p-value of RR ^b					0.0424

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_age_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		11 (35.5) / 0	14 (50.0) / 0	10 (37.0) / 0	16 (50.0) / 0
Non-responder / Imputed non-responder		20 (64.5) / 14 (45.2)	14 (50.0) / 10 (35.7)	17 (63.0) / 12 (44.4)	16 (50.0) / 11 (34.4)
Odds Ratio (95% CI) vs Placebo ^a		-	1.82 (0.63 to 5.28)	-	1.70 (0.58 to 4.94)
p-value for Odds Ratio ^a			0.2664		0.3235
Risk Ratio (95% CI) vs Placebo ^a		-	1.41 (0.76 to 2.61)	-	1.35 (0.73 to 2.50)
Reversed Risk ratio (95% CI)		-	0.71 (0.38 to 1.31)	-	0.74 (0.40 to 1.37)
p-value for Risk Ratio ^a			0.2745		0.3386
Risk Difference (95% CI) vs Placebo ^a		-	14.52 (-11.06 to 40.09)	-	12.96 (-12.72 to 38.65)
p-value for Risk Difference ^a			0.2605		0.3164
Treatment-by-subgroup p-value of RR ^b					0.9216

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_crp_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		10 (32.3) / 0	15 (53.6) / 0	11 (40.7) / 0	15 (46.9) / 0
Non-responder / Imputed non-responder		21 (67.7) / 13 (41.9)	13 (46.4) / 9 (32.1)	16 (59.3) / 13 (48.1)	17 (53.1) / 12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a		-	2.42 (0.82 to 7.14)	-	1.28 (0.45 to 3.70)
p-value for Odds Ratio ^a			0.1065		0.6384
Risk Ratio (95% CI) vs Placebo ^a		-	1.66 (0.89 to 3.12)	-	1.15 (0.63 to 2.09)
Reversed Risk ratio (95% CI)		-	0.60 (0.32 to 1.13)	-	0.87 (0.48 to 1.58)
p-value for Risk Ratio ^a			0.1140		0.6459
Risk Difference (95% CI) vs Placebo ^a		-	21.31 (-3.96 to 46.59)	-	6.13 (-19.76 to 32.03)
p-value for Risk Difference ^a			0.0968		0.6371
Treatment-by-subgroup p-value of RR ^b					0.3991

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_esr_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder / Imputed responder		12 (35.3) / 0	16 (53.3) / 0	9 (37.5) / 0	14 (46.7) / 0
Non-responder / Imputed non-responder		22 (64.7) / 15 (44.1)	14 (46.7) / 10 (33.3)	15 (62.5) / 11 (45.8)	16 (53.3) / 11 (36.7)
Odds Ratio (95% CI) vs Placebo ^a		-	2.10 (0.75 to 5.84)	-	1.46 (0.48 to 4.47)
p-value for Odds Ratio ^a			0.1540		0.5022
Risk Ratio (95% CI) vs Placebo ^a		-	1.51 (0.85 to 2.69)	-	1.24 (0.64 to 2.40)
Reversed Risk ratio (95% CI)		-	0.66 (0.37 to 1.18)	-	0.80 (0.42 to 1.55)
p-value for Risk Ratio ^a			0.1602		0.5148
Risk Difference (95% CI) vs Placebo ^a		-	18.04 (-6.45 to 42.53)	-	9.17 (-17.80 to 36.13)
p-value for Risk Difference ^a			0.1460		0.4982
Treatment-by-subgroup p-value of RR ^b					0.6574

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_cs_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		5 (29.4) / 0	3 (25.0) / 0	16 (39.0) / 0	27 (56.3) / 0
Non-responder / Imputed non-responder		12 (70.6) / 8 (47.1)	9 (75.0) / 7 (58.3)	25 (61.0) / 18 (43.9)	21 (43.8) / 14 (29.2)
Odds Ratio (95% CI) vs Placebo ^a		-	0.80 (0.14 to 4.61)	-	2.01 (0.85 to 4.75)
p-value for Odds Ratio ^a			0.7956		0.1105
Risk Ratio (95% CI) vs Placebo ^a		-	0.85 (0.24 to 3.07)	-	1.44 (0.91 to 2.29)
Reversed Risk ratio (95% CI)				-	0.69 (0.44 to 1.10)
p-value for Risk Ratio ^a			0.8040		0.1219
Risk Difference (95% CI) vs Placebo ^a		-	-4.41 (-38.65 to 29.82)	-	17.23 (-3.55 to 38.01)
p-value for Risk Difference ^a			0.7935		0.1030
Treatment-by-subgroup p-value of RR ^b					0.4304

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_mtx_i_t_x.rtf (03SEP2024 11:09)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)			> 1 relapse (N=71)
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder / Imputed responder		11 (47.8) / 0	10 (41.7) / 0	10 (28.6) / 0	20 (55.6) / 0
Non-responder / Imputed non-responder		12 (52.2) / 8 (34.8)	14 (58.3) / 10 (41.7)	25 (71.4) / 18 (51.4)	16 (44.4) / 11 (30.6)
Odds Ratio (95% CI) vs Placebo ^a		-	0.78 (0.24 to 2.55)	-	3.12 (1.15 to 8.52)
p-value for Odds Ratio ^a			0.6734		0.0265
Risk Ratio (95% CI) vs Placebo ^a		-	0.87 (0.45 to 1.68)	-	1.94 (1.06 to 3.58)
Reversed Risk ratio (95% CI)				-	0.51 (0.28 to 0.95)
p-value for Risk Ratio ^a			0.6799		0.0328
Risk Difference (95% CI) vs Placebo ^a		-	-6.16 (-35.33 to 23.01)	-	26.98 (4.51 to 49.46)
p-value for Risk Difference ^a			0.6727		0.0193
Treatment-by-subgroup p-value of RR ^b					0.0748

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ger_nrp_i_t_x.rtf (03SEP2024 11:10)

8. FACIT-F increase from Baseline $\geq$ 7.8 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
FACIT-F increase from Baseline $\geq$ 7.8 points	Gender (Male , Female)	0.6452
	Race (Caucasian/White , All other races)	0.4306
	Region (Western Countries , Rest of World (including South America))	0.6880
	Age (Age < 70 , Age $\geq$ 70)	0.0498
	Baseline CRP ($\leq$ median , > median)	0.1250
	Baseline ESR ($\leq$ median , > median)	0.4522
	Baseline CS dose ($\leq$ median , > median)	0.0241
	MTX Add-on Therapy (Yes , No)	0.7177
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.3655

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_binfatigue_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
FACIT-F increase from Baseline >=7.8 points [n (%)]					
Responder / Imputed responder		6 (28.6) / 0	7 (46.7) / 0	11 (29.7) / 0	17 (37.8) / 0
Non-responder / Imputed non-responder		15 (71.4) / 6 (28.6)	8 (53.3) / 4 (26.7)	26 (70.3) / 16 (43.2)	28 (62.2) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	2.19 (0.52 to 9.22)	-	1.44 (0.56 to 3.68)
p-value for Odds Ratio ^a			0.2766		0.4475
Risk Ratio (95% CI) vs Placebo ^a		-	1.63 (0.67 to 4.01)	-	1.27 (0.68 to 2.39)
Reversed Risk ratio (95% CI)		-	0.61 (0.25 to 1.50)	-	0.79 (0.42 to 1.48)
p-value for Risk Ratio ^a			0.2842		0.4567
Risk Difference (95% CI) vs Placebo ^a		-	18.10 (-14.87 to 51.06)	-	8.05 (-12.70 to 28.80)
p-value for Risk Difference ^a			0.2724		0.4424
Treatment-by-subgroup p-value of RR ^b					0.6452

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_gender_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
FACIT-F increase from Baseline ≥ 7.8 points [n (%)]					
Responder / Imputed responder		16 (33.3) / 0	21 (42.0) / 0	1 (10.0) / 0	3 (30.0) / 0
Non-responder / Imputed non-responder		32 (66.7) / 19 (39.6)	29 (58.0) / 14 (28.0)	9 (90.0) / 3 (30.0)	7 (70.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.45 (0.63 to 3.33)	-	3.86 (0.27 to 54.43)
p-value for Odds Ratio ^a			0.3793		0.2981
Risk Ratio (95% CI) vs Placebo ^a		-	1.26 (0.75 to 2.12)	-	3.00 (0.32 to 28.08)
Reversed Risk ratio (95% CI)		-	0.79 (0.47 to 1.34)	-	0.33 (0.04 to 3.12)
p-value for Risk Ratio ^a			0.3860		0.3357
Risk Difference (95% CI) vs Placebo ^a		-	8.67 (-10.68 to 28.02)	-	20.00 (-16.39 to 56.39)
p-value for Risk Difference ^a			0.3762		0.2633
Treatment-by-subgroup p-value of RR ^b					0.4306

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_race_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
FACIT-F increase from Baseline ≥ 7.8 points [n (%)]					
Responder / Imputed responder		10 (22.7) / 0	16 (34.0) / 0	7 (50.0) / 0	8 (61.5) / 0
Non-responder / Imputed non-responder		34 (77.3) / 18 (40.9)	31 (66.0) / 13 (27.7)	7 (50.0) / 4 (28.6)	5 (38.5) / 4 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.75 (0.68 to 4.50)	-	1.60 (0.32 to 8.00)
p-value for Odds Ratio ^a			0.2381		0.5530
Risk Ratio (95% CI) vs Placebo ^a		-	1.50 (0.76 to 2.97)	-	1.23 (0.60 to 2.51)
Reversed Risk ratio (95% CI)		-	0.67 (0.34 to 1.32)	-	0.81 (0.40 to 1.66)
p-value for Risk Ratio ^a			0.2469		0.5676
Risk Difference (95% CI) vs Placebo ^a		-	11.32 (-7.29 to 29.92)	-	11.54 (-27.57 to 50.65)
p-value for Risk Difference ^a			0.2301		0.5489
Treatment-by-subgroup p-value of RR ^b					0.6880

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_region_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
FACIT-F increase from Baseline >=7.8 points [n (%)]					
Responder / Imputed responder		6 (24.0) / 0	18 (52.9) / 0	11 (33.3) / 0	6 (23.1) / 0
Non-responder / Imputed non-responder		19 (76.0) / 10 (40.0)	16 (47.1) / 7 (20.6)	22 (66.7) / 12 (36.4)	20 (76.9) / 10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	3.56 (1.11 to 11.40)	-	0.60 (0.18 to 1.97)
p-value for Odds Ratio ^a			0.0328		0.3935
Risk Ratio (95% CI) vs Placebo ^a		-	2.21 (1.01 to 4.83)	-	0.69 (0.29 to 1.65)
Reversed Risk ratio (95% CI)		-	0.45 (0.21 to 0.99)		
p-value for Risk Ratio ^a			0.0476		0.4075
Risk Difference (95% CI) vs Placebo ^a		-	28.94 (4.73 to 53.16)	-	-10.26 (-33.58 to 13.06)
p-value for Risk Difference ^a			0.0200		0.3822
Treatment-by-subgroup p-value of RR ^b					0.0498

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_age_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
FACIT-F increase from Baseline >=7.8 points [n (%)]					
Responder / Imputed responder		11 (35.5) / 0	9 (32.1) / 0	6 (22.2) / 0	15 (46.9) / 0
Non-responder / Imputed non-responder		20 (64.5) / 12 (38.7)	19 (67.9) / 9 (32.1)	21 (77.8) / 10 (37.0)	17 (53.1) / 8 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.86 (0.29 to 2.60)	-	3.09 (0.96 to 9.92)
p-value for Odds Ratio ^a			0.7876		0.0580
Risk Ratio (95% CI) vs Placebo ^a		-	0.91 (0.44 to 1.89)	-	2.11 (0.94 to 4.76)
Reversed Risk ratio (95% CI)				-	0.47 (0.21 to 1.07)
p-value for Risk Ratio ^a			0.7915		0.0721
Risk Difference (95% CI) vs Placebo ^a		-	-3.34 (-28.01 to 21.33)	-	24.65 (0.80 to 48.50)
p-value for Risk Difference ^a			0.7872		0.0430
Treatment-by-subgroup p-value of RR ^b					0.1250

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_crp_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
FACIT-F increase from Baseline >=7.8 points [n (%)]					
Responder / Imputed responder		8 (25.8) / 0	12 (42.9) / 0	9 (33.3) / 0	12 (37.5) / 0
Non-responder / Imputed non-responder		23 (74.2) / 12 (38.7)	16 (57.1) / 7 (25.0)	18 (66.7) / 10 (37.0)	20 (62.5) / 10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	2.16 (0.70 to 6.63)	-	1.20 (0.40 to 3.59)
p-value for Odds Ratio ^a			0.1759		0.7405
Risk Ratio (95% CI) vs Placebo ^a		-	1.66 (0.78 to 3.52)	-	1.13 (0.55 to 2.29)
Reversed Risk ratio (95% CI)		-	0.60 (0.28 to 1.28)	-	0.89 (0.44 to 1.81)
p-value for Risk Ratio ^a			0.1851		0.7455
Risk Difference (95% CI) vs Placebo ^a		-	17.05 (-7.41 to 41.51)	-	4.17 (-20.81 to 29.14)
p-value for Risk Difference ^a			0.1682		0.7395
Treatment-by-subgroup p-value of RR ^b					0.4522

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_esr_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
FACIT-F increase from Baseline ≥ 7.8 points [n (%)]					
Responder / Imputed responder		7 (20.6) / 0	15 (50.0) / 0	10 (41.7) / 0	9 (30.0) / 0
Non-responder / Imputed non-responder		27 (79.4) / 12 (35.3)	15 (50.0) / 7 (23.3)	14 (58.3) / 10 (41.7)	21 (70.0) / 10 (33.3)
Odds Ratio (95% CI) vs Placebo ^a		-	3.86 (1.26 to 11.81)	-	0.60 (0.19 to 1.90)
p-value for Odds Ratio ^a			0.0188		0.3781
Risk Ratio (95% CI) vs Placebo ^a		-	2.43 (1.13 to 5.22)	-	0.72 (0.34 to 1.51)
Reversed Risk ratio (95% CI)		-	0.41 (0.19 to 0.89)		
p-value for Risk Ratio ^a			0.0232		0.3845
Risk Difference (95% CI) vs Placebo ^a		-	29.41 (6.50 to 52.33)	-	-11.67 (-37.93 to 14.59)
p-value for Risk Difference ^a			0.0127		0.3768
Treatment-by-subgroup p-value of RR ^b					0.0241

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_cs_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Yes (N=29)		No (N=89)	
		Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
FACIT-F increase from Baseline ≥ 7.8 points [n (%)]					
Responder / Imputed responder		5 (29.4) / 0	4 (33.3) / 0	12 (29.3) / 0	20 (41.7) / 0
Non-responder / Imputed non-responder		12 (70.6) / 7 (41.2)	8 (66.7) / 6 (50.0)	29 (70.7) / 15 (36.6)	28 (58.3) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.20 (0.23 to 6.34)	-	1.73 (0.70 to 4.23)
p-value for Odds Ratio ^a			0.8239		0.2295
Risk Ratio (95% CI) vs Placebo ^a		-	1.13 (0.36 to 3.54)	-	1.42 (0.79 to 2.57)
Reversed Risk ratio (95% CI)		-	0.88 (0.28 to 2.75)	-	0.70 (0.39 to 1.27)
p-value for Risk Ratio ^a			0.8294		0.2407
Risk Difference (95% CI) vs Placebo ^a		-	3.92 (-32.05 to 39.89)	-	12.40 (-7.59 to 32.39)
p-value for Risk Difference ^a			0.8247		0.2209
Treatment-by-subgroup p-value of RR ^b					0.7177

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_mtx_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
FACIT-F increase from Baseline ≥ 7.8 points [n (%)]					
Responder / Imputed responder		9 (39.1) / 0	10 (41.7) / 0	8 (22.9) / 0	14 (38.9) / 0
Non-responder / Imputed non-responder		14 (60.9) / 5 (21.7)	14 (58.3) / 8 (33.3)	27 (77.1) / 17 (48.6)	22 (61.1) / 9 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.11 (0.34 to 3.68)	-	2.15 (0.75 to 6.16)
p-value for Odds Ratio ^a			0.8602		0.1523
Risk Ratio (95% CI) vs Placebo ^a		-	1.06 (0.52 to 2.18)	-	1.70 (0.81 to 3.59)
Reversed Risk ratio (95% CI)		-	0.94 (0.46 to 1.92)	-	0.59 (0.28 to 1.24)
p-value for Risk Ratio ^a			0.8633		0.1630
Risk Difference (95% CI) vs Placebo ^a		-	2.54 (-26.29 to 31.36)	-	16.03 (-5.49 to 37.55)
p-value for Risk Difference ^a			0.8601		0.1418
Treatment-by-subgroup p-value of RR ^b					0.3655

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ger_nrp_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

9. EQ-5D VAS increase from Baseline >= 15 points at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
EQ-5D VAS increase from Baseline >= 15 points	Gender (Male , Female)	0.3595
	Race (Caucasian/White , All other races)	0.2456
	Age (Age < 70 , Age >= 70)	0.2492
	MTX Add-on Therapy (Yes , No)	0.8538

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		3 (14.3) / 0	6 (40.0) / 0	6 (16.2) / 0	10 (22.2) / 0
Non-responder / Imputed non-responder		18 (85.7) / 7 (33.3)	9 (60.0) / 4 (26.7)	31 (83.8) / 16 (43.2)	35 (77.8) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	4.00 (0.76 to 21.02)	-	1.48 (0.47 to 4.61)
p-value for Odds Ratio ^a			0.0987		0.4981
Risk Ratio (95% CI) vs Placebo ^a		-	2.80 (0.79 to 9.89)	-	1.37 (0.54 to 3.47)
Reversed Risk ratio (95% CI)		-	0.36 (0.10 to 1.26)	-	0.73 (0.29 to 1.85)
p-value for Risk Ratio ^a			0.1098		0.5057
Risk Difference (95% CI) vs Placebo ^a		-	25.71 (-4.31 to 55.74)	-	6.01 (-11.24 to 23.26)
p-value for Risk Difference ^a			0.0908		0.4904
Treatment-by-subgroup p-value of RR ^b					0.3595

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_gender_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
EQ-5D VAS increase from Baseline $\geq$ 15 points [n (%)]					
Responder / Imputed responder		7 (14.6) / 0	15 (30.0) / 0	2 (20.0) / 0	1 (10.0) / 0
Non-responder / Imputed non-responder		41 (85.4) / 20 (41.7)	35 (70.0) / 14 (28.0)	8 (80.0) / 3 (30.0)	9 (90.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.51 (0.91 to 6.94)	-	0.44 (0.03 to 7.08)
p-value for Odds Ratio ^a			0.0756		0.5460
Risk Ratio (95% CI) vs Placebo ^a		-	2.06 (0.91 to 4.65)	-	0.50 (0.05 to 5.49)
Reversed Risk ratio (95% CI)		-	0.49 (0.22 to 1.10)		
p-value for Risk Ratio ^a			0.0829		0.5706
Risk Difference (95% CI) vs Placebo ^a		-	15.42 (-0.95 to 31.78)	-	-10.00 (-43.22 to 23.22)
p-value for Risk Difference ^a			0.0645		0.5350
Treatment-by-subgroup p-value of RR ^b					0.2456

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ger_race_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		3 (12.0) / 0	11 (32.4) / 0	6 (18.2) / 0	5 (19.2) / 0
Non-responder / Imputed non-responder		22 (88.0) / 10 (40.0)	23 (67.6) / 7 (20.6)	27 (81.8) / 13 (39.4)	21 (80.8) / 10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	3.51 (0.84 to 14.72)	-	1.07 (0.28 to 4.11)
p-value for Odds Ratio ^a			0.0852		0.9186
Risk Ratio (95% CI) vs Placebo ^a		-	2.70 (0.82 to 8.89)	-	1.06 (0.35 to 3.16)
Reversed Risk ratio (95% CI)		-	0.37 (0.11 to 1.22)	-	0.95 (0.32 to 2.82)
p-value for Risk Ratio ^a			0.1032		0.9199
Risk Difference (95% CI) vs Placebo ^a		-	20.35 (-0.32 to 41.03)	-	1.05 (-19.45 to 21.55)
p-value for Risk Difference ^a			0.0536		0.9188
Treatment-by-subgroup p-value of RR ^b					0.2492

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ger_age_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		2 (11.8) / 0	2 (16.7) / 0	7 (17.1) / 0	14 (29.2) / 0
Non-responder / Imputed non-responder		15 (88.2) / 7 (41.2)	10 (83.3) / 6 (50.0)	34 (82.9) / 16 (39.0)	34 (70.8) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.50 (0.16 to 13.76)	-	2.00 (0.71 to 5.65)
p-value for Odds Ratio ^a			0.7103		0.1882
Risk Ratio (95% CI) vs Placebo ^a		-	1.42 (0.21 to 9.48)	-	1.71 (0.75 to 3.87)
Reversed Risk ratio (95% CI)		-	0.71 (0.11 to 4.72)	-	0.59 (0.26 to 1.33)
p-value for Risk Ratio ^a			0.7194		0.1990
Risk Difference (95% CI) vs Placebo ^a		-	4.90 (-22.38 to 32.18)	-	12.09 (-5.41 to 29.60)
p-value for Risk Difference ^a			0.7153		0.1733
Treatment-by-subgroup p-value of RR ^b					0.8538

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ger_mtx_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

10. HAQ-DI Standardized Score decrease from Baseline >= 0.45 points at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points	Gender (Male , Female)	0.6119
	Race (Caucasian/White , All other races)	0.6392
	Region (Western Countries , Rest of World (including South America))	0.9549
	Age (Age < 70 , Age >= 70)	0.1615
	Baseline CRP (<= median , > median)	0.1413
	Baseline ESR (<= median , > median)	0.3609
	Baseline CS dose (<= median , > median)	0.1302
	MTX Add-on Therapy (Yes , No)	0.8044
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.0337

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.
PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_binhaqdi_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder / Imputed responder		4 (19.0) / 0	4 (26.7) / 0	6 (16.2) / 0	15 (33.3) / 0
Non-responder / Imputed non-responder		17 (81.0) / 7 (33.3)	11 (73.3) / 4 (26.7)	31 (83.8) / 16 (43.2)	30 (66.7) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.55 (0.30 to 7.95)	-	2.58 (0.87 to 7.67)
p-value for Odds Ratio ^a			0.5927		0.0864
Risk Ratio (95% CI) vs Placebo ^a		-	1.40 (0.40 to 4.95)	-	2.06 (0.88 to 4.83)
Reversed Risk ratio (95% CI)		-	0.71 (0.20 to 2.52)	-	0.49 (0.21 to 1.14)
p-value for Risk Ratio ^a			0.6013		0.0981
Risk Difference (95% CI) vs Placebo ^a		-	7.62 (-21.39 to 36.63)	-	17.12 (-1.35 to 35.58)
p-value for Risk Difference ^a			0.5970		0.0688
Treatment-by-subgroup p-value of RR ^b					0.6119

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_gender_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder / Imputed responder		9 (18.8) / 0	18 (36.0) / 0	1 (10.0) / 0	1 (10.0) / 0
Non-responder / Imputed non-responder		39 (81.3) / 20 (41.7)	32 (64.0) / 14 (28.0)	9 (90.0) / 3 (30.0)	9 (90.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.44 (0.95 to 6.23)	-	1.00 (0.04 to 22.92)
p-value for Odds Ratio ^a			0.0625		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	1.92 (0.95 to 3.88)	-	1.00 (0.06 to 16.75)
Reversed Risk ratio (95% CI)		-	0.52 (0.26 to 1.05)	-	1.00 (0.06 to 16.75)
p-value for Risk Ratio ^a			0.0694		1.0000
Risk Difference (95% CI) vs Placebo ^a		-	17.25 (-0.26 to 34.76)	-	0.00 (-28.19 to 28.19)
p-value for Risk Difference ^a			0.0534		1.0000
Treatment-by-subgroup p-value of RR ^b					0.6392

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_race_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points [n (%)]					
Responder / Imputed responder		7 (15.9) / 0	14 (29.8) / 0	3 (21.4) / 0	5 (38.5) / 0
Non-responder / Imputed non-responder		37 (84.1) / 19 (43.2)	33 (70.2) / 13 (27.7)	11 (78.6) / 4 (28.6)	8 (61.5) / 4 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	2.24 (0.80 to 6.32)	-	2.29 (0.39 to 13.63)
p-value for Odds Ratio ^a			0.1248		0.3472
Risk Ratio (95% CI) vs Placebo ^a		-	1.87 (0.82 to 4.25)	-	1.79 (0.50 to 6.44)
Reversed Risk ratio (95% CI)		-	0.53 (0.24 to 1.21)	-	0.56 (0.16 to 2.00)
p-value for Risk Ratio ^a			0.1338		0.3696
Risk Difference (95% CI) vs Placebo ^a		-	13.88 (-3.32 to 31.07)	-	17.03 (-18.78 to 52.84)
p-value for Risk Difference ^a			0.1124		0.3367
Treatment-by-subgroup p-value of RR ^b					0.9549

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_region_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder / Imputed responder		3 (12.0) / 0	13 (38.2) / 0	7 (21.2) / 0	6 (23.1) / 0
Non-responder / Imputed non-responder		22 (88.0) / 10 (40.0)	21 (61.8) / 7 (20.6)	26 (78.8) / 13 (39.4)	20 (76.9) / 10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	4.54 (1.10 to 18.79)	-	1.11 (0.32 to 3.94)
p-value for Odds Ratio ^a			0.0373		0.8644
Risk Ratio (95% CI) vs Placebo ^a		-	3.19 (0.99 to 10.26)	-	1.09 (0.41 to 2.91)
Reversed Risk ratio (95% CI)		-	0.31 (0.10 to 1.01)	-	0.92 (0.34 to 2.46)
p-value for Risk Ratio ^a			0.0520		0.8665
Risk Difference (95% CI) vs Placebo ^a		-	26.24 (5.07 to 47.40)	-	1.86 (-19.97 to 23.70)
p-value for Risk Difference ^a			0.0160		0.8648
Treatment-by-subgroup p-value of RR ^b					0.1615

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_age_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder / Imputed responder		7 (22.6) / 0	7 (25.0) / 0	3 (11.1) / 0	12 (37.5) / 0
Non-responder / Imputed non-responder		24 (77.4) / 12 (38.7)	21 (75.0) / 9 (32.1)	24 (88.9) / 11 (40.7)	20 (62.5) / 8 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.14 (0.34 to 3.90)	-	4.80 (1.15 to 20.01)
p-value for Odds Ratio ^a			0.8282		0.0319
Risk Ratio (95% CI) vs Placebo ^a		-	1.11 (0.43 to 2.82)	-	3.38 (1.04 to 11.00)
Reversed Risk ratio (95% CI)		-	0.90 (0.35 to 2.30)	-	0.30 (0.09 to 0.97)
p-value for Risk Ratio ^a			0.8309		0.0437
Risk Difference (95% CI) vs Placebo ^a		-	2.42 (-19.82 to 24.66)	-	26.39 (5.40 to 47.37)
p-value for Risk Difference ^a			0.8283		0.0146
Treatment-by-subgroup p-value of RR ^b					0.1413

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_crp_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder / Imputed responder		7 (22.6) / 0	9 (32.1) / 0	3 (11.1) / 0	10 (31.3) / 0
Non-responder / Imputed non-responder		24 (77.4) / 12 (38.7)	19 (67.9) / 7 (25.0)	24 (88.9) / 11 (40.7)	22 (68.8) / 10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	1.62 (0.50 to 5.29)	-	3.64 (0.86 to 15.42)
p-value for Odds Ratio ^a			0.4147		0.0788
Risk Ratio (95% CI) vs Placebo ^a		-	1.42 (0.60 to 3.38)	-	2.81 (0.84 to 9.43)
Reversed Risk ratio (95% CI)		-	0.70 (0.30 to 1.67)	-	0.36 (0.11 to 1.19)
p-value for Risk Ratio ^a			0.4229		0.0939
Risk Difference (95% CI) vs Placebo ^a		-	9.56 (-13.64 to 32.77)	-	20.14 (-0.25 to 40.53)
p-value for Risk Difference ^a			0.4127		0.0528
Treatment-by-subgroup p-value of RR ^b					0.3609

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_esr_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder / Imputed responder		4 (11.8) / 0	11 (36.7) / 0	6 (25.0) / 0	8 (26.7) / 0
Non-responder / Imputed non-responder		30 (88.2) / 12 (35.3)	19 (63.3) / 7 (23.3)	18 (75.0) / 11 (45.8)	22 (73.3) / 10 (33.3)
Odds Ratio (95% CI) vs Placebo ^a		-	4.34 (1.18 to 16.03)	-	1.09 (0.31 to 3.84)
p-value for Odds Ratio ^a			0.0282		0.8901
Risk Ratio (95% CI) vs Placebo ^a		-	3.12 (1.09 to 8.94)	-	1.07 (0.42 to 2.71)
Reversed Risk ratio (95% CI)		-	0.32 (0.11 to 0.92)	-	0.94 (0.37 to 2.39)
p-value for Risk Ratio ^a			0.0346		0.8923
Risk Difference (95% CI) vs Placebo ^a		-	24.90 (4.13 to 45.67)	-	1.67 (-22.36 to 25.69)
p-value for Risk Difference ^a			0.0196		0.8898
Treatment-by-subgroup p-value of RR ^b					0.1302

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_cs_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder / Imputed responder		2 (11.8) / 0	2 (16.7) / 0	8 (19.5) / 0	17 (35.4) / 0
Non-responder / Imputed non-responder		15 (88.2) / 7 (41.2)	10 (83.3) / 6 (50.0)	33 (80.5) / 16 (39.0)	31 (64.6) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.50 (0.16 to 13.76)	-	2.26 (0.84 to 6.07)
p-value for Odds Ratio ^a			0.7103		0.1037
Risk Ratio (95% CI) vs Placebo ^a		-	1.42 (0.21 to 9.48)	-	1.82 (0.87 to 3.80)
Reversed Risk ratio (95% CI)		-	0.71 (0.11 to 4.72)	-	0.55 (0.26 to 1.15)
p-value for Risk Ratio ^a			0.7194		0.1143
Risk Difference (95% CI) vs Placebo ^a		-	4.90 (-22.38 to 32.18)	-	15.90 (-2.52 to 34.33)
p-value for Risk Difference ^a			0.7153		0.0898
Treatment-by-subgroup p-value of RR ^b					0.8044

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_mtx_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder / Imputed responder		7 (30.4) / 0	6 (25.0) / 0	3 (8.6) / 0	13 (36.1) / 0
Non-responder / Imputed non-responder		16 (69.6) / 6 (26.1)	18 (75.0) / 8 (33.3)	32 (91.4) / 17 (48.6)	23 (63.9) / 9 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	0.76 (0.20 to 2.84)	-	6.03 (1.50 to 24.19)
p-value for Odds Ratio ^a			0.6795		0.0120
Risk Ratio (95% CI) vs Placebo ^a		-	0.82 (0.32 to 2.13)	-	4.21 (1.29 to 13.80)
Reversed Risk ratio (95% CI)				-	0.24 (0.07 to 0.78)
p-value for Risk Ratio ^a			0.6861		0.0175
Risk Difference (95% CI) vs Placebo ^a		-	-5.43 (-31.71 to 20.84)	-	27.54 (8.99 to 46.09)
p-value for Risk Difference ^a			0.6789		0.0042
Treatment-by-subgroup p-value of RR ^b					0.0337

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ger_nrp_i_t_x.rtf (03SEP2024 11:10)

11. HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points at week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points	Gender (Male , Female)	0.2353
	Race (Caucasian/White , All other races)	0.7641
	Region (Western Countries , Rest of World (including South America))	0.0190
	Age (Age < 70 , Age $\geq$ 70)	0.2400
	Baseline CRP ($\leq$ median , > median)	0.4032
	Baseline ESR ($\leq$ median , > median)	0.1549
	Baseline CS dose ($\leq$ median , > median)	0.9177
	MTX Add-on Therapy (Yes , No)	0.5691
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.3172

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_binhaq0847_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		4 (19.0) / 0	7 (46.7) / 0	10 (27.0) / 0	14 (31.1) / 0
Non-responder / Imputed non-responder		17 (81.0) / 7 (33.3)	8 (53.3) / 4 (26.7)	27 (73.0) / 16 (43.2)	31 (68.9) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	3.72 (0.79 to 17.40)	-	1.22 (0.46 to 3.24)
p-value for Odds Ratio ^a			0.0928		0.6871
Risk Ratio (95% CI) vs Placebo ^a		-	2.45 (0.84 to 7.16)	-	1.15 (0.57 to 2.31)
Reversed Risk ratio (95% CI)		-	0.41 (0.14 to 1.19)	-	0.87 (0.43 to 1.74)
p-value for Risk Ratio ^a			0.1015		0.6917
Risk Difference (95% CI) vs Placebo ^a		-	27.62 (-3.82 to 59.06)	-	4.08 (-15.91 to 24.08)
p-value for Risk Difference ^a			0.0832		0.6854
Treatment-by-subgroup p-value of RR ^b					0.2353

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_gender_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]					
Responder / Imputed responder		13 (27.1) / 0	19 (38.0) / 0	1 (10.0) / 0	2 (20.0) / 0
Non-responder / Imputed non-responder		35 (72.9) / 20 (41.7)	31 (62.0) / 14 (28.0)	9 (90.0) / 3 (30.0)	8 (80.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.65 (0.69 to 3.92)	-	2.25 (0.14 to 35.84)
p-value for Odds Ratio ^a			0.2539		0.5460
Risk Ratio (95% CI) vs Placebo ^a		-	1.40 (0.78 to 2.53)	-	2.00 (0.18 to 21.95)
Reversed Risk ratio (95% CI)		-	0.71 (0.39 to 1.29)	-	0.50 (0.05 to 5.49)
p-value for Risk Ratio ^a			0.2616		0.5706
Risk Difference (95% CI) vs Placebo ^a		-	10.92 (-7.73 to 29.57)	-	10.00 (-23.22 to 43.22)
p-value for Risk Difference ^a			0.2481		0.5350
Treatment-by-subgroup p-value of RR ^b					0.7641

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_race_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]					
Responder / Imputed responder		7 (15.9) / 0	18 (38.3) / 0	7 (50.0) / 0	3 (23.1) / 0
Non-responder / Imputed non-responder		37 (84.1) / 19 (43.2)	29 (61.7) / 13 (27.7)	7 (50.0) / 4 (28.6)	10 (76.9) / 4 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	3.28 (1.19 to 9.03)	-	0.30 (0.05 to 1.72)
p-value for Odds Ratio ^a			0.0220		0.1680
Risk Ratio (95% CI) vs Placebo ^a		-	2.41 (1.10 to 5.26)	-	0.46 (0.14 to 1.50)
Reversed Risk ratio (95% CI)		-	0.42 (0.19 to 0.91)		
p-value for Risk Ratio ^a			0.0274		0.1988
Risk Difference (95% CI) vs Placebo ^a		-	22.39 (4.54 to 40.24)	-	-26.92 (-63.48 to 9.64)
p-value for Risk Difference ^a			0.0145		0.1419
Treatment-by-subgroup p-value of RR ^b					0.0190

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_region_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		5 (20.0) / 0	14 (41.2) / 0	9 (27.3) / 0	7 (26.9) / 0
Non-responder / Imputed non-responder		20 (80.0) / 10 (40.0)	20 (58.8) / 7 (20.6)	24 (72.7) / 13 (39.4)	19 (73.1) / 10 (38.5)
Odds Ratio (95% CI) vs Placebo ^a		-	2.80 (0.83 to 9.49)	-	0.98 (0.30 to 3.20)
p-value for Odds Ratio ^a			0.0966		0.9762
Risk Ratio (95% CI) vs Placebo ^a		-	2.06 (0.84 to 5.06)	-	0.99 (0.42 to 2.34)
Reversed Risk ratio (95% CI)		-	0.49 (0.20 to 1.19)		
p-value for Risk Ratio ^a			0.1158		0.9766
Risk Difference (95% CI) vs Placebo ^a		-	21.18 (-2.11 to 44.46)	-	-0.35 (-23.68 to 22.98)
p-value for Risk Difference ^a			0.0739		0.9762
Treatment-by-subgroup p-value of RR ^b					0.2400

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_age_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		8 (25.8) / 0	8 (28.6) / 0	6 (22.2) / 0	13 (40.6) / 0
Non-responder / Imputed non-responder		23 (74.2) / 12 (38.7)	20 (71.4) / 9 (32.1)	21 (77.8) / 11 (40.7)	19 (59.4) / 8 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.15 (0.36 to 3.72)	-	2.39 (0.74 to 7.75)
p-value for Odds Ratio ^a			0.8124		0.1419
Risk Ratio (95% CI) vs Placebo ^a		-	1.11 (0.47 to 2.60)	-	1.83 (0.79 to 4.23)
Reversed Risk ratio (95% CI)		-	0.90 (0.38 to 2.12)	-	0.55 (0.24 to 1.27)
p-value for Risk Ratio ^a			0.8154		0.1584
Risk Difference (95% CI) vs Placebo ^a		-	2.76 (-20.47 to 26.00)	-	18.40 (-5.24 to 42.04)
p-value for Risk Difference ^a			0.8125		0.1246
Treatment-by-subgroup p-value of RR ^b					0.4032

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_crp_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		6 (19.4) / 0	12 (42.9) / 0	8 (29.6) / 0	9 (28.1) / 0
Non-responder / Imputed non-responder		25 (80.6) / 12 (38.7)	16 (57.1) / 7 (25.0)	19 (70.4) / 11 (40.7)	23 (71.9) / 10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	3.12 (0.95 to 10.26)	-	0.93 (0.29 to 2.95)
p-value for Odds Ratio ^a			0.0600		0.8993
Risk Ratio (95% CI) vs Placebo ^a		-	2.21 (0.94 to 5.20)	-	0.95 (0.42 to 2.16)
Reversed Risk ratio (95% CI)		-	0.45 (0.19 to 1.06)		
p-value for Risk Ratio ^a			0.0682		0.9009
Risk Difference (95% CI) vs Placebo ^a		-	23.50 (-0.01 to 47.01)	-	-1.50 (-25.23 to 22.22)
p-value for Risk Difference ^a			0.0501		0.8994
Treatment-by-subgroup p-value of RR ^b					0.1549

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_esr_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		7 (20.6) / 0	9 (30.0) / 0	7 (29.2) / 0	12 (40.0) / 0
Non-responder / Imputed non-responder		27 (79.4) / 12 (35.3)	21 (70.0) / 7 (23.3)	17 (70.8) / 11 (45.8)	18 (60.0) / 10 (33.3)
Odds Ratio (95% CI) vs Placebo ^a		-	1.65 (0.52 to 5.29)	-	1.62 (0.50 to 5.22)
p-value for Odds Ratio ^a			0.3911		0.4128
Risk Ratio (95% CI) vs Placebo ^a		-	1.46 (0.61 to 3.49)	-	1.37 (0.63 to 2.99)
Reversed Risk ratio (95% CI)		-	0.69 (0.29 to 1.64)	-	0.73 (0.33 to 1.59)
p-value for Risk Ratio ^a			0.3986		0.4275
Risk Difference (95% CI) vs Placebo ^a		-	9.41 (-12.31 to 31.13)	-	10.83 (-15.03 to 36.69)
p-value for Risk Difference ^a			0.3898		0.4044
Treatment-by-subgroup p-value of RR ^b					0.9177

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_cs_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		2 (11.8) / 0	3 (25.0) / 0	12 (29.3) / 0	18 (37.5) / 0
Non-responder / Imputed non-responder		15 (88.2) / 7 (41.2)	9 (75.0) / 6 (50.0)	29 (70.7) / 16 (39.0)	30 (62.5) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	2.50 (0.32 to 19.68)	-	1.45 (0.59 to 3.58)
p-value for Odds Ratio ^a			0.3702		0.4160
Risk Ratio (95% CI) vs Placebo ^a		-	2.13 (0.39 to 11.70)	-	1.28 (0.70 to 2.35)
Reversed Risk ratio (95% CI)		-	0.47 (0.09 to 2.59)	-	0.78 (0.42 to 1.43)
p-value for Risk Ratio ^a			0.3864		0.4246
Risk Difference (95% CI) vs Placebo ^a		-	13.24 (-17.01 to 43.48)	-	8.23 (-11.58 to 28.04)
p-value for Risk Difference ^a			0.3772		0.4111
Treatment-by-subgroup p-value of RR ^b					0.5691

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_mtx_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)	> 1 relapse (N=71)		
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder / Imputed responder		8 (34.8) / 0	9 (37.5) / 0	6 (17.1) / 0	12 (33.3) / 0
Non-responder / Imputed non-responder		15 (65.2) / 6 (26.1)	15 (62.5) / 8 (33.3)	29 (82.9) / 17 (48.6)	24 (66.7) / 9 (25.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.12 (0.33 to 3.83)	-	2.42 (0.77 to 7.55)
p-value for Odds Ratio ^a			0.8472		0.1269
Risk Ratio (95% CI) vs Placebo ^a		-	1.08 (0.49 to 2.36)	-	1.94 (0.81 to 4.68)
Reversed Risk ratio (95% CI)		-	0.93 (0.42 to 2.03)	-	0.51 (0.21 to 1.24)
p-value for Risk Ratio ^a			0.8506		0.1376
Risk Difference (95% CI) vs Placebo ^a		-	2.72 (-25.50 to 30.94)	-	16.19 (-3.99 to 36.37)
p-value for Risk Difference ^a			0.8471		0.1140
Treatment-by-subgroup p-value of RR ^b					0.3172

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ger_nrp_i_t_x.rtf (03SEP2024 11:10)

12. SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points	Gender (Male , Female)	0.3115
	Race (Caucasian/White , All other races)	0.1460
	Region (Western Countries , Rest of World (including South America))	0.3895
	Baseline ESR (<= median , > median)	0.3264
	MTX Add-on Therapy (Yes , No)	0.9210

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_binpcs_i_t_x.rtf (05SEP2024 10:46)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder / Imputed responder		6 (28.6) / 0	4 (26.7) / 0	4 (10.8) / 0	10 (22.2) / 0
Non-responder / Imputed non-responder		15 (71.4) / 7 (33.3)	11 (73.3) / 4 (26.7)	33 (89.2) / 16 (43.2)	35 (77.8) / 13 (28.9)
Odds Ratio (95% CI) vs Placebo ^a		-	0.91 (0.19 to 4.24)	-	2.36 (0.66 to 8.41)
p-value for Odds Ratio ^a			0.9007		0.1837
Risk Ratio (95% CI) vs Placebo ^a		-	0.93 (0.31 to 2.85)	-	2.06 (0.69 to 6.12)
Reversed Risk ratio (95% CI)				-	0.49 (0.16 to 1.45)
p-value for Risk Ratio ^a			0.9037		0.1957
Risk Difference (95% CI) vs Placebo ^a		-	-1.90 (-32.56 to 28.75)	-	11.41 (-4.57 to 27.39)
p-value for Risk Difference ^a			0.9003		0.1591
Treatment-by-subgroup p-value of RR ^b					0.3115

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_gender_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points [n (%)]					
Responder / Imputed responder		7 (14.6) / 0	13 (26.0) / 0	3 (30.0) / 0	1 (10.0) / 0
Non-responder / Imputed non-responder		41 (85.4) / 20 (41.7)	37 (74.0) / 14 (28.0)	7 (70.0) / 3 (30.0)	9 (90.0) / 3 (30.0)
Odds Ratio (95% CI) vs Placebo ^a		-	2.06 (0.73 to 5.79)	-	0.26 (0.02 to 3.66)
p-value for Odds Ratio ^a			0.1690		0.2981
Risk Ratio (95% CI) vs Placebo ^a		-	1.78 (0.77 to 4.13)	-	0.33 (0.04 to 3.12)
Reversed Risk ratio (95% CI)		-	0.56 (0.24 to 1.30)		
p-value for Risk Ratio ^a			0.1771		0.3357
Risk Difference (95% CI) vs Placebo ^a		-	11.42 (-4.52 to 27.35)	-	-20.00 (-56.39 to 16.39)
p-value for Risk Difference ^a			0.1582		0.2633
Treatment-by-subgroup p-value of RR ^b					0.1460

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ger_race_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
SF-36 Standardized Physical Component Scale increase from Baseline ≥ 10 points [n (%)]					
Responder / Imputed responder		7 (15.9) / 0	12 (25.5) / 0	3 (21.4) / 0	2 (15.4) / 0
Non-responder / Imputed non-responder		37 (84.1) / 19 (43.2)	35 (74.5) / 13 (27.7)	11 (78.6) / 4 (28.6)	11 (84.6) / 4 (30.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.81 (0.63 to 5.20)	-	0.67 (0.08 to 5.31)
p-value for Odds Ratio ^a			0.2657		0.6908
Risk Ratio (95% CI) vs Placebo ^a		-	1.60 (0.69 to 3.75)	-	0.72 (0.13 to 3.95)
Reversed Risk ratio (95% CI)		-	0.62 (0.27 to 1.46)		
p-value for Risk Ratio ^a			0.2743		0.7032
Risk Difference (95% CI) vs Placebo ^a		-	9.62 (-7.10 to 26.35)	-	-6.04 (-36.62 to 24.53)
p-value for Risk Difference ^a			0.2560		0.6874
Treatment-by-subgroup p-value of RR ^b					0.3895

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ger_region_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder / Imputed responder		6 (19.4) / 0	10 (35.7) / 0	4 (14.8) / 0	4 (12.5) / 0
Non-responder / Imputed non-responder		25 (80.6) / 12 (38.7)	18 (64.3) / 7 (25.0)	23 (85.2) / 11 (40.7)	28 (87.5) / 10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a		-	2.31 (0.69 to 7.73)	-	0.82 (0.18 to 3.77)
p-value for Odds Ratio ^a			0.1686		0.7970
Risk Ratio (95% CI) vs Placebo ^a		-	1.85 (0.76 to 4.51)	-	0.84 (0.23 to 3.15)
Reversed Risk ratio (95% CI)		-	0.54 (0.22 to 1.32)		
p-value for Risk Ratio ^a			0.1786		0.8002
Risk Difference (95% CI) vs Placebo ^a		-	16.36 (-6.68 to 39.40)	-	-2.31 (-20.33 to 15.70)
p-value for Risk Difference ^a			0.1605		0.7979
Treatment-by-subgroup p-value of RR ^b					0.3264

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Patients with missing data are imputed non-responders.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ger_esr_i_t_x.rtf (03SEP2024 11:10)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder / Imputed responder		2 (11.8) / 0	2 (16.7) / 0	8 (19.5) / 0	12 (25.0) / 0
Non-responder / Imputed non-responder		15 (88.2) / 7 (41.2)	10 (83.3) / 6 (50.0)	33 (80.5) / 16 (39.0)	36 (75.0) / 11 (22.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.50 (0.16 to 13.76)	-	1.38 (0.49 to 3.84)
p-value for Odds Ratio ^a			0.7103		0.5389
Risk Ratio (95% CI) vs Placebo ^a		-	1.42 (0.21 to 9.48)	-	1.28 (0.57 to 2.86)
Reversed Risk ratio (95% CI)		-	0.71 (0.11 to 4.72)	-	0.78 (0.35 to 1.74)
p-value for Risk Ratio ^a			0.7194		0.5451
Risk Difference (95% CI) vs Placebo ^a		-	4.90 (-22.38 to 32.18)	-	5.49 (-11.99 to 22.97)
p-value for Risk Difference ^a			0.7153		0.5343
Treatment-by-subgroup p-value of RR ^b					0.9210

EFC15160_Germany_binary_PRO_NI_13SEP24 – (ohne Imputation fehlender Werte)

Weitere Analysen

1. VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]			
Responder		20/35 (57.1)	20/42 (47.6)
Non-responder		15/35 (42.9)	22/42 (52.4)
Odds Ratio (95% CI) vs Placebo ^a		-	0.68 (0.27 to 1.71)
p-value for Odds Ratio ^a			0.4083
Risk Ratio (95% CI) vs Placebo ^a		-	0.83 (0.54 to 1.29)
p-value for Risk Ratio ^a			0.4111
Risk Difference (95% CI) vs Placebo ^a		-	-9.52 (-32.18 to 13.13)
p-value for Risk Difference ^a			0.4051

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_pro_vaspat_ni_ger_i_t_x.rtf (13SEP2024 13:56)

Weitere Analysen

2. VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]			
Responder		21/31 (67.7)	30/33 (90.9)
Non-responder		10/31 (32.3)	3/33 (9.1)
Odds Ratio (95% CI) vs Placebo ^a		-	4.76 (1.14 to 19.97)
p-value for Odds Ratio ^a			0.0334
Risk Ratio (95% CI) vs Placebo ^a		-	1.34 (1.02 to 1.76)
Reversed Risk ratio (95% CI)		-	0.75 (0.57 to 0.98)
p-value for Risk Ratio ^a			0.0334
Risk Difference (95% CI) vs Placebo ^a		-	23.17 (3.63 to 42.71)
p-value for Risk Difference ^a			0.0209

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_pro_vasphy_ni_geri_t_x.rtf (13SEP2024 13:56)

Weitere Analysen

3. FACIT-F increase from Baseline $\geq$ 7.8 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
FACIT-F increase from Baseline $\geq$ 7.8 points [n (%)]			
Responder		17/36 (47.2)	24/42 (57.1)
Non-responder		19/36 (52.8)	18/42 (42.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.49 (0.60 to 3.70)
p-value for Odds Ratio ^a			0.3853
Risk Ratio (95% CI) vs Placebo ^a		-	1.21 (0.78 to 1.88)
Reversed Risk ratio (95% CI)		-	0.83 (0.53 to 1.28)
p-value for Risk Ratio ^a			0.3961
Risk Difference (95% CI) vs Placebo ^a		-	9.92 (-12.57 to 32.41)
p-value for Risk Difference ^a			0.3825

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_pro_fatigue_ni_ger_i_t_x.rtf (13SEP2024 13:56)

Weitere Analysen

4. EQ-5D VAS increase from Baseline $\geq$ 15 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
EQ-5D VAS increase from Baseline $\geq$ 15 points [n (%)]			
Responder		9/35 (25.7)	16/42 (38.1)
Non-responder		26/35 (74.3)	26/42 (61.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.78 (0.66 to 4.82)
p-value for Odds Ratio ^a			0.2540
Risk Ratio (95% CI) vs Placebo ^a		-	1.48 (0.74 to 2.96)
Reversed Risk ratio (95% CI)		-	0.67 (0.34 to 1.35)
p-value for Risk Ratio ^a			0.2667
Risk Difference (95% CI) vs Placebo ^a		-	12.38 (-8.58 to 33.34)
p-value for Risk Difference ^a			0.2431

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_gert_i_t.sas OUT=REPORT/OUTPUT/eff_pro_eq5dvas_ni_gert_i_t.x.rtf (13SEP2024 13:57)

5. HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]			
Responder		10/35 (28.6)	19/42 (45.2)
Non-responder		25/35 (71.4)	23/42 (54.8)
Odds Ratio (95% CI) vs Placebo ^a		-	2.07 (0.78 to 5.44)
p-value for Odds Ratio ^a			0.1398
Risk Ratio (95% CI) vs Placebo ^a		-	1.58 (0.84 to 2.98)
Reversed Risk ratio (95% CI)		-	0.63 (0.34 to 1.19)
p-value for Risk Ratio ^a			0.1533
Risk Difference (95% CI) vs Placebo ^a		-	16.67 (-4.91 to 38.24)
p-value for Risk Difference ^a			0.1280

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_pro_haqdi_ni_ger_i_t_x.rtf (13SEP2024 13:57)

Weitere Analysen

6. HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]			
Responder		14/35 (40.0)	21/42 (50.0)
Non-responder		21/35 (60.0)	21/42 (50.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.50 (0.60 to 3.77)
p-value for Odds Ratio ^a			0.3839
Risk Ratio (95% CI) vs Placebo ^a		-	1.25 (0.75 to 2.09)
Reversed Risk ratio (95% CI)		-	0.80 (0.48 to 1.34)
p-value for Risk Ratio ^a			0.3952
Risk Difference (95% CI) vs Placebo ^a		-	10.00 (-12.55 to 32.55)
p-value for Risk Difference ^a			0.3798

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_pro_haq0847_ni_geri_t_x.rtf (13SEP2024 13:56)

Weitere Analysen

7. SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points [n (%)]			
Responder		10/35 (28.6)	14/42 (33.3)
Non-responder		25/35 (71.4)	28/42 (66.7)
Odds Ratio (95% CI) vs Placebo ^a		-	1.25 (0.46 to 3.37)
p-value for Odds Ratio ^a			0.6548
Risk Ratio (95% CI) vs Placebo ^a		-	1.17 (0.59 to 2.32)
Reversed Risk ratio (95% CI)		-	0.86 (0.43 to 1.70)
p-value for Risk Ratio ^a			0.6602
Risk Difference (95% CI) vs Placebo ^a		-	4.76 (-16.25 to 25.77)
p-value for Risk Difference ^a			0.6529

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_pro_pcs_ni_geri_t.x.rtf (13SEP2024 13:57)

Weitere Analysen

8. SF-36 Standardized Mental Component Scale increase from Baseline $\geq$ 10 points - ITT population- Analysis of responders over time up to week 52

ITT Responder status	population	Placebo (N=58)	Sarilumab 200mg q2w (N=60)
SF-36 Standardized Mental Component Scale increase from Baseline $\geq$ 10 points [n (%)]			
Responder		5/35 (14.3)	11/42 (26.2)
Non-responder		30/35 (85.7)	31/42 (73.8)
Odds Ratio (95% CI) vs Placebo ^a		-	2.13 (0.65 to 6.99)
p-value for Odds Ratio ^a			0.2096
Risk Ratio (95% CI) vs Placebo ^a		-	1.83 (0.69 to 4.85)
Reversed Risk ratio (95% CI)		-	0.55 (0.21 to 1.44)
p-value for Risk Ratio ^a			0.2221
Risk Difference (95% CI) vs Placebo ^a		-	11.90 (-6.03 to 29.83)
p-value for Risk Difference ^a			0.1900

^a Odds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using a logistic regression model with SAS GLIMMIX procedure.

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_pro_evt_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_pro_mcs_ni_ges_i_t_x.rtf (13SEP2024 13:57)

9. VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points	Gender (Male , Female)	0.8973
	Race (Caucasian/White , All other races)	0.7988
	Region (Western Countries , Rest of World (including South America))	0.4454
	Age (Age < 70 , Age $\geq$ 70)	0.2293
	Baseline CRP ($\leq$ median , > median)	0.0706
	Baseline ESR ($\leq$ median , > median)	0.1968
	Baseline CS dose ($\leq$ median , > median)	0.8720
	MTX Add-on Therapy (Yes , No)	0.7008
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.8638

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_vaspat_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		8/14 (57.1)	5/11 (45.5)	12/21 (57.1)	15/31 (48.4)
Non-responder		6/14 (42.9)	6/11 (54.5)	9/21 (42.9)	16/31 (51.6)
Odds Ratio (95% CI) vs Placebo ^a		-	0.63 (0.12 to 3.35)	-	0.70 (0.22 to 2.20)
p-value for Odds Ratio ^a			0.5680		0.5386
Risk Ratio (95% CI) vs Placebo ^a		-	0.80 (0.35 to 1.83)	-	0.85 (0.50 to 1.44)
p-value for Risk Ratio ^a			0.5909		0.5399
Risk Difference (95% CI) vs Placebo ^a		-	-11.69 (-53.08 to 29.70)	-	-8.76 (-36.96 to 19.45)
p-value for Risk Difference ^a			0.5648		0.5358
Treatment-by-subgroup p-value of RR ^b					0.8973

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_gender_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder		18/28 (64.3)	18/35 (51.4)	2/7 (28.6)	2/7 (28.6)
Non-responder		10/28 (35.7)	17/35 (48.6)	5/7 (71.4)	5/7 (71.4)
Odds Ratio (95% CI) vs Placebo ^a		-	0.59 (0.21 to 1.66)	-	1.00 (0.08 to 13.17)
p-value for Odds Ratio ^a			0.3111		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	0.80 (0.52 to 1.23)	-	1.00 (0.16 to 6.31)
p-value for Risk Ratio ^a			0.3121		1.0000
Risk Difference (95% CI) vs Placebo ^a		-	-12.86 (-37.62 to 11.91)	-	0.00 (-52.61 to 52.61)
p-value for Risk Difference ^a			0.3033		1.0000
Treatment-by-subgroup p-value of RR ^b					0.7988

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_race_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder		13/25 (52.0)	16/33 (48.5)	7/10 (70.0)	4/9 (44.4)
Non-responder		12/25 (48.0)	17/33 (51.5)	3/10 (30.0)	5/9 (55.6)
Odds Ratio (95% CI) vs Placebo ^a		-	0.87 (0.30 to 2.52)	-	0.34 (0.05 to 2.61)
p-value for Odds Ratio ^a			0.7919		0.2815
Risk Ratio (95% CI) vs Placebo ^a		-	0.93 (0.55 to 1.58)	-	0.63 (0.26 to 1.56)
p-value for Risk Ratio ^a			0.7945		0.3222
Risk Difference (95% CI) vs Placebo ^a		-	-3.52 (-30.06 to 23.03)	-	-25.56 (-71.99 to 20.88)
p-value for Risk Difference ^a			0.7917		0.2616
Treatment-by-subgroup p-value of RR ^b					0.4454

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_region_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		6/15 (40.0)	13/27 (48.1)	14/20 (70.0)	7/15 (46.7)
Non-responder		9/15 (60.0)	14/27 (51.9)	6/20 (30.0)	8/15 (53.3)
Odds Ratio (95% CI) vs Placebo ^a		-	1.39 (0.37 to 5.21)	-	0.38 (0.09 to 1.59)
p-value for Odds Ratio ^a			0.6145		0.1772
Risk Ratio (95% CI) vs Placebo ^a		-	1.20 (0.57 to 2.56)	-	0.67 (0.35 to 1.26)
Reversed Risk ratio (95% CI)		-	0.83 (0.39 to 1.77)		
p-value for Risk Ratio ^a			0.6307		0.2112
Risk Difference (95% CI) vs Placebo ^a		-	8.15 (-23.97 to 40.26)	-	-23.33 (-56.82 to 10.15)
p-value for Risk Difference ^a			0.6109		0.1657
Treatment-by-subgroup p-value of RR ^b					0.2293

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_age_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		12/19 (63.2)	6/19 (31.6)	8/16 (50.0)	14/23 (60.9)
Non-responder		7/19 (36.8)	13/19 (68.4)	8/16 (50.0)	9/23 (39.1)
Odds Ratio (95% CI) vs Placebo ^a		-	0.27 (0.07 to 1.08)	-	1.56 (0.41 to 5.90)
p-value for Odds Ratio ^a			0.0635		0.5059
Risk Ratio (95% CI) vs Placebo ^a		-	0.50 (0.23 to 1.08)	-	1.22 (0.66 to 2.24)
Reversed Risk ratio (95% CI)				-	0.82 (0.45 to 1.51)
p-value for Risk Ratio ^a			0.0783		0.5269
Risk Difference (95% CI) vs Placebo ^a		-	-31.58 (-62.75 to -0.41)	-	10.87 (-21.79 to 43.53)
p-value for Risk Difference ^a			0.0472		0.5043
Treatment-by-subgroup p-value of RR ^b					0.0706

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger__crp_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		9/19 (47.4)	11/21 (52.4)	11/16 (68.8)	9/21 (42.9)
Non-responder		10/19 (52.6)	10/21 (47.6)	5/16 (31.3)	12/21 (57.1)
Odds Ratio (95% CI) vs Placebo ^a		-	1.22 (0.34 to 4.41)	-	0.34 (0.08 to 1.40)
p-value for Odds Ratio ^a			0.7534		0.1314
Risk Ratio (95% CI) vs Placebo ^a		-	1.11 (0.58 to 2.11)	-	0.62 (0.34 to 1.15)
Reversed Risk ratio (95% CI)		-	0.90 (0.47 to 1.72)		
p-value for Risk Ratio ^a			0.7602		0.1323
Risk Difference (95% CI) vs Placebo ^a		-	5.01 (-27.00 to 37.02)	-	-25.89 (-58.05 to 6.26)
p-value for Risk Difference ^a			0.7530		0.1111
Treatment-by-subgroup p-value of RR ^b					0.1968

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_esr_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		12/22 (54.5)	10/23 (43.5)	8/13 (61.5)	10/19 (52.6)
Non-responder		10/22 (45.5)	13/23 (56.5)	5/13 (38.5)	9/19 (47.4)
Odds Ratio (95% CI) vs Placebo ^a		-	0.64 (0.19 to 2.15)	-	0.69 (0.16 to 3.10)
p-value for Odds Ratio ^a			0.4628		0.6221
Risk Ratio (95% CI) vs Placebo ^a		-	0.80 (0.43 to 1.48)	-	0.86 (0.46 to 1.61)
p-value for Risk Ratio ^a			0.4732		0.6272
Risk Difference (95% CI) vs Placebo ^a		-	-11.07 (-40.95 to 18.81)	-	-8.91 (-45.05 to 27.24)
p-value for Risk Difference ^a			0.4592		0.6185
Treatment-by-subgroup p-value of RR ^b					0.8720

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_cs_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
VAS Pain (Patient) decrease from Baseline >= 1.5 points [n (%)]					
Responder		6/10 (60.0)	3/5 (60.0)	14/25 (56.0)	17/37 (45.9)
Non-responder		4/10 (40.0)	2/5 (40.0)	11/25 (44.0)	20/37 (54.1)
Odds Ratio (95% CI) vs Placebo ^a		-	1.00 (0.09 to 11.19)	-	0.67 (0.24 to 1.89)
p-value for Odds Ratio ^a			1.0000		0.4413
Risk Ratio (95% CI) vs Placebo ^a		-	1.00 (0.38 to 2.63)	-	0.82 (0.50 to 1.36)
p-value for Risk Ratio ^a			1.0000		0.4406
Risk Difference (95% CI) vs Placebo ^a		-	0.00 (-57.97 to 57.97)	-	-10.05 (-35.80 to 15.69)
p-value for Risk Difference ^a			1.0000		0.4378
Treatment-by-subgroup p-value of RR ^b					0.7008

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_mtx_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
VAS Pain (Patient) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder		11/17 (64.7)	8/15 (53.3)	9/18 (50.0)	12/27 (44.4)
Non-responder		6/17 (35.3)	7/15 (46.7)	9/18 (50.0)	15/27 (55.6)
Odds Ratio (95% CI) vs Placebo ^a		-	0.62 (0.14 to 2.74)	-	0.80 (0.23 to 2.74)
p-value for Odds Ratio ^a			0.5194		0.7163
Risk Ratio (95% CI) vs Placebo ^a		-	0.82 (0.45 to 1.52)	-	0.89 (0.47 to 1.69)
p-value for Risk Ratio ^a			0.5373		0.7198
Risk Difference (95% CI) vs Placebo ^a		-	-11.37 (-46.76 to 24.02)	-	-5.56 (-36.16 to 25.05)
p-value for Risk Difference ^a			0.5166		0.7161
Treatment-by-subgroup p-value of RR ^b					0.8638

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vaspat_ni_ger_nrp_i_t_x.rtf (13SEP2024 14:00)

10. VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points	Gender (Male , Female)	0.0337
	Race (Caucasian/White , All other races)	0.0001
	Region (Western Countries , Rest of World (including South America))	0.0001
	Age (Age < 70 , Age $\geq$ 70)	0.1085
	Baseline CRP ($\leq$ median , > median)	0.9472
	Baseline ESR ($\leq$ median , > median)	0.0001
	Baseline CS dose ($\leq$ median , > median)	0.6868
	MTX Add-on Therapy (Yes , No)	0.7978
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.3061

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_vasphy_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		11/12 (91.7)	8/9 (88.9)	10/19 (52.6)	22/24 (91.7)
Non-responder		1/12 (8.3)	1/9 (11.1)	9/19 (47.4)	2/24 (8.3)
Odds Ratio (95% CI) vs Placebo ^a		-	0.73 (0.03 to 16.40)	-	9.90 (1.71 to 57.35)
p-value for Odds Ratio ^a			0.8329		0.0118
Risk Ratio (95% CI) vs Placebo ^a		-	0.97 (0.71 to 1.32)	-	1.74 (1.10 to 2.75)
Reversed Risk ratio (95% CI)				-	0.57 (0.36 to 0.91)
p-value for Risk Ratio ^a			0.8441		0.0173
Risk Difference (95% CI) vs Placebo ^a		-	-2.78 (-30.34 to 24.78)	-	39.04 (13.25 to 64.82)
p-value for Risk Difference ^a			0.8352		0.0039
Treatment-by-subgroup p-value of RR ^b					0.0337

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_gender_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]					
	Responder	18/25 (72.0)	23/26 (88.5)	3/6 (50.0)	7/7 (100)
	Non-responder	7/25 (28.0)	3/26 (11.5)	3/6 (50.0)	0/7
	Odds Ratio (95% CI) vs Placebo ^a	-	2.98 (0.65 to 13.69)	-	779233.9 (0.00 to NE)
	p-value for Odds Ratio ^a		0.1561		0.9683
	Risk Ratio (95% CI) vs Placebo ^a	-	1.23 (0.92 to 1.64)	-	1.55 (NE to NE)
	Reversed Risk ratio (95% CI)	-	0.81 (0.61 to 1.09)	-	0.65 (NE to NE)
	p-value for Risk Ratio ^a		0.1615		NE
	Risk Difference (95% CI) vs Placebo ^a	-	16.46 (-5.54 to 38.47)	-	50.00 (NE to NE)
	p-value for Risk Difference ^a		0.1392		<0.0001
	Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_ges_race_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
VAS disease activity (Physician) decrease from Baseline $\geq$ 1.5 points [n (%)]					
Responder		11/21 (52.4)	22/25 (88.0)	10/10 (100)	8/8 (100)
Non-responder		10/21 (47.6)	3/25 (12.0)	0/10	0/8
Odds Ratio (95% CI) vs Placebo ^a		-	6.67 (1.46 to 30.52)	-	1.00 (0.00 to NE)
p-value for Odds Ratio ^a			0.0157		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	1.68 (1.08 to 2.62)	-	1.00 (NE to NE)
Reversed Risk ratio (95% CI)		-	0.60 (0.38 to 0.93)		
p-value for Risk Ratio ^a			0.0223		NE
Risk Difference (95% CI) vs Placebo ^a		-	35.62 (10.05 to 61.19)	-	0.00 (NE to NE)
p-value for Risk Difference ^a			0.0074		NE
Treatment-by-subgroup p-value of RR ^b					<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_ges_region_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		7/14 (50.0)	21/23 (91.3)	14/17 (82.4)	9/10 (90.0)
Non-responder		7/14 (50.0)	2/23 (8.7)	3/17 (17.6)	1/10 (10.0)
Odds Ratio (95% CI) vs Placebo ^a		-	10.50 (1.65 to 66.99)	-	1.93 (0.15 to 24.35)
p-value for Odds Ratio ^a			0.0144		0.5984
Risk Ratio (95% CI) vs Placebo ^a		-	1.83 (1.05 to 3.19)	-	1.09 (0.80 to 1.50)
Reversed Risk ratio (95% CI)		-	0.55 (0.31 to 0.96)	-	0.92 (0.67 to 1.26)
p-value for Risk Ratio ^a			0.0344		0.5832
Risk Difference (95% CI) vs Placebo ^a		-	41.30 (11.67 to 70.94)	-	7.65 (-19.64 to 34.93)
p-value for Risk Difference ^a			0.0077		0.5689
Treatment-by-subgroup p-value of RR ^b					0.1085

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_ges_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		11/16 (68.8)	14/15 (93.3)	10/15 (66.7)	16/18 (88.9)
Non-responder		5/16 (31.3)	1/15 (6.7)	5/15 (33.3)	2/18 (11.1)
Odds Ratio (95% CI) vs Placebo ^a		-	6.36 (0.58 to 69.25)	-	4.00 (0.60 to 26.59)
p-value for Odds Ratio ^a			0.1237		0.1456
Risk Ratio (95% CI) vs Placebo ^a		-	1.36 (0.94 to 1.97)	-	1.33 (0.89 to 2.01)
Reversed Risk ratio (95% CI)		-	0.74 (0.51 to 1.07)	-	0.75 (0.50 to 1.13)
p-value for Risk Ratio ^a			0.1077		0.1683
Risk Difference (95% CI) vs Placebo ^a		-	24.58 (-2.53 to 51.70)	-	22.22 (-6.84 to 51.28)
p-value for Risk Difference ^a			0.0739		0.1290
Treatment-by-subgroup p-value of RR ^b					0.9472

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gcr_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_gcr_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		10/17 (58.8)	15/18 (83.3)	11/14 (78.6)	15/15 (100)
Non-responder		7/17 (41.2)	3/18 (16.7)	3/14 (21.4)	0/15
Odds Ratio (95% CI) vs Placebo ^a		-	3.50 (0.68 to 17.89)	-	577685.4 (0.00 to NE)
p-value for Odds Ratio ^a			0.1277		0.9721
Risk Ratio (95% CI) vs Placebo ^a		-	1.42 (0.89 to 2.26)	-	1.16 (NE to NE)
Reversed Risk ratio (95% CI)		-	0.71 (0.44 to 1.12)	-	0.86 (NE to NE)
p-value for Risk Ratio ^a			0.1423		NE
Risk Difference (95% CI) vs Placebo ^a		-	24.51 (-5.64 to 54.66)	-	21.43 (NE to NE)
p-value for Risk Difference ^a			0.1077		<0.0001
Treatment-by-subgroup p-value of RR ^b					<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_ger_esr_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		12/18 (66.7)	16/17 (94.1)	9/13 (69.2)	14/16 (87.5)
Non-responder		6/18 (33.3)	1/17 (5.9)	4/13 (30.8)	2/16 (12.5)
Odds Ratio (95% CI) vs Placebo ^a		-	8.00 (0.78 to 82.29)	-	3.11 (0.43 to 22.56)
p-value for Odds Ratio ^a			0.0786		0.2501
Risk Ratio (95% CI) vs Placebo ^a		-	1.41 (0.98 to 2.03)	-	1.26 (0.83 to 1.94)
Reversed Risk ratio (95% CI)		-	0.71 (0.49 to 1.02)	-	0.79 (0.52 to 1.21)
p-value for Risk Ratio ^a			0.0610		0.2813
Risk Difference (95% CI) vs Placebo ^a		-	27.45 (2.04 to 52.86)	-	18.27 (-13.00 to 49.54)
p-value for Risk Difference ^a			0.0351		0.2410
Treatment-by-subgroup p-value of RR ^b					0.6868

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_ges_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		5/8 (62.5)	3/4 (75.0)	16/23 (69.6)	27/29 (93.1)
Non-responder		3/8 (37.5)	1/4 (25.0)	7/23 (30.4)	2/29 (6.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.80 (0.09 to 37.79)	-	5.91 (1.05 to 33.34)
p-value for Odds Ratio ^a			0.6762		0.0445
Risk Ratio (95% CI) vs Placebo ^a		-	1.20 (0.49 to 2.91)	-	1.34 (1.00 to 1.80)
Reversed Risk ratio (95% CI)		-	0.83 (0.34 to 2.02)	-	0.75 (0.56 to 1.00)
p-value for Risk Ratio ^a			0.6869		0.0528
Risk Difference (95% CI) vs Placebo ^a		-	12.50 (-48.99 to 73.99)	-	23.54 (2.07 to 45.00)
p-value for Risk Difference ^a			0.6603		0.0323
Treatment-by-subgroup p-value of RR ^b					0.7978

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_geri_mtx_i_t_x.rtf (13SEP2024 14:00)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
VAS disease activity (Physician) decrease from Baseline >= 1.5 points [n (%)]					
Responder		11/15 (73.3)	10/12 (83.3)	10/16 (62.5)	20/21 (95.2)
Non-responder		4/15 (26.7)	2/12 (16.7)	6/16 (37.5)	1/21 (4.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.82 (0.25 to 13.40)	-	12.00 (1.17 to 123.27)
p-value for Odds Ratio ^a			0.5433		0.0372
Risk Ratio (95% CI) vs Placebo ^a		-	1.14 (0.75 to 1.72)	-	1.52 (1.02 to 2.29)
Reversed Risk ratio (95% CI)		-	0.88 (0.58 to 1.33)	-	0.66 (0.44 to 0.98)
p-value for Risk Ratio ^a			0.5475		0.0417
Risk Difference (95% CI) vs Placebo ^a		-	10.00 (-22.31 to 42.31)	-	32.74 (6.42 to 59.06)
p-value for Risk Difference ^a			0.5296		0.0162
Treatment-by-subgroup p-value of RR ^b					0.3061

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_vasphy_ni_geri_nrp_i_t_x.rtf (13SEP2024 14:01)

11. FACIT-F increase from Baseline $\geq$ 7.8 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
FACIT-F increase from Baseline $\geq$ 7.8 points	Gender (Male , Female)	0.3771
	Race (Caucasian/White , All other races)	0.3353
	Region (Western Countries , Rest of World (including South America))	0.9850
	Age (Age < 70 , Age $\geq$ 70)	0.1314
	Baseline CRP ($\leq$ median , > median)	0.0920
	Baseline ESR ($\leq$ median , > median)	0.6066
	Baseline CS dose ($\leq$ median , > median)	0.0156
	MTX Add-on Therapy (Yes , No)	0.5059
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7619

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_binfatigue_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		6/15 (40.0)	7/11 (63.6)	11/21 (52.4)	17/31 (54.8)
Non-responder		9/15 (60.0)	4/11 (36.4)	10/21 (47.6)	14/31 (45.2)
Odds Ratio (95% CI) vs Placebo ^a		-	2.62 (0.48 to 14.23)	-	1.10 (0.35 to 3.45)
p-value for Odds Ratio ^a			0.2502		0.8622
Risk Ratio (95% CI) vs Placebo ^a		-	1.59 (0.71 to 3.56)	-	1.05 (0.62 to 1.78)
Reversed Risk ratio (95% CI)		-	0.63 (0.28 to 1.41)	-	0.96 (0.56 to 1.62)
p-value for Risk Ratio ^a			0.2580		0.8656
Risk Difference (95% CI) vs Placebo ^a		-	23.64 (-16.08 to 63.36)	-	2.46 (-25.85 to 30.77)
p-value for Risk Difference ^a			0.2313		0.8623
Treatment-by-subgroup p-value of RR ^b					0.3771

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_ger_gender_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
FACIT-F increase from Baseline $\geq$ 7.8 points [n (%)]					
Responder		16/29 (55.2)	21/35 (60.0)	1/7 (14.3)	3/7 (42.9)
Non-responder		13/29 (44.8)	14/35 (40.0)	6/7 (85.7)	4/7 (57.1)
Odds Ratio (95% CI) vs Placebo ^a		-	1.22 (0.44 to 3.37)	-	4.50 (0.25 to 80.35)
p-value for Odds Ratio ^a			0.6985		0.2777
Risk Ratio (95% CI) vs Placebo ^a		-	1.09 (0.70 to 1.68)	-	3.00 (0.32 to 27.90)
Reversed Risk ratio (95% CI)		-	0.92 (0.60 to 1.42)	-	0.33 (0.04 to 3.10)
p-value for Risk Ratio ^a			0.7046		0.3343
Risk Difference (95% CI) vs Placebo ^a		-	4.83 (-19.97 to 29.62)	-	28.57 (-21.34 to 78.48)
p-value for Risk Difference ^a			0.6985		0.2361
Treatment-by-subgroup p-value of RR ^b					0.3353

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_geri_race_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
FACIT-F increase from Baseline $\geq$ 7.8 points [n (%)]					
Responder		10/26 (38.5)	16/33 (48.5)	7/10 (70.0)	8/9 (88.9)
Non-responder		16/26 (61.5)	17/33 (51.5)	3/10 (30.0)	1/9 (11.1)
Odds Ratio (95% CI) vs Placebo ^a		-	1.51 (0.52 to 4.38)	-	3.43 (0.24 to 49.49)
p-value for Odds Ratio ^a			0.4454		0.3438
Risk Ratio (95% CI) vs Placebo ^a		-	1.26 (0.68 to 2.33)	-	1.27 (0.77 to 2.10)
Reversed Risk ratio (95% CI)		-	0.79 (0.43 to 1.46)	-	0.79 (0.48 to 1.30)
p-value for Risk Ratio ^a			0.4591		0.3515
Risk Difference (95% CI) vs Placebo ^a		-	10.02 (-15.83 to 35.88)	-	18.89 (-18.84 to 56.62)
p-value for Risk Difference ^a			0.4408		0.3056
Treatment-by-subgroup p-value of RR ^b					0.9850

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_geri_region_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		6/15 (40.0)	18/27 (66.7)	11/21 (52.4)	6/15 (40.0)
Non-responder		9/15 (60.0)	9/27 (33.3)	10/21 (47.6)	9/15 (60.0)
Odds Ratio (95% CI) vs Placebo ^a		-	3.00 (0.78 to 11.54)	-	0.61 (0.15 to 2.44)
p-value for Odds Ratio ^a			0.1072		0.4695
Risk Ratio (95% CI) vs Placebo ^a		-	1.67 (0.83 to 3.34)	-	0.76 (0.35 to 1.65)
Reversed Risk ratio (95% CI)		-	0.60 (0.30 to 1.20)		
p-value for Risk Ratio ^a			0.1502		0.4920
Risk Difference (95% CI) vs Placebo ^a		-	26.67 (-4.79 to 58.13)	-	-12.38 (-46.31 to 21.55)
p-value for Risk Difference ^a			0.0944		0.4635
Treatment-by-subgroup p-value of RR ^b					0.1314

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_geri_age_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		11/19 (57.9)	9/19 (47.4)	6/17 (35.3)	15/23 (65.2)
Non-responder		8/19 (42.1)	10/19 (52.6)	11/17 (64.7)	8/23 (34.8)
Odds Ratio (95% CI) vs Placebo ^a		-	0.65 (0.17 to 2.46)	-	3.44 (0.89 to 13.35)
p-value for Odds Ratio ^a			0.5207		0.0733
Risk Ratio (95% CI) vs Placebo ^a		-	0.82 (0.44 to 1.54)	-	1.85 (0.89 to 3.85)
Reversed Risk ratio (95% CI)				-	0.54 (0.26 to 1.13)
p-value for Risk Ratio ^a			0.5330		0.1005
Risk Difference (95% CI) vs Placebo ^a		-	-10.53 (-43.20 to 22.15)	-	29.92 (-0.98 to 60.82)
p-value for Risk Difference ^a			0.5176		0.0573
Treatment-by-subgroup p-value of RR ^b					0.0920

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_ger_crp_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		8/19 (42.1)	12/21 (57.1)	9/17 (52.9)	12/21 (57.1)
Non-responder		11/19 (57.9)	9/21 (42.9)	8/17 (47.1)	9/21 (42.9)
Odds Ratio (95% CI) vs Placebo ^a		-	1.83 (0.50 to 6.71)	-	1.19 (0.31 to 4.48)
p-value for Odds Ratio ^a			0.3500		0.7972
Risk Ratio (95% CI) vs Placebo ^a		-	1.36 (0.70 to 2.64)	-	1.08 (0.59 to 1.97)
Reversed Risk ratio (95% CI)		-	0.74 (0.38 to 1.43)	-	0.93 (0.51 to 1.69)
p-value for Risk Ratio ^a			0.3685		0.8035
Risk Difference (95% CI) vs Placebo ^a		-	15.04 (-16.64 to 46.72)	-	4.20 (-28.70 to 37.10)
p-value for Risk Difference ^a			0.3427		0.7971
Treatment-by-subgroup p-value of RR ^b					0.6066

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_ger_esr_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		7/22 (31.8)	15/23 (65.2)	10/14 (71.4)	9/19 (47.4)
Non-responder		15/22 (68.2)	8/23 (34.8)	4/14 (28.6)	10/19 (52.6)
Odds Ratio (95% CI) vs Placebo ^a		-	4.02 (1.12 to 14.41)	-	0.36 (0.08 to 1.66)
p-value for Odds Ratio ^a			0.0336		0.1824
Risk Ratio (95% CI) vs Placebo ^a		-	2.05 (1.02 to 4.13)	-	0.66 (0.36 to 1.21)
Reversed Risk ratio (95% CI)		-	0.49 (0.24 to 0.98)		
p-value for Risk Ratio ^a			0.0446		0.1809
Risk Difference (95% CI) vs Placebo ^a		-	33.40 (5.08 to 61.72)	-	-24.06 (-58.00 to 9.88)
p-value for Risk Difference ^a			0.0219		0.1583
Treatment-by-subgroup p-value of RR ^b					0.0156

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_geri_cs_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		5/10 (50.0)	4/5 (80.0)	12/26 (46.2)	20/37 (54.1)
Non-responder		5/10 (50.0)	1/5 (20.0)	14/26 (53.8)	17/37 (45.9)
Odds Ratio (95% CI) vs Placebo ^a		-	4.00 (0.25 to 64.16)	-	1.37 (0.49 to 3.83)
p-value for Odds Ratio ^a			0.3001		0.5397
Risk Ratio (95% CI) vs Placebo ^a		-	1.60 (0.69 to 3.69)	-	1.17 (0.70 to 1.97)
Reversed Risk ratio (95% CI)		-	0.62 (0.27 to 1.44)	-	0.85 (0.51 to 1.44)
p-value for Risk Ratio ^a			0.2709		0.5521
Risk Difference (95% CI) vs Placebo ^a		-	30.00 (-21.58 to 81.58)	-	7.90 (-17.61 to 33.41)
p-value for Risk Difference ^a			0.2310		0.5380
Treatment-by-subgroup p-value of RR ^b					0.5059

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_geri_mtx_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
FACIT-F increase from Baseline >= 7.8 points [n (%)]					
Responder		9/18 (50.0)	10/15 (66.7)	8/18 (44.4)	14/27 (51.9)
Non-responder		9/18 (50.0)	5/15 (33.3)	10/18 (55.6)	13/27 (48.1)
Odds Ratio (95% CI) vs Placebo ^a		-	2.00 (0.46 to 8.73)	-	1.35 (0.39 to 4.62)
p-value for Odds Ratio ^a			0.3449		0.6291
Risk Ratio (95% CI) vs Placebo ^a		-	1.33 (0.73 to 2.45)	-	1.17 (0.61 to 2.23)
Reversed Risk ratio (95% CI)		-	0.75 (0.41 to 1.38)	-	0.86 (0.45 to 1.64)
p-value for Risk Ratio ^a			0.3538		0.6420
Risk Difference (95% CI) vs Placebo ^a		-	16.67 (-17.89 to 51.22)	-	7.41 (-23.15 to 37.97)
p-value for Risk Difference ^a			0.3329		0.6275
Treatment-by-subgroup p-value of RR ^b					0.7619

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_fatigue_ni_ger_nrp_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

12. EQ-5D VAS increase from Baseline >= 15 points at Week 52 - ITT population

Summary table of treatment-by-subgroup p-value for all subgroups

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
EQ-5D VAS increase from Baseline >= 15 points	Gender (Male , Female)	0.2653
	Race (Caucasian/White , All other races)	0.2941
	Age (Age < 70 , Age >= 70)	0.4249
	MTX Add-on Therapy (Yes , No)	0.6714

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder		3/14 (21.4)	6/11 (54.5)	6/21 (28.6)	10/31 (32.3)
Non-responder		11/14 (78.6)	5/11 (45.5)	15/21 (71.4)	21/31 (67.7)
Odds Ratio (95% CI) vs Placebo ^a		-	4.40 (0.70 to 27.70)	-	1.19 (0.34 to 4.11)
p-value for Odds Ratio ^a			0.1093		0.7787
Risk Ratio (95% CI) vs Placebo ^a		-	2.55 (0.77 to 8.47)	-	1.13 (0.47 to 2.69)
Reversed Risk ratio (95% CI)		-	0.39 (0.12 to 1.31)	-	0.89 (0.37 to 2.11)
p-value for Risk Ratio ^a			0.1277		0.7841
Risk Difference (95% CI) vs Placebo ^a		-	33.12 (-5.34 to 71.58)	-	3.69 (-22.32 to 29.70)
p-value for Risk Difference ^a			0.0881		0.7770
Treatment-by-subgroup p-value of RR ^b					0.2653

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ni_ger_gender_i_t_x.rtf(13SEP2024 14:01)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
EQ-5D VAS increase from Baseline $\geq$ 15 points [n (%)]					
Responder		7/28 (25.0)	15/35 (42.9)	2/7 (28.6)	1/7 (14.3)
Non-responder		21/28 (75.0)	20/35 (57.1)	5/7 (71.4)	6/7 (85.7)
Odds Ratio (95% CI) vs Placebo ^a		-	2.25 (0.74 to 6.82)	-	0.42 (0.02 to 8.18)
p-value for Odds Ratio ^a			0.1485		0.5337
Risk Ratio (95% CI) vs Placebo ^a		-	1.71 (0.80 to 3.67)	-	0.50 (0.05 to 5.52)
Reversed Risk ratio (95% CI)		-	0.58 (0.27 to 1.25)		
p-value for Risk Ratio ^a			0.1657		0.5715
Risk Difference (95% CI) vs Placebo ^a		-	17.86 (-5.54 to 41.26)	-	-14.29 (-61.34 to 32.77)
p-value for Risk Difference ^a			0.1322		0.5208
Treatment-by-subgroup p-value of RR ^b					0.2941

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ni_ger_race_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder		3/15 (20.0)	11/27 (40.7)	6/20 (30.0)	5/15 (33.3)
Non-responder		12/15 (80.0)	16/27 (59.3)	14/20 (70.0)	10/15 (66.7)
Odds Ratio (95% CI) vs Placebo ^a		-	2.75 (0.60 to 12.65)	-	1.17 (0.26 to 5.19)
p-value for Odds Ratio ^a			0.1879		0.8348
Risk Ratio (95% CI) vs Placebo ^a		-	2.04 (0.65 to 6.40)	-	1.11 (0.40 to 3.07)
Reversed Risk ratio (95% CI)		-	0.49 (0.16 to 1.54)	-	0.90 (0.33 to 2.49)
p-value for Risk Ratio ^a			0.2229		0.8391
Risk Difference (95% CI) vs Placebo ^a		-	20.74 (-7.56 to 49.04)	-	3.33 (-29.04 to 35.70)
p-value for Risk Difference ^a			0.1464		0.8353
Treatment-by-subgroup p-value of RR ^b					0.4249

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ni_ger_age_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
EQ-5D VAS increase from Baseline >= 15 points [n (%)]					
Responder		2/10 (20.0)	2/5 (40.0)	7/25 (28.0)	14/37 (37.8)
Non-responder		8/10 (80.0)	3/5 (60.0)	18/25 (72.0)	23/37 (62.2)
Odds Ratio (95% CI) vs Placebo ^a		-	2.67 (0.20 to 36.22)	-	1.57 (0.51 to 4.80)
p-value for Odds Ratio ^a			0.4313		0.4266
Risk Ratio (95% CI) vs Placebo ^a		-	2.00 (0.33 to 12.19)	-	1.35 (0.63 to 2.91)
Reversed Risk ratio (95% CI)		-	0.50 (0.08 to 3.05)	-	0.74 (0.34 to 1.59)
p-value for Risk Ratio ^a			0.4523		0.4420
Risk Difference (95% CI) vs Placebo ^a		-	20.00 (-34.65 to 74.65)	-	9.84 (-14.18 to 33.86)
p-value for Risk Difference ^a			0.4434		0.4159
Treatment-by-subgroup p-value of RR ^b					0.6714

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_eq5dvas_ni_ger_mtx_i_t_x.rtf (13SEP2024 14:01)

13. HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points	Gender (Male , Female)	0.6847
	Race (Caucasian/White , All other races)	0.7283
	Region (Western Countries , Rest of World (including South America))	0.7697
	Age (Age < 70 , Age ≥ 70)	0.2953
	Baseline CRP ($\leq$ median , > median)	0.1485
	Baseline ESR ($\leq$ median , > median)	0.2619
	Baseline CS dose ($\leq$ median , > median)	0.1041
	MTX Add-on Therapy (Yes , No)	0.7149
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.1282

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_binhaqdi_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder		4/14 (28.6)	4/11 (36.4)	6/21 (28.6)	15/31 (48.4)
Non-responder		10/14 (71.4)	7/11 (63.6)	15/21 (71.4)	16/31 (51.6)
Odds Ratio (95% CI) vs Placebo ^a		-	1.43 (0.24 to 8.50)	-	2.34 (0.70 to 7.85)
p-value for Odds Ratio ^a			0.6828		0.1634
Risk Ratio (95% CI) vs Placebo ^a		-	1.27 (0.38 to 4.23)	-	1.69 (0.77 to 3.72)
Reversed Risk ratio (95% CI)		-	0.79 (0.24 to 2.61)	-	0.59 (0.27 to 1.30)
p-value for Risk Ratio ^a			0.6942		0.1894
Risk Difference (95% CI) vs Placebo ^a		-	7.79 (-31.25 to 46.83)	-	19.82 (-6.96 to 46.59)
p-value for Risk Difference ^a			0.6835		0.1435
Treatment-by-subgroup p-value of RR ^b					0.6847

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_gender_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder		9/28 (32.1)	18/35 (51.4)	1/7 (14.3)	1/7 (14.3)
Non-responder		19/28 (67.9)	17/35 (48.6)	6/7 (85.7)	6/7 (85.7)
Odds Ratio (95% CI) vs Placebo ^a		-	2.24 (0.78 to 6.42)	-	1.00 (0.04 to 27.89)
p-value for Odds Ratio ^a			0.1324		1.0000
Risk Ratio (95% CI) vs Placebo ^a		-	1.60 (0.84 to 3.03)	-	1.00 (0.06 to 17.34)
Reversed Risk ratio (95% CI)		-	0.62 (0.33 to 1.19)		
p-value for Risk Ratio ^a			0.1499		1.0000
Risk Difference (95% CI) vs Placebo ^a		-	19.29 (-5.14 to 43.72)	-	0.00 (-40.75 to 40.75)
p-value for Risk Difference ^a			0.1196		1.0000
Treatment-by-subgroup p-value of RR ^b					0.7283

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_race_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder		7/25 (28.0)	14/33 (42.4)	3/10 (30.0)	5/9 (55.6)
Non-responder		18/25 (72.0)	19/33 (57.6)	7/10 (70.0)	4/9 (44.4)
Odds Ratio (95% CI) vs Placebo ^a		-	1.89 (0.61 to 5.91)	-	2.92 (0.38 to 22.22)
p-value for Odds Ratio ^a			0.2652		0.2815
Risk Ratio (95% CI) vs Placebo ^a		-	1.52 (0.71 to 3.24)	-	1.85 (0.56 to 6.13)
Reversed Risk ratio (95% CI)		-	0.66 (0.31 to 1.41)	-	0.54 (0.16 to 1.79)
p-value for Risk Ratio ^a			0.2840		0.3132
Risk Difference (95% CI) vs Placebo ^a		-	14.42 (-10.49 to 39.34)	-	25.56 (-20.88 to 71.99)
p-value for Risk Difference ^a			0.2510		0.2616
Treatment-by-subgroup p-value of RR ^b					0.7697

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_region_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Age < 70 (N=59)		Age >= 70 (N=59)	
		Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder		3/15 (20.0)	13/27 (48.1)	7/20 (35.0)	6/15 (40.0)
Non-responder		12/15 (80.0)	14/27 (51.9)	13/20 (65.0)	9/15 (60.0)
Odds Ratio (95% CI) vs Placebo ^a		-	3.71 (0.81 to 16.97)	-	1.24 (0.29 to 5.20)
p-value for Odds Ratio ^a			0.0885		0.7640
Risk Ratio (95% CI) vs Placebo ^a		-	2.41 (0.79 to 7.37)	-	1.14 (0.47 to 2.79)
Reversed Risk ratio (95% CI)		-	0.42 (0.14 to 1.27)	-	0.87 (0.36 to 2.14)
p-value for Risk Ratio ^a			0.1238		0.7696
Risk Difference (95% CI) vs Placebo ^a		-	28.15 (-0.37 to 56.67)	-	5.00 (-28.66 to 38.66)
p-value for Risk Difference ^a			0.0529		0.7644
Treatment-by-subgroup p-value of RR ^b					0.2953

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_geri_age_it_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI Standardized Score decrease from Baseline $\geq$ 0.45 points [n (%)]					
Responder		7/19 (36.8)	7/19 (36.8)	3/16 (18.8)	12/23 (52.2)
Non-responder		12/19 (63.2)	12/19 (63.2)	13/16 (81.3)	11/23 (47.8)
Odds Ratio (95% CI) vs Placebo ^a		-	1.00 (0.26 to 3.91)	-	4.73 (1.00 to 22.25)
p-value for Odds Ratio ^a			1.0000		0.0494
Risk Ratio (95% CI) vs Placebo ^a		-	1.00 (0.42 to 2.37)	-	2.78 (0.90 to 8.61)
Reversed Risk ratio (95% CI)				-	0.36 (0.12 to 1.11)
p-value for Risk Ratio ^a			1.0000		0.0757
Risk Difference (95% CI) vs Placebo ^a		-	-0.00 (-31.74 to 31.74)	-	33.42 (4.51 to 62.34)
p-value for Risk Difference ^a			1.0000		0.0247
Treatment-by-subgroup p-value of RR ^b					0.1485

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_crp_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points [n (%)]					
Responder		7/19 (36.8)	9/21 (42.9)	3/16 (18.8)	10/21 (47.6)
Non-responder		12/19 (63.2)	12/21 (57.1)	13/16 (81.3)	11/21 (52.4)
Odds Ratio (95% CI) vs Placebo ^a		-	1.29 (0.35 to 4.78)	-	3.94 (0.82 to 19.01)
p-value for Odds Ratio ^a			0.7006		0.0857
Risk Ratio (95% CI) vs Placebo ^a		-	1.16 (0.53 to 2.57)	-	2.54 (0.80 to 8.05)
Reversed Risk ratio (95% CI)		-	0.86 (0.39 to 1.90)	-	0.39 (0.12 to 1.25)
p-value for Risk Ratio ^a			0.7088		0.1135
Risk Difference (95% CI) vs Placebo ^a		-	6.02 (-25.29 to 37.32)	-	28.87 (-0.83 to 58.57)
p-value for Risk Difference ^a			0.6994		0.0564
Treatment-by-subgroup p-value of RR ^b					0.2619

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_esr_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
HAQ-DI Standardized Score decrease from Baseline ≥ 0.45 points [n (%)]					
Responder		4/22 (18.2)	11/23 (47.8)	6/13 (46.2)	8/19 (42.1)
Non-responder		18/22 (81.8)	12/23 (52.2)	7/13 (53.8)	11/19 (57.9)
Odds Ratio (95% CI) vs Placebo ^a		-	4.12 (1.02 to 16.68)	-	0.85 (0.19 to 3.73)
p-value for Odds Ratio ^a			0.0469		0.8222
Risk Ratio (95% CI) vs Placebo ^a		-	2.63 (0.96 to 7.24)	-	0.91 (0.40 to 2.08)
Reversed Risk ratio (95% CI)		-	0.38 (0.14 to 1.05)		
p-value for Risk Ratio ^a			0.0611		0.8268
Risk Difference (95% CI) vs Placebo ^a		-	29.64 (2.88 to 56.41)	-	-4.05 (-40.55 to 32.45)
p-value for Risk Difference ^a			0.0307		0.8223
Treatment-by-subgroup p-value of RR ^b					0.1041

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_cs_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder		2/10 (20.0)	2/5 (40.0)	8/25 (32.0)	17/37 (45.9)
Non-responder		8/10 (80.0)	3/5 (60.0)	17/25 (68.0)	20/37 (54.1)
Odds Ratio (95% CI) vs Placebo ^a		-	2.67 (0.20 to 36.22)	-	1.81 (0.61 to 5.33)
p-value for Odds Ratio ^a			0.4313		0.2788
Risk Ratio (95% CI) vs Placebo ^a		-	2.00 (0.33 to 12.19)	-	1.44 (0.72 to 2.84)
Reversed Risk ratio (95% CI)		-	0.50 (0.08 to 3.05)	-	0.70 (0.35 to 1.38)
p-value for Risk Ratio ^a			0.4523		0.2997
Risk Difference (95% CI) vs Placebo ^a		-	20.00 (-34.65 to 74.65)	-	13.95 (-10.89 to 38.78)
p-value for Risk Difference ^a			0.4434		0.2658
Treatment-by-subgroup p-value of RR ^b					0.7149

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_mtx_i_t_x.rtf (13SEP2024 14:01)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		Placebo (N=23)	1 relapse (N=47) Sarilumab 200mg q2w (N=24)	Placebo (N=35)	> 1 relapse (N=71) Sarilumab 200mg q2w (N=36)
HAQ-DI Standardized Score decrease from Baseline >= 0.45 points [n (%)]					
Responder		7/17 (41.2)	6/15 (40.0)	3/18 (16.7)	13/27 (48.1)
Non-responder		10/17 (58.8)	9/15 (60.0)	15/18 (83.3)	14/27 (51.9)
Odds Ratio (95% CI) vs Placebo ^a		-	0.95 (0.22 to 4.16)	-	4.64 (1.04 to 20.67)
p-value for Odds Ratio ^a			0.9465		0.0442
Risk Ratio (95% CI) vs Placebo ^a		-	0.97 (0.40 to 2.33)	-	2.89 (0.93 to 9.00)
Reversed Risk ratio (95% CI)				-	0.35 (0.11 to 1.08)
p-value for Risk Ratio ^a			0.9483		0.0673
Risk Difference (95% CI) vs Placebo ^a		-	-1.18 (-36.70 to 34.34)	-	31.48 (5.22 to 57.75)
p-value for Risk Difference ^a			0.9465		0.0200
Treatment-by-subgroup p-value of RR ^b					0.1282

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haqdi_ni_ger_nrp_i_t_x.rtf (13SEP2024 14:02)

14. SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points at Week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points	Gender (Male , Female)	0.3431
	Race (Caucasian/White , All other races)	0.1772
	Region (Western Countries , Rest of World (including South America))	0.5264
	Baseline ESR ($\leq$ median , $>$ median)	0.3631
	MTX Add-on Therapy (Yes , No)	0.4610

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_binpcs_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder		6/14 (42.9)	4/11 (36.4)	4/21 (19.0)	10/31 (32.3)
Non-responder		8/14 (57.1)	7/11 (63.6)	17/21 (81.0)	21/31 (67.7)
Odds Ratio (95% CI) vs Placebo ^a		-	0.76 (0.14 to 4.22)	-	2.02 (0.52 to 7.86)
p-value for Odds Ratio ^a			0.7454		0.3017
Risk Ratio (95% CI) vs Placebo ^a		-	0.85 (0.30 to 2.41)	-	1.69 (0.60 to 4.81)
Reversed Risk ratio (95% CI)				-	0.59 (0.21 to 1.68)
p-value for Risk Ratio ^a			0.7576		0.3226
Risk Difference (95% CI) vs Placebo ^a		-	-6.49 (-47.10 to 34.11)	-	13.21 (-10.89 to 37.31)
p-value for Risk Difference ^a			0.7438		0.2761
Treatment-by-subgroup p-value of RR ^b					0.3431

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ni_gender_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points [n (%)]					
Responder		7/28 (25.0)	13/35 (37.1)	3/7 (42.9)	1/7 (14.3)
Non-responder		21/28 (75.0)	22/35 (62.9)	4/7 (57.1)	6/7 (85.7)
Odds Ratio (95% CI) vs Placebo ^a		-	1.77 (0.58 to 5.42)	-	0.22 (0.01 to 3.97)
p-value for Odds Ratio ^a			0.3101		0.2777
Risk Ratio (95% CI) vs Placebo ^a		-	1.49 (0.68 to 3.27)	-	0.33 (0.04 to 3.10)
Reversed Risk ratio (95% CI)		-	0.67 (0.31 to 1.48)		
p-value for Risk Ratio ^a			0.3251		0.3343
Risk Difference (95% CI) vs Placebo ^a		-	12.14 (-10.98 to 35.26)	-	-28.57 (-78.48 to 21.34)
p-value for Risk Difference ^a			0.2977		0.2361
Treatment-by-subgroup p-value of RR ^b					0.1772

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ni_geri_race_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
SF-36 Standardized Physical Component Scale increase from Baseline $\geq$ 10 points [n (%)]					
	Responder	7/25 (28.0)	12/33 (36.4)	3/10 (30.0)	2/9 (22.2)
	Non-responder	18/25 (72.0)	21/33 (63.6)	7/10 (70.0)	7/9 (77.8)
	Odds Ratio (95% CI) vs Placebo ^a	-	1.47 (0.47 to 4.64)	-	0.67 (0.07 to 6.21)
	p-value for Odds Ratio ^a		0.5052		0.7063
	Risk Ratio (95% CI) vs Placebo ^a	-	1.30 (0.59 to 2.86)	-	0.74 (0.14 to 3.91)
	Reversed Risk ratio (95% CI)	-	0.77 (0.35 to 1.70)		
	p-value for Risk Ratio ^a		0.5172		0.7238
	Risk Difference (95% CI) vs Placebo ^a	-	8.36 (-16.23 to 32.96)	-	-7.78 (-50.08 to 34.53)
	p-value for Risk Difference ^a		0.4986		0.7029
	Treatment-by-subgroup p-value of RR ^b				0.5264

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gert_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ni_gert_region_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder		6/19 (31.6)	10/21 (47.6)	4/16 (25.0)	4/21 (19.0)
Non-responder		13/19 (68.4)	11/21 (52.4)	12/16 (75.0)	17/21 (81.0)
Odds Ratio (95% CI) vs Placebo ^a		-	1.97 (0.52 to 7.48)	-	0.71 (0.14 to 3.59)
p-value for Odds Ratio ^a			0.3103		0.6665
Risk Ratio (95% CI) vs Placebo ^a		-	1.51 (0.66 to 3.44)	-	0.76 (0.21 to 2.71)
Reversed Risk ratio (95% CI)		-	0.66 (0.29 to 1.51)		
p-value for Risk Ratio ^a			0.3296		0.6741
Risk Difference (95% CI) vs Placebo ^a		-	16.04 (-14.83 to 46.91)	-	-5.95 (-33.98 to 22.08)
p-value for Risk Difference ^a			0.2995		0.6690
Treatment-by-subgroup p-value of RR ^b					0.3631

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ni_ger_esr_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
SF-36 Standardized Physical Component Scale increase from Baseline >= 10 points [n (%)]					
Responder		2/10 (20.0)	2/5 (40.0)	8/25 (32.0)	12/37 (32.4)
Non-responder		8/10 (80.0)	3/5 (60.0)	17/25 (68.0)	25/37 (67.6)
Odds Ratio (95% CI) vs Placebo ^a		-	2.67 (0.20 to 36.22)	-	1.02 (0.34 to 3.09)
p-value for Odds Ratio ^a			0.4313		0.9716
Risk Ratio (95% CI) vs Placebo ^a		-	2.00 (0.33 to 12.19)	-	1.01 (0.48 to 2.15)
Reversed Risk ratio (95% CI)		-	0.50 (0.08 to 3.05)	-	0.99 (0.47 to 2.09)
p-value for Risk Ratio ^a			0.4523		0.9721
Risk Difference (95% CI) vs Placebo ^a		-	20.00 (-34.65 to 74.65)	-	0.43 (-23.76 to 24.62)
p-value for Risk Difference ^a			0.4434		0.9716
Treatment-by-subgroup p-value of RR ^b					0.4610

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_pcs_ni_ger_mtx_i_t_x.rtf (13SEP2024 14:02)

15. HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points at week 52 - ITT population***Summary table of treatment-by-subgroup p-value for all subgroups***

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points	Gender (Male , Female)	0.1368
	Race (Caucasian/White , All other races)	0.6365
	Region (Western Countries , Rest of World (including South America))	0.0277
	Age (Age < 70 , Age $\geq$ 70)	0.4652
	Baseline CRP ($\leq$ median , > median)	0.4425
	Baseline ESR ($\leq$ median , > median)	0.1590
	Baseline CS dose ($\leq$ median , > median)	0.9265
	MTX Add-on Therapy (Yes , No)	0.1673
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.9314

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_ni_binhaq0847_i_t_x.rtf (13SEP2024 14:31)

Weitere Analysen

Per gender

ITT Responder status	population	Gender			
		Male (N=36)		Female (N=82)	
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder		4/14 (28.6)	7/11 (63.6)	10/21 (47.6)	14/31 (45.2)
Non-responder		10/14 (71.4)	4/11 (36.4)	11/21 (52.4)	17/31 (54.8)
Odds Ratio (95% CI) vs Placebo ^a		-	4.37 (0.74 to 26.02)	-	0.91 (0.29 to 2.83)
p-value for Odds Ratio ^a			0.1003		0.8622
Risk Ratio (95% CI) vs Placebo ^a		-	2.23 (0.82 to 6.01)	-	0.95 (0.52 to 1.74)
Reversed Risk ratio (95% CI)		-	0.45 (0.17 to 1.21)		
p-value for Risk Ratio ^a			0.1140		0.8643
Risk Difference (95% CI) vs Placebo ^a		-	35.06 (-3.97 to 74.10)	-	-2.46 (-30.77 to 25.85)
p-value for Risk Difference ^a			0.0760		0.8623

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_gender_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

ITT Responder status	population	Gender				
		Male (N=36)		Female (N=82)		
		Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)	
Treatment-by-subgroup p-value of RR ^b						0.1368

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gender_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_gender_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per race

ITT Responder status	population	Race			
		Caucasian/White (N=98)		All other races (N=20)	
		Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]					
	Responder	13/28 (46.4)	19/35 (54.3)	1/7 (14.3)	2/7 (28.6)
	Non-responder	15/28 (53.6)	16/35 (45.7)	6/7 (85.7)	5/7 (71.4)
	Odds Ratio (95% CI) vs Placebo ^a	-	1.37 (0.50 to 3.79)	-	2.40 (0.12 to 47.10)
	p-value for Odds Ratio ^a		0.5381		0.5337
	Risk Ratio (95% CI) vs Placebo ^a	-	1.17 (0.70 to 1.95)	-	2.00 (0.18 to 22.07)
	Reversed Risk ratio (95% CI)	-	0.86 (0.51 to 1.43)	-	0.50 (0.05 to 5.52)
	p-value for Risk Ratio ^a		0.5486		0.5715
	Risk Difference (95% CI) vs Placebo ^a	-	7.86 (-17.42 to 33.13)	-	14.29 (-32.77 to 61.34)
	p-value for Risk Difference ^a		0.5365		0.5208
	Treatment-by-subgroup p-value of RR ^b				0.6365

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_geri_race_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per region

ITT Responder status	population	Region			
		Western Countries (N=91)		Rest of World (including South America) (N=27)	
		Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]					
	Responder	7/25 (28.0)	18/33 (54.5)	7/10 (70.0)	3/9 (33.3)
	Non-responder	18/25 (72.0)	15/33 (45.5)	3/10 (30.0)	6/9 (66.7)
	Odds Ratio (95% CI) vs Placebo ^a	-	3.09 (0.99 to 9.59)	-	0.21 (0.03 to 1.72)
	p-value for Odds Ratio ^a		0.0515		0.1374
	Risk Ratio (95% CI) vs Placebo ^a	-	1.95 (0.95 to 3.99)	-	0.48 (0.16 to 1.41)
	Reversed Risk ratio (95% CI)	-	0.51 (0.25 to 1.05)		
	p-value for Risk Ratio ^a		0.0683		0.1807
	Risk Difference (95% CI) vs Placebo ^a	-	26.55 (1.54 to 51.55)	-	-36.67 (-81.77 to 8.43)
	p-value for Risk Difference ^a		0.0378		0.1044
	Treatment-by-subgroup p-value of RR ^b				0.0277

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_ges_region_i_t_x.rtf(13SEP2024 14:02)

Weitere Analysen

Per age

ITT Responder status	population	Age			
		Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=59) Sarilumab 200mg q2w (N=26)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder		5/15 (33.3)	14/27 (51.9)	9/20 (45.0)	7/15 (46.7)
Non-responder		10/15 (66.7)	13/27 (48.1)	11/20 (55.0)	8/15 (53.3)
Odds Ratio (95% CI) vs Placebo ^a		-	2.15 (0.56 to 8.34)	-	1.07 (0.27 to 4.31)
p-value for Odds Ratio ^a			0.2587		0.9226
Risk Ratio (95% CI) vs Placebo ^a		-	1.56 (0.68 to 3.56)	-	1.04 (0.49 to 2.20)
Reversed Risk ratio (95% CI)		-	0.64 (0.28 to 1.47)	-	0.96 (0.45 to 2.05)
p-value for Risk Ratio ^a			0.2954		0.9247
Risk Difference (95% CI) vs Placebo ^a		-	18.52 (-12.83 to 49.87)	-	1.67 (-32.96 to 36.29)
p-value for Risk Difference ^a			0.2396		0.9226
Treatment-by-subgroup p-value of RR ^b					0.4652

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_geri_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_geri_age_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per baseline CRP

ITT Responder status	population	Baseline CRP			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder		8/19 (42.1)	8/19 (42.1)	6/16 (37.5)	13/23 (56.5)
Non-responder		11/19 (57.9)	11/19 (57.9)	10/16 (62.5)	10/23 (43.5)
Odds Ratio (95% CI) vs Placebo ^a		-	1.00 (0.26 to 3.79)	-	2.17 (0.56 to 8.35)
p-value for Odds Ratio ^a			1.0000		0.2531
Risk Ratio (95% CI) vs Placebo ^a		-	1.00 (0.46 to 2.16)	-	1.51 (0.71 to 3.20)
Reversed Risk ratio (95% CI)		-	1.00 (0.46 to 2.16)	-	0.66 (0.31 to 1.41)
p-value for Risk Ratio ^a			1.0000		0.2847
Risk Difference (95% CI) vs Placebo ^a		-	-0.00 (-32.49 to 32.49)	-	19.02 (-13.23 to 51.27)
p-value for Risk Difference ^a			1.0000		0.2397
Treatment-by-subgroup p-value of RR ^b					0.4425

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ger_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_ger_crp_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per baseline ESR

ITT Responder status	population	Baseline ESR			
		<= median (N=59)		> median (N=59)	
		Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
	Responder	6/19 (31.6)	12/21 (57.1)	8/16 (50.0)	9/21 (42.9)
	Non-responder	13/19 (68.4)	9/21 (42.9)	8/16 (50.0)	12/21 (57.1)
	Odds Ratio (95% CI) vs Placebo ^a	-	2.89 (0.76 to 11.03)	-	0.75 (0.19 to 2.90)
	p-value for Odds Ratio ^a		0.1172		0.6687
	Risk Ratio (95% CI) vs Placebo ^a	-	1.81 (0.83 to 3.96)	-	0.86 (0.42 to 1.76)
	Reversed Risk ratio (95% CI)	-	0.55 (0.25 to 1.21)		
	p-value for Risk Ratio ^a		0.1379		0.6750
	Risk Difference (95% CI) vs Placebo ^a	-	25.56 (-5.16 to 56.29)	-	-7.14 (-40.68 to 26.39)
	p-value for Risk Difference ^a		0.1003		0.6681
	Treatment-by-subgroup p-value of RR ^b				0.1590

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_ges_esr_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per baseline CS dose

ITT Responder status	population	Baseline CS dose			
		<= median (N=64)		> median (N=54)	
		Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
	Responder	7/22 (31.8)	9/23 (39.1)	7/13 (53.8)	12/19 (63.2)
	Non-responder	15/22 (68.2)	14/23 (60.9)	6/13 (46.2)	7/19 (36.8)
	Odds Ratio (95% CI) vs Placebo ^a	-	1.38 (0.39 to 4.87)	-	1.47 (0.33 to 6.55)
	p-value for Odds Ratio ^a		0.6116		0.6029
	Risk Ratio (95% CI) vs Placebo ^a	-	1.23 (0.54 to 2.79)	-	1.17 (0.62 to 2.21)
	Reversed Risk ratio (95% CI)	-	0.81 (0.36 to 1.84)	-	0.85 (0.45 to 1.61)
	p-value for Risk Ratio ^a		0.6207		0.6224
	Risk Difference (95% CI) vs Placebo ^a	-	7.31 (-21.36 to 35.99)	-	9.31 (-26.86 to 45.48)
	p-value for Risk Difference ^a		0.6097		0.6029
	Treatment-by-subgroup p-value of RR ^b				0.9265

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_ges_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_ges_cs_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per MTX Add-on Therapy

ITT Responder status	population	MTX Add-on Therapy			
		Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=89) Sarilumab 200mg q2w (N=48)
HAQ-DI patient global assessment score decrease from Baseline >= 15 points [n (%)]					
Responder		2/10 (20.0)	3/5 (60.0)	12/25 (48.0)	18/37 (48.6)
Non-responder		8/10 (80.0)	2/5 (40.0)	13/25 (52.0)	19/37 (51.4)
Odds Ratio (95% CI) vs Placebo ^a		-	6.00 (0.44 to 81.50)	-	1.03 (0.36 to 2.89)
p-value for Odds Ratio ^a			0.1617		0.9602
Risk Ratio (95% CI) vs Placebo ^a		-	3.00 (0.62 to 14.53)	-	1.01 (0.59 to 1.73)
Reversed Risk ratio (95% CI)		-	0.33 (0.07 to 1.61)	-	0.99 (0.58 to 1.69)
p-value for Risk Ratio ^a			0.1723		0.9609
Risk Difference (95% CI) vs Placebo ^a		-	40.00 (-14.65 to 94.65)	-	0.65 (-25.23 to 26.53)
p-value for Risk Difference ^a			0.1379		0.9602
Treatment-by-subgroup p-value of RR ^b					0.1673

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two logistic regression model with SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

Note: No imputation was used for missing values.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_evt_subgroup_ni_gert_i_t.sas OUT=REPORT/OUTPUT/eff_evt_haq0847_ni_gert_mtx_i_t_x.rtf (13SEP2024 14:02)

Weitere Analysen

Per Number of relapses prior to screening

ITT Responder status	population	Number of relapses prior to screening			
		1 relapse (N=47)		> 1 relapse (N=71)	
		Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
HAQ-DI patient global assessment score decrease from Baseline $\geq$ 15 points [n (%)]					
Responder		8/17 (47.1)	9/15 (60.0)	6/18 (33.3)	12/27 (44.4)
Non-responder		9/17 (52.9)	6/15 (40.0)	12/18 (66.7)	15/27 (55.6)
Odds Ratio (95% CI) vs Placebo ^a		-	1.69 (0.39 to 7.30)	-	1.60 (0.45 to 5.73)
p-value for Odds Ratio ^a			0.4711		0.4614
Risk Ratio (95% CI) vs Placebo ^a		-	1.28 (0.65 to 2.51)	-	1.33 (0.60 to 2.97)
Reversed Risk ratio (95% CI)		-	0.78 (0.40 to 1.55)	-	0.75 (0.34 to 1.67)
p-value for Risk Ratio ^a			0.4833		0.4810
Risk Difference (95% CI) vs Placebo ^a		-	12.94 (-22.82 to 48.70)	-	11.11 (-18.45 to 40.68)
p-value for Risk Difference ^a			0.4656		0.4526
Treatment-by-subgroup p-value of RR ^b					0.9314

EFC15160_Germany_T2event_subgroup_26JUL24

Weitere Analysen

1. Time to First PMR Flare up to 52 weeks - ITT population

Overall

Efficacy endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Time to First PMR Flare (days from randomization date)	Gender (Male , Female)	0.2573
	Race (Caucasian/White , All other races)	0.3587
	Region (Western Countries , Rest of World (including South America))	0.7922
	Age (Age < 70 , Age >= 70)	0.0298
	Baseline CRP (<= median , > median)	0.6627
	Baseline ESR (<= median , > median)	0.3283
	Baseline CS dose (<= median , > median)	0.9358
	MTX Add-on Therapy (Yes , No)	0.4311
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.9426

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/inter_tte_subgroup.sas OUT=REPORT/OUTPUT/inter_tte_subgroup_pmrtime_i_t_x.rtf (26JUL2024 11:26)

Weitere Analysen

Per gender

Time to First PMR Flare (days from randomization date)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Number of patients who are censored	2 (9.5)	9 (60.0)	11 (29.7)	22 (48.9)
Number of patients with event	19 (90.5)	6 (40.0)	26 (70.3)	23 (51.1)
Median time to first event (weeks) (95% CI) ^a	0.00 (0.00 to 32.29)	NE (0.00 to NE)	16.29 (0.00 to 24.71)	24.14 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.571 (0.338 ; 0.749)	0.200 (0.049 ; 0.424)	0.432 (0.272 ; 0.583)	0.356 (0.220 ; 0.493)
2 weeks	0.571 (0.338 ; 0.749)	0.200 (0.049 ; 0.424)	0.432 (0.272 ; 0.583)	0.356 (0.220 ; 0.493)
4 weeks	0.571 (0.338 ; 0.749)	0.200 (0.049 ; 0.424)	0.432 (0.272 ; 0.583)	0.356 (0.220 ; 0.493)
12 weeks	0.571 (0.338 ; 0.749)	0.200 (0.049 ; 0.424)	0.459 (0.296 ; 0.609)	0.401 (0.259 ; 0.539)
16 weeks	0.571 (0.338 ; 0.749)	0.400 (0.165 ; 0.628)	0.486 (0.320 ; 0.634)	0.470 (0.319 ; 0.607)
20 weeks	0.619 (0.381 ; 0.788)	0.400 (0.165 ; 0.628)	0.595 (0.420 ; 0.732)	0.493 (0.340 ; 0.629)
24 weeks	0.667 (0.425 ; 0.825)	0.400 (0.165 ; 0.628)	0.649 (0.473 ; 0.779)	0.493 (0.340 ; 0.629)
32 weeks	0.667 (0.425 ; 0.825)	0.400 (0.165 ; 0.628)	0.703 (0.528 ; 0.823)	0.516 (0.361 ; 0.651)
40 weeks	0.857 (0.620 ; 0.952)	0.400 (0.165 ; 0.628)	0.703 (0.528 ; 0.823)	0.516 (0.361 ; 0.651)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_gender_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Gender			
	Male (N=36)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=15)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
52 weeks	0.905 (0.670 ; 0.975)	0.400 (0.165 ; 0.628)	0.703 (0.528 ; 0.823)	0.516 (0.361 ; 0.651)
Unstratified Log-Rank test p-value ^a		0.0061		0.1406
Hazard Ratio (95% CI) ^b	-	0.34 (0.13 to 0.86)	-	0.70 (0.40 to 1.22)
p-value for Hazard Ratio ^b		0.0229		0.2054
Treatment-by-subgroup p-value of HR ^c				0.2573

^aderived from Kaplan-Meier estimates.

^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.

^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_gender_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Per race

Time to First PMR Flare (days from randomization date)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
Number of patients who are censored	10 (20.8)	27 (54.0)	3 (30.0)	4 (40.0)
Number of patients with event	38 (79.2)	23 (46.0)	7 (70.0)	6 (60.0)
Median time to first event (weeks) (95% CI) ^a	6.00 (0.00 to 20.00)	NE (11.71 to NE)	28.71 (0.00 to NE)	18.00 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.500 (0.353 ; 0.631)	0.340 (0.214 ; 0.470)	0.400 (0.123 ; 0.670)	0.200 (0.031 ; 0.475)
2 weeks	0.500 (0.353 ; 0.631)	0.340 (0.214 ; 0.470)	0.400 (0.123 ; 0.670)	0.200 (0.031 ; 0.475)
4 weeks	0.500 (0.353 ; 0.631)	0.340 (0.214 ; 0.470)	0.400 (0.123 ; 0.670)	0.200 (0.031 ; 0.475)
12 weeks	0.521 (0.372 ; 0.650)	0.361 (0.231 ; 0.492)	0.400 (0.123 ; 0.670)	0.300 (0.071 ; 0.578)
16 weeks	0.542 (0.392 ; 0.670)	0.443 (0.303 ; 0.574)	0.400 (0.123 ; 0.670)	0.500 (0.184 ; 0.753)
20 weeks	0.646 (0.494 ; 0.763)	0.443 (0.303 ; 0.574)	0.400 (0.123 ; 0.670)	0.600 (0.253 ; 0.827)
24 weeks	0.708 (0.558 ; 0.816)	0.443 (0.303 ; 0.574)	0.400 (0.123 ; 0.670)	0.600 (0.253 ; 0.827)
32 weeks	0.729 (0.580 ; 0.833)	0.464 (0.321 ; 0.594)	0.500 (0.184 ; 0.753)	0.600 (0.253 ; 0.827)
40 weeks	0.792 (0.647 ; 0.882)	0.464 (0.321 ; 0.594)	0.600 (0.253 ; 0.827)	0.600 (0.253 ; 0.827)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_race_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Race			
	Caucasian/White (N=98)		All other races (N=20)	
	Placebo (N=48)	Sarilumab 200mg q2w (N=50)	Placebo (N=10)	Sarilumab 200mg q2w (N=10)
52 weeks	0.792 (0.647 ; 0.882)	0.464 (0.321 ; 0.594)	0.700 (0.329 ; 0.892)	0.600 (0.253 ; 0.827)
Unstratified Log-Rank test p-value ^a		0.0026		0.8081
Hazard Ratio (95% CI) ^b	-	0.51 (0.31 to 0.87)	-	0.88 (0.30 to 2.63)
p-value for Hazard Ratio ^b		0.0122		0.8205
Treatment-by-subgroup p-value of HR ^c				0.3587

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_race_i_t_x.rtf(03MAY2024 15:59)

Weitere Analysen

Per region

Time to First PMR Flare (days from randomization date)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Number of patients who are censored	11 (25.0)	26 (55.3)	2 (14.3)	5 (38.5)
Number of patients with event	33 (75.0)	21 (44.7)	12 (85.7)	8 (61.5)
Median time to first event (weeks) (95% CI) ^a	19.64 (0.00 to 24.71)	NE (14.57 to NE)	0.00 (0.00 to 40.00)	14.00 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.409 (0.265 ; 0.548)	0.277 (0.159 ; 0.408)	0.714 (0.406 ; 0.882)	0.462 (0.192 ; 0.696)
2 weeks	0.409 (0.265 ; 0.548)	0.277 (0.159 ; 0.408)	0.714 (0.406 ; 0.882)	0.462 (0.192 ; 0.696)
4 weeks	0.409 (0.265 ; 0.548)	0.277 (0.159 ; 0.408)	0.714 (0.406 ; 0.882)	0.462 (0.192 ; 0.696)
12 weeks	0.432 (0.284 ; 0.571)	0.320 (0.193 ; 0.454)	0.714 (0.406 ; 0.882)	0.462 (0.192 ; 0.696)
16 weeks	0.455 (0.305 ; 0.593)	0.430 (0.286 ; 0.565)	0.714 (0.406 ; 0.882)	0.538 (0.248 ; 0.760)
20 weeks	0.568 (0.410 ; 0.699)	0.430 (0.286 ; 0.565)	0.714 (0.406 ; 0.882)	0.615 (0.308 ; 0.818)
24 weeks	0.636 (0.477 ; 0.759)	0.430 (0.286 ; 0.565)	0.714 (0.406 ; 0.882)	0.615 (0.308 ; 0.818)
32 weeks	0.682 (0.523 ; 0.798)	0.451 (0.306 ; 0.587)	0.714 (0.406 ; 0.882)	0.615 (0.308 ; 0.818)
40 weeks	0.727 (0.570 ; 0.835)	0.451 (0.306 ; 0.587)	0.857 (0.539 ; 0.962)	0.615 (0.308 ; 0.818)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__region_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Region			
	Western Countries (N=91)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=47)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
52 weeks	0.750 (0.594 ; 0.853)	0.451 (0.306 ; 0.587)	0.857 (0.539 ; 0.962)	0.615 (0.308 ; 0.818)
Unstratified Log-Rank test p-value ^a		0.0128		0.2028
Hazard Ratio (95% CI) ^b	-	0.54 (0.31 to 0.94)	-	0.66 (0.27 to 1.61)
p-value for Hazard Ratio ^b		0.0280		0.3605
Treatment-by-subgroup p-value of HR ^c				0.7922

^aderived from Kaplan-Meier estimates.

^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.

^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__region_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Per age

Time to First PMR Flare (days from randomization date)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
Number of patients who are censored	4 (16.0)	22 (64.7)	9 (27.3)	9 (34.6)
Number of patients with event	21 (84.0)	12 (35.3)	24 (72.7)	17 (65.4)
Median time to first event (weeks) (95% CI) ^a	0.00 (0.00 to 20.29)	NE (14.00 to NE)	19.57 (0.00 to 40.00)	15.93 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.560 (0.348 ; 0.727)	0.265 (0.132 ; 0.418)	0.424 (0.256 ; 0.583)	0.385 (0.204 ; 0.563)
2 weeks	0.560 (0.348 ; 0.727)	0.265 (0.132 ; 0.418)	0.424 (0.256 ; 0.583)	0.385 (0.204 ; 0.563)
4 weeks	0.560 (0.348 ; 0.727)	0.265 (0.132 ; 0.418)	0.424 (0.256 ; 0.583)	0.385 (0.204 ; 0.563)
12 weeks	0.600 (0.384 ; 0.761)	0.265 (0.132 ; 0.418)	0.424 (0.256 ; 0.583)	0.462 (0.266 ; 0.636)
16 weeks	0.600 (0.384 ; 0.761)	0.357 (0.201 ; 0.515)	0.455 (0.282 ; 0.612)	0.577 (0.368 ; 0.739)
20 weeks	0.680 (0.461 ; 0.825)	0.357 (0.201 ; 0.515)	0.545 (0.363 ; 0.696)	0.615 (0.403 ; 0.771)
24 weeks	0.720 (0.501 ; 0.855)	0.357 (0.201 ; 0.515)	0.606 (0.420 ; 0.749)	0.615 (0.403 ; 0.771)
32 weeks	0.760 (0.542 ; 0.884)	0.357 (0.201 ; 0.515)	0.636 (0.449 ; 0.775)	0.654 (0.440 ; 0.803)
40 weeks	0.840 (0.628 ; 0.937)	0.357 (0.201 ; 0.515)	0.697 (0.510 ; 0.824)	0.654 (0.440 ; 0.803)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_age_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen


Time to First PMR Flare (days from randomization date)	Age			
	Age < 70 (N=59)		Age ≥ 70 (N=59)	
	Placebo (N=25)	Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Sarilumab 200mg q2w (N=26)
52 weeks	0.840 (0.628 ; 0.937)	0.357 (0.201 ; 0.515)	0.727 (0.541 ; 0.848)	0.654 (0.440 ; 0.803)
Unstratified Log-Rank test p-value ^a		0.0003		0.8208
Hazard Ratio (95% CI) ^b	-	0.34 (0.17 to 0.70)	-	0.94 (0.50 to 1.75)
p-value for Hazard Ratio ^b		0.0035		0.8443
Treatment-by-subgroup p-value of HR ^c				0.0298

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__age_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen



^aderived from Kaplan-Meier estimates.

^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.

^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_km_tte_subgroup_ger_i_f.sas OUT=REPORT/OUTPUT/eff_km_tte_ger_pmrttime_age_i_f_x.rtf (26JUL2024 11:28)

Weitere Analysen

Per baseline CRP

Time to First PMR Flare (days from randomization date)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Number of patients who are censored	5 (16.1)	14 (50.0)	8 (29.6)	17 (53.1)
Number of patients with event	26 (83.9)	14 (50.0)	19 (70.4)	15 (46.9)
Median time to first event (weeks) (95% CI) ^a	0.00 (0.00 to 24.00)	NE (13.14 to NE)	19.71 (0.00 to 44.14)	NE (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.516 (0.330 ; 0.674)	0.250 (0.111 ; 0.418)	0.444 (0.256 ; 0.617)	0.375 (0.213 ; 0.537)
2 weeks	0.516 (0.330 ; 0.674)	0.250 (0.111 ; 0.418)	0.444 (0.256 ; 0.617)	0.375 (0.213 ; 0.537)
4 weeks	0.516 (0.330 ; 0.674)	0.250 (0.111 ; 0.418)	0.444 (0.256 ; 0.617)	0.375 (0.213 ; 0.537)
12 weeks	0.548 (0.360 ; 0.703)	0.286 (0.135 ; 0.456)	0.444 (0.256 ; 0.617)	0.406 (0.238 ; 0.568)
16 weeks	0.581 (0.390 ; 0.731)	0.464 (0.276 ; 0.633)	0.444 (0.256 ; 0.617)	0.439 (0.265 ; 0.600)
20 weeks	0.613 (0.420 ; 0.758)	0.500 (0.306 ; 0.666)	0.593 (0.386 ; 0.750)	0.439 (0.265 ; 0.600)
24 weeks	0.677 (0.484 ; 0.812)	0.500 (0.306 ; 0.666)	0.630 (0.421 ; 0.781)	0.439 (0.265 ; 0.600)
32 weeks	0.742 (0.550 ; 0.862)	0.500 (0.306 ; 0.666)	0.630 (0.421 ; 0.781)	0.472 (0.293 ; 0.632)
40 weeks	0.839 (0.655 ; 0.929)	0.500 (0.306 ; 0.666)	0.667 (0.457 ; 0.811)	0.472 (0.293 ; 0.632)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__crp_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Baseline CRP			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
52 weeks	0.839 (0.655 ; 0.929)	0.500 (0.306 ; 0.666)	0.704 (0.494 ; 0.839)	0.472 (0.293 ; 0.632)
Unstratified Log-Rank test p-value ^a		0.0148		0.1201
Hazard Ratio (95% CI) ^b	-	0.49 (0.26 to 0.95)	-	0.64 (0.32 to 1.25)
p-value for Hazard Ratio ^b		0.0351		0.1921
Treatment-by-subgroup p-value of HR ^c				0.6627

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__crp_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Per baseline ESR

Time to First PMR Flare (days from randomization date)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Number of patients who are censored	5 (16.1)	16 (57.1)	8 (29.6)	15 (46.9)
Number of patients with event	26 (83.9)	12 (42.9)	19 (70.4)	17 (53.1)
Median time to first event (weeks) (95% CI) ^a	16.00 (0.00 to 24.71)	NE (13.14 to NE)	0.00 (0.00 to 40.00)	16.00 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.452 (0.274 ; 0.614)	0.250 (0.111 ; 0.418)	0.519 (0.319 ; 0.685)	0.375 (0.213 ; 0.537)
2 weeks	0.452 (0.274 ; 0.614)	0.250 (0.111 ; 0.418)	0.519 (0.319 ; 0.685)	0.375 (0.213 ; 0.537)
4 weeks	0.452 (0.274 ; 0.614)	0.250 (0.111 ; 0.418)	0.519 (0.319 ; 0.685)	0.375 (0.213 ; 0.537)
12 weeks	0.484 (0.302 ; 0.644)	0.286 (0.135 ; 0.456)	0.519 (0.319 ; 0.685)	0.406 (0.238 ; 0.568)
16 weeks	0.516 (0.330 ; 0.674)	0.393 (0.217 ; 0.565)	0.519 (0.319 ; 0.685)	0.505 (0.322 ; 0.663)
20 weeks	0.581 (0.390 ; 0.731)	0.429 (0.246 ; 0.600)	0.630 (0.421 ; 0.781)	0.505 (0.322 ; 0.663)
24 weeks	0.645 (0.452 ; 0.785)	0.429 (0.246 ; 0.600)	0.667 (0.457 ; 0.811)	0.505 (0.322 ; 0.663)
32 weeks	0.710 (0.516 ; 0.837)	0.429 (0.246 ; 0.600)	0.667 (0.457 ; 0.811)	0.538 (0.351 ; 0.693)
40 weeks	0.806 (0.619 ; 0.908)	0.429 (0.246 ; 0.600)	0.704 (0.494 ; 0.839)	0.538 (0.351 ; 0.693)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_esr_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Baseline ESR			
	<= median (N=59)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=28)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
52 weeks	0.839 (0.655 ; 0.929)	0.429 (0.246 ; 0.600)	0.704 (0.494 ; 0.839)	0.538 (0.351 ; 0.693)
Unstratified Log-Rank test p-value ^a		0.0045		0.2358
Hazard Ratio (95% CI) ^b	-	0.42 (0.21 to 0.83)	-	0.72 (0.37 to 1.39)
p-value for Hazard Ratio ^b		0.0134		0.3286
Treatment-by-subgroup p-value of HR ^c				0.3283

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrtime_ger__esr_i_t_x.rtf (03MAY2024 15:59)

Weitere Analysen

Per baseline CS dose

Time to First PMR Flare (days from randomization date)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
Number of patients who are censored	11 (32.4)	19 (63.3)	2 (8.3)	12 (40.0)
Number of patients with event	23 (67.6)	11 (36.7)	22 (91.7)	18 (60.0)
Median time to first event (weeks) (95% CI) ^a	24.93 (16.00 to 44.14)	NE (14.57 to NE)	0.00 (NE to NE)	14.93 (0.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.294 (0.154 ; 0.449)	0.200 (0.081 ; 0.356)	0.750 (0.526 ; 0.879)	0.433 (0.256 ; 0.599)
2 weeks	0.294 (0.154 ; 0.449)	0.200 (0.081 ; 0.356)	0.750 (0.526 ; 0.879)	0.433 (0.256 ; 0.599)
4 weeks	0.294 (0.154 ; 0.449)	0.200 (0.081 ; 0.356)	0.750 (0.526 ; 0.879)	0.433 (0.256 ; 0.599)
12 weeks	0.294 (0.154 ; 0.449)	0.233 (0.103 ; 0.394)	0.792 (0.570 ; 0.908)	0.467 (0.284 ; 0.630)
16 weeks	0.324 (0.176 ; 0.480)	0.303 (0.152 ; 0.470)	0.792 (0.570 ; 0.908)	0.600 (0.405 ; 0.750)
20 weeks	0.441 (0.273 ; 0.597)	0.338 (0.177 ; 0.506)	0.833 (0.615 ; 0.934)	0.600 (0.405 ; 0.750)
24 weeks	0.471 (0.298 ; 0.625)	0.338 (0.177 ; 0.506)	0.917 (0.706 ; 0.978)	0.600 (0.405 ; 0.750)
32 weeks	0.529 (0.351 ; 0.679)	0.373 (0.204 ; 0.542)	0.917 (0.706 ; 0.978)	0.600 (0.405 ; 0.750)
40 weeks	0.647 (0.463 ; 0.782)	0.373 (0.204 ; 0.542)	0.917 (0.706 ; 0.978)	0.600 (0.405 ; 0.750)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_cs_i_t_x.rtf (03MAY2024 16:00)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	Baseline CS dose			
	<= median (N=64)		> median (N=54)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=30)
52 weeks	0.676 (0.492 ; 0.806)	0.373 (0.204 ; 0.542)	0.917 (0.706 ; 0.978)	0.600 (0.405 ; 0.750)
Unstratified Log-Rank test p-value ^a		0.0407		0.0080
Hazard Ratio (95% CI) ^b	-	0.50 (0.24 to 1.03)	-	0.54 (0.29 to 1.02)
p-value for Hazard Ratio ^b		0.0592		0.0561
Treatment-by-subgroup p-value of HR ^c				0.9358

^aderived from Kaplan-Meier estimates.

^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.

^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_cs_i_t_x.rtf (03MAY2024 16:00)

Weitere Analysen

Per MTX Add-on Therapy

Time to First PMR Flare (days from randomization date)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
Number of patients who are censored	4 (23.5)	5 (41.7)	9 (22.0)	26 (54.2)
Number of patients with event	13 (76.5)	7 (58.3)	32 (78.0)	22 (45.8)
Median time to first event (weeks) (95% CI) ^a	0.00 (0.00 to 40.00)	2.71 (0.00 to NE)	16.29 (0.00 to 21.86)	NE (14.57 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.588 (0.325 ; 0.778)	0.500 (0.208 ; 0.736)	0.439 (0.286 ; 0.582)	0.271 (0.155 ; 0.400)
2 weeks	0.588 (0.325 ; 0.778)	0.500 (0.208 ; 0.736)	0.439 (0.286 ; 0.582)	0.271 (0.155 ; 0.400)
4 weeks	0.588 (0.325 ; 0.778)	0.500 (0.208 ; 0.736)	0.439 (0.286 ; 0.582)	0.271 (0.155 ; 0.400)
12 weeks	0.588 (0.325 ; 0.778)	0.583 (0.270 ; 0.801)	0.463 (0.307 ; 0.606)	0.292 (0.172 ; 0.423)
16 weeks	0.588 (0.325 ; 0.778)	0.583 (0.270 ; 0.801)	0.488 (0.329 ; 0.629)	0.417 (0.277 ; 0.550)
20 weeks	0.588 (0.325 ; 0.778)	0.583 (0.270 ; 0.801)	0.610 (0.444 ; 0.740)	0.438 (0.296 ; 0.571)
24 weeks	0.647 (0.377 ; 0.823)	0.583 (0.270 ; 0.801)	0.659 (0.493 ; 0.782)	0.438 (0.296 ; 0.571)
32 weeks	0.647 (0.377 ; 0.823)	0.583 (0.270 ; 0.801)	0.707 (0.543 ; 0.822)	0.458 (0.314 ; 0.591)
40 weeks	0.765 (0.488 ; 0.904)	0.583 (0.270 ; 0.801)	0.756 (0.594 ; 0.861)	0.458 (0.314 ; 0.591)

^aderived from Kaplan-Meier estimates.^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger_mtx_i_t_x.rtf (03MAY2024 16:00)

Weitere Analysen

Time to First PMR Flare (days from randomization date)	MTX Add-on Therapy			
	Yes (N=29)		No (N=89)	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=48)
52 weeks	0.765 (0.488 ; 0.904)	0.583 (0.270 ; 0.801)	0.780 (0.621 ; 0.879)	0.458 (0.314 ; 0.591)
Unstratified Log-Rank test p-value ^a		0.4381		0.0057
Hazard Ratio (95% CI) ^b	-	0.76 (0.30 to 1.91)	-	0.51 (0.30 to 0.88)
p-value for Hazard Ratio ^b		0.5591		0.0156
Treatment-by-subgroup p-value of HR ^c				0.4311

^aderived from Kaplan-Meier estimates.

^bderived using two Cox proportional hazard models for each subgroup modality, including treatment as covariate with two-sided p-value.

^cderived using a Cox proportional hazard model including treatment, subgroup and treatment-by-subgroup interaction as covariate.

Note: Time (days) is calculated from randomization to first PMR flare after clinical remission up to Week 52.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_time2event_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_tte_pmrttime_ger__mtx_i_t_x.rtf (03MAY2024 16:00)

Weitere Analysen

Per Number of relapses prior to screening

Time to First PMR Flare (days from randomization date)	Number of relapses prior to screening			
	1 relapse (N=47)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=24)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Number of patients who are censored	5 (21.7)	12 (50.0)	8 (22.9)	19 (52.8)
Number of patients with event	18 (78.3)	12 (50.0)	27 (77.1)	17 (47.2)
Median time to first event (weeks) (95% CI) ^a	0.00 (0.00 to 39.86)	NE (0.00 to NE)	16.29 (0.00 to 24.00)	NE (14.00 to NE)
Kaplan-Meier estimates for probability of a patient with event (95% CI) up to ^a				
0 weeks	0.522 (0.305 ; 0.700)	0.417 (0.222 ; 0.601)	0.457 (0.289 ; 0.610)	0.250 (0.124 ; 0.398)
2 weeks	0.522 (0.305 ; 0.700)	0.417 (0.222 ; 0.601)	0.457 (0.289 ; 0.610)	0.250 (0.124 ; 0.398)
4 weeks	0.522 (0.305 ; 0.700)	0.417 (0.222 ; 0.601)	0.457 (0.289 ; 0.610)	0.250 (0.124 ; 0.398)
12 weeks	0.565 (0.343 ; 0.738)	0.458 (0.256 ; 0.640)	0.457 (0.289 ; 0.610)	0.278 (0.145 ; 0.428)
16 weeks	0.565 (0.343 ; 0.738)	0.458 (0.256 ; 0.640)	0.486 (0.314 ; 0.637)	0.451 (0.284 ; 0.604)
20 weeks	0.609 (0.383 ; 0.774)	0.500 (0.291 ; 0.678)	0.600 (0.420 ; 0.740)	0.451 (0.284 ; 0.604)
24 weeks	0.652 (0.423 ; 0.808)	0.500 (0.291 ; 0.678)	0.657 (0.476 ; 0.789)	0.451 (0.284 ; 0.604)
32 weeks	0.652 (0.423 ; 0.808)	0.500 (0.291 ; 0.678)	0.714 (0.534 ; 0.835)	0.480 (0.310 ; 0.632)
40 weeks	0.739 (0.509 ; 0.873)	0.500 (0.291 ; 0.678)	0.771 (0.595 ; 0.879)	0.480 (0.310 ; 0.632)
52 weeks	0.783 (0.554 ; 0.903)	0.500 (0.291 ; 0.678)	0.771 (0.595 ; 0.879)	0.480 (0.310 ; 0.632)
Unstratified Log-Rank test p-value ^a		0.0738		0.0287
Hazard Ratio (95% CI) ^b	-	0.58 (0.28 to 1.22)	-	0.55 (0.30 to 1.01)
p-value for Hazard Ratio ^b		0.1506		0.0541
Treatment-by-subgroup p-value of HR ^c				0.9426

EFC15160_Germany_safety_subgroup_24JUL24 – Adverse Event Data

Weitere Analysen

1. Treatment emergent adverse events - Safety population

Any TEAE

Overall

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Any TEAE	Gender (Male , Female)	0.0001
	Region (Western Countries , Rest of World (including South America))	0.0001
	Age (Age < 70 , Age >= 70)	0.9397
	Baseline CRP (<= median , > median)	0.0001
	Baseline ESR (<= median , > median)	0.0001
	Baseline CS dose (<= median , > median)	0.2975
	MTX Add-on Therapy (Yes , No)	0.4718
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.7085

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Any TEAE [n (%)]				
Patients with any events	17 (81.0)	14 (100)	32 (86.5)	42 (93.3)
Odds Ratio (95% CI) vs Placebo ^a	-	498395.3 (0.00 to NE)	-	2.19 (0.48 to 10.07)
p-value for Odds Ratio ^a		0.9733		0.3106
Risk Ratio (95% CI) vs Placebo ^a	-	1.20 (NE to NE)	-	1.08 (0.93 to 1.26)
Reversed Risk ratio (95% CI)	-	0.83 (NE to NE)	-	0.93 (0.80 to 1.08)
p-value for Risk Ratio ^a		NE		0.3249
Risk Difference (95% CI) vs Placebo ^a	-	19.05 (NE to NE)	-	6.85 (-6.56 to 20.26)
p-value for Risk Difference ^a		<0.0001		0.3127
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_gender_gender_s_t_x.rtf (30APR2024 11:37)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Any TEAE [n (%)]				
Patients with any events	41 (93.2)	46 (100)	8 (57.1)	10 (76.9)
Odds Ratio (95% CI) vs Placebo ^a	-	421303.4 (0.00 to NE)	-	2.50 (0.43 to 14.44)
p-value for Odds Ratio ^a		0.9709		0.2921
Risk Ratio (95% CI) vs Placebo ^a	-	1.07 (NE to NE)	-	1.35 (0.76 to 2.38)
Reversed Risk ratio (95% CI)	-	0.93 (NE to NE)	-	0.74 (0.42 to 1.31)
p-value for Risk Ratio ^a		NE		0.3069
Risk Difference (95% CI) vs Placebo ^a	-	6.82 (NE to NE)	-	19.78 (-16.57 to 56.13)
p-value for Risk Difference ^a		<0.0001		0.2730
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_region_s_t_x.rtf (30APR2024 11:36)

Weitere Analysen

Per age

	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=58) Sarilumab 200mg q2w (N=25)
Any TEAE [n (%)]				
Patients with any events	21 (84.0)	32 (94.1)	28 (84.8)	24 (96.0)
Odds Ratio (95% CI) vs Placebo ^a	-	3.05 (0.49 to 18.87)	-	4.29 (0.45 to 41.24)
p-value for Odds Ratio ^a		0.2260		0.2032
Risk Ratio (95% CI) vs Placebo ^a	-	1.12 (0.92 to 1.36)	-	1.13 (0.96 to 1.34)
Reversed Risk ratio (95% CI)	-	0.89 (0.73 to 1.08)	-	0.88 (0.75 to 1.05)
p-value for Risk Ratio ^a		0.2523		0.1510
Risk Difference (95% CI) vs Placebo ^a	-	10.12 (-6.64 to 26.88)	-	11.15 (-3.61 to 25.92)
p-value for Risk Difference ^a		0.2317		0.1359
Treatment-by-subgroup p-value of RR ^b				0.9397

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_age_s_t_x.rtf (30APR2024 11:37)

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Any TEAE [n (%)]				
Patients with any events	26 (83.9)	27 (100)	23 (85.2)	29 (90.6)
Odds Ratio (95% CI) vs Placebo ^a	-	1107272 (0.00 to NE)	-	1.68 (0.33 to 8.57)
p-value for Odds Ratio ^a		0.9761		0.5255
Risk Ratio (95% CI) vs Placebo ^a	-	1.11 (NE to NE)	-	1.06 (0.87 to 1.30)
Reversed Risk ratio (95% CI)	-	0.90 (NE to NE)	-	0.94 (0.77 to 1.14)
p-value for Risk Ratio ^a		NE		0.5379
Risk Difference (95% CI) vs Placebo ^a	-	16.13 (NE to NE)	-	5.44 (-11.70 to 22.58)
p-value for Risk Difference ^a		<0.0001		0.5277
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_crp_s_t_x.rtf (30APR2024 11:38)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Any TEAE [n (%)]				
Patients with any events	30 (96.8)	27 (100)	19 (70.4)	29 (90.6)
Odds Ratio (95% CI) vs Placebo ^a	-	191927.1 (0.00 to NE)	-	4.07 (0.93 to 17.86)
p-value for Odds Ratio ^a		0.9791		0.0624
Risk Ratio (95% CI) vs Placebo ^a	-	1.03 (NE to NE)	-	1.29 (0.98 to 1.70)
Reversed Risk ratio (95% CI)	-	0.97 (NE to NE)	-	0.78 (0.59 to 1.02)
p-value for Risk Ratio ^a		NE		0.0712
Risk Difference (95% CI) vs Placebo ^a	-	3.23 (NE to NE)	-	20.25 (-0.14 to 40.65)
p-value for Risk Difference ^a		<0.0001		0.0516
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_esr_s_t_x.rtf (30APR2024 11:38)

Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=53)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=29)
Any TEAE [n (%)]				
Patients with any events	30 (88.2)	28 (93.3)	19 (79.2)	28 (96.6)
Odds Ratio (95% CI) vs Placebo ^a	-	1.87 (0.31 to 11.40)	-	7.37 (0.75 to 71.95)
p-value for Odds Ratio ^a		0.4930		0.0845
Risk Ratio (95% CI) vs Placebo ^a	-	1.06 (0.90 to 1.24)	-	1.22 (0.98 to 1.52)
Reversed Risk ratio (95% CI)	-	0.95 (0.81 to 1.11)	-	0.82 (0.66 to 1.02)
p-value for Risk Ratio ^a		0.4878		0.0793
Risk Difference (95% CI) vs Placebo ^a	-	5.10 (-9.22 to 19.41)	-	17.39 (-0.59 to 35.36)
p-value for Risk Difference ^a		0.4792		0.0578
Treatment-by-subgroup p-value of RR ^b				0.2975

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_cs_s_t_x.rtf (30APR2024 11:38)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Any TEAE [n (%)]				
Patients with any events	15 (88.2)	11 (91.7)	34 (82.9)	45 (95.7)
Odds Ratio (95% CI) vs Placebo ^a	-	1.47 (0.10 to 20.59)	-	4.63 (0.88 to 24.28)
p-value for Odds Ratio ^a		0.7684		0.0693
Risk Ratio (95% CI) vs Placebo ^a	-	1.04 (0.81 to 1.34)	-	1.15 (0.99 to 1.35)
Reversed Risk ratio (95% CI)	-	0.96 (0.75 to 1.24)	-	0.87 (0.74 to 1.01)
p-value for Risk Ratio ^a		0.7691		0.0666
Risk Difference (95% CI) vs Placebo ^a	-	3.43 (-19.48 to 26.35)	-	12.82 (-0.25 to 25.88)
p-value for Risk Difference ^a		0.7610		0.0544
Treatment-by-subgroup p-value of RR ^b				0.4718

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_mtx_s_t_x.rtf (30APR2024 11:38)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Any TEAE [n (%)]				
Patients with any events	19 (82.6)	22 (95.7)	30 (85.7)	34 (94.4)
Odds Ratio (95% CI) vs Placebo ^a	-	4.63 (0.45 to 48.08)	-	2.83 (0.50 to 16.18)
p-value for Odds Ratio ^a		0.1936		0.2372
Risk Ratio (95% CI) vs Placebo ^a	-	1.16 (0.94 to 1.43)	-	1.10 (0.94 to 1.29)
Reversed Risk ratio (95% CI)	-	0.86 (0.70 to 1.07)	-	0.91 (0.77 to 1.06)
p-value for Risk Ratio ^a		0.1765		0.2334
Risk Difference (95% CI) vs Placebo ^a	-	13.04 (-5.04 to 31.13)	-	8.73 (-5.31 to 22.77)
p-value for Risk Difference ^a		0.1532		0.2191
Treatment-by-subgroup p-value of RR ^b				0.7085

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teae_ger_nrp_s_t_x.rtf (30APR2024 11:39)

Weitere Analysen

Any mild/moderate TEAE*Overall*

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Any mild/moderate TEAE	Gender (Male , Female)	0.0001
	Region (Western Countries , Rest of World (including South America))	0.0001
	Age (Age < 70 , Age >= 70)	0.5395
	Baseline CRP (<= median , > median)	0.0001
	Baseline ESR (<= median , > median)	0.0001
	Baseline CS dose (<= median , > median)	0.2817
	MTX Add-on Therapy (Yes , No)	0.2778
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.8910

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Any mild/moderate TEAE [n (%)]				
Patients with any events	17 (81.0)	14 (100)	30 (81.1)	42 (93.3)
Odds Ratio (95% CI) vs Placebo ^a	-	498395.3 (0.00 to NE)	-	3.27 (0.76 to 13.97)
p-value for Odds Ratio ^a		0.9733		0.1090
Risk Ratio (95% CI) vs Placebo ^a	-	1.20 (NE to NE)	-	1.15 (0.96 to 1.37)
Reversed Risk ratio (95% CI)	-	0.83 (NE to NE)	-	0.87 (0.73 to 1.04)
p-value for Risk Ratio ^a		NE		0.1188
Risk Difference (95% CI) vs Placebo ^a	-	19.05 (NE to NE)	-	12.25 (-2.54 to 27.05)
p-value for Risk Difference ^a		<0.0001		0.1033
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_gender_s_t_x.rtf (30APR2024 11:39)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Any mild/moderate TEAE [n (%)]				
Patients with any events	40 (90.9)	46 (100)	7 (50.0)	10 (76.9)
Odds Ratio (95% CI) vs Placebo ^a	-	575781.3 (0.00 to NE)	-	3.33 (0.58 to 19.11)
p-value for Odds Ratio ^a		0.9702		0.1680
Risk Ratio (95% CI) vs Placebo ^a	-	1.10 (NE to NE)	-	1.54 (0.82 to 2.90)
Reversed Risk ratio (95% CI)	-	0.91 (NE to NE)	-	0.65 (0.35 to 1.22)
p-value for Risk Ratio ^a		NE		0.1823
Risk Difference (95% CI) vs Placebo ^a	-	9.09 (NE to NE)	-	26.92 (-9.64 to 63.48)
p-value for Risk Difference ^a		<0.0001		0.1419
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_region_s_t_x.rtf (30APR2024 11:37)

Weitere Analysen

Per age

	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=58) Sarilumab 200mg q2w (N=25)
Any mild/moderate TEAE [n (%)]				
Patients with any events	19 (76.0)	32 (94.1)	28 (84.8)	24 (96.0)
Odds Ratio (95% CI) vs Placebo ^a	-	5.05 (0.89 to 28.64)	-	4.29 (0.45 to 41.24)
p-value for Odds Ratio ^a		0.0666		0.2032
Risk Ratio (95% CI) vs Placebo ^a	-	1.24 (0.97 to 1.58)	-	1.13 (0.96 to 1.34)
Reversed Risk ratio (95% CI)	-	0.81 (0.63 to 1.03)	-	0.88 (0.75 to 1.05)
p-value for Risk Ratio ^a		0.0819		0.1510
Risk Difference (95% CI) vs Placebo ^a	-	18.12 (-0.80 to 37.03)	-	11.15 (-3.61 to 25.92)
p-value for Risk Difference ^a		0.0601		0.1359
Treatment-by-subgroup p-value of RR ^b				0.5395

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_age_s_t_x.rtf (30APR2024 11:39)

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Any mild/moderate TEAE [n (%)]				
Patients with any events	25 (80.6)	27 (100)	22 (81.5)	29 (90.6)
Odds Ratio (95% CI) vs Placebo ^a	-	1381875 (0.00 to NE)	-	2.20 (0.46 to 10.54)
p-value for Odds Ratio ^a		0.9757		0.3191
Risk Ratio (95% CI) vs Placebo ^a	-	1.19 (NE to NE)	-	1.11 (0.90 to 1.38)
Reversed Risk ratio (95% CI)	-	0.84 (NE to NE)	-	0.90 (0.72 to 1.12)
p-value for Risk Ratio ^a		NE		0.3348
Risk Difference (95% CI) vs Placebo ^a	-	19.35 (NE to NE)	-	9.14 (-9.04 to 27.32)
p-value for Risk Difference ^a		<0.0001		0.3182
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger__crp_s_t_x.rtf (30APR2024 11:40)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Any mild/moderate TEAE [n (%)]				
Patients with any events	29 (93.5)	27 (100)	18 (66.7)	29 (90.6)
Odds Ratio (95% CI) vs Placebo ^a	-	397090.5 (0.00 to NE)	-	4.83 (1.12 to 20.89)
p-value for Odds Ratio ^a		0.9778		0.0354
Risk Ratio (95% CI) vs Placebo ^a	-	1.05 (NE to NE)	-	1.36 (1.01 to 1.83)
Reversed Risk ratio (95% CI)	-	0.95 (NE to NE)	-	0.74 (0.55 to 0.99)
p-value for Risk Ratio ^a		NE		0.0416
Risk Difference (95% CI) vs Placebo ^a	-	6.45 (NE to NE)	-	23.96 (3.07 to 44.85)
p-value for Risk Difference ^a		<0.0001		0.0254
Treatment-by-subgroup p-value of RR ^b				<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_esr_s_t_x.rtf (30APR2024 11:40)

Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=53)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=29)
Any mild/moderate TEAE [n (%)]				
Patients with any events	29 (85.3)	28 (93.3)	18 (75.0)	28 (96.6)
Odds Ratio (95% CI) vs Placebo ^a	-	2.41 (0.42 to 13.95)	-	9.33 (0.98 to 88.70)
p-value for Odds Ratio ^a		0.3192		0.0518
Risk Ratio (95% CI) vs Placebo ^a	-	1.09 (0.92 to 1.30)	-	1.29 (1.01 to 1.65)
Reversed Risk ratio (95% CI)	-	0.91 (0.77 to 1.09)	-	0.78 (0.61 to 0.99)
p-value for Risk Ratio ^a		0.3063		0.0449
Risk Difference (95% CI) vs Placebo ^a	-	8.04 (-7.14 to 23.21)	-	21.55 (2.55 to 40.56)
p-value for Risk Difference ^a		0.2937		0.0270
Treatment-by-subgroup p-value of RR ^b				0.2817

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_cs_s_t_x.rtf (30APR2024 11:40)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Any mild/moderate TEAE [n (%)]				
Patients with any events	15 (88.2)	11 (91.7)	32 (78.0)	45 (95.7)
Odds Ratio (95% CI) vs Placebo ^a	-	1.47 (0.10 to 20.59)	-	6.33 (1.25 to 32.00)
p-value for Odds Ratio ^a		0.7684		0.0261
Risk Ratio (95% CI) vs Placebo ^a	-	1.04 (0.81 to 1.34)	-	1.23 (1.03 to 1.46)
Reversed Risk ratio (95% CI)	-	0.96 (0.75 to 1.24)	-	0.82 (0.68 to 0.97)
p-value for Risk Ratio ^a		0.7691		0.0226
Risk Difference (95% CI) vs Placebo ^a	-	3.43 (-19.48 to 26.35)	-	17.70 (3.58 to 31.82)
p-value for Risk Difference ^a		0.7610		0.0146
Treatment-by-subgroup p-value of RR ^b				0.2778

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_mtx_s_t_x.rtf (30APR2024 11:41)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Any mild/moderate TEAE [n (%)]				
Patients with any events	19 (82.6)	22 (95.7)	28 (80.0)	34 (94.4)
Odds Ratio (95% CI) vs Placebo ^a	-	4.63 (0.45 to 48.08)	-	4.25 (0.79 to 22.77)
p-value for Odds Ratio ^a		0.1936		0.0900
Risk Ratio (95% CI) vs Placebo ^a	-	1.16 (0.94 to 1.43)	-	1.18 (0.98 to 1.42)
Reversed Risk ratio (95% CI)	-	0.86 (0.70 to 1.07)	-	0.85 (0.70 to 1.02)
p-value for Risk Ratio ^a		0.1765		0.0817
Risk Difference (95% CI) vs Placebo ^a	-	13.04 (-5.04 to 31.13)	-	14.44 (-1.05 to 29.93)
p-value for Risk Difference ^a		0.1532		0.0671
Treatment-by-subgroup p-value of RR ^b				0.8910

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_teaeg12_ger_nrp_s_t_x.rtf (30APR2024 11:41)

Weitere Analysen

Any Serious TEAE

Overall

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Any serious TEAE	Region (Western Countries , Rest of World (including South America))	0.9739
	Baseline ESR (<= median , > median)	0.0258

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Any serious TEAE [n (%)]				
Patients with any events	10 (32.3)	2 (7.4)	2 (7.4)	6 (18.8)
Odds Ratio (95% CI) vs Placebo ^a	-	0.17 (0.03 to 0.88)	-	2.88 (0.51 to 16.25)
p-value for Odds Ratio ^a		0.0358		0.2248
Risk Ratio (95% CI) vs Placebo ^a	-	0.23 (0.05 to 0.99)	-	2.53 (0.54 to 11.91)
Reversed Risk ratio (95% CI)			-	0.40 (0.08 to 1.86)
p-value for Risk Ratio ^a		0.0482		0.2399
Risk Difference (95% CI) vs Placebo ^a	-	-24.85 (-44.47 to -5.23)	-	11.34 (-5.77 to 28.45)
p-value for Risk Difference ^a		0.0140		0.1896
Treatment-by-subgroup p-value of RR ^b				0.0258

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_tesae_ger_esr_s_t_x.rtf (30APR2024 15:03)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Any serious TEAE [n (%)]				
Patients with any events	11 (25.0)	8 (17.4)	1 (7.1)	0
Odds Ratio (95% CI) vs Placebo ^a	-	0.63 (0.22 to 1.78)	-	0.00 (0.00 to NE)
p-value for Odds Ratio ^a		0.3811		0.9765
Peto Odds Ratio (95% CI) vs Placebo ^a			-	0.15 (0.00 to 7.35)
p-value for Peto Odds Ratio				0.3352
Risk Ratio (95% CI) vs Placebo ^a	-	0.70 (0.31 to 1.58)	-	0.36 (0.02 to 8.06)
p-value for Risk Ratio ^a		0.3874		0.5173
Risk Difference (95% CI) vs Placebo ^a	-	-7.61 (-24.69 to 9.47)	-	-7.14 (NE to NE)
p-value for Risk Difference ^a		0.3783		<0.0001
Treatment-by-subgroup p-value of RR ^b				0.9739

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_tesae_ger_region_s_t_x.rtf (30APR2024 15:04)

Weitere Analysen

2. Treatment emergent adverse events by SOC/PT - Safety population

Any TEAE - SOC = Blood and lymphatic system disorders - Safety population

Overall

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Blood and lymphatic system disorders	Gender (Male , Female)	0.9961
	Region (Western Countries , Rest of World (including South America))	0.9712
	Baseline ESR (<= median , > median)	0.1389
	MTX Add-on Therapy (Yes , No)	0.9782
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.1741

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	2 (9.5)	4 (28.6)	3 (8.1)	11 (24.4)
Odds Ratio (95% CI) vs Placebo ^a	-	3.80 (0.55 to 26.26)	-	3.67 (0.92 to 14.62)
p-value for Odds Ratio ^a		0.1693		0.0652
Risk Ratio (95% CI) vs Placebo ^a	-	3.00 (0.60 to 15.10)	-	3.01 (0.89 to 10.20)
Reversed Risk ratio (95% CI)	-	0.33 (0.07 to 1.68)	-	0.33 (0.10 to 1.12)
p-value for Risk Ratio ^a		0.1827		0.0759
Risk Difference (95% CI) vs Placebo ^a	-	19.05 (-8.76 to 46.85)	-	16.34 (0.77 to 31.90)
p-value for Risk Difference ^a		0.1727		0.0399
Treatment-by-subgroup p-value of RR ^b				0.9961

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger_gender_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	5 (11.4)	12 (26.1)	0	3 (23.1)
Odds Ratio (95% CI) vs Placebo ^a	-	2.75 (0.87 to 8.75)	-	635454.0 (0.00 to NE)
p-value for Odds Ratio ^a		0.0852		0.9729
Peto Odds Ratio (95% CI) vs Placebo ^a			-	9.49 (0.90 to 100.20)
Reversed Peto Odds Ratio (95% CI)			-	0.11 (0.01 to 1.11)
p-value for Peto Odds Ratio				0.0614
Risk Ratio (95% CI) vs Placebo ^a	-	2.30 (0.87 to 6.06)	-	7.50 (0.42 to 132.58)
Reversed Risk ratio (95% CI)	-	0.44 (0.16 to 1.15)	-	0.13 (0.01 to 2.36)
p-value for Risk Ratio ^a		0.0935		0.1692
Risk Difference (95% CI) vs Placebo ^a	-	14.72 (-1.28 to 30.72)	-	23.08 (NE to NE)
p-value for Risk Difference ^a		0.0708		<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger__region_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Treatment-by-subgroup p-value of RR ^b				0.9712

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger_region_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	4 (12.9)	5 (18.5)	1 (3.7)	10 (31.3)
Odds Ratio (95% CI) vs Placebo ^a	-	1.53 (0.36 to 6.62)	-	11.82 (1.34 to 104.43)
p-value for Odds Ratio ^a		0.5599		0.0270
Risk Ratio (95% CI) vs Placebo ^a	-	1.44 (0.42 to 4.94)	-	8.44 (1.10 to 64.50)
Reversed Risk ratio (95% CI)	-	0.70 (0.20 to 2.40)	-	0.12 (0.02 to 0.91)
p-value for Risk Ratio ^a		0.5667		0.0399
Risk Difference (95% CI) vs Placebo ^a	-	5.62 (-13.61 to 24.84)	-	27.55 (9.60 to 45.50)
p-value for Risk Difference ^a		0.5609		0.0032
Treatment-by-subgroup p-value of RR ^b				0.1389

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger_esr_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	0	4 (33.3)	5 (12.2)	11 (23.4)
Odds Ratio (95% CI) vs Placebo ^a	-	1059090 (0.00 to NE)	-	2.20 (0.68 to 7.09)
p-value for Odds Ratio ^a		0.9689		0.1839
Peto Odds Ratio (95% CI) vs Placebo ^a	-	14.98 (1.82 to 123.03)		
Reversed Peto Odds Ratio (95% CI)	-	0.07 (0.01 to 0.55)		
p-value for Peto Odds Ratio		0.0118		
Risk Ratio (95% CI) vs Placebo ^a	-	12.46 (0.73 to 211.87)	-	1.92 (0.72 to 5.14)
Reversed Risk ratio (95% CI)	-	0.08 (0.00 to 1.36)	-	0.52 (0.19 to 1.39)
p-value for Risk Ratio ^a		0.0810		0.1943
Risk Difference (95% CI) vs Placebo ^a	-	33.33 (NE to NE)	-	11.21 (-4.73 to 27.14)
p-value for Risk Difference ^a		<0.0001		0.1656

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_tae_ger_mtx_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

	MTX Add-on Therapy			
	Yes		No	
	Placebo	Sarilumab 200mg q2w	Placebo	Sarilumab 200mg q2w
	(N=17)	(N=12)	(N=41)	(N=47)
Treatment-by-subgroup p-value of RR ^b				0.9782

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger_mtx_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	3 (13.0)	4 (17.4)	2 (5.7)	11 (30.6)
Odds Ratio (95% CI) vs Placebo ^a	-	1.40 (0.26 to 7.45)	-	7.26 (1.43 to 36.77)
p-value for Odds Ratio ^a		0.6843		0.0174
Risk Ratio (95% CI) vs Placebo ^a	-	1.33 (0.32 to 5.52)	-	5.35 (1.24 to 22.99)
Reversed Risk ratio (95% CI)	-	0.75 (0.18 to 3.10)	-	0.19 (0.04 to 0.80)
p-value for Risk Ratio ^a		0.6913		0.0243
Risk Difference (95% CI) vs Placebo ^a	-	4.35 (-16.96 to 25.66)	-	24.84 (7.64 to 42.04)
p-value for Risk Difference ^a		0.6829		0.0053
Treatment-by-subgroup p-value of RR ^b				0.1741

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teae_ger_nrp_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Any TEAE - SOC = Gastrointestinal disorders - Safety population*Overall*

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Gastrointestinal disorders	Gender (Male , Female)	0.2586
	Age (Age < 70 , Age >= 70)	0.7856
	Region (Western Countries , Rest of World (including South America))	0.9718
	Baseline CRP (<= median , > median)	0.3626
	Baseline ESR (<= median , > median)	0.7907
	Baseline CS dose (<= median , > median)	0.9950
	MTX Add-on Therapy (Yes , No)	0.4855
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2494

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Gastrointestinal disorders [n (%)]				
Patients with any events	6 (28.6)	6 (42.9)	5 (13.5)	19 (42.2)
Odds Ratio (95% CI) vs Placebo ^a	-	1.87 (0.43 to 8.19)	-	4.68 (1.51 to 14.48)
p-value for Odds Ratio ^a		0.3919		0.0081
Risk Ratio (95% CI) vs Placebo ^a	-	1.50 (0.58 to 3.85)	-	3.12 (1.27 to 7.67)
Reversed Risk ratio (95% CI)	-	0.67 (0.26 to 1.71)	-	0.32 (0.13 to 0.79)
p-value for Risk Ratio ^a		0.3988		0.0128
Risk Difference (95% CI) vs Placebo ^a	-	14.29 (-19.28 to 47.85)	-	28.71 (10.28 to 47.14)
p-value for Risk Difference ^a		0.3927		0.0027
Treatment-by-subgroup p-value of RR ^b				0.2586

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_gender_s_t_x.rtf (24JUL2024 16:49)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Gastrointestinal disorders [n (%)]				
Patients with any events	11 (25.0)	23 (50.0)	0	2 (15.4)
Odds Ratio (95% CI) vs Placebo ^a	-	3.00 (1.21 to 7.43)	-	385123.6 (0.00 to NE)
p-value for Odds Ratio ^a		0.0181		0.9739
Peto Odds Ratio (95% CI) vs Placebo ^a			-	8.67 (0.51 to 146.74)
Reversed Peto Odds Ratio (95% CI)			-	0.12 (0.01 to 1.96)
p-value for Peto Odds Ratio				0.1345
Risk Ratio (95% CI) vs Placebo ^a	-	2.00 (1.10 to 3.63)	-	5.36 (0.28 to 102.12)
Reversed Risk ratio (95% CI)	-	0.50 (0.28 to 0.91)	-	0.19 (0.01 to 3.56)
p-value for Risk Ratio ^a		0.0226		0.2644
Risk Difference (95% CI) vs Placebo ^a	-	25.00 (5.43 to 44.57)	-	15.38 (NE to NE)
p-value for Risk Difference ^a		0.0129		<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger__region_s_t_x.rtf (24JUL2024 16:49)

Weitere Analysen

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Treatment-by-subgroup p-value of RR ^b				0.9718

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_region_s_t_x.rtf (24JUL2024 16:49)

Weitere Analysen

Per age

	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=58) Sarilumab 200mg q2w (N=25)
Gastrointestinal disorders [n (%)]				
Patients with any events	5 (20.0)	16 (47.1)	6 (18.2)	9 (36.0)
Odds Ratio (95% CI) vs Placebo ^a	-	3.56 (1.06 to 11.98)	-	2.53 (0.74 to 8.66)
p-value for Odds Ratio ^a		0.0410		0.1362
Risk Ratio (95% CI) vs Placebo ^a	-	2.35 (0.98 to 5.67)	-	1.98 (0.80 to 4.93)
Reversed Risk ratio (95% CI)	-	0.42 (0.18 to 1.02)	-	0.51 (0.20 to 1.26)
p-value for Risk Ratio ^a		0.0567		0.1423
Risk Difference (95% CI) vs Placebo ^a	-	27.06 (3.60 to 50.52)	-	17.82 (-5.65 to 41.29)
p-value for Risk Difference ^a		0.0246		0.1339
Treatment-by-subgroup p-value of RR ^b				0.7856

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_age_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Gastrointestinal disorders [n (%)]				
Patients with any events	5 (16.1)	13 (48.1)	6 (22.2)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a	-	4.83 (1.39 to 16.78)	-	2.10 (0.64 to 6.84)
p-value for Odds Ratio ^a		0.0142		0.2134
Risk Ratio (95% CI) vs Placebo ^a	-	2.99 (1.20 to 7.44)	-	1.69 (0.72 to 3.96)
Reversed Risk ratio (95% CI)	-	0.33 (0.13 to 0.83)	-	0.59 (0.25 to 1.39)
p-value for Risk Ratio ^a		0.0189		0.2296
Risk Difference (95% CI) vs Placebo ^a	-	32.02 (8.65 to 55.39)	-	15.28 (-8.18 to 38.74)
p-value for Risk Difference ^a		0.0081		0.1975
Treatment-by-subgroup p-value of RR ^b				0.3626

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger__crp_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Gastrointestinal disorders [n (%)]				
Patients with any events	7 (22.6)	13 (48.1)	4 (14.8)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a	-	3.18 (1.00 to 10.11)	-	3.45 (0.93 to 12.76)
p-value for Odds Ratio ^a		0.0496		0.0631
Risk Ratio (95% CI) vs Placebo ^a	-	2.13 (0.98 to 4.64)	-	2.53 (0.90 to 7.10)
Reversed Risk ratio (95% CI)	-	0.47 (0.22 to 1.02)	-	0.40 (0.14 to 1.11)
p-value for Risk Ratio ^a		0.0562		0.0774
Risk Difference (95% CI) vs Placebo ^a	-	25.57 (1.13 to 50.01)	-	22.69 (0.75 to 44.62)
p-value for Risk Difference ^a		0.0407		0.0429
Treatment-by-subgroup p-value of RR ^b				0.7907

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_esr_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=53)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=29)
Gastrointestinal disorders [n (%)]				
Patients with any events	7 (20.6)	14 (46.7)	4 (16.7)	11 (37.9)
Odds Ratio (95% CI) vs Placebo ^a	-	3.37 (1.10 to 10.34)	-	3.06 (0.80 to 11.69)
p-value for Odds Ratio ^a		0.0337		0.1007
Risk Ratio (95% CI) vs Placebo ^a	-	2.27 (1.04 to 4.94)	-	2.28 (0.81 to 6.39)
Reversed Risk ratio (95% CI)	-	0.44 (0.20 to 0.96)	-	0.44 (0.16 to 1.23)
p-value for Risk Ratio ^a		0.0393		0.1187
Risk Difference (95% CI) vs Placebo ^a	-	26.08 (3.19 to 48.96)	-	21.26 (-2.41 to 44.94)
p-value for Risk Difference ^a		0.0262		0.0773
Treatment-by-subgroup p-value of RR ^b				0.9950

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_cs_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Gastrointestinal disorders [n (%)]				
Patients with any events	1 (5.9)	3 (25.0)	10 (24.4)	22 (46.8)
Odds Ratio (95% CI) vs Placebo ^a	-	5.33 (0.43 to 66.20)	-	2.73 (1.08 to 6.90)
p-value for Odds Ratio ^a		0.1839		0.0343
Risk Ratio (95% CI) vs Placebo ^a	-	4.25 (0.45 to 39.90)	-	1.92 (1.02 to 3.60)
Reversed Risk ratio (95% CI)	-	0.24 (0.03 to 2.21)	-	0.52 (0.28 to 0.98)
p-value for Risk Ratio ^a		0.2054		0.0419
Risk Difference (95% CI) vs Placebo ^a	-	19.12 (-9.08 to 47.31)	-	22.42 (2.74 to 42.09)
p-value for Risk Difference ^a		0.1755		0.0260
Treatment-by-subgroup p-value of RR ^b				0.4855

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_mtx_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Gastrointestinal disorders [n (%)]				
Patients with any events	6 (26.1)	9 (39.1)	5 (14.3)	16 (44.4)
Odds Ratio (95% CI) vs Placebo ^a	-	1.82 (0.50 to 6.60)	-	4.80 (1.49 to 15.51)
p-value for Odds Ratio ^a		0.3530		0.0095
Risk Ratio (95% CI) vs Placebo ^a	-	1.50 (0.62 to 3.62)	-	3.11 (1.26 to 7.70)
Reversed Risk ratio (95% CI)	-	0.67 (0.28 to 1.61)	-	0.32 (0.13 to 0.80)
p-value for Risk Ratio ^a		0.3667		0.0141
Risk Difference (95% CI) vs Placebo ^a	-	13.04 (-14.55 to 40.63)	-	30.16 (9.86 to 50.46)
p-value for Risk Difference ^a		0.3459		0.0042
Treatment-by-subgroup p-value of RR ^b				0.2494

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teae_ger_nrp_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Any mild/moderate TEAE - SOC = Blood and lymphatic system disorders - Safety population

Overall

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Blood and lymphatic system disorders	Gender (Male , Female)	0.9287
	Region (Western Countries , Rest of World (including South America))	0.9710
	MTX Add-on Therapy (Yes , No)	0.9787
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2072

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	2 (9.5)	4 (28.6)	3 (8.1)	10 (22.2)
Odds Ratio (95% CI) vs Placebo ^a	-	3.80 (0.55 to 26.26)	-	3.24 (0.80 to 13.06)
p-value for Odds Ratio ^a		0.1693		0.0976
Risk Ratio (95% CI) vs Placebo ^a	-	3.00 (0.60 to 15.10)	-	2.74 (0.80 to 9.41)
Reversed Risk ratio (95% CI)	-	0.33 (0.07 to 1.68)	-	0.36 (0.11 to 1.25)
p-value for Risk Ratio ^a		0.1827		0.1091
Risk Difference (95% CI) vs Placebo ^a	-	19.05 (-8.76 to 46.85)	-	14.11 (-1.11 to 29.34)
p-value for Risk Difference ^a		0.1727		0.0688
Treatment-by-subgroup p-value of RR ^b				0.9287

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teaeg12_ger__gender_s_t_x.rtf (24JUL2024 16:48)

Weitere Analysen

Per region

	Region		Region	
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	5 (11.4)	11 (23.9)	0	3 (23.1)
Odds Ratio (95% CI) vs Placebo ^a	-	2.45 (0.76 to 7.88)	-	635454.0 (0.00 to NE)
p-value for Odds Ratio ^a		0.1305		0.9729
Peto Odds Ratio (95% CI) vs Placebo ^a			-	9.49 (0.90 to 100.20)
Reversed Peto Odds Ratio (95% CI)			-	0.11 (0.01 to 1.11)
p-value for Peto Odds Ratio				0.0614
Risk Ratio (95% CI) vs Placebo ^a	-	2.10 (0.78 to 5.64)	-	7.50 (0.42 to 132.58)
Reversed Risk ratio (95% CI)	-	0.48 (0.18 to 1.27)	-	0.13 (0.01 to 2.36)
p-value for Risk Ratio ^a		0.1394		0.1692
Risk Difference (95% CI) vs Placebo ^a	-	12.55 (-3.15 to 28.25)	-	23.08 (NE to NE)
p-value for Risk Difference ^a		0.1159		<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teag12_ger__region_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Treatment-by-subgroup p-value of RR ^b				0.9710

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).
Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.
^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.
PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teaeg12_ger__region_s_t_x.rtf (24JUL2024 16:47)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	0	3 (25.0)	5 (12.2)	11 (23.4)
Odds Ratio (95% CI) vs Placebo ^a	-	706060.0 (0.00 to NE)	-	2.20 (0.68 to 7.09)
p-value for Odds Ratio ^a		0.9698		0.1839
Peto Odds Ratio (95% CI) vs Placebo ^a	-	13.50 (1.24 to 146.48)		
Reversed Peto Odds Ratio (95% CI)	-	0.07 (0.01 to 0.81)		
p-value for Peto Odds Ratio		0.0324		
Risk Ratio (95% CI) vs Placebo ^a	-	9.69 (0.55 to 171.98)	-	1.92 (0.72 to 5.14)
Reversed Risk ratio (95% CI)	-	0.10 (0.01 to 1.83)	-	0.52 (0.19 to 1.39)
p-value for Risk Ratio ^a		0.1217		0.1943
Risk Difference (95% CI) vs Placebo ^a	-	25.00 (NE to NE)	-	11.21 (-4.73 to 27.14)
p-value for Risk Difference ^a		<0.0001		0.1656

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_taeag12_ger_mtx_s_t_x.rtf (24JUL2024 16:48)

Weitere Analysen

	MTX Add-on Therapy			
	Yes		No	
	Placebo (N=17)	Sarilumab 200mg q2w (N=12)	Placebo (N=41)	Sarilumab 200mg q2w (N=47)
Treatment-by-subgroup p-value of RR ^b				0.9787

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_teag12_ger__mtx_s_t_x.rtf (24JUL2024 16:48)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Blood and lymphatic system disorders [n (%)]				
Patients with any events	3 (13.0)	4 (17.4)	2 (5.7)	10 (27.8)
Odds Ratio (95% CI) vs Placebo ^a	-	1.40 (0.26 to 7.45)	-	6.35 (1.24 to 32.44)
p-value for Odds Ratio ^a		0.6843		0.0270
Risk Ratio (95% CI) vs Placebo ^a	-	1.33 (0.32 to 5.52)	-	4.86 (1.12 to 21.16)
Reversed Risk ratio (95% CI)	-	0.75 (0.18 to 3.10)	-	0.21 (0.05 to 0.90)
p-value for Risk Ratio ^a		0.6913		0.0351
Risk Difference (95% CI) vs Placebo ^a	-	4.35 (-16.96 to 25.66)	-	22.06 (5.24 to 38.89)
p-value for Risk Difference ^a		0.6829		0.0109
Treatment-by-subgroup p-value of RR ^b				0.2072

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc1_taeag12_ger__npr_s_t_x.rtf (24JUL2024 16:48)

Weitere Analysen

Any mild/moderate TEAE - SOC = Gastrointestinal disorders - Safety population*Overall*

Safety endpoint	Subgroup	Overall treatment-by-subgroup p-value of HR
Gastrointestinal disorders	Gender (Male , Female)	0.2586
	Age (Age < 70 , Age >= 70)	0.7856
	Region (Western Countries , Rest of World (including South America))	0.9718
	Baseline CRP (<= median , > median)	0.3626
	Baseline ESR (<= median , > median)	0.7907
	Baseline CS dose (<= median , > median)	0.9950
	MTX Add-on Therapy (Yes , No)	0.4855
	Number of relapses prior to screening (1 relapse , > 1 relapse)	0.2494

Weitere Analysen

Per gender

	Gender			
	Male (N=35)		Female (N=82)	
	Placebo (N=21)	Sarilumab 200mg q2w (N=14)	Placebo (N=37)	Sarilumab 200mg q2w (N=45)
Gastrointestinal disorders [n (%)]				
Patients with any events	6 (28.6)	6 (42.9)	5 (13.5)	19 (42.2)
Odds Ratio (95% CI) vs Placebo ^a	-	1.87 (0.43 to 8.19)	-	4.68 (1.51 to 14.48)
p-value for Odds Ratio ^a		0.3919		0.0081
Risk Ratio (95% CI) vs Placebo ^a	-	1.50 (0.58 to 3.85)	-	3.12 (1.27 to 7.67)
Reversed Risk ratio (95% CI)	-	0.67 (0.26 to 1.71)	-	0.32 (0.13 to 0.79)
p-value for Risk Ratio ^a		0.3988		0.0128
Risk Difference (95% CI) vs Placebo ^a	-	14.29 (-19.28 to 47.85)	-	28.71 (10.28 to 47.14)
p-value for Risk Difference ^a		0.3927		0.0027
Treatment-by-subgroup p-value of RR ^b				0.2586

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teaeg12_ger__gender_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per region

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Gastrointestinal disorders [n (%)]				
Patients with any events	11 (25.0)	23 (50.0)	0	2 (15.4)
Odds Ratio (95% CI) vs Placebo ^a	-	3.00 (1.21 to 7.43)	-	385123.6 (0.00 to NE)
p-value for Odds Ratio ^a		0.0181		0.9739
Peto Odds Ratio (95% CI) vs Placebo ^a			-	8.67 (0.51 to 146.74)
Reversed Peto Odds Ratio (95% CI)			-	0.12 (0.01 to 1.96)
p-value for Peto Odds Ratio				0.1345
Risk Ratio (95% CI) vs Placebo ^a	-	2.00 (1.10 to 3.63)	-	5.36 (0.28 to 102.12)
Reversed Risk ratio (95% CI)	-	0.50 (0.28 to 0.91)	-	0.19 (0.01 to 3.56)
p-value for Risk Ratio ^a		0.0226		0.2644
Risk Difference (95% CI) vs Placebo ^a	-	25.00 (5.43 to 44.57)	-	15.38 (NE to NE)
p-value for Risk Difference ^a		0.0129		<0.0001

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teaeg12_ger__region_s_t_x.rtf (24JUL2024 16:49)

Weitere Analysen

	Region			
	Western Countries (N=90)		Rest of World (including South America) (N=27)	
	Placebo (N=44)	Sarilumab 200mg q2w (N=46)	Placebo (N=14)	Sarilumab 200mg q2w (N=13)
Treatment-by-subgroup p-value of RR ^b				0.9718

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).
Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.
^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.
PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teaeg12_ger__region_s_t_x.rtf (24JUL2024 16:49)

Weitere Analysen

Per age

	Age			
	Placebo (N=25)	Age < 70 (N=59) Sarilumab 200mg q2w (N=34)	Placebo (N=33)	Age >= 70 (N=58) Sarilumab 200mg q2w (N=25)
Gastrointestinal disorders [n (%)]				
Patients with any events	5 (20.0)	16 (47.1)	6 (18.2)	9 (36.0)
Odds Ratio (95% CI) vs Placebo ^a	-	3.56 (1.06 to 11.98)	-	2.53 (0.74 to 8.66)
p-value for Odds Ratio ^a		0.0410		0.1362
Risk Ratio (95% CI) vs Placebo ^a	-	2.35 (0.98 to 5.67)	-	1.98 (0.80 to 4.93)
Reversed Risk ratio (95% CI)	-	0.42 (0.18 to 1.02)	-	0.51 (0.20 to 1.26)
p-value for Risk Ratio ^a		0.0567		0.1423
Risk Difference (95% CI) vs Placebo ^a	-	27.06 (3.60 to 50.52)	-	17.82 (-5.65 to 41.29)
p-value for Risk Difference ^a		0.0246		0.1339
Treatment-by-subgroup p-value of RR ^b				0.7856

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_taeag12_ger_age_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline CRP

	Baseline CRP			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Gastrointestinal disorders [n (%)]				
Patients with any events	5 (16.1)	13 (48.1)	6 (22.2)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a	-	4.83 (1.39 to 16.78)	-	2.10 (0.64 to 6.84)
p-value for Odds Ratio ^a		0.0142		0.2134
Risk Ratio (95% CI) vs Placebo ^a	-	2.99 (1.20 to 7.44)	-	1.69 (0.72 to 3.96)
Reversed Risk ratio (95% CI)	-	0.33 (0.13 to 0.83)	-	0.59 (0.25 to 1.39)
p-value for Risk Ratio ^a		0.0189		0.2296
Risk Difference (95% CI) vs Placebo ^a	-	32.02 (8.65 to 55.39)	-	15.28 (-8.18 to 38.74)
p-value for Risk Difference ^a		0.0081		0.1975
Treatment-by-subgroup p-value of RR ^b				0.3626

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_taeag12_ger__crp_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline ESR

	Baseline ESR			
	<= median (N=58)		> median (N=59)	
	Placebo (N=31)	Sarilumab 200mg q2w (N=27)	Placebo (N=27)	Sarilumab 200mg q2w (N=32)
Gastrointestinal disorders [n (%)]				
Patients with any events	7 (22.6)	13 (48.1)	4 (14.8)	12 (37.5)
Odds Ratio (95% CI) vs Placebo ^a	-	3.18 (1.00 to 10.11)	-	3.45 (0.93 to 12.76)
p-value for Odds Ratio ^a		0.0496		0.0631
Risk Ratio (95% CI) vs Placebo ^a	-	2.13 (0.98 to 4.64)	-	2.53 (0.90 to 7.10)
Reversed Risk ratio (95% CI)	-	0.47 (0.22 to 1.02)	-	0.40 (0.14 to 1.11)
p-value for Risk Ratio ^a		0.0562		0.0774
Risk Difference (95% CI) vs Placebo ^a	-	25.57 (1.13 to 50.01)	-	22.69 (0.75 to 44.62)
p-value for Risk Difference ^a		0.0407		0.0429
Treatment-by-subgroup p-value of RR ^b				0.7907

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_taeag12_ger_esr_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per baseline CS dose

	Baseline CS dose			
	<= median (N=64)		> median (N=53)	
	Placebo (N=34)	Sarilumab 200mg q2w (N=30)	Placebo (N=24)	Sarilumab 200mg q2w (N=29)
Gastrointestinal disorders [n (%)]				
Patients with any events	7 (20.6)	14 (46.7)	4 (16.7)	11 (37.9)
Odds Ratio (95% CI) vs Placebo ^a	-	3.37 (1.10 to 10.34)	-	3.06 (0.80 to 11.69)
p-value for Odds Ratio ^a		0.0337		0.1007
Risk Ratio (95% CI) vs Placebo ^a	-	2.27 (1.04 to 4.94)	-	2.28 (0.81 to 6.39)
Reversed Risk ratio (95% CI)	-	0.44 (0.20 to 0.96)	-	0.44 (0.16 to 1.23)
p-value for Risk Ratio ^a		0.0393		0.1187
Risk Difference (95% CI) vs Placebo ^a	-	26.08 (3.19 to 48.96)	-	21.26 (-2.41 to 44.94)
p-value for Risk Difference ^a		0.0262		0.0773
Treatment-by-subgroup p-value of RR ^b				0.9950

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_taeag12_ger_cs_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per MTX Add-on Therapy

	MTX Add-on Therapy			
	Placebo (N=17)	Yes (N=29) Sarilumab 200mg q2w (N=12)	Placebo (N=41)	No (N=88) Sarilumab 200mg q2w (N=47)
Gastrointestinal disorders [n (%)]				
Patients with any events	1 (5.9)	3 (25.0)	10 (24.4)	22 (46.8)
Odds Ratio (95% CI) vs Placebo ^a	-	5.33 (0.43 to 66.20)	-	2.73 (1.08 to 6.90)
p-value for Odds Ratio ^a		0.1839		0.0343
Risk Ratio (95% CI) vs Placebo ^a	-	4.25 (0.45 to 39.90)	-	1.92 (1.02 to 3.60)
Reversed Risk ratio (95% CI)	-	0.24 (0.03 to 2.21)	-	0.52 (0.28 to 0.98)
p-value for Risk Ratio ^a		0.2054		0.0419
Risk Difference (95% CI) vs Placebo ^a	-	19.12 (-9.08 to 47.31)	-	22.42 (2.74 to 42.09)
p-value for Risk Difference ^a		0.1755		0.0260
Treatment-by-subgroup p-value of RR ^b				0.4855

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_taeag12_ger_mtx_s_t_x.rtf (24JUL2024 16:50)

Weitere Analysen

Per Number of relapses prior to screening

	Number of relapses prior to screening			
	1 relapse (N=46)		> 1 relapse (N=71)	
	Placebo (N=23)	Sarilumab 200mg q2w (N=23)	Placebo (N=35)	Sarilumab 200mg q2w (N=36)
Gastrointestinal disorders [n (%)]				
Patients with any events	6 (26.1)	9 (39.1)	5 (14.3)	16 (44.4)
Odds Ratio (95% CI) vs Placebo ^a	-	1.82 (0.50 to 6.60)	-	4.80 (1.49 to 15.51)
p-value for Odds Ratio ^a		0.3530		0.0095
Risk Ratio (95% CI) vs Placebo ^a	-	1.50 (0.62 to 3.62)	-	3.11 (1.26 to 7.70)
Reversed Risk ratio (95% CI)	-	0.67 (0.28 to 1.61)	-	0.32 (0.13 to 0.80)
p-value for Risk Ratio ^a		0.3667		0.0141
Risk Difference (95% CI) vs Placebo ^a	-	13.04 (-14.55 to 40.63)	-	30.16 (9.86 to 50.46)
p-value for Risk Difference ^a		0.3459		0.0042
Treatment-by-subgroup p-value of RR ^b				0.2494

^aOdds Ratio, Risk ratio, Risk Difference and related p-values are estimated by using two SAS GLIMMIX procedures for each modality of subgroup, including treatment as covariate. For zero cells, Risk ratio and related p-value is estimated by using the SAS FREQ procedure after zero cells correction applied (+0.5 for all cells in 2 x 2 table).

Peto OR calculation is based on Yusuf S et al. (Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71) and its p-value is derived using a normal approximation.

^bderived using a SAS GLIMMIX procedure including treatment, subgroup, and treatment-by-subgroup interaction as covariate.

PGM=DEVOPS/SAR153191/EFC15160/CSR_HEVA/REPORT/PGM/eff_safety_subgroup_ger_i_t.sas OUT=REPORT/OUTPUT/eff_aes_soc3_teaeg12_ger_mtx_s_t_x.rtf (24JUL2024 16:50)